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Summary 
The prevalence of type 2 diabetes is increasing in the UK. Many people with type 2 
diabetes require glucose-lowering therapy including insulin when lifestyle 
interventions fail to provide adequate glucose control. Some epidemiological studies 
report an association between insulin use in type 2 diabetes and an increased risk of 
serious adverse events when compared with other glucose-lowering therapies. 
However, these findings should be interpreted with caution due to the risk of 
confounding by indication. The aim of this thesis was to characterise the epidemiology 
of type 2 diabetes and to investigate the risk of serious adverse events associated with 
increasing insulin dose in people with type 2 diabetes prescribed insulin therapy. 
A series of retrospective, observational studies were conducted using data from the 
Clinical Practice Research Datalink. People with type 2 diabetes were identified and 
prevalence and incidence rates calculated. The risk of all-cause mortality, major 
cardiovascular events and cancer in people with type 2 diabetes who progressed to 
insulin with or without metformin were evaluated using multivariate models.  
Between 1991 and 2010, the estimated incidence and prevalence of clinically 
diagnosed and recorded type 2 diabetes increased three-fold. During the same period, 
the estimated number of people with diagnosed and recorded type 2 diabetes treated 
with insulin increased seven-fold. 
Estimated insulin dose was associated with an increased risk of all-cause mortality in 
people with type 2 diabetes receiving insulin monotherapy (aHR 1.54, 95% CI 1.32–
1.78, for 1 unit/kg/day increase in insulin dose) and in those treated with insulin with 
or without metformin (1.48, 1.31–1.70). However, the use of metformin in 
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combination with insulin was associated with a reduction in risk compared with insulin 
alone (0.60, 0.52–0.68). 
Due to the limitations associated with observational studies, further research is 
required in order to improve our understanding of the risks and benefits of exogenous 
insulin in type 2 diabetes.  
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1 Introduction 
1.1. Background 
1.1.1. Diabetes mellitus 
Diabetes mellitus is a collection of metabolic disorders characterized by prolonged 
hyperglycaemia resulting from the reduced secretion of insulin, peripheral resistance 
to the action of insulin or a combination of the two. The different classes of diabetes 
mellitus, as defined by the American Diabetes Association are presented in Table 1.1.1 
Type 1 and type 2 diabetes were also formerly known as insulin dependent diabetes 
mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM), respectively. 
However, the use of these terms is no longer recommended as they can lead to the 
characterisation of diabetes by treatment type rather than the aetiology of the 
disease. 
The World Health Organization (WHO) 1999 guidelines for the definition and diagnosis 
of diabetes mellitus and intermediate hyperglycaemia recommend that diagnosis of 
diabetes should be based on fasting plasma glucose levels or the oral glucose tolerance 
test where venous plasma glucose levels are measured two hours after ingestion of a 
75g oral glucose load (Table 1.2).2 These recommendations were further updated in 
2009 to allow the use of glycated haemoglobin (HbA1c) as a diagnostic test for 
diabetes. A diagnosis of diabetes can be made if the HbA1c level is ≥6.5% providing 
certain criteria are met: the use of stringent quality assurance tests, the use of assays 
standardised to criteria aligned to the international reference values (along with the 
recent introduction of the SI unit3) and also the absence of any conditions which 
prevent the accurate measurement of HbA1c levels.4 Unless symptoms of 
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hyperglycaemia are present or plasma glucose levels are unequivocally elevated, tests 
should be repeated on a separate day in order to confirm a diabetes diagnosis.1,2 
 
Table 1.1  Aetiological classification of diabetes mellitus (abbreviated version of the 
American Diabetes Association (ADA) classification)1 
Types of diabetes mellitus 
1. Type 1 diabetes 
A. Immune mediated 
B. Idiopathic 
2. Type 2 diabetes 
3. Other specified types 
A. Genetic defects of beta-cell function  
B. Genetic defects in insulin action 
C. Diseases of the exocrine pancreas 
D. Endocrinopathies 
E. Drug or chemical induced 
F. Infections 
G. Uncommon forms of immune-mediated diabetes 
H. Other genetic syndromes sometimes associated with diabetes 
4. Gestational diabetes mellitus 
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Table 1.2 WHO criteria for the diagnosis of diabetes and intermediate hyperglycaemia (1999 and 2011 guidelines)2,4,5 
 
Fasting glucose 
(mmol/l) 
 1hr glucose (mmol/l)  2hr glucose (mmol/l)  HbA1c (% / mmol/mol 
Normal <6.1    <7.8 (implied)  - 
IFG ≥6.1 and <7.0 and   <7.8 (if measured)  - 
IGT <7.0 and   ≥7.8 and <11.1  - 
Diabetes ≥7.0 or   ≥11.1 or ≥6.5 / 47.5 
Gestational diabetes 5.1–6.9 or >10.0* or 8.5–11.0   
* Although there are no established criteria for the diagnosis of diabetes based on the 1-hour post 75g oral glucose load. 
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Impaired glucose regulation (IGR, but also known as pre-diabetes or non-diabetic 
hyperglycaemia) occurs in people with glucose levels that are raised above normal but 
are lower than the diabetic range. Impaired glucose regulation may be referred to as 
impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) depending on 
whether the fasting glucose or plasma glucose levels following an oral glucose load are 
raised (Table 1.2). National Institute for Health and Care Excellence (NICE) guidelines 
recommend that patients with a fasting plasma glucose level of between 5.5 and 
6.9mmol/l or a HbA1c level of 6.0–6.4% (42–47mmol/mol) have a high risk of 
developing diabetes.6 These patients should be offered an intensive lifestyle change 
programme with the aim of increasing physical activity, achieving and maintaining 
weight loss and modifying diet.6 As these patients are at a higher risk of developing 
type 2 diabetes, they should also be monitored at least yearly.6 
 
1.1.2.  Type 2 diabetes 
Type 2 diabetes is a chronic, progressive condition which results from either reduced 
insulin secretion, peripheral resistance to the action of insulin or both. Therefore, the 
condition differs from type 1 diabetes, which is characterised by the destruction of 
beta cells in the pancreas usually resulting in the complete failure of insulin 
production. In this regard, type 2 diabetes has been previously seen as a more mild 
form of diabetes. However, it is now clear that type 2 diabetes is associated with a risk 
of severe macrovascular and microvascular complications and requires complex clinical 
management.7 Although type 2 diabetes is genetically determined, age of 
manifestation, its treatment requirements and its ultimate outcomes are largely 
related to obesity and physical inactivity.8 
   
 5 
1.1.2.1. Prevalence and incidence of type 2 diabetes 
In the UK, the overall prevalence of diabetes increased from 2.8% to 4.3% between 
1996 and 2005.9 In fact, the estimated number of people with diabetes in the UK has 
risen from 1.4 million to 2.9 million between 1996 and 2011 and an estimated 90% of 
these people have type 2 diabetes.10 In 2012, there was an estimated 850,000 people 
with diabetes who were unaware of their condition or undiagnosed.11 The prevalence 
of type 2 diabetes is predicted to increase to 5 million by 2025 if the current trend 
continues.11  
Worldwide, it was estimated that 347 million people had diabetes in 2008.12 In the US, 
the prevalence of diabetes is 8.3% and 90% to 95% of these people are likely to have 
type 2 diabetes.13 Type 2 diabetes is the most common non-communicable disease 
globally with low and middle income countries now dealing with the greatest burden 
of diabetes.14 Due to changes in life expectancy, diet and lifestyle, approximately 80% 
of people with diabetes live in low- to middle-income countries.14  
Type 2 diabetes traditionally affected older people and used to be known as adult 
onset diabetes. However, the prevalence of type 2 diabetes in children and young 
adults is increasing due at least in part to obesity and sedentary lifestyle.15,16 
As the early symptoms of type 2 diabetes can be mild, people with type 2 diabetes can 
remain undiagnosed for many years. In the US, it has been estimated that 25.8 million 
people had diabetes in 2010, where 18.8 million people had been diagnosed and 7.0 
million people remained undiagnosed.13 A study carried out in the US and Australia 
between 1978 and 1982, found that based on an estimate of the prevalence of 
retinopathy at diabetes diagnosis, the onset of type 2 diabetes is likely to be at least 4–
7 years prior to clinical diagnosis.17 It has been estimated that the proportion of people 
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with diabetes remaining undiagnosed or untreated in both developing and developed 
countries remains high and ranges from 24% of women in Scotland to 62% of men in 
Thailand.18 Therefore, the true prevalence of diabetes may be even higher than 
estimated. 
 
1.1.2.2. Aetiology of type 2 diabetes 
Type 1 diabetes is an autoimmune endocrine disease which is often idiopathic but 
maternal factors, environmental factors and viruses may pay a role in the development 
of some cases.14 The cause of type 2 diabetes has not been fully elucidated, however 
there are several predispositions and risk factors associated with the disease: 
 Obesity 
 Poor diet 
 Lack of exercise 
 Ageing 
 Polygenic inheritance, family history and ethnicity 
 High blood glucose during pregnancy affecting the unborn child 
Obesity is perhaps the most significant modifiable risk factor for the development of 
type 2 diabetes. The mechanism by which obesity is related to type 2 diabetes is 
through the release of adipokines from the excess deposits of adipose tissue leading to 
the development of insulin resistance.19 Data from National Health and Nutrition 
Examination Survey (NHANES) in the US has found that 85% of people with diabetes 
are overweight or obese and 55% of people are obese at diagnosis.20 In addition, being 
overweight and particularly obese, especially at a younger age, is associated with an 
increased lifetime risk of diagnosed diabetes.21 Hillier et al. demonstrated that there 
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was an inverse relationship between body mass index (BMI) and the age of onset of 
type 2 diabetes.22 The Diabetes Prevention Program (DPP) found that intensive 
lifestyle intervention with a minimum of 7% weight loss and 150 minutes of physical 
activity per week is associated with a 58% reduction in diabetes incidence.23 Physical 
activity may also have beneficial effects on insulin sensitivity.24,25  
Type 2 diabetes also has a strong genetic basis where the concordance rates for type 2 
diabetes were higher for monozygotic compared with dizygotic twins.26 In addition, 
parental history of type 2 diabetes has also been shown to influence the distribution of 
body fat, energy expenditure, and insulin sensitivity in the offspring.27 In the US, non-
Hispanic whites have a lower prevalence of diabetes than Asian Americans, Hispanics, 
non-Hispanic blacks, American Indians and Alaska Natives.28 In addition, the risk of 
developing type 2 diabetes is higher for Hispanics, Asians and Blacks compared with 
whites even after BMI is taken into account.29 However, a recent study found that 
truncal obesity accounted for the two-fold excess incidence of type 2 diabetes 
observed in Indian Asian and Afro-Caribbean women but not men.30 The reason for 
this increased risk in some ethnic groups has not been fully explained. 
 
1.1.2.3. Symptoms of type 2 diabetes 
Unlike type 1 diabetes, early symptoms of type 2 diabetes can be mild and type 2 
diabetes can remain undiagnosed for many years, as people are not always aware that 
they have the condition. Type 2 often develops slowly over a period of years and 
symptoms of type 2 diabetes include: 
 Polyuria 
 Polydipsia 
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 Polyphagia 
 Tiredness 
 Unexplained weight loss and loss of muscle bulk 
 Fungal infections e.g. thrush  
 Slow healing cuts and wounds 
 Blurred vision 
 Cramps 
 Constipation31 
 
1.1.2.4. Natural history of type 2 diabetes 
Type 2 diabetes is a chronic condition characterised by increasing insulin resistance in 
the early stages followed by progressive metabolic decompensation with the gradual 
deterioration in beta (β) cell function over time.32 As type 2 diabetes progresses, 
treatment intensification from lifestyle interventions to one or more glucose-lowering 
therapies and eventually insulin is often required. The rate of progression varies 
between individuals and depends on multiple factors including, age, obesity and 
sedentary lifestyle.32 Therefore patient education and commitment to make necessary 
lifestyle changes are important in order to modify the natural history of type 2 
diabetes. Earlier identification of people with pre-diabetes could allow appropriate 
intervention at an early stage to prevent the development of type 2 diabetes.33 
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1.1.2.5. Long term complications of type 2 diabetes 
People with type 2 diabetes are at risk of developing microvascular complications such 
as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy and macrovascular 
complications including coronary artery disease, peripheral artery disease and stroke.34 
Type 2 diabetes is a progressive condition and its severity varies. People with type 2 
diabetes may develop multiple complications, which may eventually lead to blindness, 
amputations, heart failure and stroke; whereas other people may develop no 
complications of diabetes within their lifetime. Diabetic retinopathy accounts for 1% of 
visual impairments and blindness.35 People with diabetes have a markedly increased 
risk of lower limb amputation.36 In addition, diabetes is the leading cause of renal 
failure37  and is associated with more than a two-fold increased risk of stroke in those 
with elevated fasting plasma glucose levels.38 In the WHO Multinational Study of 
Vascular Disease in Diabetes (WHO MSVDD), cardiovascular disease and renal disease 
accounted for 52% and 11% of deaths respectively in patients with type 2 diabetes.39 
Furthermore, in 2000, diabetes was attributed to 5.2% of all deaths and was the fifth 
leading cause of death worldwide.40 Therefore, appropriate management of the 
condition, is vital in order to minimise the risk of developing microvascular and 
macrovascular complications. 
 
1.1.2.6. Economic burden of type 2 diabetes 
Type 2 diabetes places a significant economic burden on the National Health Service 
(NHS). In 2010–2011, the cost of type 2 diabetes in the UK was £8.8 billion in direct 
costs and £13 billion in indirect costs.41 By 2035–2036, this is predicted to increase to 
£15.1 billion and £20.5 billion, respectively.41 This represents an increase from 10% to 
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17% of total health resource expenditure.41 In the financial year 2012–2013, 42.5 
million prescription items for diabetes were dispensed in England with a net ingredient 
cost (NIC) of £764.1 million. This was an increase on the previous financial year against 
a background of a reduction in overall prescribing costs.42 The global health 
expenditure for diabetes in people aged 20–79 years has been predicted to increase to 
$490 billion in 2030.43 
 
1.1.2.7. Management of type 2 diabetes 
1.1.2.7.1.  Aims of treatment 
The management of type 2 diabetes can be complex. The aim of treatment is to reduce 
disease progression, increase quality of life, reduce the symptoms of diabetes, reduce 
the risk of developing microvascular and macrovascular complications, increase life 
expectancy, and minimise the risk of unwanted or harmful side effects. Adequate 
control of blood glucose remains a primary goal in the management of type 2 diabetes. 
Lifestyle interventions including the provision of advice on diet, exercise, weight loss 
and smoking cessation play an important role. Many people with type 2 diabetes 
progress to glucose-lowering therapies including insulin when lifestyle interventions 
have failed to provide adequate blood glucose control.   
Minimising cardiovascular risk factors including the use of blood pressure and 
cholesterol lowering interventions where indicated also play a role in the management 
of type 2 diabetes. A previous study has shown that people with diabetes and no 
history of myocardial infarction have as high a risk of myocardial infarction as those 
patients without diabetes but with a history of myocardial infarction.44 In the Anglo-
Danish-Dutch Study of Intensive Treatment In People with Screen Detected Diabetes in 
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Primary Care (ADDITION-Europe) multicentre, randomised control trial (RCT), intensive 
management of risk factors (HbA1c, cholesterol and blood pressure) in people who had 
screened positive for type 2 diabetes resulted in a non-significant reduction in the 
composite endpoint (cardiovascular death, cardiovascular morbidity, revascularisation 
and non-traumatic amputation, hazard ratio (HR) 0.83, 95% CI 0.65–1.05) when 
compared with routine diabetes care.45 Tight blood pressure control has also been 
shown to reduce the risk of diabetes related death, stroke and the progression of 
retinopathy in people with type 2 diabetes.46 Blood pressure targets of less than 
140/80mmHg are recommended for most people with diabetes, with a target of less 
than 130/80mmHg recommended for people with type 2 diabetes and kidney, eye, or 
cerebrovascular disease.47 Statins should be considered for all patients with type 2 
diabetes over the age of 40 and also in those under the age of 40 who have signs of 
target-organ damage, HbA1c level of greater than 9%, low high-density lipoprotein 
(HDL) cholesterol and raised triglyceride concentration, hypertension, or a family 
history of premature cardiovascular disease.47 However, aspirin is now only 
recommended for secondary prevention in people with established cardiovascular 
disease.47 
 
1.1.2.7.2. Available glucose-lowering therapies 
Treatment options begin with diet modification and lifestyle interventions but often 
glucose-lowering agents are required.47 Glucose-lowering therapies currently available 
in the UK are listed in Table 1.3.47 People with type 1 diabetes require insulin from 
onset, whereas those with type 2 diabetes are likely to be switched to insulin later in 
the natural history of their disease.47
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Table 1.3 Glucose-lowering therapies available in the UK 
Class of glucose-lowering therapies Examples 
Insulin Animal insulin 
Human insulin 
Analogue insulin 
Sulfonylureas  
Glibenclamide 
Gliclazide 
Glimepiride 
Glipizide 
Tolbutamide 
Biguanide 
Metformin 
Intestinal alpha-glucosidase inhibitor 
Acarbose 
Meglitinides 
Nateglinide 
Repaglinide 
Thiazolidinediones  
Pioglitazone 
Dipeptylpeptidase-4 (DPP-4) inhibitors 
Linagliptin 
Saxagliptin 
Sitagliptin 
Vildagliptin 
Glucagon-like peptide-1 (GLP-1) agonists 
Exenatide 
Liraglutide 
Lixisenatide 
Sodium-glucose co-transporter 2 (SGLT2) inhibitors Dapagliflozin 
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1.1.3. Insulin use in type 2 diabetes 
1.1.3.1. The role of insulin in the regulation of blood glucose 
Insulin is a 51 amino acid peptide hormone (Figure 1.1)48 produced by beta cells in the 
islets of Langerhans in the pancreas. Insulin secretion is primarily influenced by glucose 
but can also be influenced by amino acids, gastrointestinal peptides (e.g. glucagon-like 
peptide 1) and neurotransmitters. The glucose transporter 2 (GLUT2 transporter) 
transfers glucose into pancreatic beta cells where it is phosphorylated into glucose-6-
phosphate by the glucokinase enzyme.49 Glucose-6-phosphate is then converted to 
adenosine triphosphate (ATP), which then inhibits ATP sensitive potassium channels to 
cause depolarisation of the beta cell membrane.49 This in turn causes voltage-gated 
calcium channels to open and insulin to be released.49  
Insulin primarily acts in the liver, skeletal muscle and adipose tissue. Insulin lowers 
blood glucose through the following metabolic effects:  
 Inhibition of gluconeogenesis in the liver and kidney. Protein breakdown and 
lipolysis of stored triglycerides is inhibited and protein synthesis is promoted. 
 Inhibition of glycogenolysis through the inhibition of glycogen phosphorylase 
and the stimulation of glycogen synthase. 
 Increased glucose uptake into adipocytes and skeletal muscle cells. 
 Increased glucose breakdown (glycolysis) in adipocytes and skeletal muscle 
cells.49 
In addition, insulin reduces the secretion of glucagon, a peptide hormone secreted by 
the alpha cells located at the periphery of the islets in the pancreas. Glucagon has the 
opposite effect of insulin in that it stimulates gluconeogenesis and glycogenolysis in 
the liver and kidney.49 
   
 14 
Figure 1.1 Chemical structure of human insulin, adapted from Sweetman et al (2014) 
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1.1.3.2. History of insulin as a treatment for diabetes  
Insulin is the oldest medicine with the largest potential to lower blood glucose. Insulin 
was first administered by Banting to Leonard Thompson in 1922.50 However, the 
product was crude and no noticeable clinical benefit was received. Collip purified the 
extract, which when injected, produced clinical benefit.50 By 1926, Abel had further 
improved the purity of insulin but this led to faster absorption and clearance from the 
body.51 To increase the duration of action of insulin, Hagedorn added an alkaline 
protein (protamine) to insulin which made it less soluble at neutral pH.51,52 Ten years 
later, Nordisk produced insulin isophane or neutral protamine Hagedorn (NPH) insulin 
by mixing soluble insulin with protein in precisely balanced proportions.51 The duration 
of action of insulin was prolonged further through the addition of zinc to soluble 
insulin.51  
Early preparations of insulin were associated with a risk of allergic reactions at the 
injection site due to the presence of residual impurities in the preparation.51 Clean 
insulins were produced through a process of multiple recrystallization (e.g. new 
monocomponent (Novo), highly purified (Nordisk) and single peak (Lilly) pork insulins). 
This meant that the development of lipodystrophies could be avoided.51 
Insulin became the first protein to be chemically sequenced (in 1955) and chemically 
synthesised (in 1963).53 However, it was not until 1978 that synthetic human insulin 
could be mass produced through recombinant DNA technology.53 In 1983, Lilly 
launched the first biosynthetic human insulin.51 By altering the structure of insulin, 
improvements in the onset and duration of action of insulin were made. This lead to 
the development of several rapid-acting e.g. (insulin lispro and insulin aspart) and long-
acting analogue insulins (e.g. insulin glargine, insulin detemir).51  
   
 16 
 
1.1.3.3. Types of insulin available 
Insulin is available in short, intermediate and long-acting form (Table 1.4).  
 
Table 1.4 Types of insulin available in the UK 
Duration of action Type Drug Name 
Short-acting Human Insulin (soluble/neutral) 
 Analogue Insulin aspart 
  Insulin lispro 
  Insulin glulisine 
Intermediate and long-acting Human Insulin zinc suspension 
  Isophane (or NPH) insulin 
  Protamine zinc insulin 
 Analogue Insulin degludec 
  Insulin detemir 
  Insulin glargine 
Biphasic Human Biphasic insulin isophane 
 Analogue Biphasic insulin aspart 
  Biphasic insulin lispro 
 
 
1.1.3.3.1. Prescribing guidelines for type 2 diabetes 
Insulin is recommended by the NICE as third line therapy for the management of type 
2 diabetes when metformin plus sulfonylurea (where indicated) are not sufficient to 
maintain a HbA1c level below 7.5%.54 Other options at the same point in the treatment 
pathway include thiazolidinediones or exenatide but it is recommended that patients 
are subsequently switched to insulin plus metformin and a sulfonylurea if HbA1c 
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remains above 7.5%.54 The addition of insulin is also recommended for those patients 
who have followed alternative treatment pathways and combinations of metformin or 
sulfonylurea plus a DPP-4 inhibitor or a thiazolidinedione are insufficient to maintain a 
HbA1c level of less than 7.5%.55 
Scottish Intercollegiate Guidelines Network (SIGN) recommend metformin as first-line 
therapy for type 2 diabetes.56 As an alternative, a sulfonylurea can be prescribed if the 
patient has an intolerance to metformin or exhibits osmotic symptoms or weight 
loss.56 The preferred second-line option is the addition of a sulfonylurea.56 
Alternatively a thiazolidinedione or DPP-4 inhibitor can be prescribed.56 GLP-1 receptor 
agonists or insulin can be used in combination with metformin or sulfonylurea if 
tolerated as third line options.56 The SIGN guidelines recommend that HbA1c levels 
should be maintained below 7% with the introduction of individualized targets where 
appropriate to balance potential benefits with harms, for example hypoglycaemia and 
weight gain.56 
ADA and European Association for Study of Diabetes (EASD) guidelines, recommend 
metformin first line where no contraindications exist.7 As second line therapy, the 
addition of a sulfonylurea, thiazolidinedione, DPP-4 inhibitor, GLP-1 receptor agonist or 
basal insulin to existing metformin therapy is recommended.7 However, at this stage, 
the EASD and ADA advocate a patient-centred approach to selecting which glucose-
lowering medication is appropriate to achieve adequate glucose control while 
minimising side effects.7 As third-line therapy, the ADA and EASD guidelines 
recommend using three or more glucose-lowering agents in combination and this can 
include insulin.7 In fact, it suggests that insulin may be the most effective choice for 
achieving target glucose levels especially when HbA1c is very high (≥9.0%).7 The 
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ADA/EASD guidelines recommend a HbA1c target of <7% for most people with type 2 
diabetes.7 However, in those people newly diagnosed, with no significant coexisting 
cardiovascular disease and long life expectancy, a HbA1c level of <6.5% may be 
appropriate providing it can be achieved without causing other significant side effects 
such as hypoglycaemia.7 Conversely, in those people with a history of severe 
hypoglycaemia, limited life expectancy, extensive comorbid conditions, or an inability 
to achieve a lower target glucose despite intensive management, a higher HbA1c target 
of less than 7.5–8% may be appropriate.7 
The International Diabetes Federation (IDF) recommends that insulin should be used as 
an option third line when a combination of metformin (where indicated) and one other 
glucose-lowering medication has failed to adequately control blood glucose 
(recommended HbA1c target of <7%).57 
 
1.1.3.4. Epidemiology of insulin use 
The number of people using insulin for type 2 diabetes in the UK is not known. 
However, the cost of insulin has increased year on year.42 For the financial year 
2005/6, the NIC of insulin for the NHS in England was £220.8 million.42 By 2012/13, this 
had increased to £320.0 million.42 This could be due in part to the use of more 
expensive insulin analogues. However, the number of prescription items for insulin 
also increased from 4.7 million to 6.2 million during the same period.42  
In the US, the 2007-2009 National Health Interview Survey found that 26% of people in 
the US with diagnosed diabetes were treated with insulin (12% receiving insulin 
monotherapy and 14% receiving insulin in combination with oral glucose-lowering 
medication).13   
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1.2. Thesis rationale  
In 2014, an estimated 6.2% of adults had diabetes.58 Although the cause of type 2 
diabetes is multi-factorial, it is largely related to obesity and physical inactivity,8 both 
of which are potentially modifiable risk factors. Life expectancy of people diagnosed 
with type 2 diabetes at the age of 50 is thought to be reduced by 6 years when 
compared to a counterpart without diabetes.59 Type 2 diabetes is associated with a risk 
of severe macrovascular and microvascular complications and diabetes currently 
accounts for 10% of total health resource expenditure in the UK.41 Type 2 diabetes 
requires complex clinical management in order to reduce the risk of developing 
complications.7 As such it is important to have an understanding of the epidemiology 
of the condition and the risks and benefits associated with glucose-lowering therapies 
used to manage hyperglycaemia in type 2 diabetes. Insulin, a commonly prescribed 
glucose-lowering therapy, has been associated with an increased risk of cardiovascular 
events, cancer and all-cause mortality in comparison with other glucose-lowering 
therapies in some epidemiological studies60–62 and this finding warrants further 
investigation. 
In order to characterise the epidemiology of type 2 diabetes and to investigate the 
prevalence, costs, risks and benefits of using insulin in type 2 diabetes, six studies were 
carried out and the specific rationale for each is outlined below.  
 
1.2.1. Incidence of type 2 diabetes 
 Between 1993 and 2010, the proportion of the UK population who were estimated to 
be obese increased from 13% to 26% for men and 16% to 26% for women.63 For 
children, the prevalence of obesity has increased between 1995 and 2010 from 11% to 
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17% and from 12% to 15% for boys and girls, respectively.63 Masso Gonzalez and 
colleagues reported an increase in the incidence of type 2 diabetes increased from 
2.60 (95% CI 2.47–2.74) per 1000 person-years in 1996 to 4.31 (4.21–4.42) per 1000 
person-years in 2005.9 However, to our knowledge there are no further up to date 
estimates of the incidence of type 2 diabetes in the UK. 
We hypothesised that between 1991 and 2010, the diagnosed incidence of type 2 
diabetes had increased and during the same period there had been an increase in the 
proportion of people diagnosed at a younger age.  
 
1.2.2. Prevalence of type 2 diabetes 
The worldwide prevalence of diabetes has been estimated as 8.3% and 382 million 
people have been estimated to have diabetes.43 Figures published using data from the 
Quality and Outcomes Framework (QOF) have reported an increase in the number of 
people with diagnosed diabetes in the UK from 1.4 million in 1996 to 3.2 million in 
2013.64 Masso Gonzalez and colleagues reported an increase in the prevalence of 
diagnosed type 2 diabetes from 2.47% in 1996 to 3.9% in 2005.9 However, to our 
knowledge, there are no up to date estimates of the UK prevalence of type 2 diabetes 
specifically. 
People with type 2 diabetes are at risk of developing microvascular and macrovascular 
complications, and have at least twice the risk of death as people without diabetes.40 
In 2005, 11.6% of deaths in people aged 20–79 in England were attributed to 
diabetes.65 However, improvements in survival have also been reported.66 The 
publication of the NICE guidelines54 and findings from the United Kingdom Prospective 
Diabetes Study (UKPDS)67, the introduction of QOF68  and the launch of glucose-
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lowering therapies with novel modes of action69 may have had an impact on glycaemic 
control in this population.  
We hypothesised that between 1991 and 2013, the prevalence of type 2 diabetes 
increased in the UK. Furthermore, we hypothesised that, during the same period, the 
survival of people type 2 diabetes had improved due to improved diabetes 
management. Following on from the previous study, improved survival and increased 
incidence would explain, at least in part, any increase in the prevalence of type 2 
diabetes observed.  
 
1.2.3. Incremental cost of analogue insulin 
In the UK, NICE has recommended insulin glargine and rapid-acting insulin analogues 
as an option for patients with type 1 diabetes but has stated that long-acting insulin 
analogues should only be used in type 2 diabetes patients in specific 
circumstances.55,70 A Cochrane review comparing long-acting insulin analogues with 
NPH insulin in type 2 diabetes patients concluded that there was no evidence of a 
beneficial effect in terms of glycemic control and only a minor benefit in terms of a 
reduction in symptomatic nocturnal hypoglycemic events.71 Despite this, successful 
marketing, the withdrawal of some human insulin products as insulin manufacturers 
focus on their newer patentable products72 and the improved pharmacokinetic profile 
of insulin analogues71,73 may have contributed to a steady increase in the use of insulin 
analogues since the launch of insulin lispro in 1996.69  
We hypothesised that the volume of insulin analogues prescribed in the UK has 
increased since their introduction. Due to the increased unit cost of insulin analogues 
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in comparison with their human insulin alternatives, we hypothesised that this would 
be associated with a high incremental cost to the NHS.  
 
1.2.4. Prevalence of type 2 diabetes treated with insulin 
An increase in the prevalence of diabetes9 is likely to lead to a corresponding increase 
in the prevalence of type 2 diabetes treated with insulin. The number of insulin items 
dispensed on NHS prescriptions in England has increased year on year.42 However, the 
number of people with type 2 diabetes treated with insulin in the UK is not known. The 
publication of the findings from UKPDS and the introduction of QOF may have 
encouraged and incentivised the initiation of insulin in people with type 2 diabetes in 
order to achieve tighter glycaemic control. The introduction of insulin analogues may 
have also overcome some of the barriers to insulin initiation, which can include both 
treatment complexity and fear of inducing hypoglycaemia.74 In the US, between 2007–
2009, 26% of patients with diabetes were using insulin, 58% were using oral glucose-
lowering agents and 16% were diet-controlled only.13 However, the number of people 
with type 2 diabetes treated with insulin in the UK is unknown. 
We hypothesised that the prevalence of people with type 2 diabetes treated with 
insulin in the UK had increased between 1991 and 2010 with a corresponding increase 
in the proportion of patients with type 2 diabetes treated with insulin during the same 
period. 
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1.2.5. The use of insulin in type 2 diabetes 
Insulin has an unlimited potential to lower blood glucose and is a well-established 
treatment for type 2 diabetes.  ADA and EASD guidelines recommend a patient-
centred approach with the aim of achieving adequate glucose control while minimising 
side effects. Two common side effects associated with insulin injections are weight 
gain and hypoglycaemia. Weight gain is associated with an increased risk of 
cardiovascular disease and should be minimised in type 2 diabetes. Two recent review 
articles, have described how both insulin and hypoglycaemia may have vascular effects 
which are thought to be greatest in people with pre-existing cardiovascular disease 
and diabetes.75,76 In addition, as a growth factor, insulin may affect cancer 
progression.77 However, this is a complex area where high glucose levels have also 
been linked to increased cancer risk.78  
Some epidemiological studies have shown that the use of insulin is associated with an 
increased risk of cardiovascular events, cancer and all-cause mortality in comparison 
with other glucose-lowering therapies.60–62 In contrast, large RCTs such as Action to 
Control Cardiovascular Risk in Diabetes (ACCORD) have found no adverse safety signals 
associated with the use of insulin.79 However, these studies were designed to assess 
the benefits of intensive glucose control rather than the safety of insulin itself.  The 
Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial demonstrated 
that insulin glargine had no statistically significant impact on cardiovascular outcomes 
and cancers compared with standard treatment.80 However, subjects could receive 
multiple glucose-lowering therapies making individual comparisons difficult.  
The findings from epidemiological studies suggest that further investigation into the 
role of both hyperinsulinaemia and exogenous insulin in type 2 diabetes is warranted 
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in order to determine how insulin should be used in people with type 2 diabetes. Any 
potential risks associated with insulin therapy need to be seen within the context of its 
glucose-lowering potential, where insulin is often ultimately required for the 
achievement of adequate glucose control due to the progressive loss of beta cell 
function over time.7 However, there is a shortage of RCTs examining the risks and 
benefits of using insulin on long term clinical outcomes such as cardiovascular events, 
cancer and death from all causes.  In the absence of well-designed RCTs, there is an 
opportunity for large-scale observational studies to investigate the safety of insulin in 
people with type 2 diabetes. However such studies should be designed in such a way 
as to minimise the risk of confounding. As stated in section 1.2., we hypothesise that 
insulin is a commonly prescribed medicine in type 2 diabetes. Therefore, any concern 
surrounding the safety of insulin in type 2 diabetes could represent a major public 
health issue. 
We hypothesised that the increasing insulin dose in type 2 diabetes would be 
associated with an increased risk of all-cause mortality, major adverse cardiac events 
(MACE) and cancer in people with type 2 diabetes.  
 
1.2.6. The use of metformin in combination with insulin in type 2 diabetes 
When used in combination, metformin may attenuate any risks associated with insulin. 
Metformin may further protect against cancer through additional AMP kinase 
dependent and independent effects.81 In addition, results from UKPDS showed that 
metformin reduced the risk of all-cause mortality, diabetes-related mortality and 
myocardial infarction versus standard care even though patients in the metformin arm 
had a mean HbA1c of 0.6% lower than standard care.82 When used in conjunction with 
   
 25 
insulin, metformin has been associated with similar glucose control, but lower insulin 
doses and less weight gain.83 In addition, relative to the use of insulin alone, the use of 
metformin in combination with insulin has been associated with a reduced risk of 
cardiovascular events, cancer and death from any cause.61 However, this study did not 
account for insulin dose. 
We hypothesised that the use of metformin in combination with insulin in people with 
type 2 diabetes would be associated with a reduced risk of all-cause mortality, MACE 
and cancer versus the use of insulin alone after adjusting for insulin dose.   
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1.3. Aims and objectives 
The aim of this thesis is to undertake a series of retrospective, cohort studies to 
characterise the epidemiology of type 2 diabetes and insulin use and to investigate the 
costs, risks and benefits of using insulin in type 2 diabetes using Clinical Practice 
Research Datalink (CPRD). Specifically, the objectives and structure of this thesis are 
described in Table 1.5. 
Each of the thesis objectives will be addressed by a separate chapter of the thesis 
(Chapters 4–10). Chapters 4–10 will all start with an introduction summarising the 
existing literature on the given topic. This will be followed by a section providing 
detailed methods for the specific study. Results are then presented, followed by a 
discussion of the study findings and a comparison with existing literature.  
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Table 1.5 Thesis objectives 
Chapter number Objective 
Chapter 2  To outline the current available evidence on the use of insulin in type 2 
diabetes. 
Chapter 3  To provide an overview of the methods and data sources used for the 
series of studies described in chapters 4–10.   
Chapter 4  To characterise the incidence of type 2 diabetes between 1991 and 2010 
and to determine if the proportion of people diagnosed by the age of 40 
has increased. 
Chapter 5 To estimate the prevalence of type 2 diabetes in the UK between 1991 
and 2010. 
Chapter 6 To estimate the prevalence and number of people using insulin in the UK 
between 1991 and 2010 by diabetes type. 
Chapter 7 To calculate the annual NHS spend on insulin in the UK between 2000 and 
2009 and to calculate the incremental cost to the NHS of prescribing 
analogue insulin preparations instead of human insulin. 
Chapter 8 To evaluate if there is an association between insulin dose and all-cause 
mortality, incident major adverse cardiovascular events (MACE), and 
incident cancer. 
Chapter 9 To determine if there is an association between insulin dose and all-cause 
mortality and other serious events in people with type 2 diabetes treated 
with insulin plus metformin and to determine if concomitant metformin 
with insulin reduces the risk of adverse events versus insulin 
monotherapy. 
Chapter 10 To discuss the main findings of the series of retrospective studies and 
their clinical and public health implications. 
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2. Literature review 
Insulin is an established glucose-lowering therapy and there is long-term clinical 
experience of the use of this therapy for the management of hyperglycaemia in 
diabetes. Type 1 diabetes is characterised by the destruction of beta cells in the 
pancreas usually resulting in the complete failure of insulin production. Therefore, 
insulin therapy is essential for all people with type 1 diabetes. Although the goal of 
reducing microvascular and macrovascular complications remains the same, type 2 
diabetes differs from type 1 diabetes as it is characterised by early insulin resistance 
and insulin remains one of an armoury of potential glucose lowering medications and 
lifestyle interventions. However, many patients with type 2 diabetes will progress to 
insulin, due in part to the progressive loss of beta-cell function over time.84 The aim of 
this chapter is to review the current evidence on the risks and benefits of using 
exogenous insulin in type 2 diabetes on these serious adverse outcomes. 
 
2.1. Complications of diabetes 
2.1.1. Macrovascular complications 
The association between diabetes and cardiovascular disease was demonstrated in the 
Framingham study.85 The mechanisms linking type 2 diabetes and macrovascular 
disease are complex and multifactorial. Type 2 diabetes is characterised by varying 
degrees of insulin deficiency and insulin resistance leading to hyperglycaemia, which 
can predispose people with type 2 diabetes to developing atherosclerosis. 
Atherosclerosis can develop in type 2 diabetes following chronic inflammation and 
endothelial injury.34 Oxidative stress plays an important role in the development of 
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diabetic complications including cardiovascular disease.86 Hyperglycaemia may cause 
vascular damage via several mechanisms including: increased polyol pathway flux, 
increased formation of advanced glycation end-products (AGEs), protein kinase C 
activation, increased flux through the hexosamine pathway, formation of oxidized 
lipids via the cyclooxygenase and lipoxygenase pathways.87,88 The ‘common soil’ 
hypothesis postulates that diabetes and cardiovascular disease share underlying 
causes.89 A period of insulin resistance and hyperinsulinaemia precedes the 
development of type 2 diabetes.90 Insulin resistance is a risk factor for cardiovascular 
disease91,92 and insulin resistance has been shown to be a predictor of cardiovascular 
risk in people without diabetes.91 Therefore, insulin resistance promotes the 
development of atherosclerosis even in the absence of hyperglycaemia. Consequently, 
macrovascular complications can precede the onset of diabetes and can often be 
present at the time of diabetes diagnosis.90 Type 2 diabetes typically develops within 
the setting of metabolic syndrome, abdominal obesity, hypertension, hyperlipidaemia 
and increased coagubility.34 These are also risk factors for the development of 
cardiovascular disease.34 Furthermore, type 2 diabetes, insulin resistance and 
hyperglycaemia may have an effect on fibrinolysis and platelet hyperreactivity.93,94 
Cardiovascular disease is the cause of death for 50% of people with type 2 diabetes.95 
People with metabolic syndrome are at a two-fold increased risk of developing 
cardiovascular disease and a five-fold greater risk of developing type 2 diabetes.90 
Haffner and colleagues reported that the risk of myocardial infarction was similar for 
people with diabetes and people without diabetes but with a prior history of 
myocardial infarction.44 Conversely, other studies have reported contradictory results. 
A meta-analysis by Bulugahapitiya and colleagues reported that patients with diabetes 
and no history of myocardial infarction had a 43% lower risk of coronary heart disease 
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events when compared with people with a previous history of myocardial infarction 
but no diabetes (summary odds ratio 0.56, 95% CI 0.53–0.60).96 Echouffo-Tcheugui and 
colleagues have therefore suggested that CVD risk in people with type 2 diabetes may 
not always be as high as for CVD survivors who do not have diabetes.97  
It has been reported that people with diabetes have more than a two-fold increased 
risk of death due to vascular causes compared with people without diabetes (2.32, 
95% CI 2.11–2.56, following adjustment for age, sex smoking status and BMI).59 People 
with type 2 diabetes are also at increased risk of mortality following a myocardial 
infarction.98,99 This has been shown to be particularly the case for women.98,99 In 
addition, the risk of stroke is higher in people with type 2 diabetes compared with no 
diabetes.100–103 Microvascular disease has been found to be an independent risk factor 
for the development of cardiovascular disease.104  
 
2.1.2. Microvascular complications 
People with type 2 diabetes are at risk of developing microvascular complications 
including neuropathy, nephropathy and retinopathy. Several mechanisms have been 
reported to link hyperglycaemia and type 2 diabetes with the development of diabetic 
retinopathy including osmotic stress due to sorbitol accumulation, formation of AGEs, 
oxidative stress and growth factors such as vascular endothelial growth factor (VEGF), 
growth hormone and transforming growth factor.34,105 Retinopathy is thought to 
develop up to seven years prior to the diagnosis of type 2 diabetes.17 
The mechanism of the development of diabetic nephropathy may contain all or some 
of the pathways described for the development of diabetic retinopathy.34 During the 
development of diabetic nephropathy, possible changes to the kidney include 
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increased glomerular basement membrane thickness, microaneurysm formation and 
mesangial nodule formation.34 Up to 7% of people with type 2 diabetes will have 
microalbuminuria at diagnosis.106 In the UK, type 2 diabetes is the leading cause of end 
stage kidney failure.11 Diabetic nephropathy is the most common cause of renal failure 
in the US and accounts for up to 44% of new cases.107 In the UKPDS, the prevalence of 
microalbuminuria, macroalbuminuria and elevated plasma creatinine or renal 
replacement therapy was 24.9%, 5.3% and 0.8%, respectively, 10 years following 
diagnosis of type 2 diabetes.108 
The development of diabetic neuropathy is not completely understood but possible 
mechanisms may include polyol accumulation, injury from AGEs and oxidative stress.34 
Diabetic peripheral neuropathy has been estimated to affect at least 20% of adults 
with diabetes.109 
Hyperglycaemia has been shown to be a risk factor for the development of 
microvascular complications in observational studies.110 In a Cochrane systematic 
review, intensive control of blood glucose reduced the risk of a composite outcome of 
microvascular diseases (relative risk (RR) 0.88, 95% CI 0.82–0.95), nephropathy (0.75, 
0.59-0.95), retinopathy (0.79, 0.68-0.92) and retinal photocoagulation (0.77, 0.61 to 
0.97) when compared with standard blood glucose control.111 In a systematic review 
and meta-analysis undertaken by Coca and colleagues, intensive control of blood 
glucose was associated with a significant reduction in the risk of micro- and 
macroalbuminuria but no significant reduction in the risk of end stage renal disease. 
However, the number of events was small. Following the 10-year follow-up to UKPDS, 
a reduction in the risk of microvascular disease (RR 24%, p=0.001) was observed 
despite the loss in the between-group difference in HbA1c after 1 year.112 
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2.1.3. Cancer 
Worldwide, it has been estimated that 384 million people have diabetes and 33 million 
people are living with cancer.14,113 In 2012, there were 14.1 million new cases of cancer 
and 8.2 million deaths related to cancer.113 The latest IDF figures indicate that the 
worldwide prevalence of diabetes in adults is 8.3%, and the number of people living 
with diabetes is predicted to increase to 592 million within the next 25 years.14 As both 
diabetes and cancer are common conditions there is considerable potential for 
overlap, with people with diabetes also developing cancer and vice versa. However, 
people with diabetes may also be at increased risk of developing cancer compared 
with the general population.84 
The association between diabetes and cancer can be partly explained by metabolic 
derangements that are related to diabetes, such as hyperglycaemia, insulin resistance, 
hyperinsulinaemia and oxidative stress.84,114,115 In type 2 diabetes, insulin resistance 
can cause hyperglycaemia, leading to increased secretion of insulin from the pancreas. 
This results in hyperinsulinaemia, which has been linked to tumour development.19 
Insulin is a growth factor with metabolic and mitogenic (cell proliferating) effects 
mediated through the insulin/insulin-like growth factor (IGF) axis.114 Insulin can bind to 
insulin receptors leading to antiapoptotic actions and mitogenesis.84 In addition, insulin 
may be associated with tumour development through a decrease in insulin like growth 
factor binding protein (IGFBP-1 and possibly IGFBP-2), leading to increased IGF-1 
bioavailability.84 IGF-1 is known to have proliferative and anti-apoptotic actions on 
target cells and has more potent mitogenic effects relative to insulin.84 IGF-1 and 
insulin receptors are expressed on most cancer cells.84 Therefore, insulin and IGF-1 
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have broad effects and cancer cells remain responsive to insulin, particularly in the 
presence of hyperinsulinaemia.19  
Hyperinsulinaemia may cause a decrease in the production and blood level of sex 
hormone binding globulin leading to an increase in testosterone levels in females and 
an increase in the circulating levels of oestrogen in both genders.84,116 Increasing levels 
of sex hormones have been linked to an increase in the risk of endometrial and 
postmenopausal breast cancer.84 Conversely, free and total testosterone levels may be 
lower in men with diabetes compared to those without diabetes and this may explain 
the lack of association between diabetes and prostate cancer.116 However, 
testosterone levels have not been consistently linked to prostate cancer risk.84  
It has been proposed that hyperglycaemia may facilitate the proliferation of cancer 
cells as cancer cells rely on aerobic glycolysis in order to generate energy and therefore 
have a high glucose requirement – the Warburg effect.117 However, hyperglycaemia is 
thought to play a less important role in the development of cancer in comparison with 
hyperinsulinaemia and cancer cells have been shown to consume high levels of glucose 
regardless of plasma glucose levels.118 A meta-analysis, which combined the results of 
four RCTs, did not find an association between improved glucose control and a 
lowering of cancer risk.119 
Obesity, the metabolic syndrome and diabetes are thought to precipitate chronic 
oxidative stress and inflammation. Oxidative stress is an imbalance between tissue 
oxidants including reactive oxygen species (ROS), free radicals and antioxidants which 
can cause cellular damage and may play a role in the development of cancer.115  
The association between diabetes and cancer may also be explained by the shared risk 
factors associated with the two diseases—for example, ageing, gender, obesity, diet, 
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physical inactivity and socioeconomic status.84,114,115 In economically developed 
countries, 78% of all newly diagnosed cancers occur in people over the age of 55 
years.13 The prevalence of type 2 diabetes also increases with increasing age.13 With 
the exception of the sex-specific cancers, males have a higher incidence of both 
diabetes and cancer.84  
Obesity is a risk factor for the development of both type 2 diabetes and cancer.120 
Excess deposits of adipose tissue release more adipokines, which can lead to insulin 
resistance and progression to type 2 diabetes.19,116 Obesity is also linked to the 
development of cancer due to an increase in the circulating levels of sex hormones.19 
In addition, as a state of chronic inflammation, obesity may affect the progression of 
cancer through the production of pro-inflammatory cytokines such as interleukin-6 and 
tumour necrosis factor-α in adipose tissue.84,115 The DPP found that weight loss and 
physical activity reduced the risk of diabetes in high risk people by 58%.121 People who 
are overweight (BMI≥25 and <30kg/m2) or obese (BMI ≥31kg/m2) are at an increased 
risk of a range of malignancies including cancers of the colon, liver, breast, 
endometrium, gallbladder, kidney, pancreas, and oesophagus.116 
The strength of the relationship between diabetes and cancer is likely to depend on 
cancer site.120 Several meta-analyses have combined the results of studies 
investigating the association between diabetes and cancer. Meta-analyses have 
demonstrated an increased risk of breast cancer in women with diabetes122,123 and 
type 2 diabetes specifically.123,124 A significant increase in the risk of colorectal cancer 
in people with diabetes has also been demonstrated in several meta-analyses.125–129 
However, Luo et al did not find a clear association between the duration of diabetes 
and the incidence of colorectal cancer.128 Larsson and colleagues combined the results 
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of 16 case-control and cohort studies and reported an association between diabetes 
and an increased risk of bladder cancer (1.24, 1.08–1.42).130 In a separate meta-
analysis, an association between diabetes and kidney cancer was demonstrated but 
there was heterogeneity between the included studies (RR 1.42, 1.06–1.91).131 Other 
meta-analyses have found an association between diabetes and endometrial cancer, 
(RR 2.10, 95% CI 1.75–2.53),132 non-Hodgkin’s lymphoma (1.22 95% CI 1.07- 1.39),133 
leukaemia (1.22, 95% CI 1.03-1.44),133 and hepatocellular carcinoma.134–136 An non-
significant association between type 2 diabetes and an increased risk of non-Hodgkin’s 
lymphoma was reported in a meta-analysis by Chao and colleagues, but they also 
reported methodological weakness in the included studies.137 A recent meta-analysis 
has demonstrated that diabetes is associated with a reduced risk of prostate cancer.138 
The studies included in all these meta-analyses were mainly observational in nature.  
Insulin is produced in the beta cells of the pancreas and transported to the liver via the 
hepatic portal vein. Therefore these organs have the highest exposure to endogenous 
insulin.84 Diabetes-related steatosis, non-alcoholic fatty liver disease and cirrhosis may 
also increase the risk of developing liver cancer.84 The relationship between diabetes 
and cancer may be further complicated by reverse causality where pancreatic cancer 
can cause abnormal production of glucose. Carstensen and colleagues found that the 
relative risk of cancer increased at diagnosis and then declined over time.139 The 
authors suggest that reverse causation and increased surveillance for cancer in the first 
few years following the diagnosis of diabetes may play a part in the increased 
incidence of cancer in people with type 2 diabetes observed.139 However, in a meta-
analysis conducted by Batabyal and colleagues, the risk of cancer was greatest soon 
after diagnosis of diabetes but diabetes remained a modest but true risk factor for 
pancreatic cancer.140 
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For other site specific cancers, the number of studies is small. However, in two 
observational studies, there was no evidence of an association between diabetes and 
ovarian141 and lung cancer.142 In two meta-analyses investigating a possible association 
between diabetes and thyroid cancer, one reported a significant increase and the 
other a non-significant increase in the incidence of thyroid cancer in people with 
diabetes.143,144 In Japan, the incidence of gastric cancer is high and one prospective 
study carried out in the Japanese population found evidence of an association 
between a modest increase in fasting plasma glucose and gastric cancer, although the 
applicability of the results to other populations is not certain.145 
Several meta-analyses have investigated the risk of mortality from cancer and 
determined that diabetes was associated with an increased risk of mortality from 
breast cancer,59,122 lung cancer,59,146 liver cancer and hepatocellular 
carcinoma,59,135,136,147 ovary,59 bladder59 and colorectal cancer.59,125,129,148 In a meta-
analysis by the Emerging Risk Factors Collaboration, diabetes was associated with an 
increase in death from any cancer (RR 2.32, 95% CI 2.11–2.56).59 Two further cohort 
studies based in the UK and the US found that the prognosis following incident cancer 
is poorer for people with diabetes.149,150 A meta-analysis by Barone and colleagues 
found that people diagnosed with cancer and pre-existing diabetes have an increased 
risk of long-term all-cause mortality versus people without diabetes (HR 1.41, 95% CI 
1.28-1.55).151 In addition to the possible mechanisms linking cancer and diabetes, 
several other possible explanations for this association have been postulated including 
the effect of glucose-lowering therapy, differences in cancer treatments based on 
clinical decisions relating to diabetes-related conditions, poorer response to cancer 
treatment, presentation with later staged cancer due to differences in screening and 
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the effect of cancer treatment, for example glucocorticoids and anti-androgens, on 
diabetes control.114,151 
 
2.1.4. All-cause mortality 
The life expectancy of a person diagnosed with diabetes at the age of 40 is estimated 
to be around 6 years less than someone without diabetes.59 A reduction in the risk of 
cardiovascular and all-cause mortality in people with diabetes152–159 and type 2 
diabetes specifically.66 Conversely, one study has reported an increase in the mortality 
burden associated with type 2 diabetes between 1970 and 1994.160 Life expectancy in 
type 2 diabetes has been shown to vary depending not only on glycaemic control but 
also on several risk factors, including blood pressure, the ratio of total:HDL cholesterol 
and diabetes duration.161 
 
2.2. Influence of insulin therapy on adverse events 
2.2.1. Mechanisms 
2.2.1.1. Preservation of β cells 
Insulin has been reported to be β cell protective through the facilitation of β-cell 
rest.162 Short term infusion of insulin has been shown to augment glucose induced β-
cell secretory response in healthy humans.163 Eight weeks of treatment with insulin 
glargine in people with type 2 diabetes receiving metformin therapy has been 
demonstrated to increase first and second phase insulin secretion.164 Early intensive 
insulin therapy in type 2 diabetes has been reported to be more likely to induce a 
sustained period of glycaemic remission in comparison with oral hypoglycaemic 
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agents.165 The long term effects on β-cell function of intensified insulin therapy have 
been described in a recent review by Retnakaran and Zinman.166 
A meta-analysis of seven studies (two of which were randomised) carried out in Asia 
found that short term intensive insulin therapy in people with early type 2 diabetes led 
to an improvement in beta cell function and insulin resistance.167 Furthermore, when 
the results of the four studies (one randomised) examining glycaemic remission were 
combined, it was shown that a high proportion of people also achieved long term, drug 
free glycaemic remission (66.2% after 3 months, 58.9% after 6 months, 46.3% after 12 
months and 42.1% after 24 months follow up).167 However, a limitation of this meta-
analysis is the lack of a comparator group, therefore potential beneficial effects of 
lifestyle interventions cannot be ruled out.167  
 
2.2.1.2. Cardiovascular disease 
The management of type 2 diabetes places emphasis on achieving normal glycaemic, 
lipid and blood pressure levels with the aim of reducing cardiovascular event risk. 
However, different classes of glucose-lowering therapies have their own mechanisms 
of action, which may lead to a different effect on cardiovascular risk. It has been 
postulated that insulin has an anti-inflammatory effect.168,169 However, it has also been 
proposed that insulin may affect cardiovascular risk through several mechanisms. 
These mechanisms are described below. 
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2.2.1.2.1. Glucose-lowering effects 
Insulin has a theoretically unlimited potential to lower blood glucose. In a pooled 
analysis of 11 RCTs, the addition of insulin glargine to existing glucose-lowering 
therapy in people with uncontrolled type 2 diabetes led to a reduction in HbA1c to ≤7% 
at 24 weeks in 68.1%, 50.4% and 56.4% of patients treated with metformin 
monotherapy, sulfonylurea monotherapy and metformin plus sulfonylurea, 
respectively.170 A decrease in HbA1c following insulin initiation has also been reported 
in several other studies.171–176 However, after an initial good response to insulin, 
glucose control has been shown to deteriorate more in obese people versus non-obese 
people.177 A recent retrospective cohort study has shown that the mean HbA1c for a 
population of type 2 diabetics using insulin was 8.3%.178 The effect of intensive glucose 
lowering on cardiovascular outcomes is discussed in Chapter 2.2.2.1. 
 
2.2.1.2.2. Hyperinsulinaemia 
A meta-analysis showed that hyperinsulinaemia is a weak risk factor for the occurrence 
of cardiovascular disease.179 Type 2 diabetes is characterised by relative insulin 
deficiency and insulin resistance. Hyperinsulinaemia is therefore a predictable 
consequence of the use of exogenous insulin in type 2 diabetes and has been linked to 
an increased risk of atherogenic effects.180,181 Insulin resistance may also increase as a 
function of increasing levels of insulin, either through endogenous insulinaemia or 
through the use of exogenous insulin.182 The administration of exogenous insulin may 
also lead to plasma concentrations of insulin that are supra-physiological. It has been 
hypothesised that, when exogenous insulin is injected into the adipose tissue, the 
concentration of insulin in the systemic circulation needs to be much higher than that 
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which occurs naturally in order for a sufficient concentration of insulin to reach the 
liver to control glucose production and/or uptake.183 Conversely, Kruszynska and 
colleagues have reported that insulin can be administered to diabetic rats without 
causing hyperinsulinaemia.184 
Ferrannini and colleagues have reported that insulin may be associated with possible 
negative (smooth muscle proliferation, vasoconstriction, extended QTc interval, fluid 
retention and prothrombotic) and positive (vasodilation, anti-inflammatory and 
antithrombotic) vascular effects.185 A recent review has discussed how insulin may be 
pro-atherogenic, particularly in the presence of insulin resistance and pre-existing 
macrovascular disease where it has been hypothesised that impaired functioning of 
the phosphatidylinositol 3-kinase (PI3K) pathway and the overstimulation of the 
Mitogen-activated protein kinase (MAPK) pathway by insulin leads to the development 
of atherosclerotic plaques in vessel walls.75 Insulin use has been hypothesised to 
increase angiogenesis within atherosclerotic plaques leading to plaque vulnerability, a 
predictor of future cardiovascular events.186 
Insulin plays a role in several tissues. For example, in type 2 diabetes, the kidney and 
sympathetic nervous system remain sensitive to insulin, and hyperinsulinaemia can 
lead to sodium retention and increased sympathetic nervous system activity, which 
could increase blood pressure.187 Two studies have shown that insulin may also reduce 
urinary sodium excretion in people with type 2 diabetes, however, the effect this has 
on blood pressure, is not clear.188,189  
It has been hypothesised that insulin has antioxidant and anti-inflammatory effects 
which may protect against endothelial dysfunction and vascular disease190 including 
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the suppression of ROS and adhesion molecule expression.168 Insulin has also been 
reported to increase the production of nitric oxide leading to vascular dilatation.168 
 
2.2.1.2.3. Hypoglycaemia 
A limitation of intensive insulin therapy is the risk of hypoglycaemia, which occurs 
more frequently in people using insulin than other glucose-lowering therapies191 and 
has been linked to dead-in-bed syndrome in type 1 diabetes.192 A recent review article 
by Nordin has discussed the mechanism by which hypoglycaemia can lead to calcium 
overload and prolongation of the QT interval, an arrhythmogenic effect that is thought 
to be greatest in patients with pre-existing cardiovascular disease and diabetes.76,193–
196  
Zoungas and colleagues analysed data from the Action in Diabetes and Vascular 
Disease-Preterax and Diamicron Modiﬁed Release Controlled Evaluation (ADVANCE) 
study and found a strong association between severe hypoglycaemia and the risk of 
major macrovascular events, major microvascular events, cardiovascular death or 
death from any cause.197 However, it is unknown whether severe hypoglycaemia 
contributes to these outcomes or whether people who experience hypoglycaemia are 
more likely to have other comorbidities which may increase their risk of these 
outcomes.197  
Stahn and colleagues have recently found that people with type 2 diabetes and a prior 
history of cardiovascular disease treated with insulin and/or sulfonylureas experienced 
a high incidence of asymptomatic severe episodes of hypoglycaemia and silent severe 
arrhythmias.198 A recent study documented that patients who received insulin doses of 
≥0.6 units/kg were at increased odds of hypoglycaemia.199 After multifactorial 
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adjustment, the higher odds of hypoglycaemia with increasing insulin doses remained 
(0.6–0.8 units/kg: odds ratio (OR) 2.10, 95% CI 1.08–4.09; 0.8 units/kg: 2.95, 1.54–
5.65). In contrast, the adjusted odds of hypoglycaemia were no higher in patients who 
received only 0.2–0.6 units/kg.  
In the ORIGIN study, severe hypoglycaemia occurred significantly more often in 
patients randomised to insulin glargine compared with those in the control arm, 
despite the low insulin requirement (6.3% vs. 1.8%; p<0.001).80 In a report from the 
ORIGIN trial, severe hypoglycaemia was associated with a greater risk of mortality 
(adjusted hazard ratio (aHR) 1.74, 95% CI 1.39–2.19), cardiovascular death (1.71, 1.27–
2.30), and arrhythmia-related death (1.77, 1.17–2.67). However, the severe 
hypoglycaemia hazard for all outcomes was higher with standard care than with 
regimens that included low-dose insulin glargine.200 
Results from two meta-analyses suggest that hypoglycaemia counteracts any benefits 
associated with intensive glucose-lowering treatment.201,202 In a study conducted by 
McCoy and colleagues, patients who report severe hypoglycaemia were at a 3.4 (95% 
CI 1.5–7.4) fold increased risk of death when compared with those who report mild or 
no hypoglycaemia.203  
 
2.2.1.2.4. Weight gain 
Weight gain is a common side effect of insulin therapy80,204,205 which could be due in 
part to the anabolic effect of insulin and increased calorie intake due to patients’ fear 
of hypoglycaemia.206,207 In a three-year, open-label, multicentre trial, the use of 
biphasic, prandial and basal insulin were associated with an increase in weight from 
baseline of 5.7kg, 6.4kg and 3.6kg, respectively.208 Insulin use has been associated with 
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an increase in weight in several RCTs.80,171,209,210 In a study using mice, Mehran et al 
have suggested that hyperinsulinaemia may play a causal role in the development of 
obesity.211 
Weight is associated with increased cardiovascular risk and cancer rates in non-
diabetics.118 Weight gain increases the risk of coronary heart disease and as such 
should be minimised in type 2 diabetes. 212,213  
 
2.2.1.3. Cancer 
Diabetes medications can influence the risk of cancer through their effects on risk 
factors that are common to both diabetes and cancer, for example weight and 
hyperglycaemia.115 However, different classes of glucose-lowering medicines have 
different mechanisms of action and are therefore also associated with different cancer 
risks.  
Insulin is a growth factor and may therefore affect cancer progression through the 
interaction with insulin receptors which have been shown to be overexpressed on 
various types of cancer cells.77,214 The risk of cancer may also vary depending on the 
type of insulin administered. For example several studies have shown that insulin 
glargine may have a higher mitogenic potency compared with other insulin analogues 
and human insulin due to its increased binding affinity to the IGF-1 receptor.215 The 
use of insulin in the presence of insulin resistance can cause hyperinsulinaemia. In 
addition, insulin can cause weight gain.80,204,205 As described in Chapter 2.1.3, both 
hyperinsulinaemia and obesity have been associated with an increased risk of cancer.   
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2.2.2. Description of studies comparing the risk of cardiovascular disease 
and cancer risk in people treated with and without insulin 
2.2.2.1. Intensive glycaemic control in type 2 diabetes 
Insulin has a theoretically unlimited potential to lower blood glucose. Poorly 
controlled, inadequately treated diabetes is associated with an increased risk of 
microvascular complications in type 1216 and type 2 diabetes.67,82 In recent years, 
several landmark RCTs have investigated the effect of intensive glycaemic control on 
macrovascular and microvascular outcomes.  
The UKPDS recruited 3,867 people with newly diagnosed type 2 diabetes and 
randomised them to receive intensive glucose-lowering treatment with insulin or 
sulfonylureas or conventional treatment with diet only.67 Patients were followed up for 
ten years.67 The target fasting plasma glucose (FPG) in the intensive group was 
<6mmol/l.67 In the conventional group, the target HbA1c was the best achievable with 
diet alone and other glucose-lowering therapies were only initiated if FPG levels 
exceeded 15mmol/l or the patient developed symptoms of hyperglycaemia.67 Versus 
conventional treatment, intensive control of blood glucose reduced microvascular risk 
by 25% (95% CI 7–40%, p=0.0099) but the effect on macrovascular outcomes was not 
statistically significant (HR myocardial infarction 0.84, 95% CI 0.71–1.00; and stroke HR 
1.11, 95% CI 0.81–1.51).67 It was not until the follow-up observational study was 
carried out ten years later that the cardiovascular benefits associated with intensive 
glucose control became apparent.112 Even though the difference in HbA1c between 
treatment arms was lost after one year, the risk of microvascular disease (risk 
reduction of 24%, p=0.001), myocardial infarction (risk reduction of 15%, p=0.01) and 
all-cause mortality (risk reduction of 13%, p=0.007) was lower for patients originally 
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randomised to receive intensive treatment after the 10-year follow-up.112 The authors 
postulated that this was a legacy effect of their prior randomization to receive 
intensive glucose control during the trial period.112  
Following on from this, three more large RCTs provided relevant data: the ACCORD 
study, ADVANCE and the Veterans Affairs Diabetes Trial (VADT). Unlike UKPDS—which 
only included people newly diagnosed with type 2 diabetes—these three trials 
included a larger proportion of patients with pre-existing cardiovascular disease. 
During the ACCORD study, the intensive-treatment arm was associated with a non-
significant 10% reduction in the composite primary outcome, but it was terminated 
early after three and a half years due to an unexplained excess of all-cause mortality in 
this group.79 When the outcomes for patients with the same HbA1c levels (above 7%) 
were compared within groups, it found that people in the intensive treatment arm 
were worse off.  A recent review article hypothesised that high doses of insulin may 
have been used in order to achieve low HbA1c values and that this may have 
contributed to the increased cardiovascular risk in intensively treated ACCORD 
patients.75 The VADT and the ADVANCE trials also did not demonstrate that intensive 
treatment was associated with a reduced risk of macrovascular events.217,218 Subgroup 
analysis of ACCORD found that people with no prior cardiovascular events or a HbA1c 
of ≤8% in the intensively treated arm had fewer fatal or non-fatal cardiovascular 
events when compared to standard treatment (p for interaction = 0.04 and 0.03, 
respectively).79 Conversely, in the ADVANCE trial, the results were similar across all 
subgroups.218 
Several meta-analyses of available long-term trials, including UKPDS, ACCORD, 
ADVANCE and VADT, have been carried out. In the largest and most recently published 
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meta-analysis by Hemmingsen and colleagues, intensive versus conventional 
management of blood glucose was not associated with a significantly different risk in 
all-cause or cardiovascular mortality but a reduction in the risk of non-fatal myocardial 
infarction was reported (RR 0.87, 95% CI 0.77–0.98).111 The risk of a composite 
outcome of microvascular disease was significantly reduced with intensive glycaemic 
control (RR 0.88, 0.82–0.95).111 However a high risk of bias was detected in many of 
the included trials.111 The meta-analysis of 13 RCTs carried out by Boussageon and 
colleagues did not find evidence of a significant decrease in the risk of all-cause 
mortality (RR 1.04, 99%CI 0.91–1.19) or cardiovascular death (1.11, 0.86–1.43) with 
intensive therapy but a reduction in the risk of non-fatal myocardial infarction (0.85, 
0.740.96) was observed.202 The meta-analysis by Mannucci and colleagues adopted 
stricter inclusion criteria and included only those RCTs where the between-group 
difference in mean HbA1c during the trial was at least 0.5% and the planned duration of 
treatment was at least 3 years.201 A significant reduction in the risk of cardiovascular 
events and myocardial infarction was observed in the intensively treated group when 
compared with conventional therapy.201 However, the reductions in stroke and 
cardiovascular mortality were not significant.201 The meta-analysis by Turnbull and 
colleagues including only UKPDS, VADT, ACCORD and ADVANCE found a 15% reduction 
in fatal and non-fatal myocardial infarction in the more intensively treated group (HR 
0.85, 95% CI 0.76– 0.94) but no significant reduction in all-cause mortality (HR 
1.04,95% CI 0.90–1.20) or cardiovascular death (1.10 95% CI 0.84–1.42).219 Post hoc 
analyses of ACCORD and ADVANCE found that severe hypoglycaemia was associated 
with an increased risk of mortality but this finding may not account for the differences 
in mortality between study arms.197,220  
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In the Steno-2 study, 80 patients were randomised to receive conventional therapy 
and 80 patients were assigned to receive intensive management targeting multiple risk 
factors including hyperglycaemia, hypertension, dyslipidaemia and microalbuminuria 
using a combination of behaviour modification and pharmacologic therapy.221 
Intensive intervention reduced the risk of cardiovascular and microvascular events by 
approximately 50% in people with type 2 diabetes and microalbuminuria.221 
An epidemiological study using data from CPRD published in The Lancet reported that, 
in people with type 2 diabetes, low HbA1c levels were associated with an increased risk 
of all-cause mortality and cardiac events as well as high levels in a U-shaped 
association.60 A similar type of association has also been observed in other 
epidemiological studies. Nicholas and colleagues conducted a case-control study, again 
using data from CPRD, and found that HbA1c levels <6.5% and >9.0% may be associated 
with an increased risk of mortality within one year for people with type 2 diabetes.222 A 
further nested case-control study using data from the Kaiser Permanente Southern 
California Health Plan demonstrated that patients with type 2 diabetes and a HbA1c 
level of ≤6% and >8% over a three year period were at increased risk of cardiovascular 
events compared with people with a mean HbA1c level of >6% and ≤8%.223 Ostgren and 
colleagues found that the J-shaped association between HbA1c and cardiovascular or 
all-cause mortality in type 2 diabetes was most pronounced in patients with a low 
educational level (HR for the lowest HbA1c decile was 1.6, 95% CI 1.2–2.1, for the low 
educational group and 1.2, 0.8–1.6, for the high educational category).224  
Although current guidelines recommend a target HbA1c of less than 7% (53 mmol/mol) 
for many people with diabetes, they also suggest that treatment targets should be 
individualised, taking into consideration a patient’s additional coexisting medical 
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conditions, life expectancy, history of hypoglycaemia and presence of diabetes 
complications.7  
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2.2.2.2. A systematic review of meta-analyses characterising the safety of 
exogenous insulin in type 2 diabetes 
2.2.2.2.1. Introduction 
Various observational studies have shown an association between the use of 
exogenous insulin in type 2 diabetes and the risk of cancer, cardiovascular events and 
all-cause mortality.60–62,223 However, observational studies can be associated with  a 
risk of confounding.  
In terms of the Oxford Centre for Evidence Based-Medicine 2011 levels of evidence, 
systematic reviews rank highly, occupying Step 1 when investigating the benefits and 
harms of treatment.225 The use of well-conducted meta-analysis to combine available 
data to produce an integrated result can be a powerful tool to summarise existing 
evidence. Therefore, the aim of this review was to identify relevant meta-analyses to 
characterise the pool of existing evidence relating to the safety of injecting insulin in 
people with type 2 diabetes, specifically the association between insulin use and the 
risk of all-cause mortality, cardiovascular events and cancer in type 2 diabetes 
compared with other glucose-lowering medicines. 
 
2.2.2.2.2. Methods 
We carried out a systematic search of the Web of Knowledge database to March 2014 
to identify relevant meta-analyses published in the previous five years. Obviously, 
these meta-analyses themselves reviewed constituent studies from a much longer 
observational period (1975–2013). The matches were restricted by publication type 
and only articles and reviews were retrieved. The search terms used are listed in the 
Table 2.1. Articles were included if: (1) they compared the effect of insulin versus at 
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least one other class of glucose-lowering agent; (2) the study population was 
composed solely of people with type 2 diabetes; (3) the investigated endpoints 
included at least one of all-cause mortality, cancer, cancer related mortality, 
cardiovascular events or cardiovascular death; (4) the article was available in the 
English language. Meta-analyses investigating only hospitalised or seriously ill people 
with type 2 diabetes were excluded. The citations of all studies included in the selected 
meta-analyses were also reviewed to identify any further, relevant meta-analyses 
detailed in the manuscript. Identified studies were screened using title, abstract and 
full text where necessary and those studies that did not answer the pre-specified 
research question were excluded at this stage. 
 
2.2.2.2.3. Results 
Of a total of 906 articles identified using the search strategy, seven meta-analyses 
were relevant and included in this review (Figure 2.1 and Table 2.2). The findings in 
terms of the risk of progression to respective events from these meta-analyses are 
summarised in Figure 2.2. 
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Table 2.1 Search terms used in the Web of Knowledge Database 
Search Number Logic Search term  
Mortality 1st  Diabetes* AND “meta-analysis” AND insulin AND * mortality OR diabetes* AND “systematic 
review” AND insulin AND *mortality OR diabetes* AND “meta analysis” AND insulin AND *mortality 
Title 
OR Diabetes* AND “meta-analysis” AND insulin AND * mortality OR diabetes* AND “systematic 
review” AND insulin AND *mortality OR diabetes* AND “meta analysis” AND insulin AND *mortality 
Topic 
NOT “type 1” or gene* Topic 
Death 1st  Diabetes* AND “meta-analysis” AND insulin AND death OR diabetes* AND “systematic review” 
AND insulin AND death OR diabetes* AND “meta analysis” AND insulin AND death 
Title 
OR Diabetes* AND “meta-analysis” AND insulin AND death OR diabetes* AND “systematic review” 
AND insulin AND death OR diabetes* AND “meta analysis” AND insulin AND death 
Topic 
Not “type 1” or gene* or *mortality Topic 
Cancer 1st  Diabetes* AND “meta-analysis” AND insulin AND cancer OR diabetes* AND “systematic review” 
AND insulin AND cancer OR diabetes* AND “meta analysis” AND insulin AND cancer 
Title 
OR Diabetes* AND “meta-analysis” AND insulin AND cancer OR diabetes* AND “systematic review” 
AND insulin AND cancer OR diabetes* AND “meta analysis” AND insulin AND cancer 
Topic 
Not “type 1” or gene* or *mortality or death Topic 
Cardio-vascular (a) 1st  Diabetes* AND “meta-analysis” AND insulin AND cardi* OR diabetes* AND “systematic review” 
AND insulin AND cardi* OR diabetes* AND “meta analysis” AND insulin AND cardi* 
Title 
OR Diabetes* AND “meta-analysis” AND insulin AND cardi* OR diabetes* AND “systematic review” 
AND insulin AND cardi* OR diabetes* AND “meta analysis” AND insulin AND cardi* 
Topic 
Not “type 1” or gene* or *mortality or death or cancer Topic 
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Cardio-vascular (b) 1st  Diabetes* AND “meta-analysis” AND insulin AND heart* OR diabetes* AND “systematic review” 
AND insulin AND heart* OR diabetes* AND “meta analysis” AND insulin AND heart* 
Title 
OR Diabetes* AND “meta-analysis” AND insulin AND heart* OR diabetes* AND “systematic review” 
AND insulin AND heart* OR diabetes* AND “meta analysis” AND insulin AND heart* 
Topic 
 Not “type 1” or gene* or *mortality or death or cancer or cardi* Topic 
Cardio-vascular (c) 1st  Diabetes* AND “meta-analysis” AND insulin AND myocard* OR diabetes* AND “systematic review” 
AND insulin AND myocard* OR diabetes* AND “meta analysis” AND insulin AND myocard* 
Title 
OR Diabetes* AND “meta-analysis” AND insulin AND myocard* OR diabetes* AND “systematic review” 
AND insulin AND myocard* OR diabetes* AND “meta analysis” AND insulin AND myocard* 
Topic 
Not “type 1” or gene* or *mortality or death or cancer or cardi* or heart* Topic 
Cardio-vascular (d) 1st  Diabetes* AND “meta-analysis” AND insulin AND stroke OR diabetes* AND “systematic review” 
AND insulin AND stroke OR diabetes* AND “meta analysis” AND insulin AND stroke 
Title 
OR Diabetes* AND “meta-analysis” AND insulin AND stroke OR diabetes* AND “systematic review” 
AND insulin AND stroke OR diabetes* AND “meta analysis” AND insulin AND stroke 
Topic 
Not “type 1” or gene* or *mortality or death or cancer or cardi* or myocard* Topic 
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Table 2.2 Summary of identified meta-analyses  
First author, 
year 
N of studies included 
(events) 
Selection criteria Intervention Duration of 
included studies 
Sources of search Quality of included studies 
Monami and 
colleagues, 
2013226  
5 (665) for all-cause 
mortality  
5 (354) for CV death 
2 (487) for CV events 
(1) RCTs 
(2) study duration of ≥24 
weeks 
(3) patients with type 2 
diabetes 
(4) sulfonylureas compared 
with placebo or other classes 
of glucose-lowering medicines 
SUs vs placebo 
or other classes 
of glucose-
lowering 
medicines 
24-577 weeks Medline, Embase, Cochrane.  
Results of unpublished trials 
retrieved from 
www.clinicaltrials.gov, 
www.merck.com/mrl/clinical_t
rials/results.html, 
www.novartisclinicaltrials.com, 
www.clinicalstudyresults.org 
and the Food and Drugs 
Administration (FDA) and 
European Medicines Agency 
(EMA) websites. 
Assessed using some of the 
parameters proposed by 
Jadad and colleagues227 The 
quality of the retrieved trials 
was heterogeneous. 
Wang and 
colleagues, 
2013228 
4 (3326) (1) Original articles of a 
quantitative assessment of the 
relationship of insulin therapy 
and the risk of colorectal 
cancer 
(2) Cohort studies 
(3) Adult, human population 
(4) Main independent variable 
is insulin 
(5) Results are expressed as 
RRs and 95% CI is provided or 
can be calculated 
(6) Estimates have been 
adjusted for age and gender. 
Insulin vs no 
insulin 
Not recorded Medline, PubMed, Web of 
Science, Embase, Chinese 
Biomedical Literature Database 
(CBM). 
No date restriction was applied 
Not assessed 
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Colmers and 
colleagues, 
2012229  
Ever insulin Vs other 
glucose-lowering 
medicines:  
10 (≥3838) for 
colorectal cancer 
4 (≥3201) for breast 
cancer 
3 (≥3325) for 
prostate cancer.  
New insulin versus 
other types of 
glucose-lowering 
medication:  
3 (≥2688) for breast 
cancer 
2 (≥2582) for 
prostate cancer 
3 (≥1300) for 
pancreatic cancer 
(1) Cohort or nest case-control 
studies 
(2) Patients with type 2 
diabetes 
(3) Outcome of incident cancer 
at any site or incident cancer 
overall 
(4) Insulin versus other 
glucose-lowering medicines or 
insulin glargine Vs other insulin 
types 
(5) Written in English 
Insulin vs other 
glucose-lowering 
medicines 
≤5.8 years but 
not recorded for 
all included 
studies 
Medline, Embase, Cochrane 
Database of Systematic 
Reviews, Database of Abstracts 
of Review Effects, Health 
Technology Assessment, 
Cochrane Central Register of 
Controlled Trials, Science 
Citation Index Expanded, 
Conference Proceedings 
Citation Index - Science, 
Scopus, reference list of 
included studies and 
consultation with experts in the 
field. Date range not specified. 
Assessed using the 
Newcastle-Ottawa scale. 
Mean=6.9 out of 8 and no 
studies were assessed to be 
at a high risk of bias 
Singh and 
colleagues, 
2013230  
7 (22,611) (1) RCTs or observational 
studies 
(2) Evaluated and clearly 
defined exposure to anti-
diabetic medication (3) 
Reported HCC incidence in 
patients with diabetes (4) 
reported RR or OR or enough 
data provided for their 
calculation 
Insulin vs no 
insulin  
≤5 years but not 
recorded for all 
included studies 
Medline, Embase and Web of 
Science from 1966 to 1st Aug 
2012 and also abstracts from 
major gastroenterology 
conferences 
Assessed using the 
Newcastle-Ottawa scale. 
Included studies ranged from 
6 to 9 (where 9 was the 
maximum possible score). 
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Hemmingsen 
and 
colleagues, 
2013231 
FGS vs insulin:  
2 (370) for all-cause 
mortality 
2 (214) for CV 
mortality 
2 (168) for non-fatal 
MI 
2 (92) for cancer.  
SGS vs insulin:  
4 (309) for all-cause 
mortality 
4 (175) for CV 
mortality 
2 (76) for cancer. 
(1) RCTs 
(2) participants ≥18 years old 
(3) participants with type 2 
diabetes 
(4) participants treated with 
SU monotherapy 
(5) study duration of ≥ 24 
weeks 
FGS or SGS vs 
insulin 
FGS vs insulin: 
4.75 to 10 years 
for all-cause 
mortality, CV 
death, non-fatal 
MI or cancer.  
SGS vs insulin: 
9mths to 10 
years for all-
cause mortality 
and CV 
mortality, 6 to 
10 years for 
cancer 
The Cochrane Library, 
MEDLINE, EMBASE, Science 
Citation Index Expanded, 
LILACS, CINAHL (all until Aug 
2011) 
GRADE Working Group 
grades of evidence used to 
assess quality. All relevant 
pooled analyses were scored 
as low quality indicating that 
further research is very likely 
to have an important impact 
on the confidence in the 
estimate of effect and is 
likely to change the estimate 
Janghorbani 
and 
colleagues, 
2012232 
8 (number of incident 
cancers = 3,169, 
number of cancer-
related deaths = 249) 
(1) Original articles 
(2) Case-control or cohort 
studies 
(3) Adult human population 
(4) Insulin use as the main 
independent variable. 
Insulin vs no 
insulin 
Not stated PubMed, ISI, EMBASE through 
January 2011 
Not assessed. 
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Franciosi and 
colleagues, 
2013233 
Observational and 
RCTs included for 
metformin vs no 
metformin. However, 
the type of studies 
included in the meta-
analysis for metformin 
vs insulin is unknown 
(1) RCT enrolling people with 
diabetes treated with 
metformin compared with a 
control group 
(2) Cohort, case control or 
nested case-control studies of 
patients with diabetes 
reporting on metformin 
exposure and cancer 
incidence/ prevalence or 
mortality 
(3) Studies in which exposure 
to metformin was assessed 
from prescription databases 
and incidence of cancer was 
derived from cancer registries 
(4) Treatment exposure of ≥24 
weeks 
(5) Studies in humans 
(6) Studies published in English 
language only. Studies where 
metformin was used to treat 
other conditions (e.g. PCOS, 
metabolic syndrome) were 
excluded. 
Metformin vs 
insulin 
≥24 weeks. 
Maximum length 
unknown as 
studies included 
in metformin 
insulin 
comparison not 
defined. 
Medline and Embase from 
1966 to April 2012. 
Methodological quality of 
RCTs assessed using risk bias 
tool exploring the following 
domains: (1) Random 
sequence generation 
(2) Allocation concealment 
(3) Blinding of investigators, 
participants and outcome 
assessments 
(4) Use of intention to treat 
analysis 
(5) Completeness of follow-
up.  
For observational studies, the 
following was assessed:  
(1) Selection of participants 
(2) Measurement of 
prognostic factors and 
outcomes 
(3) Adjustment for 
confounding 
(4) Quality of the analysis.  
Risk of bias presented for the 
53 studies (12 RCTs, 41 
observational) included in 
the meta-analysis but it is 
unclear how this referred to 
the studies included in the 
metformin vs insulin 
comparison 
CV = cardiovascular, SU = sulfonylurea, SGS = second generation sulfonylurea, FGS = first generation sulfonylurea, MI = myocardial infarction, PCOS = polycystic ovary syndrome  
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Figure 2.1 Flow diagram summarising study identification and selection 
  
906 records identified 
416 records after duplicates removed
416 records screened for eligibility 409 Records excluded
142 Effect of exogenous inuslin not investigated
35 Endpoints not relevant
7 Study population contained only hospitalised or ill patients
15 Insulin not compared to ther types of glucose-lowering medications
53 Not meta-analyses
144 Not relevant
1 Protocol only
11 Study population not exclusively type 2 diabetes
1 Foreign language
7 relevant meta-analyses identified
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Figure 2.2 Summary of the results from the identified and relevant meta-analyses 
 
When necessary, the reciprocal of the risk estimate was taken to ensure that insulin exposure was always the reference category. 
Endpoint Author Risk estimate Comparator
All-cause mortality Monami (2013) MH-OR 0.56 (0.14-2.22) Insulin Vs SU
Hemmingsen (2013) RR 0.85 (0.63-1.14) Insulin Vs FGS
Hemmingsen (2013) RR 1.04 (0.85-1.27) Insulin Vs SGS
Cardiovascular
CV death Monami (2013) MH-OR 0.58 (0.13-2.63) Insulin Vs SU
CV death Hemmingsen (2013) RR 0.74 (0.37-1.47) Insulin Vs FGS
CV death Hemmingsen (2013) RR 1.04 (0.78-1.37) Insulin Vs SGS
CV event Monami (2013) MH-OR 1.02 (0.83-1.25) Insulin Vs SU
Non-fatal MI Hemmingsen (2013) RR 0.95 (0.69-1.23) Insulin Vs FGS
Cancer
Any cancer Hemmingsen (2013) RR 1.23 (0.44-3.45) Insulin Vs FGS
Any cancer Hemmingsen (2013) RR 1.05 (0.67-1.64) Insulin Vs SGS
Incident cancer or cancer-related death Janghorbani (2012) RR 1.30 (0.89-1.90) Insulin Vs No insulin
Colorectal cancer Wang (2013) RR 1.61 (1.18-1.35) Ever ins Vs other glucose-lowering med
Colorectal cancer Colmers (2012) RR 1.12 (0.93-1.35) Ever insulin versus other glucose-lowering meds
Colorectal cancer Franciosi (2013) OR 1.33 (0.76-2.33) Insulin Vs Metformin
Hepatocellular cancer Singh (2013) OR 2.61 (1.46-4.65) Insulin Vs No insulin
Breast cancer Colmers (2012) RR 0.99 (0.88-1.11) Ever insulin versus other glucose-lowering meds
Breast cancer Colmers (2012) RR 0.99 (0.88-1.11) New insulin versus other glucose-lowering meds
Prostate cancer Colmers (2012) RR 0.86 (0.69-1.07) Ever insulin versus other glucose-lowering meds
Prostate cancer Colmers (2012) RR 0.90 (0.66-1.24) New insulin versus other glucose-lowering meds
Pancreatic cancer Colmers (2012) RR 3.18 (2.73-3.71) New insulin versus other glucose-lowering meds
Pancreatic cancer Franciosi (2013) OR 4.17 (3.13-5.56) Insulin Vs Metformin
Favours insulin Favours comparator
0
0.1 1.0 10.0
Risk estimate
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2.2.2.2.3.1. Cardiovascular events and all-cause mortality 
Two meta-analyses were identified that investigated the association between insulin 
and all-cause mortality or cardiovascular events. Monami and colleagues combined 
five RCTs and found that people with type 2 diabetes using sulfonylureas had an 
increased risk of all-cause mortality (Mantel-Haenszel odds ratio (MH-OR) 1.80, 95% CI 
0.45–7.26) and cardiovascular death (MH-OR 1.73, 95% CI 0.38–7.88) compared with 
insulin but these results were not statistically significant.226 Two RCTs were combined 
to determine that the risk of major cardiovascular events was also not significantly 
greater for people using sulfonylureas versus insulin (MH-OR 0.98, 95% CI 0.80–
1.20).226 A Cochrane systematic review of RCTs found that there was no significant 
difference in the risk of all-cause mortality (RR 1.18, 95% CI 0.88–1.59) and 
cardiovascular death (RR 1.36, 0.68–2.71) associated with FGSs compared with 
insulin.231 A non-significant result was also found for SGSs compared with insulin (RR 
0.96, 0.79–1.18, for all-cause mortality and 0.96, 0.73–1.28, for cardiovascular 
death).231  
 
2.2.2.2.3.2. Cancer 
Six meta-analyses investigated the association between insulin use and the risk of 
cancer in type 2 diabetes.228–233 Singh and colleagues combined seven observational 
studies―two cohort studies and five case-control studies) and found that the risk of 
hepatocellular cancer was significantly higher for people with type 2 diabetes using 
insulin compared with no insulin use (adjusted OR = 2.61, 95% CI 1.46–4.65).230 Wang 
and colleagues analysed four studies (one case-control and three cohort studies) and 
found that, compared with no insulin use, insulin use in type 2 diabetes was associated 
   
 60 
with an increased risk of colorectal cancer (RR=1.61).228 However, there appeared to 
be an error in the 95% confidence intervals, which were detailed as 1.18–1.35.228 In a 
meta-analysis of cohort and case-control studies, Colmers and colleagues found that 
there was an increased risk of pancreatic cancer associated with new users of insulin 
compared with no use of insulin in people with type 2 diabetes (RR 3.18, 95% CI 2.73–
3.71) but the association between insulin use and the risk of colorectal, breast or 
prostate cancer was non-significant.229 The Cochrane systematic review of RCTs 
conducted by Hemmingsen and colleagues did not identify any significant increase in 
the risk of cancer for first or SGSs versus insulin therapy in type 2 diabetes (RR 0.81, 
95% CI 0.29–2.27, and 0.95, 0.61–1.49, respectively).231 Janghorbani and colleagues 
combined the results of one case control study and seven cohort studies and found 
that the use of insulin in type 2 diabetes was associated with a non-significant increase 
in the risk of incident cancer and cancer related death (RR 1.30, 95% CI 0.89–1.90).232 
The meta-analysis by Franciosi and colleagues,233 found that the use of metformin was 
associated with a non-significant reduction in the risk of colorectal cancer (OR 0.75, 
95% CI 0.43–1.31) and a significant reduction in the risk of pancreatic cancer (OR 0.24, 
0.18–0.32) when compared with insulin. 
 
2.2.2.2.4. Discussion 
Two meta-analyses investigating the effect of insulin on the risk of all-cause mortality 
and cardiovascular events and six meta-analyses investigating the association between 
insulin use and cancer were identified. Insulin use was found to be significantly 
associated with an increased risk of hepatocellular cancer (OR 2.61, 95% CI 1.46–
4.65)230 and pancreatic cancer (3.18, 2.73–3.71).229 Insulin was also associated with a 
   
 61 
significantly increased risk of pancreatic cancer when compared with metformin (OR 
for metformin vs. insulin = 0.24, 95% CI 0.18–0.32).233 Most of the other associations 
were not significant.  
The ORIGIN trial is one of the few RCTs to investigate the effect of insulin on the risk of 
cancer and cardiovascular outcomes. As the results were only published in June 2012, 
it was not included in any of the meta-analyses identified for this review. This was a 
large scale, long-term study in which 12,612 people with type 2 diabetes and pre-
existing cardiovascular disease were followed up for a median of 6.2 years.80 ORIGIN 
found that compared with standard treatment, the use of insulin glargine over a six 
year period had a non-significant effect on cardiovascular outcomes (HR 1.02, 95% CI 
0.94–1.11 for cardiovascular death, non-fatal myocardial infarction or nonfatal stroke) 
and cancer (HR 1.00, 0.88–1.13).80 In terms of site-specific cancers, insulin glargine was 
also found to have a non-significant effect on the risk of breast, colon and prostate 
cancers. The meta-analyses by Hemmingsen and colleagues also found that there was 
no significant increased risk of cancer associated with insulin compared with 
sulfonylureas.231 Colmers and colleagues found that the risk of new or ever-use of 
insulin was not associated with an increased risk of breast, prostate or colorectal 
cancer versus no insulin use.229 The lack of an association between insulin and the risk 
of prostate cancer is not that surprising considering that diabetes is associated with a 
reduced risk of prostate cancer, possibly due to lower circulating levels of 
testosterone.234,235 The increased risk of cancer and cancer related death associated 
with insulin use was also not significant in the meta-analysis conducted by Janghorbani 
and colleagues232  but a significant increased risk of hepatocellular cancer was found 
by Singh and colleagues.230 However, the ORIGIN trial did not investigate pancreatic 
and hepatocellular cancers specifically. The results from the meta-analyses from 
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Monami and colleagues and Hemmingsen and colleagues determined that compared 
with sulfonylureas, the risk of death from all causes, cardiovascular death and 
cardiovascular events was not significantly different for insulin, a finding similar to the 
one reported from the ORIGIN trial. However, it is important to note that the 
comparison groups were not identical (sulfonylureas versus standard care).  
Sulfonylureas stimulate insulin secretion and can cause weight gain and hypoglycaemia 
and may therefore adversely affect cardiovascular risk.212,213 Some sulfonylureas may 
also impair a cardioprotective mechanism known as ischaemic preconditioning.236 In 
addition, epidemiological data have shown that, compared with metformin, all-cause 
mortality and MACE was raised for both sulfonylureas (1.75, 95% CI 1.64–1.86 and 
1.39, 1.25–1.55, respectively) and insulin monotherapy (2.20, 1.98–2.43 and 1.74, 
1.44–2.09, respectively).61 Therefore, the nature of the comparator is important in 
terms of the interpretation of the results and further studies comparing insulin use 
with other glucose-lowering agents are required.  
Patients included in the ORIGIN study were in general newly diagnosed with type 2 or 
IGT, IFG or only using one glucose-lowering therapy. The baseline HbA1c was also only 
6.4%. This HbA1c is low in comparison with ACCORD, ADVANCE and VADT at 8.1%, 7.5% 
and 9.4%, respectively.79,217,218 Furthermore, the reduction in HbA1c achieved during 
the trial was just 0.2% (in comparison with reductions of 1.4% for ACCORD, 1% for 
ADVANCE and 2.5% for VADT).79,217,218 In addition, the insulin dose was relatively low 
after six years (0.40 units per kilogram; interquartile range, 0.27 to 0.56). It has been 
suggested that the selection of this study population helped to minimise the argument 
that any association between insulin use and cardiovascular risk could be attributed to 
its use in people with more advanced type 2 diabetes.237 However, it also meant that 
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the people receiving insulin were not necessarily typical of people who would normally 
receive insulin in the real world. There was considerable cross contamination of other 
glucose-lowering therapies between groups (e.g. 65% of the insulin glargine group 
were also using other glucose-lowering agents, including 46.5% of patients using 
metformin, and 11% of the standard care group were using insulin).80 Metformin may 
therefore have mitigated any risk associated with insulin but to an unidentifiable 
extent. 
There were some limitations associated with the identified meta-analysis. Only two 
meta-analyses examining the use of insulin and the risk of cardiovascular events or all-
cause mortality in type 2 diabetes were identified. The meta-analysis conducted by 
Monami and colleagues found that there were limitations in trial quality and many of 
the studies identified did not provide information on cardiovascular events and 
mortality.  At least four of the meta-analyses investigating the use of insulin and the 
risk of cancer included only observational studies. The heterogeneity in the RR for the 
association between insulin treatment and cancer incidence and mortality in the meta-
analysis conducted by Janghorbani and colleagues was high (I2=89.0%, 
PHeterogeneity=<0.01).232 In addition, the meta-analysis combined the results from studies 
reporting cancer related deaths with studies reporting incident cancers and the quality 
of the included studies was not assessed.232 In the meta-analysis conducted by Singh 
and colleagues, considerable heterogeneity was identified among the included studies 
(Cochran’s Q test p<0.001, and I2 = 88).230 In addition, the included studies failed to 
adjust for possible confounders, most notably exposure to statins, which have been 
shown to reduce the risk of hepatocellular cancer.230 A high risk of bias was attached 
to the RCTs used to generate the pooled estimates from the Cochrane systematic 
review.231 The quality of the studies included in the meta-analysis conducted by Wang 
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and colleagues were not assessed and although heterogeneity was assessed using the 
Q statistic and the I2 statistic, these results were not presented in the paper.228 In 
addition, the number of studies excluded and the reason for exclusion was not 
provided. Colmers and colleagues suggested that the results of their meta-analysis 
should be interpreted with caution due to potential sources of heterogeneity within 
studies.229 In fact, statistical heterogeneity was too large to be able to obtain a pooled 
estimate for the overall risk of pancreatic and any cancer associated with the ever-use 
of insulin and the risk of colorectal or any cancer with the new use of insulin. 
Heterogeneity was also high in the meta-analysis by Franciosi and colleagues 
investigating the risk of colorectal cancer associated with metformin use compared 
with insulin. Several of the meta-analyses investigated the association between insulin 
use and cancer risk compared with no insulin use.229,230,232 Patients often take a 
combination of glucose-lowering therapies concomitantly and different glucose-
lowering medications may have different inherent cancer-modifying effect, e.g. 
metformin may reduce the risk of cancer through the activation of the 5' adenosine 
monophosphate-activated protein (AMP) kinase pathway.238 If the distribution of these 
concomitant medications is not the same across the two groups, this may result in an 
over- or under-estimation of the cancer risk associated with insulin. 
Meta-analyses of observational studies are still exposed to the same criticism of 
confounding by indication as individual observational studies and differences in the 
design of combined studies may also lead to bias.239 However, Ioannidis and colleagues 
have suggested that both RCTs and observational studies have their own individual 
merits.240 Furthermore, studies have shown that observational studies do not 
necessarily overestimate effect compared to RCTs.240 There is a lack of RCTs 
investigating the effect of insulin compared with glucose-lowering medicines other 
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than sulfonylureas on hard clinical endpoints such as MACE, cancer or all-cause 
mortality, and only two meta-analyses of RCT data were identified as part of our 
search strategy. With the exception of ORIGIN, whose results have only been recently 
published in 2012, the major landmark diabetes trials conducted in the last couple of 
decades, UKPDS, VADT, ACCORD and ADVANCE, investigated the effect of intensive 
control of blood glucose on the risk of microvascular and macrovascular 
complications.67,79,217,218 As these studies were not designed to assess the safety of 
insulin, subjects could receive multiple glucose-lowering therapies, which makes 
individual comparisons difficult.  
 
2.2.2.3. Randomised control trials and observational studies 
2.2.2.3.1. Cardiovascular disease 
In 2008, the FDA published guidance that recommended the inclusion of 
cardiovascular outcome trials when applying for a license for a glucose-lowering 
medication. The EMA produced their own guideline in 2012.241 However, in a review of 
cardiovascular outcomes trials, Holman and colleagues suggested that many 
pharmaceutical manufacturers conduct non-inferiority, placebo-controlled trials, 
carried out with the minimum possible follow-up in order to show an absence of 
cardiovascular toxicity with the minimum risk and cost.242 Therefore, at the time of 
licensing, the comparative effectiveness, long term safety, effects in patients with 
different clinical characteristics, and the risk benefit ratio of a glucose-lowering 
medication may not be fully understood.242 
The University Group Diabetes Programme (UGDP) conducted in 1970 was a 
randomised controlled, multicentre, head-to-head effectiveness trial. Patients were 
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randomised to receive one of four glucose-lowering regimens: variable doses of 
insulin, standard dose of insulin, phenformin or tolbutamide and also placebo.242,243 
The study reported an increased cardiovascular risk for all therapies when compared 
with placebo.242,243 Since its publications, the conduct of the UGDP has been heavily 
criticized.244 However, although this study was underpowered with controversial 
findings,244 it had far reaching consequences including to delay the introduction of 
metformin to the US market until 1994.242  
In the first Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction 
(DIGAMI) study, patients with diabetes who suffered an acute myocardial infarction 
were randomised to receive intensive insulin therapy or standard care following at 
least a 24 hour period standard treatment plus an insulin-glucose infusion.245 
Compared with standard care, insulin therapy was associated with an absolute 
reduction in mortality of 11%.245 The recently published follow-up study (mean 7.3 
years) found that intensive insulin therapy following acute myocardial infarction had a 
long –lasting effect on survival (HR 0.83, 95%CI 0.70–0.98).246 The second DIGAMI 
study (DIGAMI 2) failed to reproduce the same results as the first study using a similar 
population. Patients with type 2 diabetes and a myocardial infarction were 
randomised to one of three treatment groups: group 1, acute insulin–glucose infusion 
followed by insulin-based long-term glucose control; group 2, insulin–glucose infusion 
followed by standard glucose control; and group 3, routine metabolic management 
according to local practice.247 There were no significant differences in the risk of 
mortality between groups (HR 1.03, 95% CI 0.79–1.34, for group 1 versus group 2 and 
1.23, 95% CI 0.89–1.69 for group 2 versus group 3).247 However, less than half the 
number of planned participants were recruited to the study (1,253 instead of 3,000) 
and the predefined separation in glucose control between study arms was not 
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achieved.247 In the post hoc analysis of the DIGAMI 2 study, insulin was associated with 
a statistically significant increase in non-fatal cardiac events248 but was not associated 
with an increased risk of mortality (1.30, 0.93–1.81).248 However, not all the baseline 
characteristics, which differed between groups, were included in the multivariate 
model.248  
The results of ORIGIN, a large, multicentre RCT, have already been discussed previously 
(Chapter 2.2.2.2.4). 
In the UKPDS, patients were randomised to intensive treatment with sulfonylureas or 
insulin or standard treatment with diet.67 Insulin could be prescribed in combination 
with other glucose-lowering drugs with the aim of achieving a specific HbA1c target. 
Therefore it is difficult to determine the effect of insulin on the study endpoints. 
However, unlike those patients receiving conventional glucose lowering treatment and 
sulfonylureas, patients treated with insulin experienced a sustained increase in plasma 
insulin levels.67 Despite this, an excess of macrovascular outcomes was not observed in 
the intensively treated arm.67 In addition, patients treated with insulin were not more 
at risk of myocardial infarction.67 Other large RCTs such as ACCORD found no adverse 
safety signals associated with the use of insulin.79 However, these studies were 
designed to assess the benefits of intensive glucose control rather than the safety of 
insulin, and subjects could receive multiple glucose-lowering therapies making 
individual comparisons difficult.  
The multinational randomised controlled Hyperglycaemia and Its Effect After Acute 
Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes 
Mellitus (HEART2D) trial compared prandial insulin with basal insulin in 1,115 people 
with type 2 diabetes following acute myocardial infarction.249 The study found that 
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that there was no statistically significant difference in the composite endpoint of 
cardiovascular death, myocardial infarction, stroke, coronary revascularisation or 
hospitalisation for acute coronary syndrome between the treatment arms (HR= 1.04, 
95% CI 0.78–1.37).249 
The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) RCT 
compared insulin-sensitisation with insulin provision treatment in 2,368 people with 
type 2 diabetes and pre-existing heart disease.250 After 5 years, there was no 
statistically significant difference in survival between treatment arms (88.2% versus 
87.9%, respectively).250 However, there was some crossover of therapies between 
study arms and HbA1c levels were significantly lower in the insulin sensitisation group 
suggesting that either the insulin sensitising glucose-lowering medicines were more 
effective in terms of managing hyperglycaemia or the patients in the insulin provision 
group had more severe diabetes.250 
Several observational studies have found an association between insulin use and the 
risk of serious cardiovascular events. A retrospective study conducted by Currie et al. 
using data from the General Practice Research database (GPRD) has shown that insulin 
treatment was associated with an increased risk of cardiovascular events (1.5 fold).60 
In a nested case-control study, Colayco and colleagues reported that insulin use was 
associated with a 2.5 fold increase in the risk of cardiovascular events when compared 
with no treatment with glucose-lowering therapy.223 A separate retrospective 
observational study conducted by Currie and colleagues using data from CPRD found 
that relative to metformin monotherapy, insulin monotherapy was associated with an 
increased risk of MACE (HR 1.74, 95% CI 1.44–2.09).61 However, when prescribed in 
combination with metformin, the risk associated with insulin was not statistically 
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significant (1.22, 95% CI 0.96–1.54).61 Margolis and colleagues conducted a study using 
a different source of UK primary care data, The Health Improvement Network (THIN), 
and found that people with diabetes treated with insulin were at an increased risk of 
serious atherosclerotic disease of the heart (HR 1.2, 95% CI 1.1–1.3, for insulin; 1.03, 
0.97–1.09, for sulfonylureas; 0.8, 0.7–0.8, for biguanide; 1.2, 0.99–1.5, for meglitinides; 
and 0.5, 0.5–0.6, for thiazolidinediones).251 The risk of serious atherosclerotic disease 
increased with the duration of therapy for insulin, sulfonylureas, and biguanide, but 
decreased with duration for rosiglitazone and pioglitazone.251 However, one study 
limitation is that patients with type 2 diabetes were not selected specifically. Ostgren 
and colleagues found that insulin treatment in type 2 diabetes was associated with an 
increased risk of a composite endpoint (first hospitalisation for acute myocardial 
infarction, heart failure, or stroke or cardiovascular mortality (aHR 1.36 95% CI 1.26–
1.45) and cardiovascular death (1.46, 1.34–1.59) compared with treatment with oral 
glucose-lowering medication.224 In a retrospective study conducted by Nichols and 
colleagues using data from the Kaiser Permanente Northwest diabetes registry, the 
addition of insulin therapy was associated with 2.33 and 2.66 times increase in the 
incidence of coronary heart failure in comparison to the addition of metformin or 
sulfonylurea, respectively.252 Conversely, Hall and colleagues conducted a 
retrospective observational study using data from THIN and determined that the 
intensification of glucose-lowering therapy with insulin compared with other glucose-
lowering medicines was only associated with an increased risk of macrovascular events 
in people who had previously received only one baseline treatment (aHR 0.53, 0.42–
0.69, from one; 0.85, 0.70–1.04, from two; and 1.07, 0.50–2.30, from three baseline 
treatments).253 The corresponding figures for microvascular disease were 1.01 (0.80–
1.27), 0.99 (0.87–1.13) and 1.12 (1.67–2.07).253 It was uncommon for people to start 
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insulin when receiving only one oral glucose-lowering medication and there were 
notable differences between the baseline characteristics of this group.253 In a second 
study from the same research group, the risk of macrovascular events were similar 
when people previously receiving two or three glucose-lowering medicines were 
prescribed basal insulin compared to those prescribed pre-mix or NPH.254 
An association between cumulative insulin exposure and risk of cardiovascular 
mortality was demonstrated by Gamble and colleagues in a retrospective study using 
data from Saskatchewan Health.255 In the prospective observational Translating 
Research Into Action for Diabetes (TRIAD) study, insulin as monotherapy was 
associated with an increased risk of cardiovascular (aHR 1.55, 95% CI 1.19–2.01) and 
all-cause mortality (1.24, 1.05–1.46) in comparison with oral medication only.256 
However, no significant association was found for insulin in combination with oral 
therapy.256 Anselmino and colleagues carried out an observational study of people 
with diabetes and coronary artery disease enrolled on the Euro Heart Survey of 
Diabetes and the Heart and found that people with known diabetes treated with 
insulin were associated with an increased risk of all-cause mortality after one year 
(aHR 2.23 95% CI 1.24–4.03).257 However, no data was presented for people with type 
2 diabetes specifically. Conversely, of the people with coronary artery disease that 
were newly diagnosed with diabetes, no people receiving glucose-lowering therapy 
died, compared with 22 patients receiving no glucose-lowering therapy (p=0.002).257 In 
a retrospective study conducted using data from two Swedish registries with a mean 
follow-up time of 4.1 years, Saleh and colleagues found an increased risk of all-cause 
mortality in people with type 2 diabetes treated with insulin alone (HR 1.17, 95% CI 
1.02–1.35) or in combination (1.22, 1.06–1.40) and undergoing coronary angioplasty 
when compared with diet alone.258 Gu and colleagues conducted a study where insulin 
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naïve patients were recruited from the Shanghai Diabetes Registry and divided into an 
insulin group and a non-insulin group.259 The risk for cardiovascular mortality was not 
found to be significantly higher for people using insulin (adjusted RR 1 83, 95% CI 0.91–
3.68).259 Khalangot and colleagues conducted a cohort study and reported an 
increased risk of cardiovascular mortality in people with type 2 diabetes treated with 
insulin when compared with oral glucose-lowering therapies (aHR 2.66, 95% CI 2.28–
3.09, for insulin monotherapy and 2.51, 2.15–2.93, for insulin in combination with 
other glucose-lowering therapies).260 In a small number of people with diabetes (type 
not specified) and advanced systolic heart failure, Smooke and colleagues found that 
insulin use was associated with an increased risk of mortality (HR 4.30, 95% CI 1.69–
10.94) but non-insulin treated diabetes was not (0.95, 0.31–2.93).261 Conversely, 
Masoudi and colleagues found no association between insulin use and mortality (aHR 
0.96, 0.88–1.05) when compared with metformin, sulfonylureas, non-sulfonylurea 
secretagogues, thiazolidinediones or alpha-glycosidase inhibitors in people with 
diabetes and discharged from hospital with heart failure.262 However, the authors did 
not present data for type 2 diabetes specifically.262 
 In a systematic review and meta-analysis conducted by Eurich and colleagues, the 
results of four studies comparing insulin use with other glucose-lowering therapies in 
people with diabetes and heart failure (2 studies provide adjusted estimates as 
described above262,263 and two studies providing unadjusted estimates261,264) could not 
be pooled due to statistically significant heterogeneity between studies.265 
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2.2.2.3.2. Cancer 
Recently, associations between glucose-lowering therapies (including insulin glargine, 
pioglitazone and incretin-based drugs) and an increased risk of cancer have received 
considerable attention.266–269 In June 2009, the results of four epidemiological studies 
were published which suggested an increased risk of cancer and the use of insulin, 
particularly insulin glargine.62,270–272 Several studies have since been carried out, 
including the large randomised control ORIGIN trial. ORIGIN found that that the use of 
insulin glargine in people with type 2 diabetes had no statistically significant impact on 
cancer risk.80 However, this trial was powered to investigate cardiovascular outcomes 
rather than cancers. In addition, after six year, insulin doses remained relatively low 
(median 0.40, IQR 0.27–0.56 international units/kg).80 In 2013, both the FDA and EMA 
determined that currently available data did not indicate an increased risk of cancer 
with insulin glargine.273,274 
Meta-analyses investigating the association between insulin use and the risk of cancer 
in type 2 diabetes have been discussed previously (Chapter 2.2.2.2). In a more recent 
meta-analysis, insulin use was associated with an increased risk of lung cancer while no 
association was shown for thiazolidinediones and sulfonylureas.275 
In a retrospective observational study using data from the UK CPRD, patients with type 
2 diabetes treated with insulin were at increased risk of developing cancer when 
compared with metformin monotherapy (aHR 1.42, 95% CI 1.27–1.60).62 In addition, 
people with insulin treated type 2 diabetes were at increased risk of mortality from 
these tumours compared with people without diabetes (aHR 1.13, 95% CI 1.01–
1.27).149 There is some evidence that the use of insulin may increase cancer risk in 
comparison with metformin62,276,277 and other glucose lowering therapies.278 Increasing 
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duration of insulin exposure has also been reported to be associated with an increased 
risk of colorectal cancer (adjusted OR 1.21, 95% CI 1.03–1.42, for each incremental 
year of insulin therapy).278 One epidemiological study has also demonstrated a graded 
association between insulin exposure and death from cancer.279 Gu and colleagues 
found that insulin use was associated with an increased risk of liver cancer (adjusted 
RR 2.84, 95% CI 1.12–7.17) and cancer-related mortality (2.16, 1.39–3.35) in a 
population of previously insulin-naïve patients from the Shanghai Diabetes Registry.259 
However, compared with no insulin use, insulin use was not associated with an 
increased risk of any incident cancer (1.20, 0.89–1.62).259 In the Diabetes 
Cardiovascular Risk and Evaluation: Targets and Essential Data for Commitment if 
Treatment (DETECT) study, treatment with insulin as monotherapy or in combination 
with other glucose-lowering therapy in people with type 2 diabetes was associated 
with an increased risk of cancer related mortality when compared with people with no 
diabetes (aHR 3.96, 95% CI 1.82–8.63) whereas any glucose-lowering therapy other 
than insulin was not associated with a significantly increased risk (0.93, 0.41–.11).280 In 
a retrospective study by van Staa and colleagues, it was reported that increases in 
cancer risk associated with insulin or sulfonylurea therapy could be explained by a 
protopathic bias and found no evidence that insulin increased the risk of cancer over 
time when compared with metformin.281 
 
2.2.2.3.3. Microvascular 
In the UKPDS, a reduction in microvascular complications (RR 0.70, 95% CI 0.52–0.93) 
and retinal photocoagulation (0.67, 95%CI 0.45–0.99) was observed in people with 
type 2 diabetes treated with insulin when compared with conventional therapy.67 In a 
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RCT conducted in Japan, 110 patients were randomised to receive either multiple 
insulin injections or conventional insulin treatment.282 Compared with convention 
insulin treatment, multiple insulin injection delayed the progression of retinopathy 
(7.7% versus 32.0%, p=0.039 in the primary prevention cohort and 19.2% versus 
44.0%, p=0.049 in the secondary intervention cohort) and nephropathy (7.7% versus 
28.0%, p=0.032, and 11.5% versus 32.0%, p=0.044) after six years.282 However, this was 
a relatively small study where the study subjects were reasonably young and lean. 282 
Conversely, in a prospective cohort study, starting insulin therapy in people with type 2 
diabetes was reported to be related to worsening retinopathy.283 However, it is 
unclear whether this is a causal effect or related to disease progression.283 In a study 
by Arun and colleagues, it was hypothesised that the risk of exacerbating retinopathy 
after starting insulin may be lower than previously suggested.284  
 
2.2.2.3.4. Other side effects 
In addition to its link to cardiovascular risk, hypoglycaemia as a side effect of insulin 
therapy can cause significant morbidity285 and has been tentatively linked to an 
increased risk of dementia.286 Furthermore, insulin has been associated with an 
increased rate of fractures in people treated with insulin (OR 1.52, 95% CI 0.82–2.70) 
possibly due to an increased risk of falls.287 Patients with hypoglycaemia are also likely 
to be less satisfied with their glucose-lowering therapy where hypoglycaemia is a 
barrier to treatment adherence.288 In UKPDS, hypoglycaemia was highest in people 
treated with insulin (1.8% versus 1.0% and 1.4%, respectively).67 Weight gain was 
higher with intensive treatment compared with conventional glycaemic control and 
people treated with insulin had a higher gain in weight compared with those treated 
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with chlorpropamide or glibenclamide (2.0kg versus 2.6kg and 1.7kg, respectively).67 
Weight gain and hypoglycaemia may counteract any quality of life benefits associated 
with improved glucose control.289  
 
2.2.2.3.5. All-cause mortality 
In a retrospective observational study using data from Saskatchewan Health, a 
significant, graded association between insulin and the risk of all-cause mortality was 
observed (aHR 1.75, 95% CI 1.24–2.47, for low exposure; 2.18, 1.82–2.60, for 
moderate exposure; and 2.79, 2.36–3.30, for high exposure).255 In people identified 
from the Shanghai Diabetes Registry who were previously insulin-naïve, insulin use was 
associated with an increased risk of all-cause mortality compared with no-insulin use 
(adjusted RR 1.89, 95% CI 1.47–2.43).259 Khalangot and colleagues found that insulin 
therapy was associated with an increased risk of all-cause mortality in people with 
type 2 diabetes compared with oral glucose-lowering agents (HR 2.34, 95% CI 2.13–
2.57 and 2.12, 1.97–2.29, for insulin monotherapy and 2.22, 2.02–2.45, and 2.20, 2.04–
2.37, for insulin plus metformin, for males and females, respectively).260 
 
2.2.3. Financial cost 
In 2013/2014, 6.5 million insulin items were dispensed on NHS prescriptions in England 
at a cost of £328.3 million.290 Insulin accounts for 14.3% of all items prescribed for 
diabetes and 41% of the total cost. Injecting equipment (for example needles, syringes 
and pen devices) add to this cost. Since 2005/2006, the number of insulin items and 
their corresponding NIC has increased year on year in England.290 Since their 
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introduction, the use of insulin analogues has increased steadily and they have had an 
increasing impact on the cost of prescribing for diabetes in the UK.291 Insulin is a 
relatively expensive intervention, particularly when compared with generic glucose-
lowering drugs.47 
 
2.3. Influence of metformin on adverse events 
Metformin was originally thought to be an insulin sensitizer.115 However, metformin is 
now considered to suppress hepatic glucose production where activation of AMP-
activated protein kinase may account for many of its effects.292 Metformin has also 
been shown to induce GLP-1 secretion.293 Metformin reduces hyperglycaemia and 
hyperinsulinaemia and is associated with weight loss.115 Compared with a BMI of 
between 20 and 24, a BMI of greater than 30 has been found to be associated with an 
increased risk of all-cause mortality.294 Furthermore, hypoglycaemia rarely occurs with 
metformin295 and metformin may reduce oxidative stress.115 Metformin has been 
shown to reduce the incidence of type 2 diabetes in people who at high risk of 
developing the condition.121 
Metformin may indirectly lower the risk of cancer through the activation of AMP 
kinase causing the downregulation of key gluconeogenesis genes and the promotion of 
glucose uptake into muscle leading to a reduction in both plasma glucose and insulin 
levels.81 Studies have shown that activation of AMP kinase by metformin causes a 
reduction in mammalian target of rapamycin (mTOR) signalling in cancer cells causing a 
reduction in protein synthesis and reduced proliferation of cancer cells.81 Metformin 
may further protect against cancer through additional AMP kinase dependent and 
independent effects.81 
   
 77 
In addition, results from UKPDS showed that metformin reduced the risk of all-cause 
mortality, diabetes-related mortality and myocardial infarction versus standard care 
even though patients in the metformin arm had a median HbA1c of 0.6% lower than 
standard care.82 This suggests that metformin may have cardioprotective effects that 
cannot be fully explained by its ability to lower blood glucose. Improvement in 
endothelial dysfunction, may explain, at least in part, the reduced risk of 
cardiovascular disease associated with its use.296–298 Furthermore, data from RCTs have 
shown that metformin is associated with improvements in body weight, lipids and 
blood pressure.299,300 Metformin has also been shown to reduce plasminogen activated 
inhibitor-1, a risk factor for cardiovascular disease.301 
Metformin is primarily eliminated by filtration and active tubular secretion in the 
kidneys.302 Lactic acidosis is the most serious side effect associated with metformin 
treatment and metformin should be used with caution in people with renal 
impairment.47 Phenformin, a biguanide and the predecessor of metformin, was 
withdrawn from US and European markets in 1977 due to the risk of lactic acidosis.303 
However, a recent Cochrane review found no cases of lactic acidosis in 70,490 patient-
years of metformin use (and none in 55,451 patient-years for people not treated with 
metformin).304 The low incidence of lactic acidosis observed may be due at least in part 
to the avoidance of metformin in high-risk groups. Nevertheless, when used 
appropriately, lactic acidosis associated with metformin use is likely to be a relatively 
rare event. Even when metformin is prescribed in situations where its use is 
contraindicated, it has been found to be relatively well tolerated.305 
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2.3.1. Glucose-lowering effect 
Metformin is an effective glucose-lowering therapy and generally reduces fasting 
plasma blood glucose and HbA1c in a dose related fashion.306 A Cochrane review has 
demonstrated that metformin was associated with improved HbA1c, fasting plasma 
glucose, low-density lipoprotein (LDL) cholesterol and triglyceride levels, and BMI 
when compared with sulfonylureas.307 In the UKPDS, HbA1c levels for patients assigned 
to intensive control with metformin were similar to those receiving intensive control 
using insulin or sulfonylurea during the 10-year follow-up.82 In ADOPT (A Diabetes 
Outcome Progression Trial), the glycaemic durability of metformin was found to be 
greater than sulfonylureas but less than rosiglitazone.308 
 
2.3.2. Cardiovascular 
In the UKPDS study, a relatively small number of obese people with type 2 diabetes 
(bodyweight of more than 120% of the ideal) were randomised to receive either 
intensive glucose control using metformin  (n=342) or conventional therapy 
(predominately diet alone, n=411).82 A 33% (95% CI 13–47%) reduction in any diabetes 
related outcome, a 36% (95% CI 9–55%) reduction in all-cause mortality and a 42% 
(95% CI 9–63%) reduction in diabetes-related death with metformin treatment was 
reported.82 A secondary analysis found that intensive glucose control with metformin 
was associated with a reduction in the risk of any diabetes related outcome, all-cause 
mortality or stroke when compared with intensive glucose control with insulin, 
glibenclamide or chlorpropamide.82 The 10-year post-interventional monitoring 
programme showed a possible legacy effect for metformin (RR for any diabetes-
related endpoint =21%, p=0.001; myocardial infarction =33%, p=0.005; and all-cause 
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mortality =27%, p=0.002).112 In the absence of other RCT data, considerable emphasis 
is placed on the results of the UKPDS when recommending the use of metformin in 
prescribing guidelines. Counter intuitively, UKPDS 34 also reported an increased risk of 
diabetes related deaths (1.96, 1.02–3.75) and all-cause mortality (1.60, 1.02–2.52) with 
metformin and sulfonylurea combination therapy when compared with continued 
sulfonylurea monotherapy alone.82 However, only a small number of events were 
observed.  
In a meta-analysis of RCTs, Boussageon and colleagues found that the use of 
metformin did not significantly affect the risk of all-cause mortality (RR 0.99, 95% CI 
0.75–1.31), cardiovascular mortality (1.05, 0.67–1.64), myocardial infarction (0.90, 
0.74–1.09), strokes (0.76 0.51–1.14), heart failure (1.03, 0.67–1.59), peripheral 
vascular disease (0.90, 0.46–1.78), leg amputations (1.04, 0.44–2.44) and 
microvascular complications (0.83, 0.59–1.17).309 However significant heterogeneity 
was observed for all-cause and cardiovascular related mortality due to the inclusion of 
the two UKPDS metformin studies.309 A meta-analysis by Stevens and colleagues did 
not report a significant reduction in all-cause mortality with metformin (RR 0.94, 95% 
CI 0.79–1.12).310 However, heterogeneous comparator types and short follow-up were 
limitations of this meta-analysis.310 In a meta-analysis of patients with diabetes and 
heart failure, metformin was associated with a significant reduction in all-cause 
mortality in two studies (HR 0.86, 95% CI 0.78–0.97 when compared with other 
glucose-lowering therapies including insulin and 0.70, 0.54–0.91 when compared with 
sulfonylureas) and a similar trend was observed in a third study.265 Metformin was the 
only glucose-lowering therapy not associated with harm in patients with heart failure 
and diabetes.265 In a meta-analysis of 35 RCTs, metformin was found to significantly 
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reduce cardiovascular risk versus placebo or no therapy (MH-OR 0.79, 95% CI 0.64–
0.98) but no significant effect versus active comparators (1.03, 0.72–1.77).311 
Several observational studies have demonstrated an increased risk of cardiovascular 
events61,312–314 and cardiovascular deaths315 when sulfonylurea monotherapy was 
compared with metformin monotherapy. A randomised, double-blind, placebo-
controlled trial showed that the risk of cardiovascular events in people with type 2 
diabetes and a history of coronary heart disease was lower for metformin than for 
glipizide (aHR 0.54; 95% CI 0.30–0.90).316 A meta-analysis of clinical and observational 
studies by Phung and colleagues found that relative to metformin, the risk associated 
with sulfonylureas was 1.26 (95% CI 1.17–1.35) and 1.18 (1.13–1.24) for cardiovascular 
death and cardiovascular events, respectively.317 Selvin and colleagues showed that 
the risk of cardiovascular mortality was lower for metformin than any other 
comparator (OR 0.74, 95% CI 0.62-0.89) but that the risk for sulfonylurea was not 
significantly different to other comparators (OR 0.92, 95% CI 0.68-1.26).318 In a meta-
analysis consisting predominately of observational studies only, Eurich and colleagues 
found that people with heart failure treated with metformin had a 20% lower mortality 
rate compared with the control group who were predominately treated with 
sulfonylureas, and no increased risk of lactic acidosis was observed in the metformin 
treated subjects.319 In a retrospective cohort study, high dose metformin was not 
associated with an increased risk of developing heart failure versus low dose 
metformin (HR 1.06, 95% CI 0.81–1.41).320 Patients with established atherothrombosis 
and diabetes participating the Reduction of Atherothrombosis for Continued Health 
(REACH) registry and treated with metformin, had a lower risk of mortality versus no 
metformin use (aHR 0.76, 95% CI 0.65–0.89).321 Danish patients with type 2 diabetes 
treated with metformin in the 90 days following hospital admission with a myocardial 
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infarction had a similar risk of death, a further myocardial infarction and heart failure 
in the first year following the event as patients treated with sulfonylureas (aHR 0.96, 
95% CI 0.71–1.31; 1.21, 0.77–1.92; and 0.81, 0.51–1.29, respectively).322 Conversely, a 
meta-analysis by Monami and colleagues also found no statistically significant 
difference in the risk of death from all-causes for sulfonylureas compared with 
metformin (OR 1.29, 95% CI 0.80–2.13).226 In addition, the randomised double-blind 
controlled trial ADOPT showed that glibenclamide was associated with a lower risk of 
cardiovascular events when compared with rosiglitazone, and that metformin was 
associated with a similar risk to rosiglitazone. However, this study was not designed to 
evaluate cardiovascular outcomes.308  
 
2.3.3. Cancer 
A meta-analysis and systematic review of epidemiological studies by Decensi and 
colleagues found that the risk of cancer in people with diabetes treated with 
metformin was 31% lower than those treated with other glucose-lowering 
therapies.323 People with type 2 diabetes treated with metformin have been shown to 
have reduced risk of cancer compared to the general population.149 The Zwolle 
Outpatient Diabetes project Integrating Available Care (ZODIAC) study in the 
Netherlands found that increasing metformin dose was associated with a reduction in 
the risk of cancer (aHR 0.58, 0.36–0.93 for every 1g increase of metformin dose).324 
One observational study utilising data from CPRD found that there was no significant 
difference in the risk of malignant solid tumours and haematological malignancies 
when comparing sulfonylureas with metformin (aHR 1.06; 95% CI 0.98–1.15 and 0.98; 
0.67–1.43, respectively).325 However, other observational data61,62,326,327 and meta-
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analyses328,329 support the thesis that metformin is associated with a reduced risk of 
cancer in comparison with sulfonylurea monotherapy and  insulin monotherapy .  
Conversely, the results seen for metformin in the meta-analyses of observational 
studies have not been replicated in the meta-analyses of RCTs. A recent Cochrane 
meta-analysis combining data from RCTs did not find any significant beneficial effects 
of metformin on cancer 231. The confidence intervals calculated were broad but the 
authors concluded that even if a beneficial effect of metformin on cancer exists, it is 
likely to be smaller than estimated from observational data 231.  Stevens and 
colleagues, found that when data from RCTs was combined, metformin only reduced 
the risk of cancer versus placebo or usual care (RR 1.36, 95% CI 0.74–2.49) and not 
versus active comparators (0.98, 95% CI 0.77–1.23).310 
In terms of site-specific cancers, metformin has been associated with a decreased risk 
in lung cancer in people with diabetes but this effect was not significant when only 
those studies that adjusted for smoking status were analysed.275 In two meta-analyses 
metformin use was associated with a significant (RR 0.63, 95% CI 0.50–0.79)330 and 
non-significant reduction (OR 0.75, 95% CI 0.43–1.31)233 in the risk of colorectal 
cancer. In meta-analyses conducted by Zhang and colleagues, metformin use in type 2 
diabetes was associated with a significant reduction in liver cancer (OR 0.38, 95% CI 
0.24–0.59) and hepatocellular carcinoma (OR 0.30, 0.17–0.52), however, there was 
some heterogeneity across studies.331,332 Several meta-analyses have been carried out 
investigating the association between glucose-lowering therapies and the risk of breast 
cancer in postmenopausal women with both significant reductions 333 and non-
significant associations 328 reported for metformin. One meta-analysis did not find a 
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significant association between the risk of prostate cancer and the use of 
metformin.328 
In terms of survival following cancer diagnosis, mixed results for the effect of 
metformin have been observed. No association was found between cumulative 
metformin duration and survival in older people with recent onset diabetes following 
diagnosis of breast cancer.334 In addition, in a retrospective observational study, 
Bayraktar et al found that metformin use during adjuvant chemotherapy had no effect 
on survival in patients with triple receptor negative breast cancer and diabetes.335 
However, people with human epidermal growth factor receptor 2 positive (HER2+) 
breast cancer and diabetes had improved survival if they were receiving a 
thiazolidinedione or metformin as glucose-lowering therapy when compared with 
people with diabetes who did not receive these medicines.336 An association between 
metformin use and survival following diagnosis with colorectal cancer in people with 
diabetes has been demonstrated in a meta-analysis by Mei and colleagues.337 
Improved survival has also been reported for the use of metformin in people with 
ovarian cancer in a separate meta-analysis by Kumar and colleagues (HR 2.2, 95% CI 
1.2–3.8).338  
 
2.3.4. All-cause mortality 
The UKPDS found that overweight patients receiving intensive treatment with 
metformin monotherapy had a lower risk of any diabetes-related endpoint, stroke or 
all-cause mortality when compared with intensive treatment with insulin or 
sulfonylureas.82 Retrospective observational studies using the CPRD have reported 
that, compared with metformin monotherapy, sulfonylurea monotherapy was 
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associated with an increased risk of all-cause mortality in type 2 diabetes.61,312 A 
retrospective cohort analysis using the Saskatchewan Health Administrative Databases 
in Canada found that, relative to sulfonylurea monotherapy, metformin monotherapy 
was associated with a lower risk of a composite endpoint defined as the first non-fatal 
hospitalisation or death (aHR 0.81; 0.68–0.97).339 Other observational data comparing 
sulfonylureas with metformin have also supported the observation that sulfonylureas 
are associated with a higher risk of mortality as a class,315,340,341 and glipizide, 
glimepiride, tolbutamide and glibenclamide specifically.342 Conversely, a retrospective 
study using data from Veterans Health Administration Diabetes Epidemiology Cohort 
found that the risk of all-cause mortality was not significantly different for metformin 
monotherapy and sulfonylurea monotherapy (adjusted OR 0.87, 95% CI 0.68–1.10).343 
In addition, a meta-analysis of available RCT data did not find that metformin had a 
statistically significant effect on all-cause mortality.310 However, as the authors 
concluded, short follow-up time (average 2.8 years) was a limitation of their meta-
analysis.310 
 
2.3.5. The concomitant use of metformin in people with type 2 diabetes 
treated with insulin 
Current ADA/EASD and IDF guidelines advocate that when starting insulin, it should be 
added to existing metformin therapy and not replace it.7 NICE recommends that 
insulin is added to existing metformin plus sulfonylurea treatment.55 
When used in conjunction with insulin, metformin has been associated with similar 
glucose control, but lower insulin doses and less weight gain.83 Results from a 
randomised trial of 58 patients with newly diagnosed type 2 diabetes showed that 
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HbA1c, weight gain and the number of hypoglycaemic events were similar for insulin 
plus metformin and triple therapy with metformin, pioglitazone and glibenclamide at 3 
years.344 
In addition, relative to the use of insulin alone, the use of metformin in combination 
with insulin has been associated with a reduced risk of cardiovascular events, cancer 
and death from any cause.61,62,345 Conversely, in a recent retrospective cohort study 
using data from the Veterans Health Administration, Medicare, and National Death 
Index databases, people who were initially treated with metformin and subsequently 
added either insulin or sulfonylurea were matched in a ratio of 1:5 using propensity 
score matching.346 Compared with adding a sulfonylurea to existing metformin 
therapy, the addition of insulin was found to be associated with an increased risk of a 
composite of non-fatal cardiovascular outcomes and all-cause mortality (aHR 1.30; 
95% CI 1.07–1.58; p=0.009).346  
 
2.4. Summary 
In terms of reducing cardiovascular risk, adequate control of blood pressure and lipids 
should be emphasised because they have been shown to play a more important role in 
terms of coronary heart disease and stroke prevention in comparison with blood 
glucose.347 
Many of the large RCTs have focussed on intensive versus convention glycaemic 
control rather than the comparison between different glucose-lowering drugs. ORIGIN 
is an exception to this and selected people with type 2 diabetes and a prior history of 
cardiovascular disease. Due to its size and length of follow-up, ORIGIN provides 
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important data on the effect of insulin glargine on the risk of cardiovascular outcomes. 
However, the patients selected had low HbA1c levels at baseline and were not 
generally representative of people who receive insulin in type 2 diabetes in the real 
world.80 There is a possible argument that the results of the observational studies may 
be due to residual confounding and it is difficult to fully remove this bias. Therefore, it 
is difficult to confirm or disprove any associations between insulin and cardiovascular 
risk from these studies alone. For example, insulin is more frequently prescribed to 
people with a longer duration of diabetes and more comorbid conditions.84 
There are several difficulties associated with carrying out and interpreting research 
studying possible associations between glucose-lowering therapies and cancer and 
cardiovascular events. It is common for patients to receive a combination of two or 
more medications for lowering blood-glucose, which can complicate investigations into 
the effect of individual glucose-lowering agents on cardiovascular or cancer risk. For 
example, in the ORIGIN trial, 11% of the standard group received insulin therapy and 
46.5% of the insulin glargine group also received metformin.80 In addition, cancer can 
typically take several years to develop, therefore adequate length of follow-up is 
required. Furthermore, when comparing two or more glucose-lowering therapies, it is 
difficult to know whether any increased risk associated with one agent is due to 
detrimental effects associated with the agent or positive effects associated with the 
active comparator. 
Due to the prevalence of diabetes, even a small increase in risk of cancer or 
cardiovascular disease in people with type 2 diabetes still has the potential to affect a 
large number of people at the population level. Appropriate management of type 2 
diabetes is required in order to minimise the risk of morbidity and mortality that is 
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associated with this condition. Here we have discussed the current literature 
investigating the relative risks and benefits associated with exogenous insulin. 
However, any potential risks associated with insulin therapy need to be seen in the 
context of the need to achieve good glucose control. For example, insulin is necessary 
for all people with type 1 diabetes and also some people with type 2 diabetes where 
management of hyperglycaemia resulting from progressive loss of beta cell function is 
required.84 In a review of the current evidence, the ADA and the American Cancer 
Society concluded that the risk of developing cancer should not play a major role in the 
selection of glucose-lowering medication for the management of type 2 diabetes but 
could be a consideration for people with a high risk of cancer occurrence or 
recurrence.84 However, the adoption of a healthy lifestyle including increased physical 
activity and weight management may lead to improved outcomes for people with type 
2 diabetes.84   
Diabetes is a complex disease where both risk factors associated with the condition, 
complications arising from the condition and the management of the condition can 
play an important role in the risk of cardiovascular events, cancer or death. ORIGIN 
provided some reassurance for the use of insulin in type 2 diabetes however, it was 
not specifically designed to investigate the safety of insulin. In the absence of further 
RCTs, well designed observational studies could provide more information on the 
safety of insulin in type 2 diabetes.  
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3. Overview of methods and datasets 
This thesis comprises a series of retrospective observational studies using data from 
CPRD and the Prescription Cost Analysis (PCA). This chapter discusses the advantages 
and disadvantages of the study design. In addition, the general methods and data 
sources used for this series of retrospective studies are described and discussed. 
However, the study methodology has been adapted to suit each study individually and 
is described in detail in each Chapter.  
 
3.1. Advantages and disadvantages of retrospective observational 
studies 
In terms of evidence based medicine, randomised, controlled trials (RCTs) and 
systematic reviews of RCTs occupy the highest levels in the hierarchy of evidence, 
whereas clinical observation and expert opinion occupy the lowest levels. 
Retrospective observational studies are found at an intermediate level.348 In 2011, the 
Oxford Centre for Evidence Medicine devised Levels of Evidence to replace the 
hierarchy following criticism of inflexibility in the use of the hierarchy.225 Observational 
studies are ranked at various levels in this table depending on the research question 
and the quality of the research.225   
Retrospective observational studies have numerous advantages. They are considerably 
cheaper to carry out than prospective studies and RCTs and samples sizes can be large. 
This facilitates the study of less common diseases. Data have already been collected 
therefore studies can be quick to carry out and long length of follow-up allows 
retrospective studies to be conducted for diseases with long latency periods. Risk 
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factors are recorded prior to the occurrence of outcome reducing bias. Multiple 
outcomes can also be examined in a single study. RCTs may have ethical implications 
e.g. when a treatment is withheld or an inferior treatment is given. Retrospective 
observational studies do not have these considerations. Recent literature has shown 
that observational studies and RCTs produce comparable results.349,350 Conversely, 
Ioannidis et al. found that differences in the estimated magnitude of treatment effects 
between randomised and non-randomised studies are common but there was good 
correlation between study types.240 Retrospective studies can be used to investigate 
rates of disease over time351 and data can be collected in a standardised way to allow 
comparisons to be made over time. The population studied may be more generalizable 
to the whole population and more likely to reflect general clinical practice than RCTs 
which often apply strict selection criteria.352 In addition, RCTs contain only those 
patients who have actively signed up for the study. Retrospective observational studies 
do not require individual patient consent, therefore this type of selection bias is 
avoided.352 In addition, the research question is unknown at the time data is collected 
therefore observer bias will be reduced. 
Retrospective observational studies are also associated with some disadvantages. 
Depending on the data source, there can be a cost for acquiring the data (e.g. CPRD). 
Patients are not randomised, therefore there is the potential for a type of bias known 
as confounding by indication, where the outcome may be related to the reason a 
treatment was selected for the patient and not the treatment itself. Statistical 
methods can be used to correct for known confounders, however unknown 
confounders cannot be accounted for.353 Therefore, retrospective observational 
studies generally can only demonstrate associations whereas cause and effect should 
be ideally measured using RCTs. However Sir Austin Bradford Hill listed certain criteria 
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which, if met, could allow causation to be inferred between a risk factor and an 
outcome in observational studies.354 Depending on the data source, data may be 
collected for a purpose other than research and the researcher has limited or no 
control over data collection. Therefore, data may be incomplete, inconsistently 
recorded or inaccurate.351 In addition, missing data may not be missing completely at 
random. Observational studies do not automatically control for selection bias. 
Consequently statistical methods are required to overcome differences in baseline 
characteristics, e.g. matching, co-variance adjustment or stratification.352 Bias can also 
occur if the sample studied is not representative of the population as a whole. Unlike 
RCTs, blinding cannot be achieved using retrospective observational data. Patients and 
physicians and those assessing the outcome are aware of the nature of the treatment 
prescribed.  
The advantages and disadvantages relating to CPRD and PCA specifically are described 
in detail in sections 2.21 and 2.22. 
 
3.2. Data sources 
3.2.1. Clinical Practice Research Datalink (CPRD) 
3.2.1.1. History 
The data source used for this series of studies was CPRD.355 The database was 
established as a commercial venture in 1987 and was known as Value Added Medicinal 
Products (VAMP).356,357 In addition to providing a tool to allow general practitioners 
(GPs) to record relevant clinical information, data was also anonymised and used for 
public health research. In 1993, VAMP Ltd. was acquired by Reuters who subsequently 
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donated the database to the Department of Health in 1994 and the database was 
renamed as GPRD and operated on a not-for-profit basis.356 Under the control of the 
Medicines and Healthcare products Regulatory Agency (MHRA), the database was 
further renamed in 2012 and is now known as CPRD.358 The aim of CPRD is to combine 
the expertise of GPRD and the Department of Health’s National Institute for Health 
Research (NIHR) Research Capability Programme in order to enable researchers to 
utilise the power of large linked datasets.358 To date, more than 800 scientific articles 
based on CPRD and its predecessors have been published.359 In addition, numerous 
papers have been published that have utilised CPRD to study type 2 diabetes.360 
 
3.2.1.2. Description of the database 
CPRD’s primary care dataset is called CPRD GP Online Data (GOLD). CPRD GOLD 
contains clinically rich, pseudonymised data collected in a non-interventional manner 
from the daily record-keeping of primary-care physicians in the UK. The following 
patient information is recorded by GPs using the Vision software and is therefore 
available in CPRD GOLD: 
 Patient demographics (for confidentiality reasons, patients are attributed a 
unique patient identifier and only their year of birth is provided) 
 Signs, symptoms and diagnoses (recorded using Read codes) 
 Primary care prescriptions for medicines and devices 
 Immunisations 
 Results of investigations 
 Referrals to specialists and secondary care 
 Feedback from other care settings e.g. discharge summaries 
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 Lifestyle information such as BMI, smoking, alcohol consumption and exercise 
By September 2013, CPRD GOLD contained over 13 million research quality patients 
registered at 678 GP practices.  
 
3.2.1.3. Structure of the database 
The data was provided by CPRD as flat text files and included the following data files: 
 Practice details 
 Patient details 
 Consultations 
 Staff 
 Clinical 
 Therapy 
 Referrals 
 Tests 
 Immunisations 
Data files are linked by a unique individual patient identifier. 
 
3.2.1.4. Data linkages 
For a proportion of English practices, primary care records have been linked to the NHS 
Hospital Episode Statistics (HES) data set.361 As a result, details of inpatient admissions 
are also provided for those patients with a linked HES record. Diagnostic data in HES 
are recorded as International Classification of Diseases ICD-10 codes. Although only 
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linked HES data has been utilised in this series of studies, the following linked datasets 
are also available: 
 Death data from Office for National Statistics (ONS) mortality data 
 Cancer registry data from the National Cancer Intelligence Network (NCIN)  
 Cardiovascular registry data from the Myocardial Ischaemia National Audit 
Project (MINAP) 
 Socioeconomic data from the patient Lower Super Output Area (LSOA)361 
Patient characteristics have been shown to be similar in linked and unlinked 
practices.362 
 
3.2.1.5. Strengths and weaknesses 
CPRD GOLD data are collected in all four UK regions (England, Scotland Northern 
Ireland and Wales) and is representative of the population in terms of crude 
mortality.363,364 However, age-standardised mortality rates are 9–13% lower than the 
national average, which has been attributed to a healthy user bias and the exclusion of 
people with no exact date of death.364 The age and gender structure of CPRD GOLD is 
similar to the UK population but the size of registered practices are larger than 
average.364,365 In addition, CPRD contains a higher proportion of people living in 
Scotland, Wales and Northern Ireland and a smaller proportion of people living in 
England when compared with the UK population.365 CPRD GOLD is also a very large 
longitudinal dataset which allows even relatively rare conditions to be studied with 
adequate statistical power.366 Khan and colleagues conducted a systematic review for 
40 papers investigating the validity of diagnostic coding in GPRD and reported that the 
positive predictive value for most conditions investigated was more than 50% and 14 
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of the conditions investigated had a positive predictive value of more than 90%.367 
However, rates of diabetes and musculoskeletal conditions were underestimated in 
GPRD.367 In a more recently conducted systematic review by Herrett and colleagues, 
212 papers, each validating at least one diagnosis, were identified and the median 
proportion of cases with a confirmed diagnosis was 89% (range 24–100%).368 
Furthermore, Jick and colleagues evaluated 58 practices and found that 87% of 
patients who had a clinical diagnosis recorded in a consultant letter kept in general 
practitioners’ files also had a recorded diagnosis within their computer record.369 A 
follow-up study evaluated a further 35 practices and reported that the information in 
consultant letters was recorded on the computer in 96% of instances.370 
Prescriptions are generally computer generated and recorded simultaneously, 
improving the quality of the prescription data stored in the therapy table in CPRD.  
On receipt of the data from the contributing practices, the data is checked to ensure it 
is of adequate quality. However, as an observational dataset, the quality of the data in 
CPRD GOLD is reliant upon the accuracy of the data inputted at practice level. 
Therefore recording guidelines are provided to contributing practices to ensure that 
the data quality is as high as possible.361 In addition, once the data has been uploaded 
to CPRD, reports are sent to the practices to provide feedback.356 Inconsistencies and 
deficiencies are highlighted by CPRD and instructions and support are provided in 
order to help correct any issues.361 If these issues are not addressed by the practice, 
their data are no longer included in the dataset.361 In addition, data of questionable 
quality is flagged so that it is easily identifiable to the researcher.361  
The quality of the data stored in CPRD GOLD has improved over time. In particular, the 
introduction of the QOF as part of the new General Medical Services (GMS) Contract 
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on 1st April 2004371 has led to an improvement in data recording at practice level 
across the UK.372 QOF has incentivised practices to achieve high standards of data 
recording. The proposed implementation of a single linked NHS computer system of 
electronic patient health records (National Programme for Information Technology, 
NPfIT) may also encourage improved data completeness.372 
CPRD utilises a process that identifies patients who have non-continuous follow-up or 
poor data quality.356,361 Patients are identified as unacceptable if they meet one or 
more of the criteria described in Table 3.1.356,359,361 Patients without these issues are of 
satisfactory research quality and are flagged as acceptable in the database and account 
for approximately 88% of patients.359 
 
Table 3.1 Criteria implemented by CPRD to flag patients as unacceptable 
Data item Unacceptable value 
First registration date Empty or invalid 
Prior to year of birth 
Year of birth Missing 
Transferred out reason Missing 
Transferred out date Missing 
Prior to first registration date 
Prior to current registration date 
Current registration date Prior to first registration date 
Prior to year of birth 
Gender Not recorded as male, female or 
indeterminate 
Age >115 years at end of follow-up 
Healthcare episodes Records prior to year of birth 
Registration status Temporary 
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The overall quality of the data from contributing practices is also evaluated to ensure 
adequate continuity in data recording and avoidance of the use of data for which 
transferred out and dead patients have been removed.359,361 For practices whose data 
is an acceptable quality, an up-to-standard date is applied. This date corresponds to 
the date at which the practice is considered to have been supplying continuous high 
quality data suitable for research use and is updated each time the practice 
contributes new data to the database.361  
Data is continually being collected and added to CPRD GOLD and therefore the data 
used for this series of studies is up to date. Also as data continues to be collected, the 
database can be used to assess trends over time by the repeat application of the same 
methods. 
Although CPRD GOLD is a primary care database, due to the role of the GP in the NHS, 
some secondary data is still recorded. In the UK the GP acts as a gatekeeper and refers 
patients to specialist or secondary care when necessary and receives feedback in the 
form of discharge summaries and outpatient letters from secondary care. This 
information is recorded in CPRD GOLD. However, prior to 2002, communication from 
secondary care and test results were not received electronically and had to be entered 
onto the computer manually.366 Therefore, information before this date may not be 
complete. 
Data are recorded by the GP routinely as part of the normal course of care where the 
aim of the GP is not to produce a complete database resource for public health 
research but to record the information that in his or her opinion is important in terms 
of the overall on-going clinical care of the patient. For example, a GP may be more 
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likely to record a patient’s weight if they are obese and suffering from type 2 diabetes 
than if they were of normal weight and healthy.  
CPRD GOLD will not contain any data for prescriptions issued in secondary care or 
records for the purchase of over the counter medicines. Therefore, information on 
medications prescribed exclusively in secondary care may be sparse. In addition 
prescriptions recorded in the therapy table in CPRD only indicate what has been 
prescribed to a patient and not what has been dispensed and consumed by the 
patient. In addition, CPRD GOLD does not routinely contain information on occupation, 
employment and socioeconomic status (except in the linked datasets).366 
Although a patient may have a follow-up period from the start of the database in 1987 
to the present day, this unlikely to be the case for the majority of patients due to a 
propensity for patients to change practice and the high turnover of participating 
practices during the lifetime of the database.  
A recent systematic review by Herrett and colleagues reported on 357 validations of 
183 different diagnoses.368 However, there are still many diagnoses that have not been 
verified. In addition, diagnoses for conditions that have occurred prior to a patient’s 
CPRD registration date may not be present if they are no longer suffering from the 
condition.366 GPs have the option of recording uncoded comments as free text but this 
data is not routinely provided as part of the CPRD GOLD dataset. These free text fields 
could contain information from hospital discharge summaries, outpatient letters or 
more information on symptoms and diagnoses. However, analysing free text fields can 
be challenging and obtaining this data incurs an extra financial cost.  
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3.2.1.6. Ethical approval 
GPRD was granted a blanket ethical approval by the Multicentre Research Ethics 
Committee (MREC) in 2006 for studies that are purely observational in nature. This 
approval has since been extended to cover observational studies utilising external data 
linkages with e.g. HES. However, study protocols need to be submitted to and 
approved by the Independent Scientific Advisory Committee (ISAC) if results are to be 
published or disseminated to a third party.  
 
3.2.1.7. Data management 
Sara Jenkins-Jones is the data manager for the CPRD flat files and administers the 
linked CPRD primary care and HES data sets. She has created procedures to clean and 
dimensionalize the data for high-performance access, and bespoke tools to facilitate 
analysis and improve reproducibility.  
 
3.2.1.8. Selection criteria 
Despite the advantages of using CPRD GOLD as a data source, the selection of people 
with type 2 diabetes in CPRD is challenging due to the presence of non-specific 
diagnosis codes, conflicting diagnoses, diagnoses that conflict with prescribed glucose-
lowering therapies and also missing diagnoses or prescription history.  
For this series of retrospective cohort studies, a series of decision rules will be 
implemented in order to select diabetes cases. These decision rules are based on a 
combination of both prescription history and diagnoses. The diagnoses were taken 
from the clinical table and HES, which are the more reliable sources in CPRD.  Where 
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applicable, a wash-in was applied to ensure that only incident cases were selected and 
followed-up. The wash-in was applied to the later of a patient’s current registration 
date or the practice up-to-standard date and only acceptable patients were used in 
order to ensure that the standard of the data used was as high as possible.  
Each study required different selection criteria depending on the study aim. For 
example, studies investigating a possible association between insulin exposure and the 
risk of all-cause mortality, MACE and cancer in people with type 2 diabetes require 
relatively strict criteria for the selection of cases in order to have the best certainty 
that the cases selected have the condition you wish to investigate. CPRD GOLD is a 
large database and therefore the loss of some cases that are more uncertain would 
still allow sufficient power for detecting the association. For prevalence and incidence 
studies, the study criteria may be more relaxed to ensure a more accurate estimate of 
the epidemiology of diabetes in the general population. However, even then, the 
selection criteria can vary between studies. For example, the prevalence of insulin use 
and prevalence of diabetes studies had two different starting points. The prevalence of 
insulin studies started by selecting people with insulin prescriptions and then 
categorised these patients where possible into people with type 1 and type 2 diabetes. 
The prevalence of diabetes study however first selected people with diabetes.  
 
3.2.1.9. Definition of drug exposure 
CohortGenerator is an in-house software application developed by Sara Jenkins-Jones 
and was used to determine the periods of exposure to one or more glucose-lowering 
therapies for this series of studies. It is useful for cohort studies with complex drug 
histories where glucose-lowering agents including insulin can be used singly or in 
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combination, which frequently occurs in the management of type 2 diabetes. The 
software application allows the composition and duration of combination therapies to 
be determined by identifying cohesive, overlapping periods for the component drugs. 
Combination therapies were identified using an algorithm that identifies the first 
therapy (in start date order) and any augmenting therapy (a therapy with a start date 
within the duration of the first therapy). In order to be classed as a combination 
therapy, the component therapies must overlap by a period defined as the shorter of 
30 days or the average interval between that patient’s prescriptions for those 
therapies. The start of the combination therapy was taken as the start date of the 
augmenting therapy. The end of the combination therapy exposure period was defined 
as the earlier of the last prescription dates for the component therapies. Each patient’s 
prescription history was therefore resolved into a sequence of discrete monotherapies 
or combination therapies of interest and assigned a quality score based on duration, 
prescription frequency, gaps in the prescription history, and the ratios of prescriptions 
for each component in a combination therapy.  
 
3.2.1.10. Definition of baseline characteristics and model covariates 
3.2.1.10.1. Duration of diabetes 
The true duration of type 2 diabetes cannot be determined from CPRD GOLD as the 
symptoms of type 2 diabetes can be mild, especially in the initial stages, and the 
condition can remain undiagnosed for several years.17 Therefore the duration of 
diagnosed diabetes was used as an estimation of the degree of disease severity. The 
duration of diagnosed diabetes at baseline was calculated as the number of days 
between the diabetes presentation date and the study index date. The diabetes 
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presentation date is defined as the earlier of the first recorded diabetes diagnosis or 
the first prescription for a glucose-lowering therapy. 
 
3.2.1.10.2. Smoking status 
Subjects were characterised as current smokers, ex-smokers or non-smokers. The most 
recently recorded smoking status prior to index date was used. As part of the data 
cleaning process when a new cut of data is received from CPRD, people who have 
previously been recorded as a current smoker and then subsequently received a code 
for a non-smoker are characterised as an ex-smoker. 
In a validation study carried out by Booth and colleagues, the prevalence of smoking 
and non-smoking estimated using data from CPRD has been shown to be similar to 
that reported by the Health Survey For England 2007 to 2011, whereas the prevalence 
of former smoking was found to be underestimated in CPRD.373 
 
3.2.1.10.3. Comorbidity 
Several measures of comorbidity were used as covariates in the extended Cox model. 
The Charlson comorbidity index is a weighted index devised to take into account the 
number and severity of comorbid conditions that may influence the risk of all-cause 
mortality.374 The number of GP contacts recorded in the year prior was used as an 
alternative measure of comorbidity. 
A history of comorbid conditions including prior cancer or cardiovascular disease and a 
history of concomitant medications suggestive of cardiovascular disease were also 
used as covariates in survival modelling. A diagnosis of cancer or cardiovascular 
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disease or a prescription for antiplatelet, antihypertensive or lipid-lowering therapy 
recorded prior to the index date was used to identify a prior history of these conditions 
or concomitant medications.  
 
3.2.1.10.4. Test results 
HbA1c, as a measure of glucose control, was used as a covariate in the survival models. 
HbA1c results were identified for the study population from the test table. HbA1c at 
baseline was defined as the nearest record within 365 days before and 30 days after 
insulin initiation, searching in the following order 30 days prior, 30 days after then 365 
days prior to the index date. BMI, baseline serum creatinine, systolic blood pressure 
and total cholesterol were identified using the same search criteria. 
 
3.2.1.11. Clinical endpoints 
All-cause mortality, cancer and MACE were used as endpoints. For all-cause mortality, 
patients were followed up from their index date to their date of death as recorded in 
the currently held with a patient’s registration details in CPRD. MACE was defined as 
myocardial infarction, stroke or cardiovascular death and patients were followed up 
from their index date to the date of their first event of interest. Cancer was defined as 
all cancers except for non-melanoma skin cancer. 
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3.2.2. Prescription cost analyses 
3.2.2.1. Description of the data 
The PCA provides details on the number and cost of items dispensed by community 
pharmacies, appliance contractors and dispensing doctors and submitted to the 
relevant authority for pricing and reimbursement. They are published for each region 
of the UK (England,375 Northern Ireland,376 Scotland,377 and Wales378) . Although, the 
data reported relates to the prescriptions dispensed by community pharmacies within 
that region and not to the location of the GP practice. The PCA includes dental, 
hospital, nurse and prison prescriptions dispensed in the community but items 
dispensed by hospitals or prisons are not included. The data relates to NHS 
prescriptions only, therefore private prescriptions are also not included. PCAs are 
published at intervals varying from monthly to yearly.  Although there are some 
variations in the information provided by each region and over time, each region 
provides data for individual preparations, which are then categorised using the BNF 
hierarchy.  
 
3.2.2.2. Strengths and weaknesses 
The PCA can be used to detect trends over time provided the rate of inflation is 
adequately accounted for. In addition, the PCA is available for all four regions of the UK 
and has good coverage for GP practices. Once the data from the four regions has been 
combined, prescriptions issued in one region and dispensed in another will still be 
captured. 
However, the PCA does not include prescriptions dispensed in hospital and is therefore 
not suitable for some medications that are largely dispensed in hospital pharmacies, 
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e.g. biologics and chemotherapy. Patient level data is also not provided. In addition the 
period of time covered by each dataset varies by UK region, Scotland provides data by 
financial year and Wales and Northern Ireland provides data by calendar year. 
 
3.2.2.3. Data management 
For each individual PCA dataset (for a given time period and UK region), the headings 
of the columns were standardised. This included the standardization of the units (some 
PCAs reported their figures in thousands and others in individual units). The individual 
datasets were then combined using Microsoft Access to provide data for all four 
regions of the UK for the duration of the study period. 
 
3.2.3. Population estimates from the Office for National Statistics 
Population estimates are compiled by the ONS.379 Estimates are based on the resident 
population of the UK and are provided by year of age, gender and region of the UK. 
The estimates are developed using several data sources and statistical models.379 The 
mid-year estimates refer to the size of the population on the 30th June each year.379 
ONS produces estimates for England and Wales. The National Records of Scotland 
(NRS) and Northern Ireland Statistics & Research Agency (NISRA) produce estimates 
for Scotland and Northern Ireland, respectively. ONS then compiles and publishes the 
estimates for the UK as a whole.379 
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3.2.3.1. Strengths and weaknesses 
Data are free to access and are available for each UK region. Estimates are provided by 
age and gender, which are useful to allow multiplication by age and sex stratified 
prevalence rates in order to calculate the number of people with a condition at the 
population level.   
 
3.2.3.2. Data management  
Data sets for males, females and people overall were combined into one large dataset 
using Microsoft Access. 
 
3.2.4. Other UK databases 
Other UK based primary care databases exist, for example not-for-profit databases, 
such as QRESEARCH380 and DIN-Link381, and commercial databases, such as THIN382 and 
UK IMS disease analyser. These databases may have also provided suitable data to 
address the thesis objectives. However, as the largest validated and most widely used 
primary care database in the UK, CPRD was an appropriate choice for this series of 
studies.359 
 
3.3. Statistical methods 
3.3.1. Software 
All statistical analyses were carried out using SPSS PASW Statistics (versions 18 to 20) 
and R.383 
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3.3.2. Incidence and prevalence rates 
95% confidence intervals were calculated to provide a range of values around a 
prevalence or incidence rate that is believed to contain with 95% probability the true 
population value for the statistic. 95% Confidence intervals for incidence were 
calculated using the Byar approximation method. This is an adequately accurate 
approximation to the Poisson probabilities without the need for exact results.384 For 
prevalence rates, Wilson (or score) confidence intervals were calculated.385 This 
method is preferred to the asymptotic method but remains relatively easy to 
calculate.385  
 
3.3.3. Baseline Characteristics 
Mean (with the corresponding standard deviation (SD)) and median (with the 
corresponding interquartile range) are provided to describe the baseline 
characteristics depending on their distribution. In order to determine if there are 
statistically significant differences in the baseline characteristics between groups, 
baseline characteristics were compared where appropriate using the chi-squared test 
for categorical variables and one-way analysis of variance (ANOVA) or Kruskal–Wallis 
test for continuous variables (depending on the distribution of the parameter) and p-
values provided. When a one-way ANOVA was carried out, Levene’s test was 
employed to test for homogeneity of variances. If the assumption of homogeneity of 
variances had been violated, Welch’s F was used. Both the Brown and Forsythe F-ratio 
and Welch’s F are robust when homogeneity of variance has been broken. However, in 
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terms of power, Welch’s F is preferred except when there is an extreme mean with a 
large variance.386 
 
3.3.4. Survival analysis 
As a means of analysing censored data, time to each endpoint was evaluated using Cox 
proportional hazards modelling. The Cox proportional hazards model can be 
conducted using SPSS and is a semi-parametric model where the distribution of the 
outcome and the baseline hazard are not specified.387 Therefore, the Cox model is a 
popular alternative to parametric survival modelling. However, it is important to check 
that the proportional hazards assumption is met. The proportional hazards assumption 
was tested by examining the Pearson correlation between Schoenfeld residuals and 
the rank of survival time for cases that had progressed to death.387 In addition, the Cox 
proportional hazards model can be extended to incorporate time-dependent 
covariates.387 Interactions with time were used to assess the proportional hazards 
assumption of the extended Cox model. All covariates identified a priori were included 
in the final Cox model. 
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4. Incidence of type 2 diabetes in the UK between 1991 and 
2010 
This is the accepted version of the following article: Holden SE, Barnett AH, Peters JR, 
Jenkins-Jones S, Poole CD, Morgan CL, Currie CJ. The incidence of type 2 diabetes in 
the United Kingdom from 1991 to 2010. Diabetes Obes Metab 2013;15:844-52. doi: 
10.1111/dom.12123., which has been published in final form at 
[http://onlinelibrary.wiley.com/doi/10.1111/dom.12123/abstract]. Deviations from 
the published version of this manuscript are underlined. 
 
4.1. Introduction 
4.1.1. Background 
The incidence and prevalence of type 2 diabetes has been increasing in the UK.9 
Although the cause of type 2 diabetes is multi-factorial, it is largely related to obesity 
and physical inactivity.8 There has been an increase in the prevalence of type 2 
diabetes in children and adolescents, which is thought to be dependent on many 
factors such as obesity, diet, family history of diabetes, ethnicity, sedentary lifestyle, 
earlier onset of puberty, low birth weight and exposure to diabetes in utero.388–392  
Studies in the UK secondary care population and the USA have shown that the age of 
diagnosis of type 2 diabetes has decreased over time.393,394 Early onset type 2 diabetes 
will result in afflicted people living a larger proportion of their lives exposed to the 
toxicity of dysglycaemia, such that their complications could conceivably more reflect 
those of people with type 1 diabetes; for example, increased rates of microvascular 
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complications. The onset of type 2 diabetes prior to the age of 45 is an independent 
risk factor in the development of retinopathy after matching on diabetes duration and 
adjusting for traditional risk factors such as glycaemic control and hypertension.395  In 
addition, youth onset type 2 diabetes in Pima Indians aged less than 20 years at 
diagnosis was associated with an increased incidence of end stage renal disease and 
mortality in middle age compared with older onset diabetes.396 In terms of 
cardiovascular risk, early onset type 2 diabetes may constitute a more aggressive 
disease where, compared with non-diabetic controls, early onset type 2 diabetes (<45 
years at diagnosis) has been associated with twice the risk of macrovascular 
complications when compared to usual onset type 2 diabetes (HR 7.9 versus 3.8).397 
 
4.1.2. Aims and objectives 
This study aimed to characterise the incidence of diabetes over the past 20 years in the 
UK population. We also aimed to determine if there has been an increase in the 
proportion of people diagnosed with diabetes who were young.  
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4.2. Methods 
4.2.1. CPRD 
Patients with type 2 diabetes were identified in the CPRD. CPRD contains clinically rich 
data that are collected in a non-interventional way from the daily record-keeping of 
primary care physicians in the UK. These pseudonymised data include patient 
demographics and medical history, including diagnoses, test results and prescriptions. 
The data extract used for this study comprised records up to June 2011 and contained 
143 million patient years of computerised data of acceptable quality for research 
purposes. CPRD checks the data to ensure it is of an acceptable standard and over 550 
peer reviewed studies using CPRD have been published.1 Ethical approval for this study 
was granted by the CPRD ISAC on 23/02/2012, protocol number 12_019R. 
 
4.2.2. Selection Criteria 
Included patients had to be newly diagnosed with type 2 diabetes between 1991 and 
2010, inclusively. Patients were attributed a diagnosis of type 2 diabetes if they met 
one of the following criteria: 
1. A diagnosis of type 2 diabetes and a prescription for a glucose lowering medicine 
excluding insulin 
2. Diagnoses for type 1 or type 2 diabetes or diabetes where type not specified and 
prescriptions for more than one type of glucose-lowering medicine excluding insulin 
3. A diagnosis of type 2 diabetes, no diagnosis of type 1 diabetes, no prescription for 
exogenous insulin or a glucose-lowering medicine other than insulin 
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4. A diagnosis of type 2 diabetes, no diagnosis of type 1 diabetes, a prescription for a 
glucose-lowering medicine but no prescription for insulin 
5. A prescription for glucose biosensor strips and a medication(s) used for diabetes but 
no diagnosis of diabetes and no prescription for insulin 
6. A diagnosis for type 2 diabetes, a diagnosis of type 1 diabetes but no prescription for  
insulin 
7. A diagnosis of diabetes (type not specified) but no prescription for insulin. 
Criteria 1, 3 and 4 include no conflicting diagnoses. Criteria 2 uses conflicting diagnoses 
but is based on the assumption that the use of at least two different OHAs confirms 
the type 2 diagnosis. Criteria 5, 6 and 7 are included as patients not treated with 
insulin cannot have type 1 diabetes. 
 
4.2.3. Incidence of type 2 diabetes 
The incident date of diabetes was taken as the earlier of either the date of diagnosis of 
diabetes or the date of the first diabetes-related prescription (glucose biosensor strip, 
OHA or insulin). Cases also had a minimum ‘wash-in’ period of one year between the 
incident date and the later of the patient registration date and practice up-to-standard 
date. 
Patient data were categorised into five-year intervals by year of diagnosis and age at 
diagnosis. The percentage of all newly diagnosed patients in each age group was 
calculated by dividing the number of patients diagnosed in each age group per five-
year calendar period by the total number of patients diagnosed in the same relevant 
five-year calendar period. The percentage of patients ≤40 years at diagnosis was 
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calculated in a similar way. Incidence rates were calculated yearly and by age group 
and five-year calendar period by dividing the number of incident cases by the number 
of person-years of the at risk population (without diabetes) in CPRD for the same 
calendar year and age group where applicable. Patients were included in the person-
years estimate (denominator) from one year following the later of the up-to-standard 
date or the practice date until the earliest of their death date, date transferred out of 
practice or incident date of diabetes (patients need not necessarily have had contact 
with their general practice to be included). Incidence was compared within age groups 
over time by calculating an age-and-sex-stratified standardised incidence ratio (SIR), 
akin to a standardised mortality rate (SMR). 
 
4.2.4. Statistical analysis 
Statistical analyses were carried out using SPSS-18 and R.383 Changes in SIRs were 
compared by means of the Byar approximation Poisson method.398 Baseline 
characteristics were compared between five-year calendar periods using Mantel-
Haenszel linear-by-linear chi-squared test for categorical variables and one-way 
ANOVA or Kruskal-Wallis test for continuous variables, depending on their distribution. 
Levene’s test was employed to test for homogeneity of variances. If the assumption of 
homogeneity of variances had been violated and group sizes were unequal, Welch's F 
was used.  Differences between five-year calendar periods were explored using 
Games-Howell procedure, which can be used when population variances and sample 
sizes differ. Kendall’s tau-b was used to determine if there was a significant association 
between percentage diagnosed and five-year calendar period. Confidence intervals for 
incidence rates were calculated using the Byar approximation method and for 
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proportions using mid-P conﬁdence interval adaptation of the Clopper-Pearson 
interval.  
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4.3. Results 
4.3.1. Baseline Characteristics 
Baseline characteristics by year and age group at diagnosis are detailed in (Table 4.1). 
In each five-year calendar period, slightly more newly diagnosed patients were female 
and more patients>40 were male. For people aged ≤40 at diagnosis, BMI changed from 
a mean (SD) of 32.2 kg/m2 (7.7 kg/m2) in 1991–1995 to 31.6 kg/m2 (7.6 kg/m2) in 
1996–2000 (p=0.649), 32.6 kg/m2 (7.7 kg/m2) in 2001–2005 (p=0.003) and 30.8 kg/m2 
(8.0kg/m2) in 2006–2010 (p<0.001). For people >40 at diagnosis, mean BMI increased 
with each successive five-year calendar period from a mean of 29.2 kg/m2 (5.3 kg/m2) 
in 1991–1995 to 30.8 kg/m2 (6.1 kg/m2) in 2006–2010 (p<0.001). 
For patients aged ≤40 years at diagnosis, mean (SD) HbA1c at baseline was 8.3% (3.0%) 
in 1991–1995, decreasing to 6.1% (2.2%) in 1996–2000 (p<0.001) before increasing to 
6.7% (2.5%) in 2001–2005 (p<0.001) and 7.4% (2.6%) in 2006–2010 (p<0.001). For 
patients aged >40 years at diagnosis HbA1c was 9.0% (2.9%) in 1991–1995, decreasing 
to 7.6% (2.6%) in 1996–2000 (p<0.001), 7.5% (2.3%) in 2001–2005 (p<0.001) and 7.5% 
(2.2%) in 2006–2010 (p=0.776). Mean systolic and diastolic blood pressure and total 
cholesterol levels decreased in each five-year calendar period between 1991 and 2010 
for patients aged >40 at diagnosis. For patients ≤40 at diagnosis, systolic and diastolic 
blood pressure and total cholesterol were lower in 2006–2010 than any other year. 
The number of GP contacts—an indicator of general morbidity—in the year prior to 
diagnosis of type 2 diabetes increased during the study period from a median 
(interquartile range, IQR) of 5.0 (2.0–9.0) and 6.0 (3.0–11.0) contacts in 1991–1995 to 
7.0 (3.0–12.0, p<0.001) and 8.0 (4.0–15.0, p<0.001) contacts in 2006–2010 for patients 
aged ≤40 and >40 at diagnosis, respectively. The time to first drug treatment for type 2 
   
 115 
diabetes following diagnosis decreased from a median (IQR) of 0.4 (0.0–3.2) and 0.5 
(0.0–3.1) years in 1991–1995 to 0.0 (0.0–0.3, p<0.001) and 0.1 (0.0–0.6, p<0.001) years 
in 2006–2010 for patients aged ≤40 and >40 at diagnosis, respectively. There was no 
change in the median score for the adjusted Charlson morbidity index during the study 
period for patients aged ≤40 years at diagnosis and decreased from 4.0 (3.0–5.0) in 
1991–1995 to 3.0 (2.0–5.0) in 1996–2000, 2001–2005 and 2006–2010 for patients 
aged >40 at diagnosis. More patients had suffered from conditions that could be 
associated with a complication of diabetes prior to their diagnosis of type 2 diabetes in 
increasing five–year calendar periods and there was a significant difference between 
groups for coronary heart disease (p<0.001), cerebrovascular disease (p<0.001), 
diabetic foot and peripheral vascular disease (p<0.001), eye-related complications 
(p<0.001) and end stage renal disease (p<0.001) for patients aged >40 at diagnosis. 
 
4.3.2. Standardized incidence ratio 
The SIR increased within each five-year calendar period from 1991–1995 (SIR=100) to 
158 (CI 157–160, p<0.001), 237 (235–238, p<0.001) and 275 (273–276, p<0.001), 
respectively (Table 4.2). For those aged 40 years and under, the respective SIRs were 
217 (209–226, p<0.001), 327 (320–335, p<0.001) and 598 (589–608, p<0.001). 
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Table 4.1  Baseline characteristics for patients diagnosed with type 2 diabetes before and after 40 years of age 
Parameter 1991–1995 1996–2000 2001–2005 2006–2010 p-value 
 ≤40 >40 ≤40 >40 ≤40 >40 ≤40 >40 ≤40 >40 
N 642 10,241 2,752 29,846 7,519 81,324 15,326 108,621   
Males, n (%) 312 (49%) 5,404 (53%) 1,233 (45%) 15,613 (52%) 3,397 (45%) 42,452 (52%) 6,546 (43%) 56,925 (52%) <0.001 0.987 
Age (years), mean (SD) 32.5 (7.4) 66.0 (11.8) 30.9 (8.6) 65.3 (12.1) 31.1 (8.5) 65.1 (12.1) 29.4 (9.4) 64.2 (12.6) <0.001 <0.001 
Smoking status, n (%) 438 (68%) 7,016 (69%) 2,094 (76%) 25,329 (85%) 6,154 (82%) 74,601 (92%) 13,477 (88%) 106,938 (98%) 0.159 <0.001 
Non-smoker, n (%) 266 (61%) 4,320 (62%) 1,185 (57%) 13,835 (55%) 3,195 (52%) 33,704 (45%) 7,069 (52%) 44,701 (42%)   
Ex-smoker, n (%) 49 (11%) 1,174 (17%) 206 (10%) 5,859 (23%) 889 (14%) 25,664 (34%) 2,639 (20%) 43,431 (41%)   
Current smoker, n (%) 123 (28%) 1,522 (22%) 703 (34%) 5,635 (22%) 2,070 (34%) 15,233 (20%) 3,769 (28%) 18,806 (18%)   
HbA1c, %           
n (%) 57 (9%) 973 (10%) 1,327 (48%) 10,941 (37%) 3,879 (52%) 41,732 (51%) 4,372 (29%) 51,103 (47%)   
mean (SD) 8.3 (3.0) 9.0 (2.9) 6.1 (2.2) 7.6 (2.6) 6.7 (2.5) 7.5 (2.3) 7.4 (2.6) 7.5 (2.2) <0.001 <0.001 
BMI (kg/m2)           
n (%) 244 (38%) 4,367 (43%) 888 (32%) 12,836 (43%) 3,275 (44%) 46,774 (58%) 7,103 (46%) 70,298 (65%)   
Mean (SD) 32.2 (7.7) 29.2 (5.3) 31.6 (7.6) 29.9 (5.7) 32.6 (7.7) 30.5 (5.8) 30.8 (8.0) 30.8 (6.1) <0.001 <0.001 
Weight: males (kg)           
n (%) 128 (41%) 2,511 (46%) 437 (35%) 7,265 (47%) 1,559 (46%) 25,624 (60%) 3,080 (47%) 38,687 (68%)   
mean (SD) 95.8 (22.5) 86.5 (15.8) 97.5 (25.6) 89.5 (17.1) 100.1 (26.7) 91.7 (17.7) 96.3 (28.3) 93.6 (18.9) <0.001 <0.001 
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Parameter 
 
1991–1995 1996–2000 2001–2005 2006–2010 p-value 
≤40 >40 ≤40 >40 ≤40 >40 ≤40 >40 ≤40 >40 
Weight: females (kg)           
n (%) 120 (36%) 2,040 (42%) 505 (33%) 6,021 (42%) 1,839 (45%) 21,914 (56%) 4,312 (49%) 32,269 (62%)   
mean (SD) 86.3 (22.3) 76.1 (16.3) 83.2 (22.8) 77.7 (17.5) 87.4 (23.8) 79.2 (17.8) 80.3 (24.6) 79.7 (18.8) <0.001 <0.001 
Time to 1st treatment (years):         <0.001 <0.001 
mean (SD) 2.2 (3.4) 2.0 (3.0) 1.7 (2.5) 1.7 (2.4) 1.0 (1.7) 1.4 (2.0) 0.3 (0.7) 0.5 (0.9)   
median (IQR) 0.4 (0.0–3.2) 0.5 (0.0–3.1) 0.4 (0.0–2.4) 0.5 (0.0–2.6) 0.1 (0.0–1.2) 0.4 (0.0–2.3) 0.0 (0.0–0.3) 0.1 (0.0–0.6)   
BP           
n (%) 309 (48%) 6,241 (61%) 1,335 (49%) 19,765 (66%) 4,543 (60%) 68,199 (84%) 8,962 (58%) 93,307 (86%)   
Diastolic BP, mean (SD) 82.7 (11.1) 85.3 (10.9) 80.7 (12.3) 84.4 (10.7) 81.5 (12.1) 82.5 (11.0) 78.6 (11.8) 80.1 (10.8) <0.001 <0.001 
Systolic BP, mean (SD) 132 (19) 150 (21) 128 (19) 148 (20) 130 (18) 144 (19) 125 (17) 138 (18) <0.001 <0.001 
Number of GP contacts:         <0.001 <0.001 
mean (SD) 7.0 (6.5) 8.0 (7.3) 7.2 (7.4) 9.0 (8.3 7.3 (7.8) 9.1 (9.0) 9.1 (9.6) 10.9 (11.0)   
median (IQR) 5 (2–9) 6 (3–11) 5 (2–10) 7 (3–12) 5 (2–10) 7 (3–12) 7 (3–12) 8 (4–15)   
Total cholesterol (mmol/l)         <0.001 <0.001 
n (%) 69 (11%) 1,250 (12%) 556 (20%) 9,581 (32%) 2,832 (38%) 54,182 (67%) 5,086 (33%) 82,459 (76%)   
mean (SD) 6.0 (1.3) 6.2 (1.2) 5.5 (1.2) 5.8 (1.2) 5.4 (1.2) 5.5 (1.2) 5.3 (1.2) 5.1 (1.2)   
Charlson Index:         <0.001 <0.001 
mean (SD) 1.2 (0.8) 1.7 (1.2) 0.8 (0.8) 1.5 (1.3) 0.8 (0.9) 1.5 (1.3) 1.1 (0.8) 1.8 (1.5)   
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Parameter 
 
1991–1995 1996–2000 2001–2005 2006–2010 p-value 
≤40 >40 ≤40 >40 ≤40 >40 ≤40 >40 ≤40 >40 
median (IQR) 1 (1–1) 1 (1–2) 1 (0–1) 1 (1–2) 1 (0–1) 1 (1–2) 1 (1–1) 1 (1–3)   
Adjusted Charlson Index:         <0.001 <0.001 
mean (SD) 1.2 (0.8) 3.8 (2.0) 0.8 (0.8) 3.3 (2.2) 0.8 (0.9) 3.3 (2.3) 1.1 (0.8) 3.6 (2.5)   
median (IQR) 1 (1–1) 4 (3–5) 1 (0–1) 3 (2–5) 1 (0–1) 3 (2–5) 1 (1–1) 3 (2–5)   
Diabetic complications:           
CHD (%) 0 (0%) 0 (0.0%) 9 (0%) 1,011 (3%) 49 (1%) 5,738 (7%) 83 (1%) 9,626 (9%) 0.147 <0.001 
CVD (%) 0 (0%) 0 (0.0%) 1 (0%) 324 (1%) 14 (0%) 1,638 (2%) 42 (0%) 2,884 (3%) 0.005 <0.001 
Foot and PVD (%) 0 (0%) 0 (0.0%) 1 (0%) 138 (0%) 3 (0%) 638 (1%) 7 (0%) 956 (1%) 0.622 <0.001 
Eye (%) 0 (0%) 0 (0.0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0.849 <0.001 
ESRD (%) 0 (0%) 0 (0.0%) 3 (0%) 109 (0%) 33 (0%) 657 (1%) 134 (1%) 1,756 (2%) <0.001 <0.001 
CHD = coronary heart disease, CVD = cerebrovascular disease, PVD = peripheral vascular disease, ESRD = end stage renal disease. Smoking status was the nearest status recorded 
prior to the index date. For BMI, HbA1c, weight, blood pressure (BP), total cholesterol the nearest record to the index date was taken, provided it was no more than 365 days prior 
to or 30 days after the index date. The number of GP contacts represents the number of GP contacts in the year prior to the index date. Diabetic complications refer to whether 
patient had record of a diabetic complication prior to index date. 
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Table 4.2  Standardized incidence ratio (SIR: 1991–1995=100) for ﬁve-yearly periods to 
2010. 
Year group Observed Expected SIR 95% CI p 
All subjects 
1991–1995 10,883 n/a 100 
   
1996–2000 32,596 20,601 158 157 160 <0.001 
2001–2005 88,835 37,545 237 235 238 <0.001 
2006–2010 123,932 45,135 275 273 276 <0.001 
Males 
1991–1995 5,716 n/a 100 
   
1996–2000 16,846 10,945 154 152 156 <0.001 
2001–2005 45,849 20,209 227 225 229 <0.001 
2006–2010 63,471 24,499 259 257 261 <0.001 
Females 
1991–1995 5,167 n/a 100 
   
1996–2000 15,750 9,656 163 161 166 <0.001 
2001–2005 42,986 17,336 248 246 250 <0.001 
2006–2010 60,461 20,636 293 291 295 <0.001 
Under 40 years 
1991–1995 577 n/a 100 
   
1996–2000 2,496 1,148 217 209 226 <0.001 
2001–2005 6,798 2,077 327 320 335 <0.001 
2006–2010 14,073 2,352 598 589 608 <0.001 
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4.3.3. Specific incidence rates 
The estimated incidence of clinically diagnosed and recorded type 2 diabetes increased 
between 1991 and 2002 from 169 newly diagnosed people per 100,000 person-years 
(95% CI 160–178) to 448 (95% CI 442–455) before decreasing to 376 (95% CI 371–382) 
per 100,000 in 2006 (Figure 4.1). By 2009, the incidence of type 2 diabetes had 
increased to 533 (95% CI 526–539) per 100,000 before decreasing slightly to 515 (95% 
CI 509–521) per 100,000 in 2010. The incidence of type 2 diabetes for males and 
females followed a similar pattern, but incidence was higher for males than for 
females. HbA1c levels at baseline were 9.3% (95% CI 8.5%–10.2%), 7.1% (95% CI 7.0%–
7.1%), 7.7% (95% CI 7.6%–7.7%), 7.4% (95% CI 7.4%–7.4%) and 7.3% (95% CI 7.2%–
7.3%) in 1991, 2002, 2006, 2009 and 2010, respectively. 
The incidence rate for diagnosed and recorded type 2 diabetes increased with each 
increasing five-year calendar period for all age groups and for both genders, with the 
exception of females who were 90 years and over, where the incidence rate fell from 
482 to 452 people per 100,000 in the final two five-year calendar periods (Figure 4.2a 
and Figure 4.2b). Overall, between 1996 and 2005, the incidence rate was highest in 
the 70–74 age group at 892 and 1,415 people per 100,000 for 1996–2000 and 2001–
2005, respectively. For 1991–1995, the incidence rate was highest in the 75–79 age 
group at 605 people per 100,000. In 2006–2010, the highest incidence rates were seen 
in the 70–74 and 75–79 age groups at 1,486 per 100,000. After the age of 40 years, the 
incidence was higher in males for each five-year calendar period (Figure 4.2a and 
Figure 4.2b). However, females had a higher incidence than did males for many of the 
age groups below 40 years, including the age groups between 20 and 34 years for all 
five-year calendar periods.
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Figure 4.1  Incidence of diagnosed and recorded type 2 diabetes per 100,000 population by year 
  
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
HbA1c 9.3 9.4 9.0 9.2 8.7 8.4 7.7 7.4 7.5 7.2 7.1 7.1 7.5 7.7 7.7 7.7 7.6 7.6 7.4 7.3
Male 183 186 187 173 200 201 220 265 292 387 455 472 401 413 397 400 468 508 553 536
Female 156 158 153 152 177 180 195 231 263 347 407 426 361 370 358 354 418 459 514 495
Overall 169 172 170 162 188 190 207 248 277 366 430 448 380 391 377 376 442 483 533 515
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Figure 4.2  Age-speciﬁc incidence of new cases of type 2 diabetes per 100,000 population by year 
a) Males 
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b) Females 
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A larger percentage of patients were diagnosed between 65 and 69 years of age 
between 1991 and 2005 than any other age group. However, between 2006 and 2010, 
the most common age at diagnosis was lower, at 60–64 years. For males, the largest 
percentage of patients was diagnosed between 65 and 69 years of age from 2001–
2005, but between 60 and 64 years of age for 1991–1995, 1996–2000 and 2006–2010 
(Figure 4.3a). The largest percentage of females was diagnosed between the ages of 70 
to 74 years for 1991–2005 (Figure 4.3c). This had decreased to 60–64 years of age 
between 2006 and 2010. 
The percentage of patients aged 40 years or less at diabetes diagnosis increased with 
each increasing five-year calendar period for males (Figure 4.3b) and increased 
between 1991–1995 and 2006–2010 in females (Figure 4.3d). However, there was no 
increase observed between 1996–2000 and 2001–2005. Overall, the percentage of 
patients diagnosed on or before the age of 40 years was 5.9% (95% CI 5.5%–6.3%), 
8.4% (95% CI 8.2%–8.7%), 8.5% (95% CI 8.3%–8.6%)and 12.4% (95% CI 12.2%–12.5%) 
for 1991–1995, 1996–2000, 2001–2005 and 2006–2010, respectively. There was a 
significant association between five-year calendar period and the number of patients 
diagnosed before and after the age of 40 (p<0.001). However, there were differences 
between the incidence in males and females, where the incidence was higher in 
females at earlier ages.
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Figure 4.3  Percentage of new cases of type 2 diabetes between 1991 and 2010 by age group and calendar period 
a) Males, all ages  b) Males diagnosed at or before 40 years of age 
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Females, all ages 
a) Females diagnosed at or before 40 years of age 
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4.4. Discussion 
4.4.1. Main findings 
The incidence of clinically diagnosed and recorded type 2 diabetes increased markedly 
between 1991 and 2010 in most age groups. Furthermore, the incidence rate 
increased with increasing age until 75 years of age. Importantly, not only was the 
overall incidence increasing, the proportion of people who were aged 40 years or less 
at diagnosis doubled. 
The study results could reflect an increase in the incidence of type 2 diabetes in the UK 
population and a decrease in the age of onset. However, other factors may also have 
contributed to this increase including earlier detection of type 2 diabetes in at risk 
groups, improved recording of type 2 diabetes in CPRD and implementation of new 
criteria for the diagnosis of type 2 diabetes. These factors are discussed in more detail 
below in Chapter 4.4.2. 
 
4.4.2. Comparison with existing literature 
The incidence results are supported by incidence and prevalence rates previously 
demonstrated for the UK,9 USA399 and worldwide.400 Conversely, between 2004 and 
2006, the incidence of diabetes in Denmark has decreased slightly.156 The primary 
modifiable risk factor contributing to development of type 2 diabetes is energy balance 
as measured by BMI as a proxy for obesity. In the general UK population, both the 
prevalence and severity of obesity has been rising since 1993.63 Between 1993 and 
2010, the proportion of the UK population who were estimated to be obese increased 
from 13% to 26% for men and 16% to 26% for women.63 For children, the prevalence 
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of obesity has increased between 1995 and 2010 from 11% to 17% and from 12% to 
15% for boys and girls, respectively.63 However, the percentage of adults meeting 
recommended levels for physical activity increased in the UK from 32% and 21% in 
1997 to 42% and 31% in 2008 for men and women, respectively.63 There is an inverse 
relationship between BMI and age of onset of type 2 diabetes22 and intensive lifestyle 
intervention with a minimum of 7% weight loss and 150 minutes of physical activity 
per week reduced the incidence rate for diabetes by 58%.23 A study based in Germany 
revealed that severe weight gain between the ages of 25 and 40 was associated with a 
higher risk of diabetes than if weight was stable in early adulthood and increased in 
later life (1.5 and 4.3 times the risk for males and females, respectively) and the age at 
diagnosis was also lowered (five and three years for males and females, 
respectively).401 For the study period, there was an increase in mean BMI at baseline 
for people diagnosed after the age of 40 for each successive five-year calendar period 
and both male and female weight increased in each five-year group during the study 
period. However, for people aged 40 years or less at diagnosis, the mean BMI 
fluctuated between five-year calendar periods. A similar pattern was also observed for 
mean weight for both males and females in this age group. The decrease in 2006–2010 
could be partly accounted for by the increased percentage of children and adolescents 
diagnosed in this five-year calendar period.  
The increase in the incidence of type 2 diabetes and the proportion of patients aged 40 
years or less at diagnosis may be due, at least in part, to enhanced detection of type 2 
diabetes. Unlike type 1 diabetes, the symptoms of type 2 diabetes are not always 
obvious and the condition can remain undiagnosed for many years. A study carried out 
between 1978 and 1982 found that the actual onset of type 2 diabetes may be at least 
four to seven years before clinical diagnosis.17 Therefore, enhanced detection of type 2 
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diabetes may have an impact on how soon diagnosis is achieved after onset of the 
condition. Although systematic population screening for type 2 diabetes is not 
recommended in the UK, early detection of type 2 diabetes in high risk groups is likely 
to have contributed to the increased incidence rate observed over the study period.402 
In the last decade, changes to the GMS and Pharmacy Contracts, the implementation 
of the National Diabetes Framework, and local initiatives have increased the 
awareness of diabetes.403,404 For example, the QOF was introduced on 1st April 2004.404 
In addition, changes have been made to the criteria for diagnosing type 2 diabetes 
during the study period. In 2000, the WHO new diagnostic criteria for the diagnosis of 
diabetes were implemented in the UK, which included lowering the threshold for 
diagnosing diabetes by FPG from 7.8 mmol/l to 7.0 mmol/l.405 These changes would 
have led to an increase in the number of patients diagnosed with type 2 diabetes and a 
decrease in the age at diagnosis. If the increase in incidence is a result of enhanced 
detection, this could be viewed positively as patients will receive appropriate diabetes 
care at an earlier stage of their disease. In support of this theory of an ascertainment 
effect, HbA1c levels at baseline followed an inverse pattern when compared with 
annual incidence rates for type 2 diabetes. However, it is important to note that there 
were a large amount of missing data in the earlier years of the study period. Blood 
pressure and total cholesterol decreased throughout the study period, which may be 
an indication of improved detection of type 2 diabetes in patients who are already 
being treated for hypercholesterolaemia and hypertension. The increased use of 
statins is likely to account for the reduction in baseline cholesterol seen during the 
study period. In a meta-analysis conducted by Rajpathak and colleagues, statin use was 
associated with a small increased risk of diabetes (RR 1.13, 95% CI 1.03–1.23) when 
hypothesis-testing RCTs were combined. However, this increase in risk was no longer 
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significant following the addition of data from West of Scotland Coronary Prevention 
Study (WOSCOPS), a hypothesis-generating RCT (1.06, 95% CI 0.93–1.25 ).406 However, 
when used for primary and secondary prevention of cardiovascular disease, statins 
have been show to significantly reduce the risk of cardiovascular events and death.407–
410 During the study period, more diabetic complications have been recorded in 
relation to increasing five-year calendar periods. This could indicate a number of 
factors; for example, improved survival of patients with advanced disease, or patients 
suffering from more advanced disease at diagnosis. Improved recording of diagnoses 
in CPRD could also account for this trend. There was a sharp increase in the annual 
incidence between 1999 and 2002, followed by a decline and a plateau between 2003 
and 2006. One possible explanation could be that enhanced detection of type 2 
diabetes between 1999 and 2002 could have led to the removal of patients from the 
undiagnosed population that would have otherwise presented later in the course of 
their disease i.e. during the period 2003 to 2006. The proportion of people diagnosed 
prior to the age of 40 was higher for females compared with males and this percentage 
increased with increasing 5-year calendar period. This is likely to be due to an 
increased focus on gestational diabetes as a marker for the later development of type 
2 diabetes leading to improved detection and an earlier diagnosis. 
Irrespective of the cause, the results of this study show that type 2 diabetes is common 
under the age of 40 years. Earlier onset type 2 diabetes (aged <40 years at recorded 
diagnosis) could result in longer disease duration and lead to an increased risk of 
developing diabetic complications. This is likely to place an increasing burden on 
healthcare resources, and increased patient morbidity may lead to a poorer quality of 
life. An earlier age of onset of type 2 diabetes may also lead to mortality occurring at a 
younger age. The Framingham Heart Study showed that the risk of CHD and CHD-
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related death increased with increasing duration of diabetes.411 However, the current 
definition of diabetes is different to the definition used in the Framingham Heart 
Study. The Northern Manhattan Study found that diabetes duration was 
independently associated with an increased risk of ischaemic stroke.412 In addition, 
youth onset type 2 diabetes has been linked to an increased risk of developing diabetic 
complications including cardiovascular disease and retinopathy.393,397,413 The Vascular 
Risk Assessment and Management Programme called NHS Health Check has been 
gradually introduced in England for everyone aged 40 to 74.414 However, it is 
important to consider if screening programmes should include patients under the age 
of 40 as earlier diagnosis will lead to the earlier initiation of appropriate diabetes care 
and treatment. Conversely, the results from the Anglo-Danish-Dutch Study of Intensive 
Treatment In People with Screen Detected Diabetes in Primary Care (ADDITION)-
Cambridge trial demonstrated that an invitation to one round of screening for type 2 
diabetes in people aged 40–69 at high risk of having prevalent undiagnosed diabetes 
was not associated with a reduction in all-cause, cardiovascular-related or diabetes-
related mortality where median duration of follow-up was 9.6 years.415  
A study based on the population of Cardiff and the Vale of Glamorgan found that 
diabetes prevalence increased from 2.5% to 3.9% between 1996 and 2005 and during 
the same period the percentage of patients with diagnosed diabetes with recorded 
complications relating to diabetes decreased.416 It was hypothesised that the increase 
in prevalence was largely due to an ascertainment effect.416 Therefore, as the 
incidence of diagnosed type 2 diabetes increases, a similarly large increase in diabetes 
complications may not necessarily follow if patients are diagnosed earlier in the course 
of their disease.416 
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Medical conditions like type 2 diabetes may be better recorded in CPRD in more recent 
years and this could have contributed to the increase in incidence rate over time. The 
introduction of QOF incentivised GPs to keep accurate records of patients with 
diabetes.404 However, the diabetes presentation date was taken as the earlier of the 
first diagnoses for diabetes or the first prescription for a glucose-lowering therapy.  
 
4.4.3. Strengths and weaknesses of the study 
As already discussed, the main limitation of this study is the use of age of diagnosis to 
understand any trends in the age of onset of type 2 diabetes. In addition, the recording 
of measurements such as weight, BMI, total cholesterol, smoking status and BP 
improved during the study period. For BMI, the percentage of patients with a recorded 
BMI increased from 38% in 1991–1995 to 46% in 2006–2010 for those patients aged 40 
years or less at diagnosis and this may be skewed as overweight patients are more 
likely to have their weight measured. In addition, a consensus statement 
recommending the use of a Diabetes Control and Complications Trial (DCCT)-aligned 
HbA1c method in the UK was not published until 2000 and HbA1c levels in the early 
period may not have been standardised throughout the UK.417 Therefore, comparisons 
of mean HbA1c levels between five-year calendar periods should be interpreted with 
caution. One other study limitation concerns the allocation of a diagnosis of type 2 
diabetes to patients in CPRD: in particular, the coding of diabetes may have changed in 
recent years. The term IDDM was used more commonly in earlier years, whereas ‘type 
1 diabetes’ is now more frequently used. Some people with type 2 diabetes and 
receiving prescriptions for insulin may have been attributed a code for IDDM, leading 
to diabetes type being misclassified; this may exaggerate any increase in incidence 
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seen during the study period. In addition, the criteria used in this study to attribute a 
diagnosis of type 2 diabetes to CPRD patients did not utilise BMI or laboratory data, 
which might have improved the classification of diabetes type.418 Age was not used to 
classify diabetes type in this study as we were specifically investigating the proportion 
of people with type 2 diabetes in younger age groups. 
 
4.4.4. Conclusion 
The incidence of clinically diagnosed and recorded type 2 diabetes has increased three-
fold between 1991 and 2010. The proportion people with type 2 diabetes diagnosed 
with the condition before the age of 40 continued to increase as a proportion of those 
diagnosed and these people have a greater opportunity to develop long-term 
complications.  
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5. Prevalence, glucose control and survival of people with type 
1 and type 2 diabetes in the UK from 1991 to 2013 
5.1. Introduction 
5.1.1. Background 
In England in 2012, 26% of adults were obese (BMI ≥30kg/m2), and approximately one 
in three girls and boys aged 2 to 15 years was classed as either overweight or obese.419 
Obesity is the primary risk factor driving incident type 2 diabetes. Using data from UK 
general practice, the prevalence of diabetes in the UK was estimated to be 2.8% in 
1995, increasing to 4.3% in 2005.9 Figures published by Diabetes UK using data from 
QOF reported that the number of people with diabetes in the UK increased from 1.4 
million in 1996 to 2.8 million in 2010.420 The incidence of type 2 diabetes increased 
markedly between 1991 and 2010 in the UK from 169 to 515 per 100,000 person-
years.421 During the same period, the percentage of people aged ≤40 years at diagnosis 
increased with each increasing five-year calendar period (5.9% for 1991–1995 and 
12.4% for 2006–2010).421 In addition, the prevalence of people injecting insulin also 
increased from 2.4 per 1000 population in 1991 to 6.7 per 1000 in 2010.422 This trend 
was largely due to an increase in the prevalence of insulin users with a diagnosis of 
type 2 diabetes.422 A recent study published in JAMA found that the prevalence of 
diabetes in the US doubled between 1990 and 2008 before reaching a plateau 
between 2008 and 2012.423 
People with type 2 diabetes are at risk of developing microvascular and macrovascular 
complications, and their risk of death as people is at least twice that of people without 
diabetes.40 In 2010–2011 in the UK, type 2 diabetes cost an estimated £9 billion in 
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direct costs and £13 billion in indirect costs and accounted for approximately 10% of all 
NHS resource expenditure.41 In 2005, 11.6% of deaths in people aged 20–79 in England 
were attributed in some way to diabetes.65 In people with type 1 and type 2 diabetes, 
life expectancy is thought to be reduced by 20 and 10 years, respectively.424–426 
Diabetes is the fifth leading cause of death in the world.40 
 
5.1.2. Aims and objectives 
The aim of this study was to characterise the prevalence of diabetes over the past 23 
years in the UK population, and to determine whether glucose control and the risk of 
all-cause mortality have changed during the same period.  
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5.2. Methods 
5.2.1. The Clinical Practice Research Datalink (CPRD) 
The data source used for this study was CPRD primary care dataset (CPRD GOLD).427 
CPRD GOLD contains clinically rich, pseudonymised data collected in a non-
interventional manner from the daily record-keeping of primary-care physicians in the 
UK. The dataset includes: patient demographic and registration information, 
consultations, medical history and diagnoses, test results, immunisations, referrals, 
outpatient letters and prescriptions. CPRD GOLD is broadly representative of the UK 
population and contains to date over 12 million research-quality patients registered at 
660 practices. The data extract used in this study included records up to June 2012. 
For a proportion of participating practices between 1997 and 2011, CPRD records have 
been linked to the NHS HES dataset. Details of inpatient admissions were therefore 
available between these dates for those patients with a linked HES record. 
The CPRD ISAC approved the protocol for this study on 22nd September 2014 
(reference number 14_172AR). 
 
5.2.2. Patient selection criteria 
In this retrospective study, patients denoted by CPRD as being of acceptable research 
quality were identified if they had type 1 or type 2 diabetes and presented with 
diabetes before or during the study period (1991–2013). A diagnosis of type 1 or type 2 
diabetes was allocated based on a series of decision rules, which utilised the following 
patient information: age at diagnosis, diagnosis type (type 1, type 2 or type 
unspecified, recorded as Read codes in primary care data or as ICD-10 codes in HES 
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data), history of prescriptions for insulin and other types of glucose-lowering 
medications, BMI and HbA1c (see Table 5.1). Only those patients with at least one 
recorded prescription for a glucose-lowering medication or at least one diagnosis for 
diabetes recorded in the CPRD GOLD clinical table or in HES were included in the study. 
Patients with a wash-in of at least 365 days between the first prescription for a 
glucose-lowering medication and the later of the patient registration date and the up-
to-standard date of their practice were included in a survival analysis comparing the 
risk of all-cause mortality by year of onset of treated type 2 diabetes.  
 
5.2.3. Calculation of diabetes prevalence 
The date of diabetes presentation was taken as the earlier of the first diagnosis of 
diabetes or the first prescription for a medicine used to lower blood glucose. Patients 
with secondary diabetes were excluded from the study. Patients were classed as a 
prevalent case from the later of their date of diabetes presentation and their practice’s 
up-to-standard date until their censor date (defined as the earliest of their transfer-out 
date or date of death, if applicable, and the end of the study period).  
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Table 5.1 Decisions rules implemented to assign a diagnosis of type 1 or type 2 diabetes to people with diabetes 
Rule T1 T2 T0 Insulin GLT Age BMI 
Diabetes 
type 
HbA1c Notes 
1 1a 1 
 
1 0 31–39 <=25 1  
 
2 1a 1 
 
1 0 <=30 
 
1  
 
3 1a 0 
 
1 0 
  
1  
 
4 
IDDM (no 
T1) 
0 
 
1 0 31–39 <=25 1  
 
5 
IDDM (no 
T1) 
0 
 
1 0 <=30 
 
1  
 
6 1a 0 
 
0 0 <=30 
 
1  
 
7 1a 0 
 
0 0 31–39 <=25 1  
 
8 0 0 
 
1 0 <=30 
 
1  
 
9 0 0 
 
1 0 31–39 <=25 1  
 
10 1 1 
 
0 0 
  
2  
 
11 0 0 1 0 Met 
  
2  
Must have >=1 t0 
diagnostic code 
11yb 0 0 1 0 Met   2 >=6.5% 
T0 non-diagnostic 
codes only 
12 0 0 1 0 0 
  
2  
Must have >=1 t0 
diagnostic code 
12yc 0 0 1 0 0   2 >=6.5% 
T0 non-diagnostic 
codes only 
13 
    
GLT (non-
met)   
2  
 
14 0 1 
  
0 
  
2  
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Rule T1 T2 T0 Insulin GLT Age BMI 
Diabetes 
type 
HbA1c Notes 
15 
 
1 
  
Met 
  
2  
 
16 0 0 
 
1 0 >=40 
 
DM  
 
17 0 0 
 
1 0 
31–39 or is 
null 
>25 or is null DM  
 
18 
IDDM (no 
T1) 
0 
 
1 0 31–39 >25 or null DM  
 
19 
IDDM (no 
T1) 
0 
 
1 0 >=40 or null 
 
DM  
 
20 1 0 
  
Met 
  
DM  
 
21 0 0 
 
1 Met 
  
DM  
 
22 1 0 
 
0 0 
  
DM  
Remainder (not rule 
6 or 7) 
23 1 1 
 
1 0 
  
DM  
Remainder (not rule 
1 or 2) 
11x 0 0 1 0 Met   Not DM 
None or 
<6.5% 
T0 non-diagnostic 
codes only 
12x 0 0 1 0 0   Not DM 
None or 
<6.5% 
T0 non-diagnostic 
codes only 
24 0 0 0 0 0/Met 
  
Not DM  
 a Must have at least one non-IDDM T1 code  
b  Include these rules as a sensitivity analysis only 
Met = metformin, GLT = glucose-lowering therapy, T1 = type 1 diabetes, T2 = type 2 diabetes, T0 = unspecified diabetes type, GLT = glucose-lowering therapy
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The method used to calculate point prevalence was similar to that used in censuses. 
Patients having a diabetes presentation date prior to the mid-year point (30th June) 
and a censor date after that mid-year point were included as a prevalent case in that 
year regardless of their duration of diabetes. Crude prevalence was calculated by 
dividing the number of people with diabetes in CPRD at the mid-year point of each 
year from 1991 to 2013 by the total number of patients who were alive and registered 
at an up-to-standard practice on the same date. Age- and sex- standardised prevalence 
rates were also calculated using 1991 as the reference year. 
Age- and sex-stratiﬁed prevalence of type 1 and type 2 diabetes was multiplied by the 
total UK population from data from the ONS428 to produce an estimate of the number 
of people with diabetes in the UK.  
The prevalence of type 2 diabetes by treatment type was calculated by dividing the 
number of patients with type 2 diabetes using each type of glucose-lowering 
medication (insulin or oral glucose-lowering medicines and GLP-1 agonists) by the total 
number of patients with a registered status in CPRD at the mid-year point. The index 
date was taken as the date of the patient’s first prescription for glucose-lowering 
medication or insulin, which needed to occur prior to the mid-year point. An in-house 
application was used to reconcile periods of combined exposure to multiple glucose-
lowering therapies. A gap longer than 90 days between prescriptions for the same 
glucose-lowering medication was used to indicate discontinuation of that treatment. 
The end of the course of therapy was taken as the last prescription date plus 30 days. 
However, as type 2 diabetes is a chronic progressive condition, it is unusual for 
patients to discontinue therapy. Therefore, for patients who had previously received 
prescriptions for glucose-lowering medication but no glucose-lowering regimen 
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identified at the mid-year point, the last observed glucose-lowering regimen was 
carried forward. Diet-controlled patients were identified if they had type 2 diabetes 
but had received no prescriptions for a glucose-lowering medication prior to the mid-
year point.   
 
5.2.4. Statistical analysis 
Wilson (or score) 95% confidence intervals were calculated for prevalence rates. The 
number of people with diabetes in the UK was projected for the year 2020 by fitting a 
linear regression line to the estimates for the years between 2000 and 2013. 
For the survival analysis, time to death was evaluated for incident cases of type 1 
diabetes or treated type 2 diabetes using the Cox proportional hazards model, 
adjusted for index, age and sex. Patients were followed to their censor date. The 
proportional hazards assumption was tested by examining the Pearson correlation 
between Schoenfeld residuals and the rank of survival time for cases that had 
progressed to death. The proportional hazards assumption was also tested using 
interactions between the covariates and time. aHRs are presented with the 95% 
confidence intervals. Analyses were carried out using Microsoft Excel and IBM SPSS 
Statistics version 20. 
 
5.2.5. Sensitivity analyses 
A sensitivity analysis was carried out using only those patients whose records were 
eligible for linkage to HES data from 1997 to 2011. Here, prevalent cases of diabetes 
were identified from diagnoses recorded in either HES or CPRD GOLD and from 
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prescriptions recorded in CPRD GOLD. Classification of diabetes type was also 
determined using data from both the CPRD and HES sources. The denominator data 
was restricted to patients in CPRD who were HES eligible.  
In a separate sensitivity analysis, the percentage of patients with diabetes of unknown 
type was calculated for each GP practice contributing data to CPRD and the prevalence 
of diabetes by year was then calculated using only those patients registered at a 
practice with ≤1% and ≤2% of diabetes patients having an unknown type.  
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5.3. Results 
5.3.1. Patient demographics 
The demographic characteristics of people with diabetes are detailed in Table 5.2. 
Overall, the mean age of the prevalent population of people with diabetes increased 
from 62.9 years to 64.8 years between 1991 and 2013 and the percentage of males 
increased from 52% to 56% during this period. For people with type 1 diabetes, the 
age of the prevalent population increased from 35.8 years in 19991 to 38.6 years in 
2013 and the duration of diagnosed diabetes increased from 14.5 years to 15.5 years 
during this period. For type 2 diabetes, the age of the prevalent population decreased 
from 66.9 years in 1991 to 66.8 years in 2013 while the duration of diabetes increased 
from 4.3 years to7.2 years. 
 
5.3.2. Crude prevalence of diabetes 
The crude prevalence of diagnosed type 1 diabetes increased from 0.19% (95% CI 
0.18%–0.19%) to 0.32% (0.31%–0.32%) between 1991 and 2013, and the crude 
prevalence of diagnosed type 2 diabetes increased year on year from 1.32% (1.30%–
1.34%) to 4.54% (4.52%–4.56%) during the same period (Table 5.3). The combined 
crude prevalence of diagnosed type 1 and type 2 diabetes increased from 1.66% 
(1.64%–1.69%) in 1991 to 4.94% (4.92%–4.96%) in 2013.
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Table 5.2  Patient Demographics 
Parameter 
Year 
1991 1995 2000 2005 2010 2013 
Type 1 diabetes 
 
 
          
Prevalent cases, n 2,006  3,319 
 
8,162 
 
13,339 
 
14,575 
 
13,978 
 
Males, n (%) 1,100  (55%) 1,918 (58%) 4,756 (58%) 7,792 (58%) 8,580 (59%) 8,205 (59%) 
Age, mean (median), years 35.8  (34.0) 37.3 (35.0) 38.3 (37.0) 39.2 (39.0) 39.0 (39.0) 38.6 (39.0) 
Diabetes duration, median (IQR), 
yearsa 
14.5  (6.3–23.5) 15.3 (6.4-24.5) 14.5 (6.5-25.5) 14.7 (6.2-26.5) 15.5 (6.9-27.5) 15.5 (7.0-27.9) 
BMI, mean (SD), kg/m2b 24.4  (3.3) 24.7 (3.6) 25.3 (4.1) 25.4 (4.5) 25.5 (4.7) 25.4 (4.8) 
Weight, mean (SD), kgb 69.8 (13.2) 71.6 (13.4) 72.8 (15.2) 73.1 (17.3) 73.5 (18) 73.1 (18.4) 
Systolic BP, mean (SD), mmHgb 131.3 (20.6) 131.5 (19.7) 131.3 (19.1) 128.6 (17.3) 126.9 (16.3) 126.2 (15.7) 
Total cholesterol, mean (SD), mmol/lb 6.0 (2.0) 5.4 (1.2) 5.1 (1.1) 4.7 (1.0) 4.6 (1.0) 4.6 (1.0) 
Serum creatinine, mean (SD), µmol/lb 100.1 (66.8) 93.7 (32.7) 93.5 (42.2) 91.7 (43.0) 83.9 (41.2) 81.3 (39.0) 
Smoking status 
            
non-smoker, n (%) 1,148 (57%) 1,962 (59%) 4,692 (57%) 7,697 (58%) 8,232 (56%) 7,626 (55%) 
ex-smoker, n (%) 122 (6%) 320 (10%) 948 (12%) 2,202 (17%) 2,627 (18%) 2,501 (18%) 
current smoker, n (%) 512 (26%) 831 (25%) 2,135 (26%) 3,044 (23%) 3,027 (21%) 2,710 (19%) 
Charlson Index, median (IQR)c 1.0 (1.0-2.0) 1.0 (1.0-2.0) 1.0 (1.0-2.0) 2.0 (1.0-2.0) 2.0 (1.0-2.0) 2.0 (1.0-3.0) 
Antihypertensive therapy, n (%)d 224 (11%) 489 (15%) 1,790 (22%) 4,361 (33%) 4,736 (32%) 4,167 (30%) 
Lipid-lowering therapy, n (%)d 18 (1%) 68 (2%) 681 (8%) 4,529 (34%) 5,616 (39%) 4,958 (35%) 
Antiplatelet therapy, n (%)d 56 (3%) 169 (5%) 730 (9%) 2,848 (21%) 2,812 (19%) 2,141 (15%) 
Prior cancer, n (%)c 25 (1%) 59 (2%) 169 (2%) 380 (3%) 489 (3%) 511 (4%) 
Prior large vessel disease, n (%)c 71 (4%) 167 (5%) 456 (6%) 877 (7%) 911 (6%) 845 (6%) 
Prior visual problems, n (%)c 404 (20%) 896 (27%) 2,453 (30%) 5,107 (38%) 7,547 (52%) 7,650 (55%) 
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1991 1995 2000 2005 2010 2013 
Type 2 diabetes 
            
Prevalent cases, n 14,202 
 
26,773 
 
76,531 
 
155,936 
 
201,554 
 
200,957 
 
Males, n (%) 7,422 (52%) 14,121 (53%) 41,104 (54%) 85,085 (55%) 112,008 (56%) 112,822 (56%) 
Age, mean (median), years 66.9 (68.0) 66.8 (68.0) 66.4 (68.0) 66.2 (67.0) 66.6 (67.0) 66.8 (68.0) 
Diabetes duration, median (IQR), yearsa 4.3 (1.5-8.8) 4.6 (2.1-9.2) 5.0 (2.0-9.5) 4.6 (2.2-9.3) 6.3 (2.9-10.4) 7.2 (3.4-11.7) 
BMI, mean (SD), kg/m2b 27.9 (5.1) 28.4 (5.2) 29.3 (5.4) 30.1 (5.8) 30.8 (6.0) 30.7 (6.0) 
Weight, mean (SD), kgb 77.3 (16.2) 79.0 (16.4) 82.2 (17.5) 84.9 (18.8) 87.1 (19.5) 87.2 (19.6) 
Systolic BP, mean (SD), mmHgb 149.0 (22.0) 147.0 (20.0) 145.0 (19.0) 137.4 (16.9) 134.0 (16.0) 133.0 (15.0) 
Total cholesterol, mean (SD), mmol/lb 6.3 (1.3) 5.9 (1.3) 5.3 (1.1) 4.5 (1.1) 4.3 (1.1) 4.3 (1.1) 
Serum creatinine, mean (SD), µmol/lb 90.8 (26.9) 99.2 (33.0) 97.6 (33.3) 95.5 (34.0) 89.4 (35.5) 87.8 (35.8) 
Smoking statuse 
            
non-smoker, n (%) 8,198 (58%) 1,6114 (60%) 41,337 (54%) 76,442 (49%) 97,602 (48%) 99,885 (50%) 
ex-smoker, n (%) 1,428 (10%) 4,331 (16%) 19,110 (25%) 55,520 (36%) 74,999 (37%) 72,808 (36%) 
current smoker, n (%) 2,384 (17%) 4,577 (17%) 13,820 (18%) 23,404 (15%) 28,639 (14%) 27,850 (14%) 
Charlson Index, median (IQR)c 1.0 (1.0-2.0) 2.0 (1.0-2.0) 2.0 (1.0-3.0) 2.0 (1.0-3.0) 2.0 (1.0-4.0) 2.0 (1.0-4.0) 
Antihypertensive therapy, n (%)d 5,157 (36%) 11,742 (44%) 44,549 (58%) 117,114 (75%) 154,302 (77%) 150,873 (75%) 
Lipid-lowering therapy, n (%)d 303 (2%) 1,300 (5%) 18,046 (24%) 109,022 (70%) 157,346 (78%) 153,666 (76%) 
Antiplatelet therapy, n (%)d 1,622 (11%) 5,223 (20%) 24,242 (32%) 80,006 (51%) 95,972 (48%) 78,307 (39%) 
Prior cancer, n (%)c 730 (5%) 1,728 (6%) 5,575 (7%) 14,586 (9%) 23,318 (12%) 25,765 (13%) 
Prior large vessel disease, n (%)c 2,965 (21%) 6,619 (25%) 19,128 (25%) 39,967 (26%) 48,177 (24%) 46,175 (23%) 
Prior visual problems, n (%)c 2,339 (16%) 6,456 (24%) 20,605 (27%) 51,005 (33%) 88,462 (44%) 95,543 (48%) 
a Time between diabetes presentation date and mid year point (30/06). 
b The nearest record within the specific year, searching in the following order: 30 days prior, 30 days after, 180 days prior and then 184 days after the index date. 
c Based on diagnoses recorded prior to the mid year point (30/06). 
d Presence of one or more prescriptions for drug class in the specific year. 
e Nearest recorded smoking status prior to the mid year point (30/06). If no diagnosis is recorded prior to the mid year point, the nearest recoded smoking status after mid year point was used.
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Table 5.3 Crude prevalence of diagnosed diabetes between 1991 and 2013 
Year CPRD 
population 
Type 1 diabetes Type 2 diabetes Diabetes of unknown type Type 1 and type 2 diabetes 
Cases Prevalence (95%CI) Cases Prevalence (95%CI) Cases Prevalence (95%CI) Cases Prevalence (95%CI) 
1991 1,076,146 2,006 0.19% (0.18%–0.19%) 14,202 1.32% (1.30%–1.34%) 1,706 0.16% (0.15%–0.17%) 17,914 1.66% (1.64%–1.69%) 
1992 1,191,397 2,292 0.19% (0.18%–0.20%) 17,028 1.43% (1.41%–1.45%) 1,798 0.15% (0.14%–0.16%) 21,118 1.77% (1.75%–1.80%) 
1993 1,371,781 2,687 0.20% (0.19%–0.20%) 20,708 1.51% (1.49%–1.53%) 2,055 0.15% (0.14%–0.16%) 25,450 1.86% (1.83%–1.88%) 
1994 1,490,222 3,024 0.20% (0.20%–0.21%) 23,621 1.59% (1.57%–1.61%) 2,122 0.14% (0.14%–0.15%) 28,767 1.93% (1.91%–1.95%) 
1995 1,601,020 3,319 0.21% (0.20%–0.21%) 26,773 1.67% (1.65%–1.69%) 2,204 0.14% (0.13%–0.14%) 32,296 2.02% (2.00%–2.04%) 
1996 1,816,415 3,881 0.21% (0.21%–0.22%) 31,905 1.76% (1.74%–1.78%) 2,417 0.13% (0.13%–0.14%) 38,203 2.10% (2.08%–2.12%) 
1997 2,107,577 4,555 0.22% (0.21%–0.22%) 38,292 1.82% (1.80%–1.83%) 2,646 0.13% (0.12%–0.13%) 45,493 2.16% (2.14%–2.18%) 
1998 2,409,111 5,279 0.22% (0.21%–0.23%) 46,426 1.93% (1.91%–1.94%) 3,041 0.13% (0.12%–0.13%) 54,746 2.27% (2.25%–2.29%) 
1999 2,853,992 6,468 0.23% (0.22%–0.23%) 58,231 2.04% (2.02%–2.06%) 3,487 0.12% (0.12%–0.13%) 68,186 2.39% (2.37%–2.41%) 
2000 3,516,695 8,162 0.23% (0.23%–0.24%) 76,531 2.18% (2.16%–2.19%) 4,252 0.12% (0.12%–0.12%) 88,945 2.53% (2.51%–2.55%) 
2001 3,805,202 9,252 0.24% (0.24%–0.25%) 90,886 2.39% (2.37%–2.40%) 4,438 0.12% (0.11%–0.12%) 104,576 2.75% (2.73%–2.76%) 
2002 4,245,243 10,684 0.25% (0.25%–0.26%) 110,861 2.61% (2.60%–2.63%) 4,685 0.11% (0.11%–0.11%) 126,230 2.97% (2.96%–2.99%) 
2003 4,445,520 11,647 0.26% (0.26%–0.27%) 125,848 2.83% (2.82%–2.85%) 4,595 0.10% (0.10%–0.11%) 142,090 3.20% (3.18%–3.21%) 
2004 4,663,313 12,579 0.27% (0.27%–0.27%) 142,333 3.05% (3.04%–3.07%) 4,489 0.10% (0.09%–0.10%) 159,401 3.42% (3.40%–3.43%) 
2005 4,784,550 13,339 0.28% (0.27%–0.28%) 155,936 3.26% (3.24%–3.28%) 4,267 0.09% (0.09%–0.09%) 173,542 3.63% (3.61%–3.64%) 
2006 4,811,131 13,790 0.29% (0.28%–0.29%) 166,751 3.47% (3.45%–3.48%) 4,045 0.08% (0.08%–0.09%) 184,586 3.84% (3.82%–3.85%) 
2007 4,869,132 14,118 0.29% (0.29%–0.29%) 177,256 3.64% (3.62%–3.66%) 4,013 0.08% (0.08%–0.09%) 195,387 4.01% (4.00%–4.03%) 
2008 4,880,882 14,326 0.29% (0.29%–0.30%) 186,700 3.83% (3.81%–3.84%) 4,021 0.08% (0.08%–0.08%) 205,047 4.20% (4.18%–4.22%) 
2009 4,885,729 14,574 0.30% (0.29%–0.30%) 195,180 3.99% (3.98%–4.01%) 3,983 0.08% (0.08%–0.08%) 213,737 4.37% (4.36%–4.39%) 
2010 4,825,358 14,575 0.30% (0.30%–0.31%) 201,554 4.18% (4.16%–4.19%) 3,887 0.08% (0.08%–0.08%) 220,016 4.56% (4.54%–4.58%) 
2011 4,763,251 14,563 0.31% (0.30%–0.31%) 206,633 4.34% (4.32%–4.36%) 3,858 0.08% (0.08%–0.08%) 225,054 4.72% (4.71%–4.74%) 
2012 4,676,468 14,523 0.31% (0.31%–0.32%) 208,616 4.46% (4.44%–4.48%) 3,760 0.08% (0.08%–0.08%) 226,899 4.85% (4.83%–4.87%) 
2013 4,425,503 13,978 0.32% (0.31%–0.32%) 200,957 4.54% (4.52%–4.56%) 3,574 0.08% (0.08%–0.08%) 218,509 4.94% (4.92%–4.96%) 
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Selecting only those practices in which ≤1% of diabetes patients are of unknown 
diabetes type, the prevalence of type 1 and type 2 diabetes increased from 0.31% 
(0.29%–0.34%) and 2.95% (2.87%–3.03%) in 2003 (where there was a sufficiently large 
population) to 0.32% (0.31%–0.33%) and 4.61% (4.56%–4.65%) in 2013, respectively 
(Table 5.4a). Selecting only those practices where ≤2% of diabetes patients were of 
unknown diabetes type, the prevalence of type 1 and type 2 diabetes increased from 
0.29% (0.28%–0.30%) and 2.94% (2.91%–2.98%) in 2003 to 0.32% (0.31%–0.32%) and 
4.66% (4.63%–4.68%) in 2013, respectively (Table 5.4b). 
For those patients who were HES-eligible, the prevalence of type 1 and type 2 diabetes 
increased from 0.17% (0.16%–0.18%) and 1.84% (1.82%–1.87%) in 1997 to 0.23% 
(0.22%–0.23%) and 4.40% (4.37%–4.42%) in 2011 (Table 5.5). During the same period, 
the overall prevalence of diabetes increased from 2.16% (2.13%–2.19%) to 4.75% 
(4.72%–4.77%). 
 
5.3.3. Prevalence of diabetes by age 
For 6 selected calendar years (1991, 1995, 2000, 2005, 2010 and 2013), the prevalence 
of diabetes increased with increasing calendar year for age groups above the age of 25 
(Figure 5.1a). The prevalence of diabetes increased with increasing age group until the 
age of 70–84 years, depending on study year (the highest prevalence rates were in the 
75–79 age group in 1991, 2005, 2010 and 2013, the 70–74 age group in 2000 and the 
80–84 age group in 1995). The prevalence rates of type 1 diabetes, type 2 diabetes and 
treated type 2 diabetes by age group and calendar year are shown in Figure 5.1b, c and 
d. 
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Table 5.4 Prevalence of type 1 and type 2 diabetes in practices where less than a) 1% and b) 2% of patients have unknown diabetes type 
a) 
Year 
Type 1 diabetes Type 2 diabetes 
Patients registered at selected 
practices 
 
Number of cases Prevalence (95% CI) Number of cases Prevalence 
Number of 
patients 
% of total CPRD 
population 
 
1993 13 0.20% (0.12%–0.34%) 124 1.87% (1.57%–2.23%) 6,629 0.48% 
 
1994 7 0.18% (0.09%–0.36%) 61 1.53% (1.19%–1.95%) 4,000 0.27% 
 
1995 27 0.15% (0.10%–0.22%) 327 1.81% (1.63%–2.02%) 18,030 1.13% 
 
1996 51 0.23% (0.18%–0.30%) 328 1.49% (1.34%–1.66%) 22,021 1.21% 
 
1997 18 0.22% (0.14%–0.34%) 145 1.75% (1.49%–2.06%) 82,74 0.39% 
 
1998 38 0.23% (0.17%–0.31%) 288 1.73% (1.55%–1.94%) 16,608 0.69% 
 
1999 87 0.26% (0.21%–0.32%) 729 2.19% (2.04%–2.36%) 33,229 1.16% 
 
2000 122 0.30% (0.25%–0.36%) 910 2.22% (2.08%–2.36%) 41,049 1.17% 
 
2001 193 0.28% (0.24%–0.32%) 1,675 2.41% (2.30%–2.52%) 69,573 1.83% 
 
2002 260 0.27% (0.24%–0.31%) 2,469 2.61% (2.51%–2.71%) 94,700 2.23% 
 
2003 542 0.31% (0.29%–0.34%) 5,109 2.95% (2.87%–3.03%) 172,976 3.89% 
 
2004 882 0.29% (0.27%–0.31%) 9,523 3.13% (3.07%–3.20%) 303,804 6.51% 
 
2005 1,287 0.29% (0.28%–0.31%) 14,499 3.32% (3.26%–3.37%) 437,334 9.14% 
 
2006 1,604 0.31% (0.30%–0.33%) 18,406 3.57% (3.52%–3.62%) 516,189 10.73% 
 
2007 1,785 0.31% (0.30%–0.33%) 21,230 3.71% (3.67%–3.76%) 571,614 11.74% 
 
2008 2,078 0.31% (0.30%–0.32%) 25,737 3.84% (3.80%–3.89%) 669,781 13.72% 
 
2009 2,548 0.31% (0.30%–0.33%) 32,865 4.04% (4.00%–4.08%) 813,834 16.66% 
 
2010 2,741 0.31% (0.30%–0.33%) 37,766 4.31% (4.26%–4.35%) 876,804 18.17% 
 
2011 2,876 0.32% (0.31%–0.33%) 40,291 4.43% (4.39%–4.48%) 908,758 19.08% 
 
2012 3,084 0.32% (0.31%–0.33%) 43,196 4.47% (4.43%–4.51%) 966,597 20.67% 
 
2013 2,895 0.32% (0.31%–0.33%) 41,489 4.61% (4.56%–4.65%) 900,566 20.35% 
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b) 
Year 
Type 1 diabetes Type 2 diabetes 
Patients registered at selected 
practices 
 
Number of cases Prevalence (95% CI) Number of cases Prevalence 
Number of 
patients 
% of total CPRD 
population 
 
1991 4 0.09% (0.03%–0.23%) 95 2.13% (1.74%–2.60%) 4,463 0.41% 
 
1992 11 0.10% (0.05%–0.17%) 169 1.49% (1.28%–1.73%) 11,339 0.95% 
 
1993 21 0.15% (0.10%–0.23%) 201 1.47% (1.28%–1.69%) 13,664 1.00% 
 
1994 67 0.18% (0.14%–0.23%) 606 1.65% (1.52%–1.78%) 36,754 2.47% 
 
1995 80 0.20% (0.16%–0.25%) 665 1.65% (1.53%–1.77%) 40,407 2.52% 
 
1996 78 0.21% (0.17%–0.26%) 625 1.69% (1.57%–1.83%) 36,919 2.03% 
 
1997 149 0.22% (0.19%–0.26%) 1,297 1.92% (1.82%–2.03%) 67,451 3.20% 
 
1998 189 0.23% (0.20%–0.27%) 1,530 1.87% (1.78%–1.96%) 81,882 3.40% 
 
1999 330 0.24% (0.21%–0.26%) 2,881 2.05% (1.98%–2.13%) 140,417 4.92% 
 
2000 504 0.24% (0.22%–0.27%) 4,703 2.27% (2.21%–2.33%) 207,275 5.89% 
 
2001 935 0.26% (0.24%–0.27%) 8,990 2.45% (2.40%–2.51%) 366,268 9.63% 
 
2002 1,605 0.27% (0.26%–0.28%) 16,107 2.71% (2.66%–2.75%) 595,327 14.02% 
 
2003 2,691 0.29% (0.28%–0.30%) 27,668 2.94% (2.91%–2.98%) 940,878 21.16% 
 
2004 3,844 0.29% (0.28%–0.29%) 42,941 3.19% (3.16%–3.22%) 1,346,903 28.88% 
 
2005 5,438 0.29% (0.28%–0.30%) 62,662 3.37% (3.34%–3.39%) 1,861,091 38.90% 
 
2006 6,720 0.30% (0.29%–0.31%) 80,109 3.59% (3.57%–3.62%) 2,229,994 46.35% 
 
2007 7,756 0.30% (0.29%–0.31%) 96,309 3.74% (3.71%–3.76%) 2,577,913 52.94% 
 
2008 8,065 0.30% (0.29%–0.31%) 105,721 3.94% (3.92%–3.96%) 2,683,005 54.97% 
 
2009 8,657 0.30% (0.30%–0.31%) 116,691 4.10% (4.08%–4.12%) 2,846,883 58.27% 
 
2010 9,426 0.31% (0.30%–0.31%) 129,684 4.22% (4.20%–4.25%) 3,070,251 63.63% 
 
2011 9,799 0.31% (0.30%–0.32%) 139,197 4.42% (4.39%–4.44%) 3,152,629 66.19% 
 
2012 9,797 0.31% (0.31%–0.32%) 142,604 4.53% (4.51%–4.55%) 3,149,316 67.34% 
 
2013 9,914 0.32% (0.31%–0.32%) 145,193 4.66% (4.63%–4.68%) 3,118,196 70.46% 
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Table 5.5 Prevalence of diabetes in HES eligible patients 
Year CPRD 
population 
Type 1 diabetes Type 2 diabetes Diabetes of unknown type Type 1 and type 2 diabetes 
Cases Prevalence (95% CI) Cases Prevalence (95% CI) Cases Prevalence (95% CI) Cases Prevalence (95% CI) 
1997 1,249,523 2,117 0.17% (0.16%–0.18%) 23,012 1.84% (1.82%–1.87%) 1,864 0.15% (0.14%–0.16%) 26,993 2.16% (2.13%–2.19%) 
1998 1,403,674 2,410 0.17% (0.16%–0.18%) 27,536 1.96% (1.94%–1.98%) 2,105 0.15% (0.14%–0.16%) 32,051 2.28% (2.26%–2.31%) 
1999 1,701,659 2,964 0.17% (0.17%–0.18%) 35,162 2.07% (2.05%–2.09%) 2,468 0.15% (0.14%–0.15%) 40,594 2.39% (2.36%–2.41%) 
2000 2,150,872 3,774 0.18% (0.17%–0.18%) 47,322 2.20% (2.18%–2.22%) 3,149 0.15% (0.14%–0.15%) 54,245 2.52% (2.50%–2.54%) 
2001 2,309,587 4,167 0.18% (0.18%–0.19%) 56,097 2.43% (2.41%–2.45%) 3,404 0.15% (0.14%–0.15%) 63,668 2.76% (2.74%–2.78%) 
2002 2,536,073 4,632 0.18% (0.18%–0.19%) 67,575 2.66% (2.64%–2.68%) 3,718 0.15% (0.14%–0.15%) 75,925 2.99% (2.97%–3.01%) 
2003 2,630,665 4,987 0.19% (0.18%–0.19%) 76,073 2.89% (2.87%–2.91%) 3,814 0.14% (0.14%–0.15%) 84,874 3.23% (3.21%–3.25%) 
2004 2,718,426 5,235 0.19% (0.19%–0.20%) 84,540 3.11% (3.09%–3.13%) 3,862 0.14% (0.14%–0.15%) 93,637 3.44% (3.42%–3.47%) 
2005 2,801,441 5,602 0.20% (0.19%–0.21%) 92,954 3.32% (3.30%–3.34%) 3,862 0.14% (0.13%–0.14%) 102,418 3.66% (3.63%–3.68%) 
2006 2,857,959 5,889 0.21% (0.20%–0.21%) 100,728 3.52% (3.50%–3.55%) 3,850 0.13% (0.13%–0.14%) 110,467 3.87% (3.84%–3.89%) 
2007 2,940,088 6,177 0.21% (0.20%–0.22%) 108,331 3.68% (3.66%–3.71%) 3,893 0.13% (0.13%–0.14%) 118,401 4.03% (4.00%–4.05%) 
2008 2,933,958 6,266 0.21% (0.21%–0.22%) 113,499 3.87% (3.85%–3.89%) 3,854 0.13% (0.13%–0.14%) 123,619 4.21% (4.19%–4.24%) 
2009 2,965,067 6,508 0.22% (0.21%–0.22%) 119,521 4.03% (4.01%–4.05%) 3,808 0.13% (0.12%–0.13%) 129,837 4.38% (4.36%–4.40%) 
2010 2,940,780 6,611 0.22% (0.22%–0.23%) 123,929 4.21% (4.19%–4.24%) 3,699 0.13% (0.12%–0.13%) 134,239 4.56% (4.54%–4.59%) 
2011 2,892,224 6,630 0.23% (0.22%–0.23%) 127,119 4.40% (4.37%–4.42%) 3,613 0.12% (0.12%–0.13%) 137,362 4.75% (4.72%–4.77%) 
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Figure 5.1  Prevalence of diabetes by age group  
                  a) Diabetes overall                     b) Type 1 diabetes 
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                 c) Type 2 diabetes              d) Type 2 diabetes treated with glucose-lowering medicines 
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In 1991, the prevalence of type 1 diabetes was highest between the ages of 30 and 34 
years (0.33%, Figure 5.1b). By 2013, the highest prevalence of type 1 diabetes occurred 
between the ages of 20 and 24 years (0.48%). 
The crude prevalence of diagnosed type 2 diabetes increased each year for each age 
group and generally increased with increasing age group until 75–79 years of age in all 
years between 2000 and 2013 (Figure 5.1c). The crude prevalence of diagnosed type 2 
diabetes was generally higher in males than females above the age of 40: in 1991 this 
was 2.94% (2.88%–3.01%) in males versus 2.34% (2.28%–2.40%) in females; in 2013, it 
was 9.95% (9.90%–10.01%) versus 7.29% (7.24%–7.33%), respectively (Figure 5.2). 
Below the age of 40, the crude prevalence of type 2 diabetes in males and females was 
similar: 0.06% (0.05%–0.07%) in males versus 0.08% (0.07%–0.09%) in females in 1991 
and 0.25% (0.24%–0.26%) versus 0.22% (0.21%–0.22%) in 2013, respectively. Between 
1992 and 1998, prevalence was highest in people aged 80–84; between 1999 and 
2001, however, prevalence was highest in people aged 70–74. 
 
5.3.4. Prevalence of type 2 diabetes by glucose-lowering regimen 
The crude prevalence of people with diagnosed type 2 diabetes treated with insulin 
increased from 0.09% (95% CI 0.09%–0.10%) in 1991 to 0.67% (0.66%–0.68%) in 2013 
(Figure 5.3). Over the same period, the prevalence of people with type 2 diabetes 
treated with glucose-lowering agents other than insulin and with diet and exercise also 
increased from 0.75% (0.73%–0.77%) and 0.48% (0.46%–0.49%) in 1991 to 2.89% 
(2.88%–2.91%) and 0.98% (0.97%–0.99%), respectively.  
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Figure 5.2  Prevalence of type 2 diabetes by age for a) males and b) females 
a) 
 
b)  
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Figure 5.3  Prevalence of type 2 diabetes by treatment type 
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5.3.5. Age- and sex-standardised prevalence of diabetes 
Age- and sex-standardised prevalence of type 1 and type 2 diabetes increased from 
0.2% and 1.3% in 1991 to 0.3% and 4.3% in 2013, respectively (Figure 5.4). The 
corresponding figures for diabetes overall were 1.7% in 1991and 4.7% in 2013, 
respectively. 
 
5.3.6. Estimated number of people in the UK with diabetes 
The estimated number of people with diabetes in the UK increased year on year from 
879,900 (879.9k) (95% CI 815.0k–952.7k) in 1991 to 3,060k (2,998k–3,124k) in 2013 
(Figure 5.5 and Table 5.6). In 1991 there were 106.3k (95% CI 84.9k–136.1k) people 
with type 1 diabetes and 689.6k (639.4k–747.9k) people with type 2 diabetes. By 2013, 
this had increased to 201.6k (95% CI 184.0k–221.4k) people with type 1 diabetes and 
2,808.3k (2,753.3k–2,865.3k) people with type 2 diabetes. By 2020, there will be a 
projected 4 million people with diabetes in the UK.
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Figure 5.4 Age- and sex-standardised prevalence of diabetes (1991 = reference year) 
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Diabetes unknown type 0.2% 0.2% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1%
Type 2 diabetes 1.3% 1.4% 1.5% 1.6% 1.7% 1.7% 1.8% 1.9% 2.0% 2.2% 2.4% 2.6% 2.8% 3.0% 3.2% 3.4% 3.5% 3.7% 3.8% 4.0% 4.1% 4.2% 4.3%
Type 1 diabetes 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3%
Diabetes overall 1.7% 1.8% 1.8% 1.9% 2.0% 2.1% 2.1% 2.2% 2.4% 2.5% 2.7% 2.9% 3.1% 3.4% 3.6% 3.7% 3.9% 4.1% 4.2% 4.4% 4.5% 4.6% 4.7%
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Figure 5.5  Estimated number of people with type 1 and type 2 diabetes in the UK between 1991 and 2013 (see Table 5.6 for data with confidence 
intervals) 
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Table 5.6  Estimated number of people with type 1 and type 2 diabetes in the UK between 1991 and 2013 (data for Figure 5.5) 
Year 
Number of people with type 1 
diabetes x1000 (95% CI) 
Number of people with type 2 
diabetes x1000 (95% CI) 
Number of people with diabetes of 
unknown type x1000 (95% CI) 
Number of people with type 1 or 
type 2 diabetes x1000 (95% CI) 
1991 106.3 (84.9–136.1) 689.6 (639.4–747.9) 83.9 (65.8–110.3) 879.9 (815.0–952.7) 
1992 109.8 (88.9–138.3) 748.8 (698.4–806.4) 80.1 (63.2–104.5) 938.7 (875.0–1009.6) 
1993 112.1 (92.0–138.7) 792.9 (744.1–848.0) 79.7 (63.7–102.2) 984.6 (923.4–1052.2) 
1994 116.4 (96.6–142.2) 834.3 (786.1–888.3) 76.0 (60.9–97.1) 1026.7 (966.5–1092.7) 
1995 119.2 (99.6–144.4) 882.4 (834.7–935.5) 73.7 (59.3–93.8) 1075.2 (1015.9–1140.0) 
1996 123.6 (104.6–147.6) 925.1 (878.8–976.3) 71.3 (57.8–89.8) 1120.0 (1062.9–1181.9) 
1997 125.3 (107.3–147.7) 966.5 (922.1–1015.0) 67.9 (55.5–84.6) 1159.6 (1105.4–1218.0) 
1998 127.5 (110.3–148.5) 1031.3 (988.2–1078.1) 68.7 (56.9–84.4) 1227.6 (1175.3–1283.5) 
1999 132.1 (115.8–151.6) 1103.3 (1062.2–1147.6) 67.1 (56.1–81.3) 1302.5 (1252.9–1355.2) 
2000 135.8 (120.7–153.5) 1190.3 (1151.5–1231.6) 67.0 (57.0–79.6) 1393.1 (1346.7–1441.9) 
2001 142.9 (127.9–160.5) 1316.3 (1276.8–1358.0) 65.1 (55.6–77.1) 1524.3 (1477.6–1573.4) 
2002 148.6 (133.9–165.5) 1447.4 (1408.2–1488.8) 62.0 (53.2–73.1) 1658.1 (1611.9–1706.3) 
2003 155.3 (140.5–172.2) 1580.1 (1540.1–1622.1) 58.6 (50.1–69.1) 1794.0 (1747.2–1842.7) 
2004 160.6 (145.8–177.5) 1713.0 (1672.3–1755.7) 54.9 (46.9–65.0) 1928.6 (1881.3–1977.8) 
2005 167.3 (152.3–184.3) 1848.1 (1806.1–1891.9) 51.5 (43.7–61.2) 2066.9 (2018.4–2117.2) 
2006 173.4 (158.1–190.7) 1975.8 (1932.5–2021.1) 49.0 (41.4–58.5) 2198.2 (2148.3–2249.9) 
2007 176.9 (161.5–194.3) 2095.3 (2050.8–2141.7) 48.5 (41.0–57.9) 2320.7 (2269.8–2373.5) 
2008 180.8 (165.1–198.4) 2218.3 (2172.5–2266.0) 48.8 (41.3–58.3) 2447.9 (2395.6–2502.1) 
2009 185.0 (169.1–202.8) 2341.6 (2294.4–2390.6) 48.8 (41.3–58.3) 2575.3 (2521.7–2630.8) 
2010 188.8 (172.7–207.0) 2477.6 (2428.6–2528.4) 48.7 (41.1–58.3) 2715.1 (2659.6–2772.5) 
2011 193.2 (176.6–211.8) 2601.4 (2550.7–2654.0) 49.5 (41.8–59.2) 2844.1 (2786.7–2903.3) 
2012 197.5 (180.6–216.6) 2707.1 (2654.7–2761.4) 49.6 (41.8–59.4) 2954.2 (2895.1–3015.3) 
2013 201.6 (184.0–221.4) 2808.3 (2753.3–2865.3) 50.3 (42.3–60.6) 3060.2 (2998.1–3124.3) 
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5.3.7. HbA1c by year and glucose-lowering regimen in people with type 2 diabetes 
For people with type 2 diabetes, HbA1c decreased from 8.6% (71mmol/mol) in 1991 to 
7.5% (58mmol/mol) in 2013 (where 10% and 86% of patients had a recorded HbA1c 
level in those respective years, Figure 5.6). From 1991 onwards, HbA1c was higher for 
people using insulin regimens than in those using non-insulin glucose lowering 
regimens: in 1991, this was 9.5% (80mmol/mol) versus 9.0% (75mmol/mol); in 2013, 
8.7% (71mmol/mol) and 7.5% (58mmol/mol), respectively). People with type 2 
diabetes controlled with diet and exercise had the lowest average HbA1c for the entire 
study period: 8.1% (65mmol/mol) in 1991 and 6.9% (51mmol/mol) in 2013. For people 
with type 1 diabetes, HbA1c levels decreased from 9.7% (82mmol/mol) in 1991 to 8.6% 
(70mmol/mol) in 2013. In these respective years, 7% and 71% of patients had a 
recorded HbA1c value. 
 
5.3.8. HbA1c and fasting plasma glucose at diabetes presentation in people with 
type 2 diabetes 
The percentage of incident cases of type 2 diabetes with no HbA1c or FPG recorded at 
baseline decreased from 95% in 1991 to 10% in 2013 (Figure 5.7). During the same 
period, the percentage of incident cases with an HbA1c ≥ 6% (42mmol/mol) and/or FPG 
level ≥7mmol/l increased from 4% to 76% while the percentage of incident cases with 
at least one HbA1c or FPG measurement at presentation but with no HbA1c record ≥6% 
or FPG record ≥7mmol/l fluctuated from 6% in 1991 to 14% in 2002 to 5% in 2013). 
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Figure 5.6 HbA1c by year and therapy type as a three-year rolling average 
HbA1c per year was defined as the nearest record within the specific year, searching in the following order: 30 days prior, 30 days after, 180 days prior and then 184 days after the 
index date.  
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Figure 5.7 HbA1c and fasting plasma glucose (FPG) at time of diagnosis of type 2 diabetes 
  
0%
2%
4%
6%
8%
10%
12%
14%
16%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
1
9
9
1
1
9
9
2
1
9
9
3
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
%
 o
f 
p
at
ie
n
ts
 w
it
h
 a
t 
le
as
t 
o
n
e
 r
e
co
rd
e
d
 H
b
A
1
c 
o
r 
FP
G
%
 o
f 
in
ci
d
e
n
t 
ca
se
s 
o
f 
ty
p
e
 2
 d
ia
b
et
e
s 
HbA1c is null and FPG is null
HbA1c>=6% and FPG>=7mmol/l
HbA1c is null and FPG>=7mmol/l
HbA1c>=6% and FPG is null
HbA1c<6% and FPG>=7mmol/l
HbA1c>=6% and FPG<7mmol/l
HbA1c is null and FPG<7mmol/l
HbA1c<6% and FPG is null
HbA1c<6% and FPG<7mmol/l
 no Hba1c of >=6% or FPG of
>=7mmol/l
   
 163 
Year 
HbA1c <6% 
and 
FPG<7mmol/l 
HbA1c <6% 
and FPG is 
null 
HbA1c is null 
and 
FPG<7mmol/l 
HbA1c >=6% 
and 
FPG<7mmol/l 
HbA1c <6% 
and 
FPG>=7mmol/
l 
HbA1c >=6% 
and FPG is 
null 
HbA1c is null 
and 
FPG>=7mmol/
l 
HbA1c >=6% 
and 
FPG>=7mmol/
l 
HbA1c is null 
and FPG is 
null 
 No HbA1c of 
>=6% or FPG 
of >=7mmol/l 
1991 0% 0% 0% 0% 0% 3% 2% 0% 95% 6% 
1992 0% 1% 0% 0% 0% 4% 2% 0% 94% 14% 
1993 0% 1% 0% 0% 0% 7% 4% 1% 88% 7% 
1994 0% 1% 1% 0% 0% 9% 4% 1% 84% 10% 
1995 0% 2% 1% 0% 0% 10% 3% 1% 82% 13% 
1996 0% 2% 1% 0% 0% 13% 4% 2% 77% 12% 
1997 0% 3% 1% 0% 0% 16% 5% 3% 72% 14% 
1998 0% 4% 1% 0% 0% 20% 6% 3% 66% 14% 
1999 0% 3% 1% 1% 0% 23% 6% 5% 61% 12% 
2000 0% 4% 1% 1% 0% 24% 8% 5% 55% 13% 
2001 1% 4% 2% 2% 1% 26% 9% 7% 49% 13% 
2002 1% 4% 3% 2% 1% 26% 11% 9% 43% 14% 
2003 1% 3% 4% 2% 1% 27% 13% 12% 38% 13% 
2004 1% 3% 4% 3% 1% 26% 13% 15% 34% 12% 
2005 1% 2% 5% 4% 1% 27% 13% 17% 31% 11% 
2006 1% 2% 5% 4% 1% 27% 14% 17% 29% 12% 
2007 1% 2% 5% 4% 1% 27% 13% 18% 29% 12% 
2008 1% 2% 5% 4% 1% 27% 13% 20% 27% 11% 
2009 1% 2% 5% 4% 1% 29% 12% 20% 26% 11% 
2010 1% 2% 4% 5% 1% 30% 12% 23% 22% 9% 
2011 1% 2% 5% 6% 1% 30% 12% 25% 18% 9% 
2012 1% 2% 4% 7% 1% 37% 9% 27% 13% 7% 
2013 1% 2% 3% 8% 1% 45% 6% 25% 10% 5% 
 FPG and HbA1c at time of diagnosis was defined as the highest recorded value 365 days before or 30 days after the diabetes presentation data
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5.3.9. Survival by year for incident diabetes cases 
5,706 patients with type 1 diabetes and 186,921 patients with type 2 diabetes were 
followed up for a median of 6.3 and 4.5 years, respectively. Crude event rates for type 
1 and type 2 diabetes were 8.3 and 33.7 deaths per 1,000 person-years, respectively. 
For people with type 1 diabetes, increasing year of first receiving an insulin 
prescription was only associated with a statistically significant change in the risk of all-
cause mortality for 1996–2000: aHR 0.59 (95% CI 0.37–0.93); reference years 2001–
2005 (Figure 5.8). For people with type 2 diabetes, increasing year of first receiving a 
first prescription for a glucose-lowering medicine was associated with a decrease in 
the risk of mortality: aHR 1.75 (95% CI 1.60–1.92) in 1991 and 0.58 (0.48–0.70) in 2013 
(reference year = 2001).  
In people with type 2 diabetes, estimated median survival increased from 14 years in 
1991 to 18 years in 2000 and 22 years in 2009 (Figure 5.8c).
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Figure 5.8  Age- and sex-adjusted hazard ratios for all-cause mortality by year of initiating glucose-lowering therapy for type 2 diabetes 
a) Adjusted hazard ratios for type 1 diabetes from the earliest of diabetes diagnosis or first prescription for insulin 
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b) Adjusted hazard ratios for type 2 diabetes from first glucose-lowering drug exposure 
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c)  Estimated median survival for patients with type 2 diabetes from first glucose-lowering drug exposure 
 
 
For b), the proportional hazards assumption was violated for age. Therefore age was added as a Heaviside function (<=180 days and >180 days) 
For c), survival curves did not cross 0.5 for years after 2009.
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5.4. Discussion 
The estimated prevalence of clinically diagnosed and recorded diabetes trebled 
between 1991 and 2013, largely due to an increase in the prevalence of type 2 
diabetes. Improvements in glucose control and survival were observed in type 2 
diabetes but not in type 1 diabetes. 
Diabetes UK estimated that the prevalence of diabetes was 4% in 2009, slightly lower 
than our estimate of 4.3%.420 However, results from a study of diabetes prevalence in 
a resident population of Cardiff were similar to those estimated in this study (2.3% in 
1996, increasing to 3.4% in 2005).416 The trend of increasing prevalence of type 2 
diabetes has also been observed worldwide. The latest IDF figures indicated that the 
worldwide prevalence of diabetes in adults is 8.3%, equating to 384 million people.14  
 
5.4.1. Type 1 diabetes 
5.4.1.1. Prevalence 
The estimated prevalence of diagnosed and recorded type 1 diabetes increased from 
0.19% (95% CI 0.18%–0.19%) in 1991 to 0.32% (95% CI 0.31%–0.32%) in 2013. The 
prevalence of type 1 diabetes has been estimated to have been 0.3% in 1996, and 0.4% 
for males and 0.3% for females in 1997.429,430 We have previously reported an increase 
in the prevalence of type 1 diabetes from 0.1% in 1991 to 0.2% in 2010.422 Here we 
have report a higher crude prevalence of type 1 diabetes: 0.2% in 1991, increasing to 
0.3% in 2013. Possible explanations for this discrepancy include: different methods for 
accounting for gaps between prescriptions, differences in selection criteria, time 
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between diabetes diagnosis and the first prescription for insulin and time between the 
last prescription for insulin and the censor date. 
The prevalence of type 1 diabetes calculated using data from both CPRD and HES was 
lower than that calculated using only CPRD data. This could indicate a regional 
difference in the prevalence of type 1 diabetes as all HES eligible practices were 
English. However, more patients in the analysis using data from both CPRD and HES 
were classified as diabetes of unknown type. 
Increasing prevalence of type 1 diabetes could also be partly due to an increase in 
incidence. The World Health Organization’s (WHO) Multinational Project for Childhood 
Diabetes (DIAMOND) found that the incidence of type 1 diabetes increased 
significantly worldwide between 1991 and 1999 with increases of 4.0% in Asia, 3.2% in 
Europe and 5.3% in North America reported 431. In Colorado, USA, the incidence of 
type 1 diabetes increased 1.6-fold between 1978 and 2004 in young people aged 0–17 
years 432. The EURODIAB ACE Study Group reported an annual increase in type 1 
diabetes incidence of 3.4% (95% CI 2.5%–4.4%) between 1989–1994 in Europe 433. 
 
5.4.1.2. Glucose control 
HbA1c levels in people with type 1 diabetes remained relatively stable from 2000 
onwards, where mean HbA1c was 8.6% in 2000 and 2013. The UK’s NICE recommends 
an HbA1c target of 7.5% for glycaemic control in people with type 1 diabetes.70 The 
ADA recommends an HbA1c target of less than 7.5% in people below 18 years, less than 
7.0% in adults and less than 7.5%–8.5% (depending upon morbidity) in older adults.434 
In the USA, 17% of young people with type 1 diabetes have been found to have poor 
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glycaemic control (HbA1c >9.5%).435 In Germany and Austria, HbA1c in children and 
young adults with type 1 diabetes decreased from 8.9% in 1995 to 8.0% in 2012.436 
The DCCT and long-term Epidemiology of Diabetes Interventions and Complications 
(EDIC) follow-up study found that intensive blood-glucose control reduced the risk of 
microvascular and cardiovascular complications in type 1 diabetes.216,437 In a recently 
published Cochrane review, the risk of developing microvascular complications was 
reduced for retinopathy (RR=0.27, 95% CI 0.18–0.42), nephropathy (0.56, 0.46–0.68) 
and neuropathy (0.35, 0.23–0.53) for intensive glycaemic control versus conventional 
treatment.438 However, due to the small number of events, no firm conclusion could 
be reached regarding macrovascular outcomes.438 In a recent paper from the 
EURODIAB cohort, a U-shaped association was reported between HbA1c and all-cause 
mortality, with the lowest risk being reported for patients with an HbA1c of 7–8%.439 
Other studies have reported an association between worsening glycaemic control and 
increased risk of cardiovascular disease and cardiovascular and all-cause mortality.440–
442 Even people with good glycaemic control (HbA1c ≤6.9%) had double the risk of 
death when compared with people without diabetes.442 
 
5.4.1.3. Relative survival 
There was no reduction in all-cause mortality in those with type 1 diabetes during the 
study period. However, the length of follow-up from disease incidence was relatively 
short (mean 7.0, median 6.3 years). Therefore, our estimates are likely to relate to 
short-term mortality in type 1 diabetes rather than mortality due to diabetic 
complications such as cardiovascular disease. A study using data from 13 population-
based EURODIAB registers found that there was significant excess mortality in people 
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with type 1 diabetes diagnosed in childhood in the absence of late diabetic 
complications.443 One-third of deaths were directly attributed to diabetes and many of 
these deaths mentioned ketoacidosis.443 Duration of type 1 diabetes has been shown 
to be associated with a higher adjusted mean rate of cardiovascular disease (4% for 
durations of 21–40 years versus 0.8% for 1–20 years).441 
Several studies have reported a reduction in the risk of all-cause and cardiovascular 
mortality66,444–446 and a corresponding increase in life expectancy over time in people 
with type 1 diabetes.447 However, one study reported that mortality rates for people 
with type 1 diabetes only decreased between 1968 and 1984, before reaching a 
plateau between 1984 and 1998.448 People with type 1 diabetes diagnosed between 
the ages of 0–14 had improved survival in 1970–1974 compared with 1985–1989.449 
However, the reverse was true for people diagnosed between the ages of 15–29.449 
Nephropathy was found to be the biggest factor in the excess mortality seen in type 1 
diabetes.445,450 Amputation and poor visual acuity have also been reported to be 
significant predictors of mortality in people with type 1 diabetes.451 
 
5.4.2. Type 2 diabetes 
5.4.2.1. Prevalence 
We have previously demonstrated that the incidence of diagnosed and recorded type 
2 diabetes increased three-fold in the UK between 1991 and 2010 and that the 
percentage of people diagnosed before the age of 40 years increased with each 
increasing five-year calendar period (5.9% for 1991–1995 and 12.4% for 2006–
2010).421 Previous studies have estimated that the prevalence of type 2 diabetes was 
1.2% in 1996429 and 2.0% for males and 1.7% for females in 1997 (in Clwyd, Wales).430 
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Masso González and colleagues reported an increase in prevalence of type 2 diabetes 
from 2.6% to 4.3% between 1996 and 2005.9 
The increase in type 2 diabetes prevalence is linked to obesity. Between 1993 and 
2010, the proportion of obese people increased from 13% to 26% for men and from 
16% to 26% for women.13 The age of onset of type 2 diabetes has been shown to be 
inversely related to BMI,22 and intensive lifestyle intervention with a minimum of 7% 
weight loss and 150 minutes of physical activity per week has been shown to reduce 
the incidence rate for diabetes by 58%.23  
The increase in the prevalence of type 2 diabetes may also be due to increasing 
diabetes ascertainment. As the early symptoms of type 2 diabetes can be mild, people 
with type 2 diabetes can remain undiagnosed for many years.17 Improved detection of 
type 2 diabetes through, for example, the implementation in the UK of the National 
Diabetes Framework, NHS Health Checks and QOF, may have led to earlier diagnosis of 
type 2 diabetes. In addition, changes were made to the criteria for diagnosing type 2 
diabetes during the study period, including the introduction of the WHO’s new 
diagnostic criteria.405 Here we found evidence that there has been misclassification of 
type 2 diabetes, and of a magnitude that was surprisingly high. Furthermore, as the 
longevity of the UK population increases, more people live long enough to develop 
type 2 diabetes.452 In addition, improvements in diabetes management have also 
increased life expectancy for people with diabetes.152,452–456 Improved recording of 
diabetes diagnoses may have occurred during the study period. 
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5.4.2.2. Glucose control 
NICE and EASD/ADA guidelines recommend HbA1c targets of 6.5% and 7%, 
respectively, although a target of 7.5% may be necessary for some people.7,55 HbA1c 
levels remained higher than NICE recommendations for those people with type 2 
diabetes treated with insulin regimens during the study period. Other observational 
studies have also shown that patients with type 2 diabetes have poor control and 
delayed treatment intensification.457–461 
The UKPDS found that intensive control of blood glucose reduced the risk of 
developing microvascular but not macrovascular complications.67 However, after the 
10-year follow-up observational study, cardiovascular benefits associated with 
intensive control were reported.112 Subsequent randomised controlled trials and meta-
analyses have not demonstrated that intensive treatment was associated with a 
significantly reduced risk of cardiovascular events79,217,218 or mortality.111 Observational 
studies have reported a U-shaped association between HbA1c levels and an increased 
risk of all-cause mortality and cardiac events.60,222–224 
 
5.4.2.3. Relative survival 
Reduced risk of all-cause mortality in people with type 2 diabetes suggests that the 
overall management of this condition has improved. In people with type 2 diabetes, 
estimated median survival increased from 14 years in 1991 to 22 years in 2009. To put 
this in context, for 63 years olds (the mean age of subjects in this analysis), overall life 
expectancy increased from 15.3 years in 1991 to 19.1 years in 2009 for males and from 
19.3 years to 21.9 years, respectively, for females.462 However, this is not a direct 
comparison as mean and median survival has been compared. During the study period, 
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reductions in systolic blood pressure and total cholesterol were observed for people 
with type 2 and type 1 diabetes, whilst the number of people receiving 
antihypertensive, lipid-lowering and antiplatelet therapy increased. Life expectancy in 
type 2 diabetes has been shown to vary depending on several risk factors, including 
HbA1c, blood pressure, the ratio of total:HDL cholesterol and diabetes duration.161 The 
launch of novel glucose-lowering medications,69 diabetes teaching programmes, 
improved detection of diabetic complications and tobacco reforms may have also 
contributed to improved survival during the study period. Numerous studies have 
reported a reduced risk of all-cause and cardiovascular disease mortality in people 
with diabetes,152–159 and with type 2 diabetes specifically.66 However, one study has 
reported that improvement in survival of people with diabetes between 1971–1986 
and 1988–2000 was limited to men.463 A US population study found that the mortality 
burden associated with diabetes mellitus increased significantly from 1970–1994.160 
However, earlier diagnosis of type 2 diabetes through improved detection and changes 
in diagnostic criteria may cause an apparent improvement in survival following 
diabetes diagnosis, even in the absence of a genuine improvement in survival following 
true diabetes onset. The contribution of earlier diagnosis to the overall improvement 
in survival observed during the study period cannot be quantified. 
 
5.4.3. Study limitations 
CPRD GOLD is a very large longitudinal dataset which has been shown to be 
representative of the population in terms of crude mortality and the age and gender 
structure.364,365 However, age-standardised mortality rates are 9–13% lower than the 
national average.364 In a systematic review, a positive predictive value of more than 
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50% was reported for most conditions investigated.367 Patient consulting rates for 
diabetes were reported to be lower in GPRD when compared with those obtained 
from the 4th National Study of Morbidity Statistics from General Practice (MSGP4) in a 
study conducted between September 1991 and August 1992.464 However, data 
recording practices differed between sources.464 Chronic conditions may only be 
recorded at diagnosis in GPRD whereas every consultation was recorded in MSGP4.464 
In a more recently conducted systematic review, Herrett and colleagues, reported that 
the median proportion of cases with a confirmed diagnosis was 89% (range 24–
100%).368 and these data are generally representative of the UK population. However, 
misclassification of diabetes type was possible due to the recording of conflicting 
diagnoses or the absence of a record for a specific diabetes type. Changes to the 
coding of diabetes may have occurred in recent years. ‘Insulin-dependent diabetes 
mellitus’ or IDDM was commonly used in earlier years, and some people with type 2 
diabetes receiving prescriptions for insulin may have been attributed a code for IDDM 
leading to misclassiﬁcation. HbA1c or glucose levels were not used in the selection 
criteria. However, a series of decision rules was applied to maintain consistency in 
patient selection (Table 5.1).  
The true prevalence of diabetes cannot be calculated from CPRD, as the number of 
people with undiagnosed diabetes cannot be determined, although improved 
detection of diabetes may have led to better diagnosis of type 2 diabetes in more 
recent years. The symptoms of type 2 diabetes can be mild, and people with the 
condition may remain undiagnosed initially. Conversely, severe symptoms develop 
quickly after the onset of type 1 diabetes. This condition is therefore normally 
diagnosed and treated quickly.  
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5.4.4. Conclusion 
The estimated prevalence of diagnosed and recorded type 2 diabetes increased 
markedly and consistently in the UK over the two decades between 1991 and 2013.  
Improvements in glucose control and survival were observed in people with type 2 
diabetes but not in people with type 1 diabetes. However, the short follow-up time 
needs to be taken into account when interpreting survival in type 1 diabetes. In 
addition to higher incidence, improved survival in people with type 2 diabetes explains, 
in part, the increased prevalence rates observed between 1991 and 2013.  
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6. Prevalence of insulin use and an estimate of the number of 
insulin users in the UK between 1991 and 2010 
This is the accepted version of the following article: Holden SE, Gale EA, Jenkins-Jones 
S, Currie CJ. How many people inject insulin? UK estimates from 1991 to 2010. 
Diabetes Obes Metab 2014:16:553-9. This study has been published in final form at 
[http://onlinelibrary.wiley.com/doi/10.1111/dom.12260/abstract]. Deviations from 
the published version of this manuscript are underlined. The discussion is based on the 
accepted version of the manuscript published by Diabetes Obesity and Metabolism 
and the submitted and pre-peer reviewed drafts of the manuscript. 
 
6.1. Introduction 
6.1.1. Background 
In the UK, the overall prevalence of diabetes increased from 2.8% to 4.3% between 
1996 and 2005. This has been largely driven by an increase in the prevalence of type 2 
diabetes.9 In terms of the UK population as a whole, the estimated number of people 
with diabetes has risen from 1.4 million to 2.8 million between 1996 and 2010.420 The 
management of patients with diabetes involves the lowering of blood glucose and the 
control of cardiovascular risk factors. Type 1 diabetes results from the autoimmune 
destruction of insulin producing beta cells in the pancreas and therefore the use of 
exogenous insulin is essential in these patients. However, type 2 diabetes is a 
progressive condition characterised by insulin resistance and relative insulin 
insufficiency and can be managed by one or a combination of lifestyle factors, oral 
glucose-lowering medication, non-insulin injectable glucose-lowering medication and 
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insulin. NICE generally recommends insulin as third line therapy in type 2 diabetes 
when metformin and a sulfonylurea, where tolerated have not adequately controlled 
HbA1c levels.55  
UKPDS reported that improved glucose control through the earlier use of glucose-
lowering therapies (insulin and sulfonylureas) reduced the risk of microvascular but 
not macrovascular complications, all-cause mortality or quality of life.67 In addition, the 
UKPDS demonstrated that the use of metformin was associated with a reduced risk of 
diabetes-related endpoints. Subsequently, metformin has been recommended as first 
line therapy for many people with type 2 diabetes.82 UKPDS may have also influenced 
clinical practice as lower targets were advocated for blood glucose control. This may 
have encouraged the early elective use of insulin. 
Currently, there are no estimates of the number of people with type 1 and type 2 
diabetes using insulin in the UK. However, the number of items and overall volume of 
insulin dispensed has increased year on year (Chapter 7). Between 2000 and 2009, the 
total annual cost of insulin in the UK increased from £156 million in 2000 to £359 
million in 2009 (adjusted to 2010 prices) (Chapter 7). This is, at least in part, due to the 
introduction of more expensive insulin analogues and the more frequent use of insulin 
in type 2 diabetes. In England alone, the total cost of medicines used to treat diabetes 
increased from £573.9 million to £725.1 million between 2005/6 and 2009/10 and the 
cost of insulin prescriptions increased from £220.8 million to £307.5 million during the 
same period.465 In the US, 25.8 million people (8.3% of the population) had diabetes in 
2010466 and the number of people treated with insulin increased from 3.4 million 
(33.4%) in 1997 to 5.7 million (27.5%) in 2010. However, this represented a decrease in 
the proportion of people with diabetes using insulin in people over 40.467–469  
   
 179 
 
6.1.2. Aims and objectives 
The aim of this study was to calculate the rates of insulin and the relative rates of 
insulin use in type 1 and type 2 diabetes in the UK population.   
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6.2. Methods 
6.2.1. CPRD 
The data source used for this study was CPRD. CPRD contains clinically rich, 
pseudonymized data collected in a non-interventional manner from the daily record 
keeping of primary care physicians in the UK. These data include patient demographics 
and registration information, consultations, medical history and diagnoses, test results, 
immunizations, referrals, outpatient letters and prescriptions. CPRD is broadly 
representative of the UK population and contains to date over 12 million research- 
quality patients registered at 660 practices. The data extract used in this study 
included records up to June 2012. 
 
6.2.2. Prevalence of insulin use in the UK 
In this retrospective study, patients denoted by CPRD as being of research quality were 
identified if they had received a prescription for insulin within the study period (1991 
to 2010). The index date was the date of a patient’s first prescription for insulin. 
Patients were classed as a prevalent case until the date of their last insulin prescription 
or the date of their transferring out of practice or the end of the study period, 
whichever was earliest. Patients using insulin were assigned a diagnosis of type 1 or 
type 2 diabetes using a series of decision rules based on age at diagnosis, diagnosis 
type (type 1, type 2, or type unspecified), and history of prescriptions for insulin and 
other glucose-lowering medicines (Table 6.1). Patients were assigned a diagnosis of 
secondary diabetes if they had a code suggestive of secondary diabetes in their CPRD 
record. A small number of patients who had unclassifiable diabetes type were assigned 
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to type 1 or type 2 depending on the ratio of patients with type 1 to type 2 diabetes 
amongst known cases stratified by age (five-year groups) and sex. 
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Table 6.1 Decision rules implemented to assign a diagnosis of type 1 or type 2 diabetes to the insulin users. 
Type 1 diagnosis Type 2 diagnosis Diagnosis of 
unknown 
diabetes type 
Insulin Rx OHA 
prescription 
More than one 
OHA 
Age at 
presentation 
Diabetes type Extra criteria 
1 1 1 1 1 1 <35 2  
1 1 1 1 1 1 >=35 2  
1 1 1 1 1 0 <35 2  
1 1 1 1 1 0 >=35 2  
1 1 1 1 0 0 <35 1  
1 1 1 1 0 0 >=35 2 12-month wash-in 
1 1 0 1 1 1 <35 2  
1 1 0 1 1 1 >=35 2  
1 1 0 1 1 0 <35 2  
1 1 0 1 1 0 >=35 2  
1 1 0 1 0 0 <35 1  
1 1 0 1 0 0 >=35 2 12-month wash-in 
1 0 1 1 1 1 <35 2  
1 0 1 1 1 1 >=35 2  
1 0 1 1 1 0 <35 1 If OHA<1yr 
1 0 1 1 1 0 >=35 x  
1 0 1 1 0 0 <35 1  
1 0 1 1 0 0 >=35 1  
1 0 0 1 1 1 <35 2  
1 0 0 1 1 1 >=35 2  
1 0 0 1 1 0 <35 1 If OHA<1yr 
1 0 0 1 1 0 >=35 x  
1 0 0 1 0 0 <35 1  
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Type 1 diagnosis Type 2 diagnosis Diagnosis of 
unknown 
diabetes type 
Insulin Rx OHA 
prescription 
More than one 
OHA 
Age at 
presentation 
Diabetes type Extra criteria 
1 0 0 1 0 0 >=35 1  
0 1 1 1 1 1 <35 2  
0 1 1 1 1 1 >=35 2  
0 1 1 1 1 0 <35 2  
0 1 1 1 1 0 >=35 2  
0 1 1 1 0 0 <35 2  
0 1 1 1 0 0 >=35 2 12-month wash-in 
0 1 0 1 1 1 <35 2  
0 1 0 1 1 1 >=35 2  
0 1 0 1 1 0 <35 2  
0 1 0 1 1 0 >=35 2  
0 1 0 1 0 0 <35 2  
0 1 0 1 0 0 >=35 2 12-month wash-in 
0 0 1 1 1 1 <35 2  
0 0 1 1 1 1 >=35 2  
0 0 1 1 1 0 <35 1 If OHA<1yr 
0 0 1 1 1 0 >=35 2 12-month wash-in 
0 0 1 1 0 0 <35 1  
0 0 1 1 0 0 >=35 2 12-month wash-in 
0 0 0 1 1 1 <35 2  
0 0 0 1 1 1 >=35 2  
0 0 0 1 1 0 <35 1 If OHA<1yr 
0 0 0 1 1 0 >=35 2 12-month wash-in 
0 0 0 1 0 0 <35 1  
0 0 0 1 0 0 >=35 x  
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The method used to calculate the point prevalence of insulin use was similar to that of 
a census. If a patient was using insulin at the mid-year point they were included as a 
prevalent case regardless of their duration of therapy. However, in order to be 
included, the patient had to have a prescription for insulin issued on or before 30th 
June of the year in question and a prescription issued on or after 30th June of the same 
year. Although theoretically a patient could have been included as a prevalent case if 
they had only received one prescription for insulin provided it was issued on exactly 
the 30th June, the majority of patients included will have received at least two 
prescriptions for insulin before and after the mid-year point. The prevalence of insulin 
use was then calculated by dividing the number of insulin users in CPRD on the 30th 
June each year from 1991 to 2010 by the number of patients in CPRD on the same 
date. The prevalence of type 1 and type 2 diabetes was calculated using the same 
formula. The age- and sex-stratified prevalence of insulin use per diabetes type was 
then multiplied by the total UK population from data from the ONS428 to produce an 
estimate of the number of insulin users in the UK.  
Treatment patterns per year were determined for prevalent cases of type 2 diabetes 
treated with insulin. The percentage of patients with type 2 diabetes using insulin was 
then calculated by dividing the number of patients with type 2 diabetes using insulin 
by the total number of patients with type 2 diabetes (i.e. those patients with type 2 
diabetes using insulin or other glucose-lowering medicines or being diet-controlled) at 
the mid-year point. Diet-controlled patients were identified if they had type 2 diabetes 
but had received no prescriptions for a glucose-lowering medication prior to the mid-
year point (relaxed criteria). As a sensitivity analysis, we also applied more strict 
selection criteria for diet-controlled diabetes where at least one of the following 
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criteria must also apply: more than one prescription for a glucose biosensor strip or a 
Read code for diabetes on diet only.  
 
6.2.3. Incident cases of insulin use 
Baseline characteristics were generated only for incident cases of insulin use. Incident 
cases were identified as patients who had received their first prescription for insulin 
within the study period and had a wash-in period of at least 365 days between their 
registration date and their first insulin prescription.  
 
6.2.4. Statistical analysis 
Wilson (or score) 95% confidence intervals were calculated for prevalence rates,385 and 
the linear-by-linear Chi-square test was used to test if there was any association 
between calendar year and the number of insulin users in CPRD. All statistical analysis 
was carried out in SPSS PASW Statistics 18. 
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6.3. Results 
6.3.1. Baseline characteristics 
The overall mean age at insulin initiation increased with each increasing five-year 
period from 52.5 years (SD 20.5) in 1991–1995 to 58.1 (19.9) in 2005–2010 (Table 6.2). 
Between 1991–1995 and 2006–2010, the baseline mean (SD) HbA1c at insulin initiation 
was 10.0% (2.6%) in 1991–1995, 9.7% (2.0%) in 1996–2000, 9.7% (1.9%) in 2001–2005, 
and 9.8% (2.0%) in 2006–2010. The baseline characteristics for incident cases of insulin 
use are detailed in Table 6.2. 
 
6.3.2. CPRD: total users and prevalence of insulin treatment 
The number of insulin users at the mid-year point in CPRD increased from 8,065 in 
1991 to 42,518 in 2010 (Table 6.3). During the same period, the number of people in 
CPRD increased from 3.32 million to 6.34 million. The crude prevalence of insulin use 
increased from 1.74 (95% CI 1.69–1.78) and 0.67 (0.64–0.70) per 1,000 people in 1991, 
to 2.23 (2.20–2.27) and 4.38 (4.32–4.43) per 1,000 in 2009, before decreasing to 2.21 
(2.18–2.25) and 4.34 (4.29–4.39) per 1,000 people in 2010, for patients with type 1 
(P<0.001) and type 2 (P<0.001) diabetes, respectively. The overall crude prevalence of 
insulin use increased from 2.43 (2.38–2.49) per 1,000 people in 1991 to 6.76 (6.70–
6.83) per 1,000 people in 2009, before decreasing to 6.71 (6.64–6.77) per 1,000 people 
in 2010 (P<0.001). 
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Table 6.2 Baseline characteristics in CPRD for incident cases of insulin use 
Parameter 1991–1995 1996–2000 2001–2005 2006–2010 
n 6,033 13,386 19,557 17,037 
Male, n (%) 3,126 (51.8) 7,047 (52.6) 11,021 (56.4) 10,008 (58.7) 
Age at first insulin Rx, years 
    
Mean (SD) 52.5 (20.5) 56.3 (19.5) 58.0 (19.1) 58.1 (19.9) 
Median (IQR) 57.0 (38.0–68.0) 61.0 (46.0–70.0) 62.0 (49.0–72.0) 62.0 (49.0–72.0) 
Smoking, n (%) 
    
Non- 3,441 (57.0) 7,123 (53.2) 8,619 (44.1) 6,174 (36.2) 
Ex- 656 (10.9) 2,637 (19.7) 6,565 (33.6) 7,242 (42.5) 
Current 1,236 (20.5) 2,860 (21.4) 3,856 (19.7) 3,008 (17.7) 
Unknown 700 (11.6) 766 (5.7) 517 (2.6) 613 (3.6) 
HbA1c (%)      
n (%) 841 (14) 5,349 (40) 14,382 (74) 14,187 (83) 
Mean (SD), % 10.0 (2.6) 9.7 (2.0) 9.7 (1.9) 9.8 (2.0) 
Mean (SD), mmol/mol 85.4 (27.9) 83.0 (21.8) 82.0 (21.2) 83.8 (22.4) 
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Table 6.3 Number and prevalence of insulin use in CPRD 
Year 
Number of cases CPRD Number of 
people in 
CPRD 
Prevalence per 1,000 population (95% CI) 
Type 1 
diabetes 
Type 2 
diabetes 
Secondary 
diabetes 
Total 
Type 1 
diabetes 
Type 2 
diabetes 
Secondary 
diabetes 
Total 
1991 5,767 2,227 71 8,065 3,316,316 1.74 (1.69–1.78) 0.67 (0.64–0.70) 0.02 (0.02–0.03) 2.43 (2.38–2.49) 
1992 6,316 2,824 100 9,240 3,569,712 1.77 (1.73–1.81) 0.79 (0.76–0.82) 0.03 (0.02–0.03) 2.59 (2.54–2.64) 
1993 6,838 3,472 122 10,432 3,838,099 1.78 (1.74–1.82) 0.90 (0.88–0.94) 0.03 (0.03–0.04) 2.72 (2.67–2.77) 
1994 7,317 4,228 142 11,687 4,122,398 1.77 (1.73–1.82) 1.03 (1.00–1.06) 0.03 (0.03–0.04) 2.84 (2.78–2.89) 
1995 7,590 4,962 169 12,721 4,381,006 1.73 (1.69–1.77) 1.13 (1.10–1.16) 0.04 (0.03–0.04) 2.90 (2.85–2.95) 
1996 8,142 5,867 203 14,212 4,638,588 1.76 (1.72–1.79) 1.26 (1.23–1.30) 0.04 (0.04–0.05) 3.06 (3.01–3.11) 
1997 8,907 7,204 247 16,358 4,861,244 1.83 (1.79–1.87) 1.48 (1.45–1.52) 0.05 (0.04–0.06) 3.36 (3.31–3.42) 
1998 9,529 8,560 297 18,386 5,044,775 1.89 (1.85–1.93) 1.70 (1.66–1.73) 0.06 (0.05–0.07) 3.64 (3.59–3.70) 
1999 10,079 10,514 350 20,943 5,218,564 1.93 (1.89–1.97) 2.01 (1.98–2.05) 0.07 (0.06–0.07) 4.01 (3.96–4.07) 
2000 10,743 12,995 420 24,158 5,395,114 1.99 (1.95–2.03) 2.41 (2.37–2.45) 0.08 (0.07–0.09) 4.48 (4.42–4.53) 
2001 11,301 15,203 469 26,973 5,539,020 2.04 (2.00–2.08) 2.74 (2.70–2.79) 0.08 (0.08–0.09) 4.87 (4.81–4.93) 
2002 11,868 17,376 552 29,796 5,664,016 2.10 (2.06–2.13) 3.07 (3.02–3.11) 0.10 (0.09–0.11) 5.26 (5.20–5.32) 
2003 12,474 19,633 615 32,722 5,796,955 2.15 (2.11–2.19) 3.39 (3.34–3.43) 0.11 (0.10–0.11) 5.64 (5.58–5.71) 
2004 12,969 22,087 706 35,762 5,939,605 2.18 (2.15–2.22) 3.72 (3.67–3.77) 0.12 (0.11–0.13) 6.02 (5.96–6.08) 
2005 13,699 24,307 796 38,802 6,103,500 2.24 (2.21–2.28) 3.98 (3.93–4.03) 0.13 (0.12–0.14) 6.36 (6.29–6.42) 
2006 13,944 25,681 865 40,490 6,191,800 2.25 (2.21–2.29) 4.15 (4.10–4.20) 0.14 (0.13–0.15) 6.54 (6.48–6.60) 
2007 14,068 26,658 923 41,649 6,276,979 2.24 (2.20–2.28) 4.25 (4.20–4.30) 0.15 (0.14–0.16) 6.64 (6.57–6.70) 
2008 14,227 27,622 962 42,811 6,334,429 2.25 (2.21–2.28) 4.36 (4.31–4.41) 0.15 (0.14–0.16) 6.76 (6.69–6.82) 
2009 14,259 27,922 986 43,167 6,382,181 2.23 (2.20–2.27) 4.38 (4.32–4.43) 0.15 (0.15–0.16) 6.76 (6.70–6.83) 
2010 14,017 27,530 971 42,518 6,338,431 2.21 (2.18–2.25) 4.34 (4.29–4.39) 0.15 (0.14–0.16) 6.71 (6.64–6.77) 
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6.3.3. Estimates of UK insulin users 
The estimated number of insulin users in the UK increased from 136,800 (95% CI 
120,700–155,200) in 1991 to 421,300 (399,800–444,100) in 2010 (Table 6.4). In 1991, 
more people using insulin had type 1 diabetes than had type 2 diabetes (98,400 
[85,000–114,300] versus 37,000 [30,200–46,200]). By 2010, this situation had 
reversed, where 134,900 (123,100–148,000) and 277,400 (262,800–293,300) had type 
1 and type 2 diabetes, respectively (Table 6.4). 
 
6.3.4. Insulin use in type 2 diabetes 
The prevalence rate of people with type 2 diabetes injecting insulin increased from 
0.67 (0.64–0.70) per 1,000 people in 1991 to 4.34 (4.29–4.39) per 1,000 people in 
2010: a 6.5-fold increase (Table 6.3). The total number of people with type 2 diabetes 
injecting insulin increased from 37,000 (30,200–460,200) in 1991 to 277,400 (262,800–
293,300) in 2010: a 7.5-fold increase (Table 6.4). 
Taking prevalent cases of insulin use for patients with type 2 diabetes, the majority of 
patients in 1991 were treated with insulin alone (97%; Figure 6.1), with the largest 
percentage of patients receiving premixed insulin (52%). By 2010, more patients were 
treated with a combination of insulin plus at least one type of oral glucose-lowering 
medication (63%) than with insulin alone (37%), with the largest percentage of 
patients (43%) receiving a combination of premixed insulin plus metformin.
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Table 6.4 Estimated number of insulin users in the UK 
 
 
Estimated number of insulin users x1,000 (95% CI) 
Year Type 1 diabetes Type 2 diabetes Secondary diabetes Total 
1991 98.4 (85.0–114.3) 37.0 (30.2–46.2) 1.3 (0.6–4.5) 136.8 (120.7–155.2) 
1992 100.5 (87.4–115.8) 43.8 (36.6–53.3) 1.7 (0.8–4.9) 146.0 (130.0–164.3) 
1993 101.3 (88.6–116.2) 50.5 (43.0–60.2) 1.9 (1.0–5.0) 153.8 (137.8–171.9) 
1994 101.0 (88.8–115.3) 57.8 (50.0–67.6) 2.1 (1.1–5.0) 161.0 (145.1–178.7) 
1995 98.9 (87.1–112.6) 64.3 (56.3–74.2) 2.3 (1.2–5.2) 165.5 (149.9–183.0) 
1996 100.4 (88.8–113.7) 72.4 (64.0–82.4) 2.6 (1.5–5.5) 175.3 (159.6–192.7) 
1997 105.0 (93.4–118.3) 85.6 (76.7–96.1) 2.9 (1.7–5.8) 193.5 (177.3–211.4) 
1998 108.5 (96.9–121.7) 98.8 (89.4–109.9) 3.4 (2.0–6.3) 210.7 (194.1–228.9) 
1999 111.3 (99.7–124.4) 118.4 (108.3–130.2) 3.9 (2.4–6.9) 233.6 (216.4–252.3) 
2000 115.2 (103.6–128.3) 142.9 (131.9–155.5) 4.5 (2.9–7.6) 262.6 (244.6–282.1) 
2001 118.6 (107.0–131.7) 164.1 (152.3–177.3) 4.9 (3.2–8.1) 287.6 (268.9–307.7) 
2002 122.2 (110.5–135.3) 184.1 (171.8–197.9) 5.6 (3.8–8.9) 311.9 (292.7–332.6) 
2003 125.7 (114.0–138.7) 204.9 (192.0–219.2) 6.1 (4.2–9.5) 336.7 (316.9–357.8) 
2004 128.1 (116.4–141.2) 226.4 (213.0–241.2) 6.9 (4.8–10.3) 361.4 (341.1–383.0) 
2005 132.5 (120.7–145.6) 244.9 (231.1–260.1) 7.6 (5.4–11.1) 385.0 (364.3–407.0) 
2006 133.7 (122.0–146.8) 256.2 (242.2–271.6) 8.1 (5.9–11.7) 398.1 (377.2–420.4) 
2007 133.9 (122.2–146.9) 264.4 (250.1–279.9) 8.6 (6.3–12.2) 406.8 (385.7–429.2) 
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Year Type 1 diabetes Type 2 diabetes Secondary diabetes Total 
2008 135.0 (123.4–148.0) 273.6 (259.1–289.3) 8.9 (6.6–12.5) 417.4 (396.2–440.0) 
2009 135.1 (123.4–148.2) 276.7 (262.2–292.6) 9.1 (6.7–12.8) 420.9 (399.6–443.6) 
2010 134.9 (123.1–148.0) 277.4 (262.8–293.3) 9.1 (6.7–12.8) 421.3 (399.8–444.1) 
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Figure 6.1 Treatment patterns for prevalent cases of insulin use with type 2 diabetes 
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The estimated percentage of patients in CPRD with type 2 diabetes and using insulin 
increased from 5% in 1991 to 16% in 2009, before decreasing slightly to 15% in 2010 
(Figure 6.2). For patients with type 2 diabetes treated with at least one concomitant 
oral glucose-lowering medicine, 9%, 20%, and 19% of patients were using insulin in 
1991, 2009, and 2010, respectively. 
The prevalence of type 1 and type 2 diabetes in the UK between 1991 and 2010 is 
listed in Table 6.5. 
 
Table 6.5 Prevalence of diabetes in the UK 1991–2010 
Year Prevalence of type 
1 diabetes 
Prevalence of type 
2 
Overall prevalence 
of diabetes 
1991 0.1% 1.1% 1.4% 
1992 0.1% 1.2% 1.4% 
1993 0.1% 1.3% 1.5% 
1994 0.1% 1.3% 1.5% 
1995 0.1% 1.4% 1.6% 
1996 0.1% 1.5% 1.7% 
1997 0.2% 1.5% 1.8% 
1998 0.2% 1.6% 1.9% 
1999 0.2% 1.7% 2.0% 
2000 0.2% 1.8% 2.1% 
2001 0.2% 2.0% 2.2% 
2002 0.2% 2.1% 2.4% 
2003 0.2% 2.3% 2.6% 
2004 0.2% 2.5% 2.8% 
2005 0.2% 2.6% 2.9% 
2006 0.2% 2.8% 3.1% 
2007 0.2% 2.9% 3.3% 
2008 0.2% 3.2% 3.5% 
2009 0.2% 3.4% 3.7% 
2010 0.2% 3.6% 4.0% 
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Figure 6.2 The percentage of patients with type 2 diabetes using insulin 
  
Red line = percentage of all patients diagnosed with type 2 diabetes using insulin; blue line = percentage of all patients with type 2 diabetes using insulin when the more strict 
criteria for selecting diet-controlled patients was applied (>1 prescription for a glucose biosensor strip or a Read code for diabetes on diet only); green line = percentage of treated 
patients with type 2 diabetes using insulin. The shaded section represents the difference between the percentage of patients using insulin when the strict and relaxed criteria are 
used for the selection of patients with diet-controlled type 2 diabetes. 
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6.4. Discussion 
6.4.1. Main findings 
The estimated number of people injecting insulin in the UK increased three-fold over 
the 20-year study period from 1991–2010. During the same interval, there was a 
seven-fold increase in the number of people assigned a diagnosis of type 2 diabetes 
and treated with insulin as against a 30% increase in those assigned a diagnosis of type 
1 diabetes. These estimates should, however, be treated with caution because 
diagnostic classification has changed over the last 20 years and the clinical subdivision 
of the two types of diabetes may be imprecise. The proportion of those with a 
diagnosis of type 2 diabetes treated insulin increased from 5% to 15% over the period, 
reaching a plateau after 2005 (Figure 6.2). Almost all insulin users with type 2 diabetes 
were treated with an insulin monotherapy regimen in the first decade of observation, 
whereas two-thirds of insulin users with type 2 diabetes received insulin in 
combination with at least one other glucose-lowering medication in the second decade 
of observation. 
 
6.4.2. Comparison with existing literature 
A previous study from a UK region reported the prevalence of type 1 diabetes for 
males and females in 1997 to be 0.4% (95% CI 0.379–0.43%) and 0.28% (95% CI 0.25–
3.0%), respectively.430 They also reported that 12% of patients with type 2 diabetes 
injected insulin.430 This estimate is higher than the one calculated for this study, where 
in 1997 the prevalence of type 1 diabetes was 0.18%, and 15% of patients with type 2 
diabetes were estimated to be treated with insulin. A further study based on the 
population of Poole in Dorset, England, estimated that the overall prevalence of insulin 
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use was 0.5% in 1996, in comparison with 0.3% calculated for this study.429 One 
possible explanation for this was the poor recording of prescriptions in earlier years of 
the CPRD database. Alternatively, in our study, a gap of longer than 6 months between 
insulin prescriptions was used to indicate that insulin treatment had been 
discontinued. This may have led to the exclusion of patients who collected their 
prescriptions intermittently.  US data from the Center for Disease Control and 
prevention 2011 National Diabetes Fact Sheet suggest that, in 2007–2009, 26% of 
patients with diabetes were using insulin, 58% were using oral glucose-lowering agents 
and 16% were diet-controlled only.13 The corresponding figures for this study are 
similar with 22% of all patients with diabetes using insulin, 58% using other glucose-
lowering drugs and 20% diet-controlled for the same time period. 
The prevalence of type 1, type 2 and diabetes overall calculated for this study 
increased from 0.1%, 1.1% and 1.4% in 1991 to 0.2%, 3.6% and 4.0% in 2010, 
respectively (Table 6.5). The overall prevalence of diabetes is similar to the prevalence 
of 4.26% published in 2010 by Diabetes UK, which translated to an estimated 2.8 
million people in the UK with diabetes.420 This increase in the prevalence of diabetes 
may be due at least in part to more enhanced detection of subclinical type 2 diabetes 
and increased survival for people with diabetes. Increased survival could account for 
the increased use of insulin between 1991 and 2010 as more people live long enough 
to progress to insulin treatment. 
A change in the management of people with type 2 diabetes requiring insulin therapy 
emerged during the study period, where the use of regimens that combined oral 
glucose-lowering therapies with insulin increased from 13% in the first decade of 
observation to 52% in the second. A similar pattern has also been reported in the USA: 
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in 1997, 2.3 million people with diabetes were treated with insulin alone versus 1.1 
million people receiving combination therapy. By 2010, 2.8 million people were 
receiving insulin alone and 2.9 million were on combination therapy.467 The proportion 
of people prescribed insulin in combination with metformin increased substantially 
following the publication of the results from UKPDS in 1998 even though this study did 
not report results for this combination therapy specifically. Current NICE Guidelines 
recommend that insulin is added to existing glucose-lowering therapy instead of using 
insulin alone.54 In addition, in 2006, EASD and ADA guidelines recommended that 
insulin should be added to existing metformin therapy rather than switching patients 
to insulin monotherapy.470 
Although there has been an increase in the estimated number of insulin users in the 
UK, there has also been an increase in the number of people in the UK with diabetes. 
Diabetes UK has published figures to show that the number of people with diabetes in 
the UK has increased from 1.4 million in 1996 to 2.8 million in 2010.420 However, the 
percentage of patients with type 2 diabetes prescribed insulin increased from 5% to 
16% between 1991 and 2009 before decreasing slightly to 15% in 2010. Therefore, the 
increase in the number of insulin users in the UK represents a change in treatment 
pattern with an increase in the prescribing of insulin for type 2 diabetes.  Masso-
Gonzalez et al also found that the percentage of prevalent cases treated with insulin 
increased between 1996 and 2005 from 15.1% to 15.5%. However, this increase was 
smaller than the increase of 7% to 15% found during the same period in this study. 
The proportion of people with type 2 diabetes treated with insulin increased three-fold 
during the study period, with the sharpest increase occurring during the period 1995 
to 2005. The increased use of insulin in type 2 diabetes may reflect influences such as 
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the publication of findings from the UKPDS in 1998 and recommendations from NICE in 
2002 advocating tighter blood glucose control. The results of UKPDS suggested that 
intensive control of glucose levels using insulin or sulfonylureas reduced the risk of 
developing microvascular complications and a decrease in the risk of myocardial 
infarction and death was observed during the ten year follow-up.67 NICE guidelines 
recommend a general target for HbA1c levels of 6.5%, although it also suggests that a 
target of 7.5% when initiating a third line agent such as insulin.54 Furthermore, the 
introduction of the QOF, launched in the UK on 1st April 2004404 may have further 
promoted the initiation of insulin in people with type 2 diabetes by providing 
incentives for achieving lower glucose targets. Marketing may have also played a role, 
particularly following the launch of the basal insulin analogues (insulin glargine in 2000 
and insulin detemir were launched in 200469). In addition, long-acting insulin 
analogues have been associated with a lower risk of hypoglycaemia when compared 
with compared to NPH insulin71 and insulin glargine can be administered as a once-
daily dose. As regimen complexity and fear of inducing hypoglycaemia have been cited 
as possible barriers to the initiation of insulin, then overcoming these barriers may 
have led to the increased prescribing of insulin. 
However, the baseline characteristics for type 2 diabetes patients do not support the 
early initiation of insulin. There was little change in the baseline HbA1c levels at insulin 
initiation during the study period (10.0%, 9.7%, 9.7% and 9.8% for 1991–1995, 1996–
2000, 2001–2005 and 2006–2010, respectively), although these values are for both 
type 1 and type 2 diabetes. Furthermore, between 2001 and 2007, HbA1c levels for 
patients with type 2 diabetes remained relatively constant (8.5% in 2001 and 8.4% in 
2007), suggesting that more aggressive control of blood glucose was not achieved.178 
Brown and colleagues also found evidence of a delay in the initiation of insulin in type 
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2 diabetes in a US population of members of the Kaiser Permanente Northwest 
Region, where the average patient accumulated nearly five HbA1c -years of excess 
glycaemic burden of more than 8.0% from diagnosis to insulin initiation.457 During the 
study period, the age at insulin initiation increased from 52.5 years in 1991–1995 to 
58.1 years in 2006–2010, despite a reduction in the age of onset of type 2 diabetes 
during the same period. However, this may reflect ageing of the population as a whole. 
The increase in the prevalence of insulin use was followed by a plateau after 2005 and 
a small decline in insulin use the last few years of the study. One possible explanation 
for this is the introduction and increased use of the GLP-1 agonists (exenatide in 2006 
and liraglutide in 200969).  In 2012, the EASD and ADA produced guidelines 
recommending a more patient centred approach to type 2 diabetes management, 
although the recommended HbA1c target was not changed.7 In addition, the QOF 
Indicator Advisory Committee has recommended that the target for HbA1c should be 
increased to 7.5%.471 Decreasing prevalence of insulin use among people with diabetes 
has also been observed in the US where the prevalence has fallen from 36% in 1995 to 
22% in 2007.469 In contrast to our study results, the NHS has continued to spend an 
increasing amount on insulin and the number of insulin items dispensed in England has 
increased year on year between 2009/10 and 2010/11.291  
 
6.4.3. Strengths and weaknesses of the study 
This study had several limitations. CPRD GOLD is a large dataset and has been shown 
to be representative of the population in terms of crude mortality and the age and 
gender structure.364,365 However, age-standardised mortality rates are 9–13% lower 
than the national average, which has been attributed to a healthy user bias and the 
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exclusion of people with no exact date of death364 CPRD GOLD is also a very large 
longitudinal dataset. In a systematic review, Khan and colleagues reported that the 
positive predictive value for most conditions investigated was more than 50%.367 
However, rates of diabetes and musculoskeletal conditions were underestimated in 
GPRD.367 In a more recently conducted systematic review, Herrett and colleagues, 
reported that the median proportion of cases with a confirmed diagnosis was 89% 
(range 24–100%).368 During the study period, the size of the population in CPRD 
increased dramatically (3.3 to 6.3 million). Therefore, during the earlier study years, 
the database is likely to be less representative of the UK population. In addition, 
prescriptions and diagnoses may have been less well recorded in the early stages of 
the data source. The distinction between type 1 and type 2 diabetes data is always 
problematic in observational studies, particularly because diagnostic criteria and the 
coding of diabetes have changed over time. IDDM and NIDDM were the preferred 
terms prior to 1997; they have now been replaced with the terms type 1 and type 2 
diabetes, respectively.367 In our study, all those with diagnostic codes for only IDDM 
were included in the group of patients with type 1 diabetes. Inconsistent recording of 
diabetes diagnosis was a further concern. An age-based distinction (e.g. between those 
diagnosed before and after age 30) would have potentially been more robust, but our 
study design did not permit us to ascertain age at first diagnosis for all subjects 
because it was a prevalence study. Thus, although our study design did permit 
accurate estimates of total insulin use, the ascribed ratio between type 1 and type 2 
diabetes should be interpreted with caution, especially in earlier years. The impact of 
misclassification may have been to slightly inflate the number of people with type 1 
diabetes in earlier years and, correspondingly, to slightly reduce the number of people 
with type 2 diabetes. The effect would obviously disproportionately impact type 1 
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diabetes. The overall numbers and the general patterns are thought to be reliable, but 
people with type 2 diabetes using insulin monotherapy are more likely to remain 
unclassified than patients prescribed other glucose-lowering drugs. In the last few 
years, patients with diet-controlled type 2 diabetes have not been routinely prescribed 
glucose biosensor strips for the self-monitoring of blood glucose.472 This may have 
resulted in an underestimation of the diet-controlled type 2 diabetes group with an 
overestimation of the percentage of patients with type 2 diabetes using insulin.  
 
6.4.4. Conclusion 
Between 1991 and 2010, there has been a major increase in the estimated number of 
people with type 2 diabetes using insulin. However, this does not appear to be a result 
of the earlier introduction of insulin in response to national guidelines, since the 
baseline HbA1c level at which insulin is initiated has not fallen over 20 years and has 
remained high throughout the study period. As baseline HbA1c remained high 
throughout the study period (approximately 10.0%), this suggests that national policies 
may not have been fully implemented.  The increased use of insulin in type 2 diabetes 
may therefore represent a true change in the demographics of the type 2 diabetic 
population with an increase in the proportion of patients with more advanced type 2 
diabetes, rather than a change in clinical practice. The rising prevalence of insulin use 
may reflect both increasing incidence and longer survival of people with type 2 
diabetes.  However, during the last few years of the study period, a small decrease in 
the proportion of people with type 2 diabetes treated with insulin was observed, and 
this reflects the more recent pattern of usage in the US. Further research is required to 
determine if this trend continues.  
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There has been a significant change in the management of people with the proportion 
of people receiving insulin in combination with metformin increasing substantially. This 
is in line with current evidence and guidelines.   
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7. Annual cost of insulin to the NHS between 2000 and 2009 
and the incremental cost of analogue insulin to the NHS 
This chapter is based on the accepted version of the following article: Holden SE, Poole 
CD, Morgan CL, Currie CJ. Evaluation of the incremental cost to the National Health 
Service of prescribing analogue insulin. BMJ Open 2011;1:e000258.,which has been 
published in final form at [http://bmjopen.bmj.com/content/1/2/e000258.long]. 
 
7.1. Introduction 
7.1.1. Background 
The number of people diagnosed with diabetes in the UK has risen to 2.8 million,473–476 
with approximately 90% of these having type 2 diabetes.477 People with type 1 
diabetes require insulin from onset, whereas those with type 2 diabetes will tend to be 
switched to insulin later in the natural history of their disease.478 
Currently, there are three different types of insulin by molecular origin on the market. 
From oldest to newest, these are animal insulin, human insulin and analogue insulin. 
Human insulin was introduced in the 1980s and was thought to be less immunogenic 
than animal insulin, thus leading to lower antibody titres. However, no clinically 
relevant differences, in terms of adverse effects or glycaemic control, between animal 
(particularly purified porcine insulin) and human insulin could be detected.479 Despite 
this lack of evidence, human insulin was used routinely and the use of animal insulin 
declined rapidly.51,479  
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Insulin analogues were developed through structural modification of human-sequence 
insulin to better mimic the pharmacokinetic profile of endogenous insulin, thereby 
achieving more optimal onset or duration of action and simpler, more convenient 
dosing regimens.51,480 Long-acting insulin analogues can be injected once daily and 
short-acting insulin analogues injected closer to meal times without affecting post-
prandial glucose control.481 Since their launch, the use of analogue insulin has 
increased steadily and they have had an increasing impact on the amount of money 
the NHS spends on diabetes.482 In England, the annual NIC of analogue insulin in 2004-
2005 was £109.8 million (55% of total insulin cost) and by 2009-2010, this had risen to 
£255.2 million per year (85.3% of the total cost of insulin).482 The Institute for Quality 
and Efficiency in Healthcare (IQWiG) in Germany has disputed whether the benefits of 
analogue insulin are sufficient to outweigh their increased cost.483,484 In the UK, NICE 
recommends the use of human NPH insulin first-line.  Insulin glargine is only 
recommended in specific circumstances, and not as first-line therapy.485  
 
7.1.2. Aims and objectives 
The aim of this study was to characterise the pattern of insulin prescriptions dispensed 
between 2000 and 2009, inclusively, for the whole of the UK, and to evaluate the 
marginal financial cost to the NHS of using analogue insulin instead of its equivalent 
human insulin preparation. This analysis formed the basis of the cost-saving estimates 
presented by the BMJ and Channel 4 News.486  
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7.2. Methods 
The data underpinning this study were open-source data from the four prescription 
pricing agencies for England,375 Northern Ireland,376 Scotland,377 and Wales.378 The PCA 
for England, Northern Ireland, and Wales describe the quantity and NIC of all NHS 
prescriptions dispensed in primary care in the constituent country. The NIC refers to 
the cost of the drug before any discounts, and does not include any dispensing costs or 
fees.487 The PCA for Scotland details gross ingredient cost (GIC), which is equivalent to 
NIC in the PCAs for England, Northern Ireland, and Wales.488 The PCAs for the four 
countries from 2000 to 2009 were then combined378. Data were grouped into insulin 
types according to their molecular origin (analogue, human-sequence and animal-
sequence) and also into individual insulin types (insulin soluble, insulin isophane, 
insulin zinc suspension mixed, insulin zinc suspension crystalline, biphasic isophane 
insulin, protamine zinc insulin, insulin aspart, insulin lispro, insulin detemir, insulin 
glargine, biphasic insulin aspart, biphasic insulin lispro, and insulin glulisine). For the 
Welsh data from 2000 to 2004, it was necessary to calculate the quantity of each type 
of insulin dispensed from the NIC per unit quantity from the PCA for England, Scotland, 
or Northern Ireland, since the Welsh PCA data did not include this information until 
2005. If the drug name in the PCA did not specify a presentation i.e. vial, pre-filled pen 
or cartridge, then it was assumed to be a vial. 
All costs were adjusted for inflation, and they are reported in UK pounds at 2010 prices 
using the gross domestic product deflator published by HM Treasury.489 The 
incremental cost of analogue insulin was calculated by summing the NIC of analogue 
insulin and then subtracting the cost of dispensing the same volume of insulin as 
insulin of human origin.  
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The incremental cost of analogue insulin was also calculated by assuming that if 
patients prescribed analogue insulin had alternatively received human insulin, they 
would still have received the same presentation i.e., a vial, a prefilled pen, or cartridge 
for a reusable pen device, since patients and clinicians favour the ease-of-
administration offered by pen devices.490,491 Using data from a previous analysis of all 
prescribing costs for diabetes throughout the UK,178 we were further able to estimate 
the relative volumes of analogue and human insulin prescribed by the type of 
diabetes. 
 
7.3. Results 
7.3.1. Net ingredient cost of insulin in the UK, 2000–2009 
Over the 10-year period the NHS spent a total of £2,732 million (M) on insulin 
prescriptions. Prescriptions for analogue insulin accounted for £1,629M (59%), human 
insulin £1,056M (39%) and animal insulin £47.2M (2%). 
The annual, total cost of insulin increased from £156M in 2000 to £359M in 2009, a 
130% increase (Figure 7.1). In 2000, the annual cost of analogue insulin was £18.2M, 
which represented only 12% of total insulin cost, but the cost of human insulin was 
£131M or 84% of the total cost of insulin. From 2005, by which time all the currently 
marketed insulin analogues had been launched―spending on analogue insulin 
increased from £192M (66% of total insulin costs) to £305M (85% of total insulin cost) 
in 2009. During the same period, the annual cost of human insulin fell from £95.3M 
(33%) to £51.1M (14%). The cost of animal insulin per year also decreased from 
£7.42M (5%) in 2000 to just £3.07M (1%) in 2009.
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Figure 7.1 The total annual cost of insulin prescriptions for the UK, 2000–2009  
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Total 156.1 186.9 212.5 242.3 274.6 290.6 317.5 336.3 355.8 359.1
Analogue 18.2 32.4 50.2 92.9 142.0 191.9 238.0 265.8 292.4 304.9
Human 130.5 147.4 155.9 143.8 127.9 95.3 76.5 67.6 60.1 51.1
Animal 7.4 7.1 6.4 5.6 4.7 3.5 3.0 3.0 3.4 3.1
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7.3.2. Incremental cost of analogue insulin in the UK, 2000–2009 
The unit cost of each insulin preparation is listed in Table 7.1. Overall, analogue insulin 
cost on average £2.31 per ml, and was therefore 47% more expensive than human 
insulin at £1.57 per ml. In 2009, the mean NIC per ml was £1.27 for human insulin and 
£2.25 for analogue insulin. The NIC per ml of human and analogue insulin peaked 
between 2003 and 2004, respectively. The 2009 NIC per ml was a 27% decrease for 
human insulin and a 7% decrease for analogue insulin from 2004 (Table 7.2).  
 
Table 7.1 Net ingredient cost (NIC) and volume of analogue and human insulin by 
presentation for the UK, 2000–2009 
Insulin formulation NIC£2010 Volume (ml) % NIC£2010/ml 
Analogue insulin £1,628,566,983 706,275,942 
 
£2.31 
Pen £705,567,792 285,036,913 40% £2.48 
Penfill £839,695,265 362,630,874 51% £2.32 
Vial £83,303,925 58,608,155 8% £1.42 
Human insulin £1,055,956,518 671,922,946 
 
£1.57 
Pen £218,790,437 117,962,069 18% £1.85 
Penfill £645,030,389 373,850,061 56% £1.73 
Vial £192,135,692 180,110,816 27% £1.07 
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Table 7.2 Average net ingredient cost (NIC) per millilitre in the UK, 2000–2009 
Year 
NIC£2010/ml for human 
insulin 
NIC£2010/ml for analogue 
insulin 
2000 £1.60 £2.24 
2001 £1.69 £2.24 
2002 £1.76 £2.25 
2003 £1.75 £2.33 
2004 £1.74 £2.41 
2005 £1.38 £2.36 
2006 £1.37 £2.34 
2007 £1.37 £2.27 
2008 £1.35 £2.30 
2009 £1.27 £2.25 
 
These unit costs translated into an estimate of the maximum, annual, incremental cost 
of dispensing analogue insulin assuming that all analogue prescriptions dispensed 
could have been alternatively prescribed as human insulin. Assuming 100% conversion, 
the annual incremental cost of analogue insulin increased from £5.18M in 2000 to 
£133M in 2009 (Table 7.3). Overall, for the 10-year period, the total incremental cost 
of analogue insulin was £625M at 100% conversion and £312M at 50% conversion. 
Between 2005 and 2009, the incremental cost of analogue insulin was £538M at 100% 
conversion and £269M at 50% conversion. 
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Table 7.3 Incremental cost of analogue insulin in the UK, 2000–2009 
Year 
Incremental cost (£2010) 
(assuming 100% conversion 
analogue to human insulin) 
Incremental cost (£2010) 
(assuming 50% conversion 
analogue to human insulin) 
2000 £5,183,001 £2,591,500 
2001 £8,065,849 £4,032,924 
2002 £10,795,155 £5,397,578 
2003 £23,143,753 £11,571,877 
2004 £ 39,529,331 £19,764,666 
2005 £79,448,570 £39,724,285 
2006 £98,317,347 £49,158,673 
2007 £106,139,197 £53,069,598 
2008 £121,376,170 £60,688,085 
2009 £132,895,201 £66,447,601 
Total for 2000 to 2009 £624,893,574 £312,446,787 
 
7.3.3. Estimated cost by diabetes type 
People with type 2 diabetes accounted for an estimated £86.0M of NHS expenditure in 
2000 on human and analogue insulin, increasing to £229M (+166%) in 2009. For type 1 
diabetes these values were £62.7M and £127M respectively (+103%). Over the whole 
period, the total cost of insulin prescribing for type 2 diabetes was £950M for insulin 
analogues and £708M for human insulin (Table 7.4). The incremental cost of analogue 
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insulin for patients with type 2 diabetes was estimated at £306M at 100% conversion 
and £153M at 50% conversion. 
 
7.3.4. Incremental cost of analogue insulin in the UK taking insulin presentation into 
account, 2000–2009 
Human insulin is more likely to be dispensed as a vial when compared to insulin 
analogues, which are typically administered as a pen device (Table 7.1). In calculating 
the incremental cost of analogue insulin, when assuming that all those receiving 
analogue insulin had been dispensed human insulin instead but the presentation 
remained the same i.e., vial, pen or a pen-fill device, then the incremental cost of 
analogue insulin in the UK between 2000 and 2009 would have been £271M at 50% 
conversion and £541M at 100% conversion, compared with £625M at 100% conversion 
(Table 7.3) if insulin presentation is not taken into account.  
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Table 7.4 Estimated change in net ingredient cost (NIC) and volume of human and analogue insulin prescribed to patients with type 1 and type 2 
diabetes in the UK, 2000–2009 cost 
Year NIC£2010 for type 1 diabetes NIC£2010 for type 2 diabetes Volume (ml) for type 1 diabetes Volume (ml) for type 2 diabetes 
 
Total analogue Total Human Total analogue Total Human Total analogue Total Human Total analogue Total Human 
2000 £11,228,382 £51,444,334 £6,923,103 £79,075,954 5,038,092  33,056,509  3,050,474  48,350,233  
2001 £17,858,968 £55,211,316 £14,564,748 £92,155,033 8,001,813  33,577,135  6,443,335  53,816,755  
2002 £25,764,159 £57,242,261 £24,410,582 £98,670,067 11,520,222  33,039,547  10,827,941  55,441,680  
2003 £45,316,250 £49,420,126 £47,585,514 £94,338,575 19,667,109  28,663,444  20,145,487  53,383,153  
2004 £65,066,374 £40,577,834 £76,937,127 £87,354,455 27,296,077  23,712,414  31,672,369  49,905,829  
2005 £82,462,748 £28,231,889 £109,393,916 £67,039,353 35,341,564  21,196,772  45,841,398  47,609,677  
2006 £97,342,547 £21,284,207 £140,625,903 £55,238,238 42,215,106  15,771,316  59,651,444  40,046,916  
2007 £105,277,447 £17,662,770 £160,494,779 £49,900,346 46,896,096  13,048,606  70,028,562  36,438,609  
2008 £113,178,916 £14,924,884 £179,215,091 £45,134,839 49,542,256  11,113,432  77,455,050  33,486,730  
2009 £114,597,696 £12,375,736 £190,322,726 £38,711,902 51,543,528  9,734,567  84,098,018  30,547,933  
Total £678,093,486 £348,375,355 £950,473,489 £707,618,762 297,061,863  222,913,742  409,214,078  449,027,514  
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7.4. Discussion 
7.4.1. Main findings 
Since their launch, insulin analogues have had an increasingly noteworthy impact on 
the amount of resource used to manage diabetes. The inflation-adjusted, annual cost 
to the NHS of insulin increased from £156M in 2000 to £359M in 2009 (a two-fold 
increase). During the same period, NHS spending on analogue insulin increased from 
£18M (12% of total insulin cost) per year to £305M (85% of total insulin cost) and at 
the same time, NHS annual spending on human insulin fell from £130M (84%) to 
£51.1M (14%). If all dispensations for analogue insulin between 2000 and 2009 had 
used the equivalent human insulin, we estimate the NHS would have saved £625M. 
 
7.4.2. Comparison with existing literature 
The pharmacokinetic profiles of insulin analogues do appear to improve glycaemic 
control and reduce the incidence of hypoglycaemia (particularly nocturnal), compared 
with human insulin equivalents.71,73Long-acting insulin analogues have a longer 
duration of action and, in the case of insulin glargine, no peak plasma concentrations 
when compared with NPH insulin.492,493 Short-acting insulin analogues have a lower 
tendency for self-association, faster absorption and higher peak plasma concentrations 
that are achieved more quickly than with soluble human insulin.494 This can result in 
improved dosing schedules for the insulin analogues. Additionally, insulin detemir has 
been associated with less weight gain than other long-acting insulin formulations.175 
A Cochrane systematic review compared short-acting insulin analogues with regular 
human insulin and found a small, statistically significant improvement in glycaemic 
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control for people with type 1 diabetes but no benefit in patients with type 2 
diabetes.73 Both analogue and human insulin were associated with similar levels of 
hypoglycaemia.73 The Cochrane review comparing long-acting insulin analogues with 
NPH insulin in type 2 diabetes concluded that there was no evidence of a beneficial 
effect in terms of glycaemic control and only a minor benefit in terms of nocturnal 
hypoglycaemic events.71 The longest trial comparing insulin glargine and NPH insulin 
found that, over five years’ observation, there was a similar progression to retinopathy 
but less improvement in the HbA1c level for insulin glargine as the mean HbA1c change 
from baseline was -0.55% with insulin glargine and -0.76% with NPH insulin (the least 
square mean difference was 0.21 higher with NPH insulin, 95% CI  0.06–0.35; 
p=0.0053).495 Epidemiological data from the UK indicates that, despite general 
improvements in the provision of diabetes care and the introduction of insulin 
analogues, there has been no observable improvement in HbA1c levels for patients 
with type 2 diabetes treated with exogenous insulin.60 There is currently no systematic 
means of measuring the clinical benefits associated with analogue insulin, such as rate 
of symptomatic or nocturnal hypoglycaemia, making it difficult to judge the real-world 
cost effectiveness of these drugs. However, an analysis of open-source HES data shows 
that growth in hospital admissions for hypoglycaemia has exceeded growth in the 
prescribing of insulin.496 
The cost effectiveness of analogue insulin is likely to vary depending on the type of 
diabetes, the clinical characteristics of the individual patient and the type of analogue 
insulin in question. For example rapid-acting insulin analogues in patients with type 1 
diabetes are likely to be a cost-effective use of finite healthcare resources.497 In the 
UK, NICE has recommended that insulin glargine and rapidly-acting insulin analogues 
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are an option for the control of blood-glucose in patients with type 1 diabetes but has 
stated that human insulin should be prescribed as first-line therapy and long acting 
analogues such as insulin glargine and premixed insulin should only be used in certain 
specific circumstances.55,70 NICE has determined that insulin glargine borders on being 
cost effective at current willingness to pay thresholds in people with type 1 diabetes 
but that it is not cost effective in type 2 diabetes.485 In Germany, IQWiG has stated that 
there are insufficient studies investigating the long-term effects of using insulin 
analogues and that rapid-acting and long acting insulin analogues have no proven 
superiority over human insulin for type 1 and type 2 diabetes.483,484,498,499 A similar 
recommendation has been made by Canadian Agency for Drugs and Technologies in 
Health (CADTH) where NPH insulin is recommended as first line and the use of insulin 
analogues are only recommended for patients who experience significant 
hypoglycaemia.500 If bolus insulin therapy is required, CADTH again recommends 
human insulin as first line therapy for patients with type 2 diabetes but rapid-acting 
insulin analogues can be used first line in type 1 diabetes sufferers.500 In New Zealand, 
insulin glargine and insulin detemir were only recommended with special authority 
criteria, although there is now agreement to widen access to insulin glargine.501,502 In a 
study of US patients with private insurance, a large increase in the prevalent use of 
insulin analogues has been observed.503 The WHO has found that some countries 
spend a significant amount of their drug budget on insulin analogues and there are 
problems with the lack of availability of human insulin.504 They have advised that 
insulin analogues offer no clinical advantage over human insulin and suggested that 
insulin analogues may not be cost-effective in low- and middle-income countries.504 In 
a recent feature article for the BMJ, it was suggested that insulin remains unaffordable 
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in many countries and even though insulin is off-patent, the availability of generic 
products is limited.505  
The popularity of the insulin analogues could be due in part to successful marketing. 
Some of the manufacturers of insulin analogues also provided professional support to 
GPs at the same time that their analogue insulin was marketed, although this was not 
conditional on the doctor prescribing their insulin.486 Insulin analogues were also 
available in new devices that may be more appealing to patients and easier to use than 
the devices used to administer human insulin.486 The fact that 40% of analogue insulin 
was prescribed as a prefilled pen device compared with just 18% for human insulin 
supports this.  
As insulin manufacturers focus on newer, patentable insulin analogue products, they 
have withdrawn some of their older human insulin products, where a move to 
patented insulin products has notable commercial benefits to manufacturers. Patients 
using these products have required conversion to an alternative product, which might 
contain either human insulin or an insulin analogue. In 2005, Novo Nordisk 
discontinued Actrapid penfills and recommended Novorapid as an alternative product. 
They also withdrew Insulatard Flexpen and Monotard from their range of human 
insulin at the same time.506 Since the withdrawal of Mixtard 30 at the end of 2010, the 
90,000 users will have been changed to an alternative product.72 It will be interesting 
to repeat this study to assess whether these patients have been switched to human 
insulin (the equivalent product is Humulin M3) or indeed to analogue insulin. The Drug 
and Therapeutics Bulletin has estimated that if all the users of Mixtard 30 were 
switched to Novomix 30, it would result in an increase in cost of £9 million to the NHS 
in England alone.72 
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The increase in the annual inflation-adjusted NHS cost between 2000 and 2009 can be 
partly accounted for by the increase in prevalence of diabetes in the UK during this 
time. In 1996, it was estimated that 1.4million people in the UK had diabetes.420 By 
2004, this figure had risen to 1.8million507 and by 2009, 2.6 million people in the UK 
had diabetes.508 People with type 2 diabetes can be managed with one or more of diet, 
oral glucose-lowering medication or insulin where as people with type 1 diabetes are 
dependent on exogenous insulin. However, the estimated volume of analogue and 
human insulin dispensed to patients with type 2 diabetes is far greater than for type 1 
diabetes. This can be explained by the prevalence of type 2 and type 1 diabetes in the 
UK. It has been estimated that approximately 90% of people with diabetes in the UK 
have type 2 diabetes. It can be further explained by the nature of type 2 diabetes. It is 
characterised by insulin resistance. Patients with type 2 diabetes are more likely to be 
overweight or obese than people with type 1 diabetes.509 Therefore, people with type 
2 diabetes using insulin often receive higher insulin doses. Furthermore, results from 
UKPDS may have influenced the increased prescribing of insulin to people with type 2 
diabetes so that lower HbA1c levels could be obtained.112 
 
7.4.3. Strengths and weaknesses of the study 
This study had inherent limitations. The calculation of the incremental cost of analogue 
insulin was based on the assumption that the same volume of insulin would be 
prescribed if patients were switched from analogue to human insulin. The PCA for 
Wales from 2000 to 2004 did not contain the quantity of insulin dispensed, which was 
necessary to calculate the incremental cost. The quantity, therefore, needed to be 
calculated from the NIC per quantity figures from the PCAs for England, Scotland, and 
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Northern Ireland. However, certain products in the Welsh PCA were not available for 
the other regions for the same year, so figures from the previous years had to be used 
and adjusted for inflation. Some drugs were listed only under their generic name in the 
Welsh PCA and so a weighted-average NIC per quantity was taken from the branded 
products in the English PCA. The same approach was taken when the drug name 
description did not specify whether the cartridge size was 1.5ml or 3ml (when these 
were the only cartridge sizes on the market). In addition there were two drug names, 
Human Actraphane and Human Protaphane vials, that had no matches in any of the 
other PCAs for any year. These are Novo Nordisk products, which tend to carry the 
same cost per unit depending on whether they are vial, penfill, or prefilled pen and are 
not dependent on what type of human insulin is in the device. Therefore, the NIC per 
quantity used for these two products was the NIC per quantity of the other Novo 
Nordisk vials. These assumptions were unlikely to have impacted upon the estimates 
as a whole, since the NIC and volume relating to these products and country was only 
small.  
Another limitation was that the PCA only informs us about how much of each type of 
insulin was dispensed; thus, there was no way of determining how much insulin was 
dispensed to people with type 2 diabetes specifically. However, it is likely that the level 
of type 1 diabetes remained relatively constant over the study period, while the 
number of people with type 2 diabetes is known to have increased considerably.416  
The assumption that all patients using insulin analogues could be equally well treated 
with human insulin is also likely to be unrealistic. Dr Adler, chair of the NICE guidance 
committee, has suggested that 90% of patients with type 2 diabetes could receive 
human insulin instead of long-acting insulin analogues with around two-thirds of these 
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patients remaining on human insulin.486 At this moment, however, there is no 
definitive figure of how many people with diabetes could have received human insulin 
instead of analogue insulin.  
This study did not take into account any other savings that could have been made as a 
result of treatment with insulin analogues as opposed to human insulin. It is not 
known whether the use of insulin analogues would lead to a reduction in hospital 
admissions for hypoglycaemia, reduced prescribing of products used to treat 
hypoglycaemia or test strips for glucose monitoring. In addition, reduced dosing 
frequency for the long-acting insulin analogues may also lead to a reduction in the 
associated equipment required for injecting insulin, for example needles, and an 
improvement in patient compliance.  
 
7.4.4. Conclusion 
At the macroeconomic level, we know that the rise of insulin analogues has had a 
substantial financial impact on the NHS. Despite the wholesale shift to analogue insulin 
in high-income countries, there is a lack of literature on the long-term efficacy and 
safety of the insulin analogues. The methodological rigor of previous RCTs comparing 
human insulin with insulin analogues has been criticised, especially the over reliance 
on proxy measures of outcome as the primary endpoints.71,73,504 RCTs of a longer 
duration are required to demonstrate whether insulin analogues are superior to 
human insulin for long-term patient-important outcomes, such as mortality, morbidity 
and quality of life. Until such evidence is available, adherence to prescribing guidelines 
would reduce the cost of prescribing insulin in diabetes.  
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8. Glucose-lowering with exogenous insulin monotherapy in 
type 2 diabetes: dose association with all-cause mortality, 
cardiovascular events, and incident cancer  
This is the accepted version of the following article: Holden SE, Jenkins-Jones S, 
Morgan CL, Schernthaner G, Currie CJ. Glucose-lowering with exogenous insulin 
monotherapy in type 2 diabetes: dose association with all-cause mortality, 
cardiovascular events and cancer. Diabetes Obes Metab 2015 17:350-62. doi: 
10.1111/dom.12412. This has been published in final form at 
[http://onlinelibrary.wiley.com/doi/10.1111/dom.12412/abstract]. Deviations from 
the published version of this manuscript are underlined. 
 
8.1. Introduction 
8.1.1. Background 
The number of people with type 2 diabetes treated with insulin in the UK increased 
from 37,000 in 1991 to 277,000 people in 2010,422and at considerable financial cost.510 
Although the use of insulin monotherapy in type 2 diabetes has decreased since 1991, 
it has been estimated that 37% of people with type 2 diabetes received insulin 
monotherapy in 2010.422  
Insulin is recommended as third-line therapy when metformin and sulfonylurea, where 
indicated, have failed to maintain glucose control.55 There are few RCTs that compare 
the use of insulin to alternative glucose-lowering regimens in type 2 diabetes. Whilst 
insulin has a theoretically unlimited potential to lower blood glucose, there are now a 
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range of observational studies that have elicited a J-shaped association between 
glucose control and all-cause mortality and other serious outcomes, showing that the 
optimal HbA1c level is between 7% to 7.5% 60,223,224,511,512. The UKPDS demonstrated 
that intensive control of blood glucose reduced microvascular risk. However, it was not 
until after the 10-year follow-up that the cardiovascular benefits associated with 
intensive glucose were detected 67,112. Meta-analyses of RCTs have shown that 
intensive glucose control did not significantly affect the risk of all-cause mortality or 
cardiovascular events 201,202. In addition, several epidemiological studies have reported 
an association between insulin use and all-cause mortality and serious adverse events 
in people with type 2 diabetes 60,61,223,255. 
A recently published study demonstrated that when compared with other glucose-
lowering regimens, there was an increased association between insulin and all-cause 
mortality, MACE, cancer and other outcomes in people with type 2 diabetes, but 
insulin dose was not accounted for in this study 61. A recent study in the BMJ found 
that insulin treatment in people with type 2 diabetes when included as a covariate in a 
multivariable model of all-cause mortality, had an aHR of 3.42 (2.61–4.48) 513. A 
legitimate criticism of these and other epidemiological studies is the potential for 
confounding by indication or channelling bias. That is, those treated with insulin are at 
a more advanced stage in the natural history of the disease or they have phenotypic 
characteristics that require a switch to insulin. However, if a dose association exists in 
people with type 2 diabetes treated with insulin, particularly insulin monotherapy, this 
could help to reduce this risk of this bias.  
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8.1.2. Aims and objectives 
The aim of this retrospective cohort study was, therefore, to determine if there was an 
association between insulin dose and all-cause mortality, incident MACE, and incident 
cancer in people with type 2 diabetes. 
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8.2. Methods 
8.2.1. Data source 
The data used for this study came from the CPRD.427 CPRD contains pseudonymised 
data collected from the daily record keeping of participating primary-care physicians in 
the UK. These data include patient demographics, consultations, medical history, test 
results, referrals, and prescriptions. CPRD is broadly representative of the UK 
population and contains over 12 million patients registered at 660 practices. For a 
proportion of these practices in England, CPRD records have been linked to NHS HES. 
The data extract used in this study contains records up to January 2013. 
Approval for this study was granted by the CPRD ISAC (reference number 11_017). 
 
8.2.2. Patients 
Patients with type 2 diabetes were selected if their records were classed by CPRD as 
being of ‘acceptable’ research quality and if at least one of the following criteria 
applied: more than one diagnostic record exclusively for type 2 diabetes; prescriptions 
for at least two different classes of glucose-lowering medication other than insulin; or 
one diagnostic code for type 2 diabetes (irrespective of any records for conflicting or 
unspecific diabetes diagnoses) plus prescriptions for at least one glucose-lowering 
medication excluding insulin. Patients were only included if they had received their 
first prescription for insulin after 1st January 2000 and were receiving insulin 
monotherapy. This was because of potential confounding by concomitant metformin 
in particular. The study index date was defined as the date of first insulin prescription, 
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and cases were required to have a wash-in period of at least 365 days from the later of 
the patient’s registration date and CPRD’s practice ‘up-to-standard’ date.  
Patients were excluded from the analysis if they had any record for secondary 
diabetes. Patients with a history of large vessel disease (defined as prior myocardial 
infarction [MI], stroke, angina, and or coronary revascularisation) or cancer were 
excluded from analyses in which MACE or cancer were the respective endpoints.  
 
8.2.3. Study endpoints 
The primary outcomes for the study were all-cause mortality; incident MACE, defined 
as myocardial infarction (MI), stroke, or cardiovascular death; and incident cancer 
(excluding non-melanoma skin cancer). For patients who had progressed to an event, 
the censor date was defined as the patient’s date of death, cancer, or MACE, provided 
that the event date recorded was no more than 90 days after the end of recorded 
data, the date of regimen change (including drug cessation or additional drug 
inclusion), or the date of their last prescription for insulin. Otherwise the cases were 
censored. The censor date was defined as the earliest of: the end of a patient’s 
recorded data (the earlier of their transfer-out date or the end of the current CPRD 
data extract); or 90 days after their date of transfer to an alternative glucose-lowering 
regimen (including the addition of any other concomitant glucose-lowering 
medication); or their last prescription for insulin.  
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8.2.4. Estimation of insulin dose 
Unlike many prescriptions for glucose-lowering medications, dose is rarely specified 
when prescribing insulin. Therefore weight-standardised daily insulin exposure had to 
be estimated from the volume of insulin prescribed as follows. First, the number of 
international units prescribed was estimated for each insulin prescription issued during 
the study period. Conflicting information existed for some prescriptions recorded in 
CPRD; therefore decision rules were devised in order to maintain a consistent 
approach (Appendix 2). The number of international units for each prescription was 
divided by the nearest recorded weight measurement. For each patient, cumulative 
average insulin dose was calculated on a yearly basis by dividing the sum of the 
international units per kg (units/kg) represented by the insulin prescriptions received 
between the index date and the end of the specific year by the number of days 
observed from the index date to the end of the same year. For patients with an 
incomplete year of observation, the denominator was the number of days the patient 
had been receiving prescriptions between the first and last prescription for insulin plus 
the days between the penultimate and last prescription. Patients were excluded from 
the analysis if the volume of insulin prescribed could not be determined for one or 
more prescriptions, there was no recorded weight measurement, or their estimated 
average insulin dose across the follow-up period was greater than 4 units/kg/day. Only 
patients with at least two prescriptions for insulin were included as this was a 
requirement for the calculation of daily dose. Patients with a gap longer than 180 days 
between prescriptions for insulin were assumed to have stopped taking their insulin 
and then restarted. In order to avoid an immortal time bias due to the exclusion of 
people with only one prescription for insulin (thereby ensuring that no patients could 
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die before their second insulin prescription), only those patients with at least 180 days’ 
follow-up were included in the study. This was because a patient’s first and second 
insulin prescription could be between 1 and 179 days apart.  
 
8.2.5. Statistical methods 
Time to each clinical endpoint was evaluated using Cox proportional hazards 
modelling. The index date for the modelling was taken as the first prescription for 
insulin plus 180 days. People with events (cancer or MACE) prior to this date were 
excluded from the relevant analysis. The following baseline covariates were identified 
a priori and included in the Cox proportional hazards model: age, serum creatinine, 
BMI, duration of diabetes, index year, Charlson morbidity index 374, and the number of 
GP contacts in the year prior (an alternative measure of morbidity) as continuous 
covariates, and HbA1c (quartiles), exposure to prior lipid-lowering therapy, prior anti-
platelet therapy, prior antihypertensive therapy, gender, insulin regimen, history of 
cancer or large vessel disease, and smoking status as categorical variables. Many of 
these covariates have been identified previously as potential predictors of mortality in 
people with type 2 diabetes 61. However, index year was added to account for 
differences in clinical practice over the study period. Where a patient had no HbA1c 
measurement in a 12-month period, the last observation was carried forward. Missing 
baseline values for serum creatinine, HbA1c, and BMI were imputed using multiple 
imputation.  
Total cumulative weight-standardised insulin exposure was estimated for each 
subsequent year following insulin initiation and analysed as a time-dependent 
continuous variable updated annually. Cumulative insulin exposure has been modelled 
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previously using a different method for calculating dose 255 and was chosen for this 
study primarily because of the postulated mechanism by which hyperinsulinaemia is 
related to cancer 514 and cardiovascular morbidity 182,515. In addition, cumulative insulin 
exposure is less sensitive to changes in the collection of prescriptions just prior to an 
event or limitations in the calculation of insulin exposure in the final (part) year of 
patient follow-up. However, average annual weight-standardised insulin exposure, 
average annual weight-standardised insulin exposure modelled with a lag time of one 
year, and average weight-standardised insulin exposure in the first year after the index 
date were also investigated in a sensitivity analysis (the latter two were modelled to 
address a potential bias that insulin dose may have changed markedly prior to an 
event of interest).  
The proportional hazards assumption for the main overall models was tested by 
examining the Pearson correlation between Schoenfeld residuals and the rank of 
survival time for cases that had progressed to death. Interactions with time were used 
to assess the proportional hazards assumption of the extended Cox model. A test of 
heterogeneity between subgroups was conducted for each subgroup analysis using 
interactions between the subgroup covariate and study arm. Baseline differences 
between cohorts were assessed by univariate analysis appropriate to the distribution 
of the parameter.  All analyses were carried out using SPSS.  
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8.3. Results 
8.3.1. Numbers of cases and total follow-up 
We identified 6,484 eligible subjects with type 2 diabetes who progressed to insulin 
monotherapy as their first exposure to insulin (Table 8.1). These subjects were 
followed up for an average of 3.3 years (median 2.3), representing a total follow-up 
period of 21,310 years.   
  
8.3.2. Baseline characteristics 
The overall, average age at baseline was 64.3 (median 67.0) years and 56% of subjects 
were male. The mean (SD) estimated prescribed insulin dose was 0.75 (0.40) 
units/kg/day. The distribution of estimated insulin dose is illustrated in Figure 8.1. In 
order to show how the baseline characteristics varied across the range of estimated 
insulin doses, these are detailed across insulin dose quartiles (Table 8.1).  
There were notable differences across the four dose groups. The parameters that 
varied in a largely consistent gradient across the estimated dose values and that also 
achieved significance at the conventional level included the proportion of males (from 
63% in the lowest estimated insulin dose quartile to 51% in the highest, p<0.001), age 
at baseline (65.0 years to 63.4 years respectively, p=0.004), diabetes duration 
(5.2years to 6.8 years respectively, p<0.001), existing large vessel disease (30% to 25% 
respectively, p=0.004) and HbA1c (9.2%, 9.8%, 9.9%, and 9.9% respectively, p<0.001). 
Notable parameters where values were less consistent across estimated dose groups 
included serum creatinine (highest value 99.0 µmol/l, lowest 91.0 µmol/l, p<0.001) and 
BMI (highest value 29.0 kg/m2, lowest 27.9 kg/m2, p<0.001). In addition, median 
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Charlson index was higher in the lowest estimated insulin dose quartiles (3 versus 2, 
p=0.004). There was a difference in the profile of the insulin regimen used across these 
groups; for example, in the lowest dose group 64% were treated throughout with a 
premixed insulin regimen, versus 49% in the highest dose group (overall p<0.001).  
 
8.3.3. Numbers of outcome events and crude event rates 
After people with prior events were excluded where relevant, the numbers of events 
of interest were as follows: 1,110 deaths, 342 incident MACE, and 382 incident 
cancers, with respective rates of 61.3, 26.4, and 24.6 events per 1,000 person years. 
The unadjusted rates of these events by insulin dose group, using each individual’s 
mean estimated insulin dose for the first year following the index date, are detailed in 
Figure 8.2.  
 
8.3.4. Risk of all-cause mortality 
There was an association between estimated insulin dose and the risk of all-cause 
mortality. The aHR in relation to an increase in estimated insulin dose of 1 
units/kg/day was 1.54 (1.32–1.78, Figure 8.3). The results of a sensitivity analysis in 
which different estimates of insulin dose were included in the Cox model are 
presented in Table 8.2.  
There was no evidence of a difference in treatment effect between subgroups (test for 
heterogeneity: p>0.05 for all subgroups). 
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Table 8.1 Baseline characteristics by average estimated insulin dose over the study period 
Parameter 
Estimated prescribed insulin dose quartile (units/kg/day) All identified study 
patients 0.074–0.479 0.480–0.666 0.667–0.913 0.914–3.884 p-value 
Number of people, n (%) 1,622 (25%) 1,624 (25%) 1,616 (25%) 1,622 (25%) 
 
6,484 
 
Males, n (%) 1,017 (63%) 910 (56%) 887 (55%) 829 (51%) <0.001 3,643 (56%) 
Age at index, mean (median), years 65.0 (68.0) 64.7 (67.0) 63.9 (66.0) 63.4 (65.0) 0.004 64.3 (67.0) 
HbA1c, mean (%)a 9.1 (2.2) 9.6 (2.1) 9.9 (2.2) 9.9 (2.2) <0.001 9.6 (2.2) 
Systolic blood pressure, mean (SD), mmHGa 135.9 (19.3) 135 (19.8) 135.3 (19.6) 136.3 (19.5) 0.305 135.6 (19.5) 
Smoking statusb: 
        
0.126 
  
Non-smoker, n (%) 600 (37%) 619 (38%) 669 (41%) 661 (41%) 
 
2,549 (39%) 
Ex-smoker, n (%) 686 (42%) 680 (42%) 626 (39%) 655 (40%) 
 
2,647 (41%) 
Current smoker, n (%) 336 (21%) 325 (20%) 321 (20%) 306 (19%) 
 
1,288 (20%) 
Triglycerides, median (IQR), mmol/la 1.7 (1.2–2.5) 1.7 (1.2–2.5) 1.9 (1.3–2.8) 2.1 (1.3–3.2) <0.001 1.8 (1.2–2.7) 
HDL, median (IQR), mmol/la 1.2 (0.9–1.4) 1.2 (1.0–1.5) 1.2 (1.0–1.4) 1.1 (0.9–1.4) 0.003 1.2 (0.9–1.4) 
Total cholesterol, mean (SD), mmol/la 4.7 (1.2) 4.7 (1.2) 4.8 (1.3) 4.7 (1.2) 0.192 4.7 (1.2) 
Serum creatinine, median (IQR), µmol/la 99 (79–137) 95 (76-128) 96 (77–126) 91 (75–121) <0.001 95.0 (77.0-128.0) 
DM duration, median (IQR), yearsc 5.2 (1.6–10.2) 6.3 (2.2–11.1) 6.7 (2.5–12.1) 6.8 (2.9–11.1) <0.001 6.2 (2.2–11.1) 
BMI, mean (SD), kg/m2a 29.0 (6.0) 27.9 (5.9) 28.2 (6.0) 27.9 (5.8) <0.001 28.2 (5.9) 
Weight, mean (SD), kg 83.3 (18.0) 78.8 (17.4) 78.9 (18.4) 77.9 (18.5) <0.001 79.7 (18.2) 
Glucose-lowering therapies year prior: 
           
Metformin 864 (53%) 964 (59%) 985 (61%) 1,076 (66%) <0.001 3,889 (60%) 
Sulfonylureas 1,067 (66%) 1,262 (78%) 1,340 (83%) 1,366 (84%) <0.001 5,035 (78%) 
Thiazolidinediones 298 (18%) 389 (24%) 424 (26%) 430 (27%) <0.001 1,541 (24%) 
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Parameter 
Estimated prescribed insulin dose quartile (units/kg/day) All identified study 
patients 0.074–0.479 0.480–0.666 0.667–0.913 0.914–3.884 p-value 
DPP-4 inhibitors 51 (3%) 44 (3%) 59 (4%) 47 (3%) 0.442 201 (3%) 
GLP1-agonists 12 (1%) 15 (1%) 16 (1%) 22 (1%) 0.351 65 (1%) 
Meglitinides 52 (3%) 54 (3%) 54 (3%) 51 (3%) 0.987 211 (3%) 
General morbidity: 
           
Prior large vessel disease, n (%) 491 (30%) 436 (27%) 409 (25%) 411 (25%) 0.004 1,747 (27%) 
Prior cancer, n (%) 217 (13%) 221 (14%) 184 (11%) 162 (10%) 0.004 784 (12%) 
Prior vision problems, n (%)d 617 (38%) 601 (37%) 615 (38%) 608 (37%) 0.914 2,441 (38%) 
Prior antihypertensives, n (%) 1116 (69%) 1079 (66%) 1130 (70%) 1135 (70%) 0.102 4,460 (69%) 
Prior lipid-lowering drugs, n (%) 927 (57%) 902 (56%) 928 (57%) 952 (59%) 0.343 3,709 (57%) 
Prior anti-platelet drugs, n (%) 761 (47%) 760 (47%) 747 (46%) 756 (47%) 0.981 3,024 (47%) 
Charlson index, median (IQR) 3.0 (2.0–4.0) 2.0 (1.0–4.0) 2.0 (1.0–4.0) 2.0 (1.0–4.0) <0.001 2.0 (2.0–4.0) 
GP contacts prior year, median (IQR) 15.0 (8.0–25.0) 15.0 (8.0–23.0) 15.0 (9.0-25.0) 15.0 (9.0–25.0) 0.648 15.0 (8.0–25.0) 
Insulin regimene: 
        
<0.001 
  
Basal–bolus 84 (5%) 142 (9%) 190 (12%) 232 (14%) 
 
648 (10%) 
Basal 304 (19%) 141 (9%) 115 (7%) 98 (6%) 
 
658 (10%) 
Premix 1,031 (64%) 993 (61%) 905 (56%) 791 (49%) 
 
3,720 (57%) 
Other or variesf 203 (13%) 348 (21%) 406 (25%) 501 (31%) 
 
1,458 (22%) 
a The nearest record to the index providing it was no more than 365 days before or 30 days after the index date. The search was conducted in the following order: -30 days, +30 
days and -365 days. 
b Nearest recorded status recorded prior to index date. 
c Time between diabetes presentation  date (defined as the date of first recorded diabetes diagnosis or first prescription for a glucose-lowering agent) and the index date. 
d  Vision problems include cataracts, glaucoma, retinopathy, maculopathy, macular degeneration, iritis/uveitis, scotoma, papilloedema, nerve palsy, and vision impairments or 
blindness  
e During study follow-up. 
f This category also includes people who switch between the three different insulin regimens.  
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Figure 8.1  Distribution of (a) estimated daily insulin dose and (b) weight-standardised  estimated daily insulin dose (units/kg/day) for those who 
were alive and remained on treatment with insulin monotherapy 
a) 
 
  
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
Fr
eq
u
en
cy
 (
%
)
Insulin dose (units/day)
Year 1 Year 2 Year 3 Year 5 Year 10
   
233 
 
b) 
 
Number of patients included in each year: year 1 = 6,484; year 2 = 5,084; year 3 = 3,566; year 5 = 1,964; year 10 = 365  
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Figure 8.2  Crude event frequency and event rate per 1,000 person years by average estimated insulin dose quartile in the first year following index 
date*  
 
*1st insulin dose quartile = 0.074–0.479 units/kg/day, 2nd quartile = 0.480–0.666 units/kg/day, 3rd quartile = 0.667–0.913 units/kg/day, 4th quartile = 0.914–3.884 units/kg/day
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Figure 8.3  Adjusted hazard ratios for the association between estimated insulin dose 
and all-cause mortality for all cases and for specific phenotypic subgroups 
 
Model specification: Charlson index; BMI; age; gender; prior GP contacts; smoking status; HbA1c; serum 
creatinine; histories of antiplatelet therapy, lipid-lowering therapy, large vessel disease;  duration of 
diabetes; insulin regimen; and index year. Estimated cumulative insulin dose was added as a yearly 
updated time-dependent covariate. History of prior cancer and prior antihypertensive therapy initially 
violated the proportional hazards assumption of the Cox model and so were added as Heaviside 
functions (< and ≥1095 days). The insulin regimen category ‘other’ includes people who have received 
more than one of the following regimens: basal, basal-bolus or premix. 
Subgroup aHR 95%CI p-value n/N p-value	for	
test	of	
heterogeneity
Overall 1.54 (1.32−1.78) <0.001 (1,100/6,484)
Gender
Male 1.72 (1.41−2.09) <0.001 (649/3,643)
Female 1.30 (1.02−1.66) 0.031 (461/2,830) 0.07
Age	(years)
≤65 1.51 (1.10−2.07) 0.011 (250/3,073)
>66 1.44 (1.22−1.72) <0.001 (860/3,408) 0.60
Charlson	comorbidity	index
≤2 1.88 (1.46−2.42) <0.001 (357/3,320)
≥3 1.38 (1.14−1.66) 0.001 (753/3,148) 0.12
Prior	large	vessel	disease
No 1.53 (1.28−1.84) <0.001 (707/4,733)
Yes 1.57 (1.19−2.07) 0.001 (403/1,747) 0.68
Prior	cancer
No 1.61 (1.38−1.90) <0.001 (908/5,700)
Yes 1.07 (0.68−1.69) 0.761 (202/783) 0.15
Baseline	HbA1c	(%)
≤8.5 1.67 (1.30−2.15) <0.001 (370/1,884)
>8.5	and	≤10.5 1.56 (1.17−2.09) 0.003 (318/1,847)
>10.5 1.30 (0.93−1.81) 0.122 (276/1,725)
missing 1.51 (1.03−2.20) 0.033 (146/1,012) 0.41
Insulin	regimen
Basal-bolus	or	premix 1.53 (1.25−1.87) <0.001 (753/4,368)
Basal 1.82 (1.21−2.73) 0.004 (124/626)
Other 1.34 (1.01−1.78) 0.043 (233/1,444) 0.50
BMI	(kg/m2)
≤28 1.64 (1.30−2.06) <0.001 (481/2,806)
>28 1.57 (1.17−2.09) 0.002 (379/2,422)
Missing 1.40 (1.05−1.87) 0.023 (250/1,244) 0.59
Diabetes	duration	(years)
≤6 1.47 (1.16−1.85) 0.001 (382/3,160)
>6 1.54 (1.26−1.88) <0.001 (728/3,318) 0.92
0	
0.5	 5.0	
aHR	
1.0	
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Table 8.2  Sensitivity analysis exploring the effect of different estimations of insulin exposure on the aHR for mortality, MACE, and cancer 
 
All-cause mortality MACE Cancer 
Estimated insulin dose covariate and model description aHR 95% CI p-value aHR 95% CI p-value aHR 95% CI p-value 
Average insulin dose in year 1 as a continuous covariate 1.43 (1.23-1.66) 0.000 1.245 (0.95-1.64) 0.117 1.260 (1.00-1.63) 0.079 
Continuous time-dependent covariate (no Heaviside functions) 1.52 (1.34-1.72) 0.000 
   
1.187 (0.94-1.5) 0.147 
Continuous time-dependent covariate (cases with missing values 
excluded) 1.57 (1.34-1.84) 0.000 1.308 (0.97-1.76) 0.076 1.402 (1.07-1.83) 0.013 
Continuous time-dependent covariate 1.52 (1.34-1.73) 0.000 1.233 (0.97-1.57) 0.089 1.189 (0.94-1.5) 0.143 
Time-dependent insulin dose group (units/kg/day)a                   
<=0.5 1                 
>0.5 and <=1.0 0.90 (0.78-1.04) 0.167             
>1.0 and <=1.5 1.19 (0.99-1.44) 0.067             
>1.5 1.90 (1.50-2.40) 0.000             
Time-dependent insulin dose quartile (units/kg/day)a 
         0.066-0.459 1 
        0.460-0.637 0.87 (0.73-1.05) 0.145 
      0.638-0.878 0.93 (0.78-1.11) 0.405 
      0.879-4.000 1.21 (1.02-1.44) 0.027 
      Time-dependent lag continuous insulin dose (year-1) 1.44 (1.25-1.65) 0.000 1.394 (1.09-1.79) 0.008 1.376 (1.09-1.74) 0.008 
Time-dependent cumulative continuous insulin dose 1.54 (1.32-1.78) 0.000 1.374 (1.05-1.81) 0.023 1.350 (1.04-1.75) 0.024 
Time-dependent continuous insulin dose (last year adjusted) 1.19 (1.02-1.37) 0.022 1.145 (0.89-1.48) 0.302 1.132 (0.89-1.45) 0.321 
Time-dependent quartile of insulin dose (last year adjusted) 
(units/kg/day)ab 
         0.066-0.459 1 
        0.460-0.637 0.70 (0.59-0.83) 0.000 
      0.638-0.878 0.74 (0.63-0.87) 0.000 
      0.879-4.000 0.75 (0.64-0.89) 0.001             
Average continuous insulin dose in year 1, endpoint = end of data 
or eventc 1.28 (1.15–1.43) <0.001       
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a Only provided for all-cause mortality endpoint where there was evidence of a non-linear relationship between estimated insulin dose and endpoint (tested by adding the squared 
dose as a yearly time-updated covariate into the model in addition to the original yearly time-updated insulin dose covariate). 
b Proportional hazards assumption was violated for estimated insulin dose. 
c Patients were followed to end of data or death (regimen change of insulin cessation was not used as an endpoint). 
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8.3.5. Risk of incident major adverse cardiovascular events 
The association between estimated insulin dose and the risk of MACE was not so clear 
(Figure 8.4). The aHR for estimated insulin exposure was not lower than unity in any of 
the 20 subgroups and there was no evidence of a difference in effect of increasing 
estimated insulin exposure between subgroups (test for heterogeneity: p>0.05 for all 
subgroups) 
 
8.3.6. Risk of incident cancer 
The overall pattern of association with incident cancer was also not as clear as that for 
all-cause mortality (aHR=1.35, 1.04–1.75, Figure 8.5). An increased aHR for the 
association between estimated insulin dose and incident cancer was observed for 
males when compared with females (1.84, 1.35–2.52 versus 0.78, 0.48–1.28, p-value 
for test of heterogeneity = 0.006): and people with a history of large vessel disease 
when compared with those without a history of large vessel disease (1.97, 1.20–3.22, 
versus 1.15, 0.83–1.58, p-value for test of heterogeneity = 0.034).   
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Figure 8.4  Adjusted hazard ratios for the association between estimated insulin dose 
and MACE for all cases and for specific phenotypic subgroups 
 
Model specification: Charlson index; BMI; age; gender; prior GP contacts; smoking status; HbA1c; serum 
creatinine; histories of antiplatelet therapy, lipid-lowering therapy, antihypertensive therapy, cancer, 
large vessel disease;  duration of diabetes; insulin regimen; and index year. Estimated cumulative insulin 
dose was added as a yearly updated time-dependent covariate. The insulin regimen category ‘other’ 
includes people who have received more than one of the following regimens: basal, basal-bolus or 
premix. 
  
Subgroup aHR 95%CI p-value n/N p-value	for	
test	of	
heterogeneity
Overall 1.37 (1.05−1.81) 0.023 342/4,657
Gender
Male 1.23 (0.82−1.85) 0.327 177/2,434
Female 1.53 (1.06−2.21) 0.024 165/2,215 0.34
Age	(years)
≤65 1.40 (0.86−2.28) 0.178 115/2,533
>66 1.33 (0.96−1.85) 0.085 227/2,123 0.85
Charlson	comorbidity	index
≤2 1.63 (1.10−2.40) 0.014 173/2,879
≥3 1.08 (0.73−1.60) 0.697 169/1,713 0.41
Prior	cancer
No 1.38 (1.04−1.83) 0.027 304/4,093
Yes 1.07 (0.41−2.82) 0.892 38/542 0.73
Baseline	HbA1c	(%)
≤8.5 1.26 (0.73−2.17) 0.409 89/1,121
>8.5	and	≤10.5 1.61 (0.98−2.66) 0.061 102/1,369
>10.5 1.40 (0.84−2.33) 0.195 105/1,360
missing 1.32 (0.58−2.97) 0.506 46/733 0.68
Insulin	regimen
Basal-bolus	or	premix 1.29 (0.90−1.84) 0.168 234/3,066
Basal 1.14 (0.32−4.01) 0.841 22/378
Other 1.74 (1.08−2.78) 0.022 86/1,135 0.60
BMI	(kg/m2)
≤28 1.62 (1.07−2.45) 0.023 135/2,028
>28 1.38 (0.84−2.24) 0.200 140/1,711
Missing 1.06 (0.56−2.01) 0.865 67/863 0.93
Diabetes	duration	(years)
≤6 1.42 (0.94−2.16) 0.094 126/2,405
>6 1.42 (0.97−2.07) 0.068 216/2,246 0.56
0	
0.1	 1.0	
aHR	
5.0	
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Figure 8.5 Adjusted hazard ratios for the association between estimated insulin dose 
and incident cancer for all cases and for specific phenotypic subgroups. 
 
Model specification: Charlson index; BMI; age; prior GP contacts; HbA1c; serum creatinine; histories of 
antiplatelet therapy, lipid-lowering therapy, antihypertensive therapy, cancer, large vessel disease;  
duration of diabetes; insulin regimen; and index year. Estimated cumulative insulin dose was added as a 
yearly updated time-dependent covariate. Smoking status and gender initially violated the proportional 
hazards assumption of the Cox model and so were added as Heaviside functions (<1095 and ≥1095 days 
and <730 and ≥730 days, respectively ). The insulin regimen category ‘other’ includes people who have 
received more than one of the following regimens: basal, basal-bolus or premix  
Subgroup aHR 95%CI p-value n/N p-value	for	
test	of	
heterogeneity
Overall 1.35 (1.04−1.75) 0.024 382/5597
Gender
Male 1.84 (1.35−2.52) <0.001 239/3154
Female 0.78 (0.48−1.28) 0.326 143/2443 0.006
Age	(years)
≤65 1.38 (0.85−2.24) 0.197 112/2768
>66 1.25 (0.92−1.71) 0.156 270/2804 0.52
Charlson	comorbidity	index
≤2 1.19 (0.79−1.80) 0.395 189/3255
≥3 1.46 (1.04−2.06) 0.030 193/2332 0.72
Prior	large	vessel	disease
No 1.15 (0.83−1.58) 0.405 276/4088
Yes 1.97 (1.20−3.22) 0.007 106/1499 0.03
Baseline	HbA1c	(%)
≤8.5 1.50 (0.97−2.33) 0.067 119/1555
>8.5	and	≤10.5 1.36 (0.83−2.23) 0.224 116/1595
>10.5 1.34 (0.78−2.32) 0.294 97/1499
missing 1.19 (0.54−2.63) 0.672 50/888 0.08
Insulin	regimen
Basal-bolus	or	premix 1.28 (0.89−1.84) 0.183 247/3754
Basal 0.74 (0.22−2.43) 0.614 32/513
Other 1.45 (0.97−2.18) 0.072 103/1305 0.60
BMI	(kg/m2)
≤28 1.99 (1.40−2.83) <0.001 171/2351
>28 1.18 (0.73−1.92) 0.494 133/2103
Missing 0.67 (0.33−1.36) 0.272 78/1072 0.67
Diabetes	duration	(years)
≤6	years 1.24 (0.83−1.83) 0.295 161/2769
>6	years 1.43 (1.00−2.05) 0.049 221/2820 0.42
0	
0.1	 1.0	
aHR	
5.0	
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8.4. Discussion 
Adding to recent observational data that report an association between people with 
type 2 diabetes treated with insulin and the risk of adverse outcomes,60 here we found 
that there was an association between the estimated dose of prescribed insulin 
exposure and increased risk of all-cause mortality. A statistically significant association 
with MACE and cancer was also observed. The patterns of association were generally 
consistent in relevant phenotypic subgroups. This finding was resonant with previous 
findings.60 
One possible explanation for our findings is that exposure to higher insulin doses could 
have harmful effects. Insulin resistance and hyperinsulinaemia are thought to increase 
basal insulin signalling, which in turn contributes to insulin resistance and 
atherosclerosis.182 Meta-analyses have suggested that hyperinsulinaemia is a weak risk 
indicator for cardiovascular disease.179 In addition, hyperinsulinaemia can lead to 
tumour growth.514 In comparison with endogenous insulin secretion, injection of 
exogenous insulin may result in the exposure of peripheral tissues to a higher 
concentration of insulin.516 However, conversely, a study using streptozotocin-diabetic 
rats has shown that peripheral insulin delivery can lead to adequate glucose control 
without inducing hyperinsulinaemia.184 
Hypoglycaemia, a common side effect of injected insulin, has been shown to prolong 
the QT interval and cause Ca2+ overload, leading to malignant ventricular arrhythmias, 
an effect thought to be greatest in people with pre-existing diabetes and 
cardiovascular disease.76,195 Stahn and colleagues have recently found that people with 
type 2 diabetes and a prior history of cardiovascular disease treated with insulin 
and/or sulfonylureas experienced a high incidence of asymptomatic severe episodes of 
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hypoglycaemia and silent severe arrhythmias.198 A recent study documented that 
patients who received insulin doses of ≥0.6 units/kg were at increased odds of 
hypoglycaemia.199 After multifactorial adjustment, the higher odds of hypoglycaemia 
with increasing insulin doses remained (0.6–0.8 units/kg: OR 2.10 [95% CI 1.08–4.09], 
p=0.028; 0.8 units/kg: 2.95 [1.54–5.65], p=0.001). In contrast, the adjusted odds of 
hypoglycaemia were no higher in patients who received only 0.2–0.6 units/kg. In the 
ORIGIN study,80 severe hypoglycaemia occurred significantly more often in patients 
randomised to insulin glargine compared with those in the control arm, despite the 
low insulin requirement (6.3% vs. 1.8%; p<0.001). Remarkably, in a very recent report 
from the ORIGIN trial,200 severe hypoglycaemia was associated with a greater risk of 
mortality (aHR=1.74, 95% CI 1.39–2.19, p<0.001), cardiovascular death (1.71, 1.27–
2.30, p<0.001), and arrhythmia-related death (1.77, 1.17–2.67, p=0.007). However, the 
severe hypoglycaemia hazard for all outcomes was higher with standard care than with 
regimens that included low-dose insulin glargine. 
Links between injected insulin and the three outcomes investigated here have been 
reported previously, but importantly, very few RCTs have compared insulin-based, 
glucose-lowering regimens with other glucose-lowering regimens. The ORIGIN study 
compared insulin glargine with standard treatment in people with type 2 diabetes and 
found that insulin glargine had a no statistically significant impact on cardiovascular 
outcomes and cancers.80 This result appears to conflict with our findings; however, it is 
important to note that the patients included in the ORIGIN study had type 2 diabetes 
treated with no more than one glucose-lowering therapy or had IGT or IFG.80 The 
insulin dose was relatively low after six years (0.40 units per kg; IQR, 0.27 to 0.56). In 
addition, 65% of the insulin glargine group were also using other glucose-lowering 
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agents (46.5% combined glargine with metformin) and 11% of the standard care group 
were using insulin.80 In the UKPDS, patients treated with insulin experienced a 
sustained increase in plasma insulin levels.67 Despite this, an excess of macrovascular 
outcomes was not observed in the intensively treated arm.67 In addition, patients 
treated with insulin were not more at risk of myocardial infarction.67 However, the 
UKPDS was not specifically designed to assess the safety of insulin in type 2 diabetes. 
Observational studies have shown that insulin treatment was associated with an 
increased risk of cardiovascular events (2.5-fold)223 and of MIs, and that risk increased 
with increasing insulin exposure.251 During the follow-up to the DIGAMI 2 study, insulin 
was associated with a statistically significant increase in non-fatal cardiac events.248 
However, there were some limitations to the original study where less than half the 
number of planned participants were recruited to the study and FPG levels were above 
target and similar in the three study groups.247 Patients using exogenous insulin have 
increased risk of cancer-related mortality in comparison with metformin277 and other 
therapies,278 and there is a graded association between insulin exposure and death 
from cancer has been reported.279 A recent systematic review and meta-analysis 
concluded that the use of exogenous insulin is associated with several types of 
cancer.517 In terms of all-cause mortality, insulin-based treatment has been associated 
with a higher risk of mortality when compared with combination therapies of oral 
glucose-lowering medications (aHR=1.5, 1.4–1.6) 60. In a retrospective observational 
study based in Denmark, Mogensen and colleagues found that insulin was associated 
with a significantly increased risk of all-cause mortality when compared with 
metformin plus sulfonylurea, DPP-4 inhibitors, and GLP-1 agonists, and with a 
significantly increased risk of cardiovascular mortality when compared with metformin 
plus sulfonylurea or DPP-4 inhibitors 518. In addition, a graded association has been 
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found between insulin exposure and mortality.255 In the Wisconsin Epidemiologic 
Study of Diabetic Retinopathy (WESDR), a significant association was found between 
exogenous insulin exposure and all-cause and ischaemic mortality after adjusting for 
age and sex (HR 1.70, 95% CI 1.23–2.34 per unit/kg/day increase) but this association 
became non-significant following multivariate adjustment (1.20, 0.85–1.69).519  
One of the main criticisms of this type of observational study is the possibility of 
confounding by indication, where the glucose-lowering regimen prescribed is not 
independent of the severity of the disease or phenotype. In addition, the outcome may 
be dependent upon other factors that are either unknown or cannot be fully adjusted 
for in the statistical modelling. The effect has been here minimised by our selecting 
only those patients initiated on insulin monotherapy. However, this study is 
complicated in that increasing insulin dose could be a measure of diabetes 
deterioration. Duration of diagnosed diabetes was used as a potential covariate in the 
Cox proportional hazards model, although true diabetes duration could not be 
determined as the length of time diabetes remained undiagnosed is not quantifiable. 
Epidemiological analysis of the CRPD data does not allow us to answer the clinically 
relevant question of why some patients received large amounts of insulin that 
translated into high estimated daily doses of insulin (>1.5 units/kg/day). We cannot 
exclude the possibility that these patients had a particularly high degree of insulin 
resistance on starting their insulin therapy. Insulin resistance is known to be a strong 
predictor of macrovascular complications including coronary heart disease and stroke 
520,521. However, obesity is linked to insulin resistance 522 and mean BMI was similar 
across the four dose groups (Table 8.1). It is plausible that this confounding by 
indication may not have been fully accounted for within the Cox proportional hazards 
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model. However, with the exception of large vessel disease and sex subgroups for the 
cancer endpoint, the results remained consistent across a wide range of subgroup 
analyses. Wastage of insulin may have led to an overestimation of insulin dose, 
particularly for patients whose insulin dose is within the highest insulin dose quartile. 
Insulin exposure was calculated from the volume of insulin prescribed. We were 
unable to determine from the data whether the patient collected or used all the insulin 
prescribed to them. A larger proportion of patients in the high dose insulin groups 
switched between basal-bolus, premix or basal insulin regimens (31% versus 13% in 
the highest and lowest insulin dose quartiles). At each switch, a certain amount of 
insulin is likely to be wasted leading to an overestimation of their insulin dose. Patients 
who switch may also be the least well-controlled. When quartiles of estimated insulin 
dose were added to the Cox proportional hazards model, the highest mortality effect 
was seen in the top quartile of estimated insulin dose (2nd quartile = 0.90, 95% CI 0.78–
1.04; 3rd quartile = 1.19, 0.99–1.44; 3rd quartile = 1.90 1.50–2.40). 
Irrespective of the causality between high insulin dose and mortality, attempts to 
reduce the insulin dosage by the concomitant use of other drugs such as metformin, 
pioglitazone, GLP-receptor agonists, or SGLT2 inhibitors could be considered.   
 
8.4.1. Study limitations 
CPRD contains data collected from routine practice, therefore some data may be 
missing and coding imperfections may lead to the misclassification of diabetes type. 
However, only those patient records meeting CPRD’s own research-quality criteria 
were included in this study, and rules were applied to maintain consistency in the 
selection of patients with type 2 diabetes. Insulin doses in type 1 and latent 
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autoimmune diabetes of adulthood (LADA) may be lower than those prescribed in type 
2 diabetes, which is characterised by insulin resistance. Therefore, there is a possibility 
that the association between estimated insulin dose and adverse outcomes could be 
explained by the increased risk of adverse outcome in people with type 2 diabetes 
compared with those with type 1 diabetes or LADA. However, the Collaborative 
Atorvastatin Diabetes Study (CARDS) found that vascular complications were similar in 
patients with LADA or type 2 diabetes 523. This is contrary to the hypothesis that the 
lower risk of MACE may be explained by the inadvertent inclusion of LADA patients in 
our study. 
The site of initiation of insulin (primary or secondary care) has not been investigated. 
People who initiate in hospital may have more comorbidities than those who start 
insulin in primary care and may receive different dose titration. In addition, patients 
initiating insulin as monotherapy may have more co-morbidities (for example cardiac 
or renal disease) compared with patients adding insulin to existing glucose-lowering 
therapy, for example metformin. In this study, the percentage of people with a history 
of large vessel disease was relatively high. Average baseline creatinine levels were also 
relatively high. In addition, a high proportion of subjects had previously received other 
glucose-lowering agents, which had been stopped prior to the initiation of insulin. The 
reasons for this cannot be deduced from the data. Although there is no reason to 
suggest that these patients are not reflective of people who initiate insulin 
monotherapy in the general population, this may affect the generalisability of the 
results.  
Retrospective observational studies can only demonstrate possible associations with 
events; prospective RCTs are required to establish causality. However, retrospective 
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observational studies are considerably cheaper to carry out than large RCTs whilst still 
achieving large sample sizes. 
Insulin dose is rarely recorded in CPRD. Therefore, exposure was estimated using the 
total number of international units prescribed per year to generate an average weight-
standardised daily dose. There were some limitations to the methods used to estimate 
the number of units of insulin prescribed (Appendix 2). Although we used a consistent 
approach throughout, the rules applied might have led to an under- or overestimation 
of the prescribed number of international units. These limitations are likely to have 
introduced noise into the analysis that would have disguised any underlying patterns 
of association.  
Insulin detemir is less potent than other insulins. The concentration of the proprietary 
formulation of insulin detemir is four times that of other insulins (2,400 compared with 
600 nmol/ml) so that the volume of insulin detemir administered is equivalent to other 
insulin products. Although this seems to be the case for type 1 diabetes, in type 2 
diabetes, higher volumes of insulin detemir may need to be administered in order to 
produce the same glucose-lowering effect as equivalent insulin products 524. A 
sensitivity analysis was therefore carried out. The aHR for patients who received at 
least one detemir prescription (N=617) was 1.58 (95% CI 0.81–3.06; p=0.177). For 
those patients who did not receive at least one prescription for insulin detemir during 
the study period (N=5,867), the aHR for estimated insulin dose was 1.54 (1.32–1.81). 
We assumed that there was a direct association between the amount of insulin 
prescribed and the amount injected. The presence of a prescription record in CPRD can 
only indicate that insulin was prescribed: we could not determine whether the patient 
collected that prescription from the pharmacy or whether they used all of the insulin. 
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The assumption that patients will use their whole insulin supply before they reorder 
their next prescription is also likely to be unrealistic. Patients may waste some of their 
insulin. Prescriptions for insulin may not be regularly collected every 28 days as is 
common for oral medication. Therefore, in order to gauge how long a patient’s last 
prescription for insulin would last, it was necessary to use the time between a patient’s 
last and penultimate prescription.  
Patient follow-up was relatively short (an average of 3.3 years). This may be shorter 
than the period of time that some conditions need to develop (e.g. some cancers), 
which may have been influenced by previous glucose-lowering regimens. However, no 
one has postulated that insulin causes cancer—the thesis is that insulin has growth-
promoting effects, which would be observed as a change in the rate of cancer 
detection. Furthermore, MACE and death are acute events. 
Insulin dose was estimated using various methods before adding it into the Cox 
proportional hazard model (Table 8.2) and similar results were produced. However, for 
all-cause mortality, the relationship between insulin dose and the endpoint did not 
seem to be linear when insulin exposure was modelled as an annual, average, weight-
standardised dose. Possible explanations for this finding could include hospitalisation 
prior to an event, leading to a reduction in the ordering of insulin prescriptions in 
primary care. However, as a sensitivity analysis, quartiles of average, yearly-updated 
insulin dose were added to the Cox model and the second and third quartiles were not 
significantly different from the first insulin dose quartile. Only the fourth quartile was 
associated with a significantly higher aHR. However, categorising a continuous 
covariate may have led to some loss of power. The number of people included in some 
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of the subgroup analyses was small and in these cases over-fitting of the model may 
have occurred. 
 
8.4.2. Conclusion 
Any potential risks associated with insulin therapy need to be seen in the context of its 
potential to lower blood glucose, where achieving adequate glucose control is 
important in reducing the risk of microvascular events in particular.67 However, insulin 
replacement therapy in type 2 diabetes is now common, whereas it was relatively 
uncommon 20 years ago.422  
Here we have demonstrated a dose association between exogenous insulin and all-
cause mortality, MACE and cancer in people with type 2 diabetes. Limitations 
associated with both the estimation of insulin dose and also the retrospective 
observational nature of the study mean that this hypothesis should be tested using an 
interventional study design. Further research is now needed to investigate the risks 
and benefits of exogenous insulin in people with type 2 diabetes. These findings are in 
agreement with previously published studies reporting associations between insulin 
use in type 2 diabetes and serious adverse outcomes60,223,248,251,255,277–279,517,518 but 
contrary to findings from ORIGIN.80   
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9. Impact of concomitant metformin on insulin-treated type 2 
diabetes 
9.1. Introduction 
9.1.1. Background 
The rate of insulin use in type 2 diabetes increased more than six-fold in the UK 
between 1991 and 2010.422 In 1991, almost all patients with type 2 diabetes used 
insulin as monotherapy.422 By 2010, 42% of these patients were prescribed insulin in 
combination with metformin; the percentage treated with insulin monotherapy 
decreased to 37%.422 The USA has also seen a trend towards increased prescribing of 
insulin in combination with oral hypoglycaemic agents.467 A Cochrane review reported 
that bedtime NPH insulin in combination with oral hypoglycaemic agents provided 
comparable glycaemic control to insulin monotherapy but with generally lower doses 
of insulin.83 A position statement of the ADA and the EASD recommends that 
metformin therapy be continued when insulin is initiated.7 
A possible association between increasing estimated insulin dose and increased all-
cause mortality in people with type 2 diabetes treated with insulin monotherapy has 
been reported.525 Previous data have also demonstrated a direct association between 
insulin exposure and mortality.255 A recent article published in JAMA by Roumie et al 
found that the addition of insulin to existing metformin treatment was associated with 
an increased risk of cardiovascular events and all-cause mortality versus the addition 
of sulfonylurea in people with type 2 diabetes.346 We recently reported that people 
with type 2 diabetes using insulin were at an increased risk of a combined endpoint 
defined as first MACE, first cancer, or mortality, with the risk being significantly higher 
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for users of insulin monotherapy compared with users of insulin plus concomitant 
metformin.61 However, this study did not account for insulin exposure. In addition to 
its potential for lowering concomitant insulin dose,83 metformin may protect against 
cancer through AMP dependent and independent mechanisms,81 improve endothelial 
dysfunction,296–298 body weight, lipids and blood pressure299,300 and has been shown to 
reduce plasminogen activated inhibitor-1, a risk factor for cardiovascular disease.301 
Relative to the use of insulin alone, the use of metformin in combination with insulin 
has been associated with a reduced risk of cardiovascular events, cancer and death 
from any cause.61,62,345  
 
9.1.2. Aims and objectives 
The aim of this study was to determine if combining insulin with metformin reduced 
the risk of adverse outcome compared with insulin monotherapy, taking insulin dose 
into account.  
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9.2. Methods 
9.2.1. Data source 
The data source was the CPRD,427 a longitudinal database collating pseudonymised 
data collected in a non-interventional way from 660 participating primary-care 
practices throughout the UK. CPRD is representative of the UK population and contains 
13 million patients and approximately five million are actively registered and can be 
followed prospectively. CPRD is linked to hospital data. Data were from January 2000 
to January 2013. Approval for this study was granted by the CPRD ISAC (reference 
number 11_017). 
 
9.2.2. Patients 
Patients were included if they had more than one diagnosis exclusively for type 2 
diabetes, or prescriptions for at least two differing classes of glucose-lowering 
medication other than insulin, or at least one diagnosis for type 2 diabetes plus 
prescriptions for at least one glucose-lowering medication excluding insulin. Patients 
were included only if they initiated a regimen of insulin monotherapy or insulin in 
combination with metformin. The study index date was defined as the date of first 
insulin prescription, with a wash-in period of ≥365 days. 
Patients were excluded if they had any record for secondary diabetes, an estimated 
yearly average insulin dose greater than 4 units/kg/day, insulin prescribed on only one 
occasion, or no recorded weight. Patients with a prior history of large vessel disease or 
cancer were excluded from analyses in which MACE or cancer were the respective 
endpoints. Only patients with at least two prescriptions for insulin were included as 
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this was a requirement for the calculation of daily dose. In order to avoid an immortal 
time bias due to the exclusion of people with only one prescription for insulin (thereby 
ensuring that no patients could die before their second insulin prescription), only those 
patients with at least 180 days’ follow-up were included in the study. A gap of more 
than 180 days between prescriptions was used as an indicator of treatment 
discontinuation. 
In order to determine whether patients prescribed insulin plus metformin were at a 
greater risk of all-cause mortality than patients prescribed alternative glucose-lowering 
regimens, we also compared patients treated with insulin plus metformin and insulin 
monotherapy with a reference group of subjects treated with metformin plus 
sulfonylurea combination therapy. The selection criteria for the metformin and 
Sulfonylurea cohort have been described previously.61 For this comparison only, any 
patients included in more than one therapy group were excluded from the analysis in 
order to prevent immortal time bias.  
 
9.2.3. Study endpoints 
The primary outcome was all-cause mortality, with a secondary endpoint of the first of 
incident MACE (defined as incident myocardial infarction, stroke, angina, and or 
coronary revascularisation), incident cancer (excluding non-melanoma skin cancer), or 
death. The censor date was defined as the earliest of: the end of a patient’s recorded 
data, 90 days after their date of transfer to an alternative glucose-lowering, or their 
last prescription for insulin.  
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9.2.4. Estimation of insulin dose 
Weight-standardized daily insulin exposure (units/kg/day) was estimated from the 
volume of insulin prescribed. For each insulin prescription, the quantity was converted 
to the number of international units prescribed and divided by the nearest recorded 
weight measurement. The cumulative average insulin dose was calculated on an 
annualized basis. 
 
9.2.5. Statistical methods 
Time to each endpoint was evaluated using Cox proportional hazards modelling. Time 
zero for the Cox model and the calculation of the crude event rates was taken as the 
first prescription for insulin plus 180 days. People with events (cancer or MACE) prior 
to this date were excluded from the relevant analysis. The following baseline 
covariates were identified a priori and included in the Cox proportional hazards model 
as continuous covariates: age, serum creatinine, BMI, duration of diabetes, index year, 
Charlson comorbidity index,374 and the number of GP contacts in the year prior to 
index date. Metformin exposure, HbA1c, gender, insulin regimen, history of cancer or 
large vessel disease, smoking status, and prior exposure to lipid-lowering, anti-platelet, 
and antihypertensive therapies were included as categorical variables. Missing 
baseline values were imputed using multiple imputation for serum creatinine, HbA1c, 
and BMI.  
Cumulative weight-standardized insulin exposure was estimated for each subsequent 
year following insulin initiation and analysed as a time-dependent variable,255 selected 
because of the postulated mechanism by which prolonged hyperinsulinaemia is related 
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to cancer514 and cardiovascular morbidity.182,515 In addition, cumulative insulin 
exposure is less sensitive to changes in prescriptions patterns. Other measures of 
insulin exposure were evaluated in sensitivity analysis.  
aHRs were calculated with 95% confidence intervals. The proportional hazards 
assumption was tested by examining the Pearson correlation between Schoenfeld 
residuals and the rank of survival time for cases that had progressed to death. Where 
appropriate, interactions with time were used to assess the proportional hazards 
assumption. A test of heterogeneity between subgroups was conducted for each 
subgroup analysis using interactions between the subgroup covariate and study arm. 
Baseline characteristics were compared using the chi-squared test for categorical 
variables and one-way ANOVA or Kruskal–Wallis test for continuous variables, 
depending on their distribution. Levene’s test was employed to test for homogeneity 
of variances. If the assumption of homogeneity of variances was violated, Welch’s F 
was used.  
Patients prescribed insulin monotherapy were matched to patients prescribed insulin 
plus metformin by propensity score, incorporating age, gender, year of index exposure, 
diabetes duration, BMI, serum creatinine, GP contacts in the 12 months to index date, 
HbA1c, Charlson index, smoking status, history of prior cancer, history of prior large 
vessel disease, prior exposure to antihypertensives, lipid-lowering therapy or 
antiplatelet therapy and line of therapy. Only patients with complete (i.e. non-
imputed) data for the matching criteria were considered for matching. Propensity 
matching was carried out using IBM SPSS Statistics 20 using the SPSS R Essentials plug-
in. Logistic regression was used to generate the propensity score. Nearest neighbour 
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1:1 matching was implemented and the caliper was set at 0.1 of the standard deviation 
of the logit of the propensity score.  
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9.3. Results 
We identified 12,020 subjects with type 2 diabetes who progressed to insulin 
treatment as monotherapy or in combination with metformin (Table 9.1).  Of these, 
5,536 were prescribed insulin plus metformin and 6,484 were prescribed insulin 
monotherapy. Subjects were followed up for an average of 3.5 (median 2.5) years; a 
total follow-up of 41,747 years.  
 
9.3.1. Baseline characteristics 
Baseline characteristics by regimen are detailed in Table 9.1, separating the insulin into 
lower and higher estimated doses at the median across both groups. Patients treated 
with insulin plus metformin were younger than those treated with insulin 
monotherapy (60.0 years versus 64.3 years, p<0.001). People in the insulin plus 
metformin group had higher mean BMI (31.2kg/m2 versus 28.2kg/m2 for insulin plus 
metformin and insulin monotherapy, respectively, p<0.001) and lower median serum 
creatinine levels (83.0 versus 95.0 µmol/l, p<0.001). More patients receiving insulin 
monotherapy had a history of large vessel disease (27% versus 14% for insulin 
monotherapy and insulin plus metformin, respectively, p<0.001) and cancer (12% 
versus 8%, p<0.001). The baseline characteristics for propensity matched patients are 
detailed in Table 9.2.
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Table 9.1  Baseline characteristics by first exposure to each selected glucose-lowering regimen and average estimated insulin dosea over the study 
period 
Parameter 
Insulin monotherapy Insulin plus metformin 
 
Metformin plus 
sulfonylurea 
p-value 
Lower Dose Higher Dose Lower Dose Higher Dose 
 
Number of people, n (%) 3,087 (10) 3,397 (10) 2,922 (9) 2,614 (8) 
 
20,346 (63) 
 
Males, n (%) 1,845 (60) 1,798 (53) 1,682 (58) 1,504 (58) 
 
12,234 (60) <0.001 
Age at index, mean (median), years 64.8 (67.0) 63.8 (66.0) 60.4 (62.0) 59.5 (60.0) 
 
62.4 (63.0) <0.001 
HbA1c, mean (SD), % 9.4 (2.2) 9.9 (2.2) 9.9 (1.9) 10.1 (1.7) 
 
8.9 (1.8) <0.001 
Systolic blood pressure, mean (SD), mmHg 135 (20) 136 (20) 137 (17) 137 (17) 
 
138 (17) <0.001 
Smoking status: 
           
<0.001 
Non-smoker, n (%) 1,156 (37) 1,393 (41) 1,104 (38) 987 (38) 
 
7,744 (38) 
 
Ex-smoker, n (%) 1,303 (42) 1,344 (40) 1,238 (42) 1,133 (42) 
 
9,153 (45) 
 
Current smoker, n (%) 628 (20) 660 (19) 580 (20) 494 (19) 
 
3,449 (17) 
 
Total cholesterol , mean (SD), mmol/l 4.7 (1.2) 4.7 (1.2) 4.6 (1.1) 4.6 (1.1) 
 
4.6 (1.2) <0.001 
Serum creatinine, median (IQR), µmol/l 97 (77–132) 93 (76–123) 83 (71–98) 83 (71–97) 
 
85 (74–98) <0.001 
Diabetes duration, median (IQR), years 5.7 (1.8–10.7) 6.7 (2.7–11.5) 6.8 (3.3–10.8) 7.0 (4.1–11.1) 
 
2.8 (1.1–5.2) <0.001 
BMI, mean (SD), kg/m2 28.4 (5.9) 28.1 (5.9) 31.1 (6.0) 31.4 (5.8) 
 
31.2 (6.2) <0.001 
General morbidity: 
            
Prior large vessel disease, n (%) 887 (29) 860 (25) 441 (15) 353 (14) 
 
2,498 (12) <0.001 
Prior cancer, n (%) 410 (13) 374 (11) 234 (8) 201 (8) 
 
1,619 (8) <0.001 
Prior antihypertensives, n (%) 2,083 (67) 2,377 (70) 2,027 (69) 1,920 (73) 
 
14,720 (72) <0.001 
Prior lipid-lowering drugs, n (%) 1,744 (56) 1,965 (58) 2,032 (70) 1,876 (72) 
 
13,314 (65) <0.001 
Prior anti-platelet drugs, n (%) 1,448 (47) 1,576 (46) 1,387 (47) 1,289 (49) 
 
10,048 (49) 0.002 
Charlson morbidity index, median (IQR) 2 (1–4) 2 (1–4) 2 (1–3) 2 (1–3) 
 
1 (1–2) <0.001 
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Parameter 
Insulin monotherapy Insulin plus metformin  Metformin plus 
sulfonylurea 
p-value 
Lower Dose Higher Dose Lower Dose Higher Dose  
GP contacts prior year, median (IQR) 15 (8–24) 15 (9–25) 13 (7–21) 13 (8–22)  9 (5–15) <0.001 
Insulin regimen: 
           
<0.001 
Basal–bolus, n (%) 216 (7) 432 (7) 264 (9) 436 (17) 
 
– 
  
Basal, n (%) 436 (14) 222 (7) 869 (30) 361 (14) 
 
– 
  
Premix, n (%) 1,926 (62) 1,794 (53) 1,372 (47) 1,120 (43) 
 
– 
  
Other or varies, n (%) 509 (16) 949 (28) 417 (14) 697 (27) 
 
– 
  
a Lower-dose insulin: ≤0.648units/kg/day; higher-dose insulin: >0.6480units/kg/day (where the median insulin dose =0.648 units/kg/day). When comparing metformin plus 
sulfonylurea with the two insulin regimens in the Cox proportional hazards model, duplicate cases were removed. These duplicates have been excluded from the baseline 
characteristics for the metformin plus sulfonylurea group but not for the two insulin regimens. This is because these duplicate cases are included in the analyses comparing the 
two insulin regimens only.  
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Table 9.2  Baseline Characteristics for propensity matched patients 
Parameter Insulin monotherapy Insulin plus metformin p-value 
Number of people, n (%) 2,757 (50%) 2,757 (50%) 
 
Males, n (%) 1,584 (57%) 1,564 (57%) 0.586 
Age at index, mean (median), years 61.9 (63.0) 61.8 (63.0) 0.066 
HbA1c, mean (SD), % 9.9 (2.2) 9.9 (1.8) 0.776 
Systolic blood pressure, mean (SD), mmHg 134.7 (18.4) 136 (17.5) 0.013 
Smoking status: 
 
 
 
 
0.084 
Non-smoker, n (%) 1,043 (38%) 1,007 (37%) 
 
Ex-smoker, n (%) 1,153 (42%) 1,232 (45%) 
 
Current smoker, n (%) 561 (20%) 518 (19%) 
 
Total cholesterol, mean (SD), mmol/l 4.7 (1.2) 4.6 (1.1) <0.001 
Serum creatinine, median (IQR), µmol/l 86 (72.0–103.0) 87 (74.0–103.0) 0.062 
Diabetes duration, median (IQR), years 6.2 (2.6–11.0) 6.8 (3.6–10.9) <0.001 
BMI, mean (SD), kg/m2 29.2 (6.1) 29.7 (5.5) 
 
General morbidity: 
 
 
 
 
 
Prior large vessel disease, n (%) 524 (19%) 502 (18%) 0.446 
Prior cancer, n (%) 285 (10%) 266 (10%) 0.394 
Prior antihypertensive, n (%) 1,916 (69%) 1,932 (70%) 0.639 
Prior lipid-lowering drugs, n (%) 1,874 (68%) 1,906 (69%) 0.353 
Prior anti-platelet drugs, n (%) 1,303 (47%) 1,306 (47%) 0.936 
Charlson morbidity index, median (IQR) 2 (1.0–3.0) 2 (1.0–3.0) 0.515 
GP contacts prior year, median (IQR) 15 (9–24) 14 (8–24) 0.130 
 261 
 
9.3.2. Crude event rates 
There were 1,486 deaths amongst patients using any insulin regimen, a rate of 41.5 
(95% CI 39.4–43.6) deaths per 1,000 person-years. After excluding people with prior 
cancer and MACE, 1,428 patients experienced the combined endpoint, a rate of 58.1 
(55.1–61.1) events per 1,000 person-years. Crude event rates were highest for insulin 
monotherapy for both all-cause mortality and the combined endpoint. Patients in the 
higher estimated insulin dose groups for both insulin regimens were associated with 
an increased crude event rate for the combined endpoint but a decreased crude event 
rate for all-cause mortality (Figure 9.1). 
For the propensity matched patients, there were 534 deaths and 674 combined 
events. The corresponding event rates were 32.8 (30.1–35.7) and 59.0 (54.7–63.6) 
events per 1,000 person-years. 
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Figure 9.1  Crude event rate per 1,000 person-years by first exposure to each selected glucose-lowering regimen and average estimated insulin dose 
over the study perioda 
 
 
a Lower-dose insulin: ≤0.648 units/kg/day; higher-dose insulin: >0.6480 units/kg/day (where the median insulin dose =0.648 units/kg/day). When comparing metformin plus sulfonylurea 
with the two insulin regimens in the Cox proportional hazards model, duplicate cases were removed. These duplicates have been excluded from the baseline characteristics for the 
metformin plus sulfonylurea group but not from the two insulin regimens. This is because these duplicate cases are included in the analyses comparing the two insulin regimens only. 
The number of deaths and combined events in each group were: 186 and 251 for low dose insulin plus metformin, 190 and 309 for high dose insulin and metformin, 492 and 346 for low 
dose insulin monotherapy and 618 and 522 for high dose insulin monotherapy, respectively. There were 1,027 deaths in people treated with metformin plus sulfonylurea 
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9.3.3. All-cause mortality 
Across all insulin users, the aHR for all-cause mortality in relation to an increase in 
estimated cumulative average insulin dose of 1 unit/kg/day was 1.48 (95% CI 1.30–
1.70). The aHR for patients prescribed concomitant metformin―where patients with 
no exposure to metformin was used as the reference group―was 0.60 (0.52–0.68) 
(Figure 9.2). The point estimate for the aHR for patients prescribed concomitant 
metformin was lower than unity in all subgroups. Tests for heterogeneity revealed a 
significant interaction between treatment arm and age (p=0.024), HbA1c (p=0.04) and 
Charlson index (p=0.001), when added as continuous covariates. In addition, the risk of 
all-cause mortality associated with insulin plus metformin when compared with insulin 
monotherapy was significantly different in people with or without a history of large 
vessel disease (aHR = 0.52, 95% CI 0.45–0.62 and 0.86, 95% CI 0.68–1.09, respectively, 
test for heterogeneity p<0.001). A sensitivity analysis in which insulin exposure was 
estimated using a variety of methods prior to inclusion into the Cox model gave 
consistent results (Table 9.3). 
For propensity matched patients, the aHR for all-cause mortality for cumulative insulin 
dose was 1.78 (95% CI 1.41–2.24). The aHR for patients prescribed concomitant 
metformin was 0.62 (0.52–0.75).  
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Figure 9.2  Adjusted hazard ratios for all-cause mortality for insulin plus metformin 
compared with insulin monotherapy 
 
Notes: Insulin dose (units/kg/day) was added as a cumulative dose as an annually updated time-
dependent covariate. Prior antihypertensive therapy and history of cancer violated the proportional 
hazards assumption of the Cox model and so were added as Heaviside functions (<1,095 and ≥1,095 
days). When the analysis was split on a covariate, the covariate was removed from the model. 
Subgroup aHR 95%CI p-value n/N p-value	for	
test	of	
heterogeneity
Overall 0.60 (0.52-0.68) <0.001 1,486/12,020
Gender <0.001
Male 0.58 (0.49-0.69) <0.001 884/6,829
Female 0.61 (0.49-0.75) <0.001 602/5,178 0.89
Age	(years)
≤65 0.46 (0.36-0.59) <0.001 389/6,699
>66 0.61 (0.52-0.71) <0.001 1097/5,315 0.02
Charlson	comorbidity	index
≤2 0.53 (0.43-0.66) <0.001 523/7,071
≥3 0.65 (0.55-0.77) <0.001 963/4,924 0.00
Prior	large	vessel	disease
No 0.52 (0.45-0.62) <0.001 969/9,472
Yes 0.86 (0.68-1.09) 0.215 517/2,541 <0.001
Prior	cancer
No 0.60 (0.52-0.70) <0.001 1,222/10,801
Yes 0.65 (0.47-0.90) 0.009 264/1,218 0.15
Baseline	HbA1c	(%)
≤8.5 0.56 (0.44-0.71) <0.001 566/4,044
>8.5	and	≤10.5 0.48 (0.36-0.63) <0.001 325/3,064
>10.5 0.76 (0.59-0.97) 0.026 408/3,409
missing 0.65 (0.44-0.97) 0.033 187/1,479 0.04
Insulin	regimen
Basal-bolus	or	premix 0.54 (0.46-0.65) <0.001 952/7,560
Basal 0.79 (0.57-1.11) 0.174 222/1,884
Other 0.62 (0.47-0.83) 0.001 312/2,570 0.13
BMI	(kg/m2)
≤28 0.67 (0.55-0.81) <0.001 696/5,051
>28 0.55 (0.44-0.69) <0.001 477/5,067
Missing 0.65 (0.48-0.87) 0.005 313/1,892 0.36
Diabetes	duration	(years)
≤6	years 0.57 (0.47-0.70) <0.001 623/6,336
>6	years 0.62 (0.51-0.74) <0.001 863/5,682 0.32
Creatinine,	µmol/l
<130 0.52 (0.45-0.61) <0.001 859/8,627
≥130 0.69 (0.44-1.10) 0.117 377/1,473
Missing 0.42 (0.30-0.58) <0.001 250/1,917 0.87
0	
0.3	 aHR	 1.0	
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Table 9.3  Sensitivity analysis exploring the effect of different estimations of insulin exposure for the all-cause mortality endpoint in people 
prescribed insulin monotherapy or insulin in combination with metformin 
 Analytical approach to insulin dose 
aHR for insulin ±metformin 
All-cause mortality Combined endpoint 
Insulin dose covariate and model description aHR 95% CI p-value aHR 95% CI p-value 
Baseline continuous insulin dosea  0.60 (0.52—0.69) <0.001 0.71 (0.63―0.81) <0.001 
Continuous time-dependent covariate (cases with missing values 
excluded)b 0.62 (0.53―0.73) <0.001 0.75 (0.65―0.87) <0.001 
Continuous time-dependent covariateb 0.60 (0.52―0.68) <0.001 0.71 (0.63―0.8) <0.001 
Time-dependent insulin dose group (units/kg/day)c 0.59 (0.52―0.68) <0.001       
Time-dependent insulin dose quartile (units/kg/day)cd 0.59 (0.52―0.68) <0.001 
   Time-dependent lag continuous insulin dose (year-1)e 0.59 (0.51―0.67) <0.001 0.71 (0.63―0.8) <0.001 
Time-dependent cumulative continuous insulin dosef 0.60 (0.52―0.68) <0.001 0.71 (0.63―0.8) <0.001 
Time-dependent continuous insulin dose (last year adjusted)g 0.59 (0.52―0.68) <0.001 0.71 (0.62―0.8) <0.001 
Time-dependent quartile of insulin dose (last year adjusted) dg 0.63 (0.55―0.72) <0.001       
a Average daily, weight-standardized insulin dose in year 1, introduced into the Cox model as a continuous covariate. 
b Yearly-updated average, daily, weight-standardized insulin dose introduced into the Cox model as a continuous covariate. 
c Yearly-updated average, daily, weight-standardized insulin dose introduced into the Cox model as a categorical covariate.  
d Provided as there was evidence of a non-linear relationship between insulin dose and endpoint (tested by adding the squared dose as an annually updated covariate into the 
model in addition to the original annually updated insulin dose covariate and assessing if significant). 
e As b but a lag of one year applied. 
f Cumulative weight-standardized insulin exposure was estimated for each subsequent year following insulin initiation and analysed as a time-dependent variable. 
g The dose for the final part year of the follow-up was take as the average, weight-standardised insulin dose for the 365 day period prior to the censor date for those patients with 
a follow-up of ≥365 days
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9.3.4. Combined endpoint 
There was an association between estimated insulin dose and the combined endpoint 
(aHR=1.35, 95% CI 1.18–1.54, Figure 9.3). Patients treated with concomitant 
metformin had a reduced risk of the combined endpoint (0.71, 0.63–0.80) when 
compared to those treated with insulin monotherapy. The point estimate for the aHR 
for the risk of the combined endpoint in people treated with insulin plus metformin 
when compared with insulin monotherapy was less than unity for all subgroups and 
there was no statistically significant difference between subgroups (p-value for test of 
heterogeneity >0.05 for all subgroups, Figure 9.3).  
For propensity matched patients, the aHR for the combined endpoint was 1.68 (95% CI 
1.36–2.08). The aHR for patients prescribed concomitant metformin was 0.76 (0.64–
0.91).  
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Figure 9.3  Adjusted hazard ratios for the combined endpoint for insulin plus 
metformin compared with insulin monotherapy 
 
Notes: Final model specification: insulin exposure, therapy (±metformin), HbA1c, BMI, diabetes duration, 
index year, insulin regimen, smoking status, serum creatinine, prior cancer, prior large vessel disease, 
prior lipid-lowering therapy, prior antihypertensive therapy, prior antiplatelet therapy, prior GP 
contacts, Charlson comorbidity index, gender, and age at index. Insulin dose (units/kg/day) was added 
as a cumulative dose as an annually updated time-dependent covariate. The number of GP contacts in 
the year prior violated the proportional hazards assumption of the Cox model and therefore a time 
interaction for this covariate was also included in the model.  
Subgroup aHR 95%CI p-value n/N p-value	for	
test	of	
heterogeneity
Overall 0.71 (0.63-0.80) <0.001 1,428/8,361
Gender
Male 0.68 (0.58-0.81) <0.001 789/4,523
Female 0.73 (0.60-0.88) 0.001 639/3,835 0.62
Age	(years)
≤65 0.62 (0.51-0.75) <0.001 553/5,359
>66 0.69 (0.59-0.81) <0.001 875/2,997 0.39
Charlson	comorbidity	index
≤2 0.65 (0.56-0.76) <0.001 876/6,284
≥3 0.78 (0.63-0.97) 0.023 552/2,077 0.11
Baseline	HbA1c	(%)
≤8.5 0.76 (0.61-0.95) 0.016 481/2,526
>8.5	and	≤10.5 0.63 (0.50-0.80) <0.001 366/2,253
>10.5 0.71 (0.56-0.90) 0.005 417/2,587
Missing 0.67 (0.46-0.99) 0.047 164/991 0.23
Insulin	regimen
Basal-bolus	or	premix 0.66 (0.56-0.78) <0.001 876/5,122
Basal 0.86 (0.61-1.22) 0.403 207/1,294
Other 0.71 (0.55-0.91) 0.007 345/1,918 0.40
BMI	(kg/m2)
≤28 0.90 (0.75-1.08) 0.266 641/3,474
>28 0.62 (0.51-0.76) <0.001 537/3,640
Missing 0.63 (0.45-0.86) 0.004 250/1,233 0.53
Diabetes	duration	(years)
≤6	years 0.62 (0.51-0.75) <0.001 607/4,557
>6	years 0.76 (0.64-0.90) 0.001 821/3,804 0.17
Creatinine,	µmol/l
<130 0.78 (0.67-0.90) 0.302 930/6,257
≥130 0.47 (0.27-0.84) 0.011 256/756
Missing 0.58 (0.43-0.79) <0.001 242/1,347 0.23
0	
0.3	
aHR	
1.0	
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9.3.5. Comparison of lower and higher estimated insulin dose prescribed as 
monotherapy or in combination with metformin versus sulfonylurea plus 
metformin 
There was an increased risk of all-cause mortality in patients in the higher-dose insulin 
plus metformin and the lower- and higher-dose insulin monotherapy groups relative to 
lower-dose insulin plus metformin (aHR 1.27, 0.96–1.68; 1.58, 1.25–2.00; 2.04, 1.62–
2.56; respectively Figure 9.4). The aHR for all-cause mortality was similar in people 
treated with metformin plus sulfonylurea combination therapy and lower-dose insulin 
plus metformin combination therapy (aHR 0.94, 0.76–1.17). Although not statistically 
significant, users of higher-dose insulin generally had a higher aHR versus users of 
lower-dose insulin. 
For the combined endpoint, the aHR was significantly lower for people treated with 
metformin plus sulfonylurea (0.78, 0.65–0.93) and significantly higher for people in the 
lower and higher dose insulin monotherapy groups (1.32, 1.07–1.63 and 1.57, 1.29–
1.92, respectively) when compared with those in the lower dose insulin plus 
metformin group.   
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Figure 9.4  Adjusted hazard ratios for a) all-cause mortality and b) the combined 
endpoint 
a) 
 
b) 
 
Notes: Model specification: categorical variable comprising insulin exposure and therapy 
(metformin plus sulfonylurea, lower and higher dose insulin monotherapy, and lower and 
higher dose insulin plus metformin), HbA1c, BMI, diabetes duration, index year, smoking 
status, serum creatinine, prior cancer, prior large vessel disease, prior lipid-lowering therapy, 
prior antihypertensive therapy, prior antiplatelet therapy, prior GP contacts, Charlson 
comorbidity index, gender, and age at index. The combined insulin exposure and therapy 
variable was added to the Cox model as an annually updated time-dependent covariate. 
Prior cancer violated the proportional hazards assumption of the Cox model and so was 
entered as a Heaviside function (≤365 and >365 days). Selection criteria: start of therapy 
occurs between 1 January 2000 and 31 December 2010, aged ≥35 years at diabetes 
diagnosis, wash-in of ≥180 days prior to diabetes diagnosis, wash-in of ≥365 days between 
the start of therapy and later of the practice up-to-standard date and the current 
registration date.  
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9.4. Discussion 
The risk of all-cause mortality and other serious adverse events was reduced markedly 
in insulin-treated people receiving concomitant metformin. Importantly, we accounted 
for insulin dose. This finding was stable following propensity score matching.  
In the UKPDS, people using metformin had a reduced risk of all-cause mortality, 
diabetes-related mortality and myocardial infarction versus those treated with 
standard care even though patients treated with metformin had similar median HbA1c 
was similar in each treatment arm (7·4% for metformin and 8·0% for the conventional 
group).82 This suggests that metformin may have cardioprotective, an effect that 
cannot be solely explained by its ability to lower blood glucose.526,527 In addition, in 
vitro studies suggest that metformin may protect against cancer through the activation 
of activated protein kinase (AMPK).62 A systematic review carried out by Goudswaard 
and colleagues demonstrated that insulin plus metformin was associated with less 
weight gain and reduced insulin requirements compared with insulin monotherapy.83 
However, the studies included in this systematic review were in general of short 
duration. A more recent systematic review of RCTs conducted by Hemmingsen et al did 
not find that insulin plus concomitant metformin was associated with a reduced risk of 
all-cause or cardiovascular mortality compared with insulin alone in people with type 2 
diabetes.528 However, the meta-analysis was again limited by the small number of 
reported events of interest.528 The REACH study selected patients with 
atherothrombosis and showed that treatment with metformin was associated with an 
aHR for mortality of 0.76 (95% CI 0.65–0.89) compared with no metformin use.321 The 
HOME (Hyperinsulinemia: the Outcome of its Metabolic Effects) trial found that the 
addition of metformin to insulin therapy reduced the risk of macrovascular disease 
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(0.61, 0.40–0.94).345 Epidemiological data using CPRD has demonstrated that insulin 
monotherapy was associated with a significantly higher risk of MACE, cancer, or death 
than was insulin in combination with metformin (1.51, 1.28–1.78),61 but this study did 
not account for insulin dose. Evidence from the Danish National Patient Register found 
that the aHR for all-cause mortality in comparison with sulfonylurea therapy was 0.96 
(0.82–1.13) for insulin plus metformin and 1.14 (1.06–1.20) for insulin monotherapy.529 
In a retrospective observational data using the GPRD, the predecessor of CPRD, van 
Staa and colleagues determined that differences in cancer risk observed for different 
glucose-lowering therapies in the 6 months after initiation decreased over time, 
indicating protopathic bias.281 However, in this study, people who were censored or 
experienced an event within 6 months of starting the therapy of interest were 
excluded from the analysis. 
The ORIGIN trial80 showed that, compared with standard care, low-dose insulin 
glargine had no statistically significant effect on cancer and cardiovascular outcomes. 
However, by the end of the study, 47% of the patients allocated to the insulin glargine 
group were also receiving metformin therapy (compared with 60% in the standard-
care group) and 47% of patients in the standard-care group had received treatment 
with sulfonylureas, and 11% insulin. Here we have shown that, after adjusting for 
estimated cumulative insulin exposure, people prescribed metformin in combination 
with insulin had a reduced risk of all-cause mortality in comparison with people 
prescribed insulin monotherapy, and that people receiving low-dose insulin plus 
metformin combination therapy had the same outcome as people receiving metformin 
plus sulfonylurea combination therapy. However, users of metformin plus sulfonylurea 
had a significantly lower risk of the combined endpoint versus users of lower dose 
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insulin plus metformin. In a retrospective cohort study, Roumie et al also found that 
the addition of insulin to existing metformin therapy was associated with an increased 
risk of non-fatal cardiovascular events and all-cause mortality when compared with the 
addition of sulfonylureas (aHR 1.30, 95% CI 1.07–1.58).346 Conversely, Tzoulaki and 
colleagues found that both FGS and SGS were associated with an increased risk of all-
cause mortality relative to insulin monotherapy.312 The UGDP study found treatment 
with sulfonylureas to be associated with significantly higher cardiovascular mortality 
than was treatment with dietary measures alone.244 One possible explanation for this 
finding is the impairment of a cardioprotective mechanism known as ischemic 
preconditioning.236 However, whilst metformin and sulfonylurea therapy is relatively 
cheap, insulin is more expensive.42 Similar results for lower-dose insulin plus 
metformin and metformin plus sulfonylurea cannot be taken as evidence of insulin’s 
safety. However, the addition of metformin in combination with sulfonylurea has been 
shown to reduce the risk of MACE, all-cause mortality, and stroke compared with 
sulfonylurea alone530 and in this study has been shown to attenuate the risk of all-
cause mortality and other serious events when added to insulin. Conversely, data from 
the UKPDS found that when people with raised FPG (6.1–15.0mmol/l) treated with 
sulfonylureas were randomised to receive metformin in addition to sulfonylurea or 
sulfonylurea as monotherapy, the people treated with metformin plus sulfonylurea 
had a higher risk of all-cause mortality (RR 1.60, 1.02–2.52).82  
Associations between insulin dose and cancer, and between insulin dose and all-cause 
mortality have also been reported previously.255,277,531 Possible explanations for this 
dose response have been discussed.525 
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9.4.1. Study limitations 
There are several potential limitations to consider.525 Retrospective observational 
studies can only demonstrate possible associations with events; prospective 
randomized controlled trials are required to establish causality. Since these data are 
from routine practice, some data were missing.  Two systematic reviews have been 
conducted to summarise findings from published studies validating diagnoses recorded 
in CPRD. Khan and colleagues reported that the positive predictive value for most 
conditions investigated was more than 50%.367 However, rates of diabetes and 
musculoskeletal conditions were underestimated.367 Herrett and colleagues, reported 
that the median proportion of cases with a confirmed diagnosis was 89% (range 24–
100%).368 Only those patient records meeting CPRD’s research quality criteria were 
included. Rules were applied to maintain consistency in the selection of patients with 
type 2 diabetes. However, misclassification of diabetes type was possible and was 
more likely to affect patients prescribed insulin monotherapy.  
There were potential limitations to the methods used to estimate insulin dose. Under- 
and over-estimations of prescribed quantities were possible due to inconsistencies 
between fields in the prescriptions table or ambiguities in the quantities prescribed, 
but rules were devised to maintain consistency (Appendix 2).  It is also possible that 
patients using both metformin and insulin may be less compliant with their insulin as 
this would not be their sole means of controlling blood glucose. The exclusion of 
people with no weight measurement may have led to the elimination of sicker or more 
obese patients where weight measurement is more challenging. 
One of the main criticisms of this type of observational study is the possibility of 
confounding by indication. This has been minimized by our selection of only those 
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patients initiated on insulin for the majority of the analyses; however, differences in 
the baseline characteristics do exist. To partly address this, patients were matched by 
propensity score. In addition, subgroup analyses were carried out. There was evidence 
of a difference in treatment effect for all-cause mortality in the subgroup analyses 
using age, Charlson index, prior large vessel disease and HbA1c. However, the point 
estimates for the aHR for all-cause mortality for insulin plus metformin versus insulin 
monotherapy were less than unity in all subgroups. For the combined endpoint, 
treatment effect was not significantly different between any of the subgroups tested. 
Confounding should also be considered when comparing metformin plus sulfonylurea 
with those on insulin. There is an argument that increasing insulin dose could be a 
measure of diabetes deterioration. However, when, as a sensitivity analysis, estimated 
insulin dose was entered into the Cox model as dose in year 1 rather than as a time-
dependent covariate, the aHRs were 1.40 (1.22–1.60) for all-cause mortality and 1.22 
(1.07–1.40) for the combined endpoint. Due to the risk of lactic acidosis, metformin 
should be used with caution in renal impairment.47 From the baseline characteristics, 
19% of patients in the insulin monotherapy group had a creatinine level of >130µmol/l 
in comparison with 3% in the insulin plus metformin group; this did not impact our 
findings in sensitivity analysis.   
The number of events should be at least 10 times the predictor degrees of freedom in 
the model.532 Therefore, over-fitting of the model may have occurred for some of the 
subgroup analyses.  
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9.4.2. Conclusion 
People with type 2 diabetes treated with insulin plus concomitant metformin had a 
markedly reduced risk of death and other serious outcomes compared with people 
treated with insulin monotherapy. Studies are needed to determine the risks and 
benefits of injecting insulin in type 2 diabetes, and the possible benefits associated 
with the administration of concomitant metformin.   
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10. Discussion of overall findings 
10.1. Main findings 
10.1.1. Summary 
Between 1991 and 2010, the estimated incidence and prevalence of clinically 
diagnosed and recorded type 2 diabetes increased three-fold and the estimated 
number of people with diagnosed and recorded type 2 diabetes treated with insulin 
increased seven-fold. Estimated insulin dose was associated with an increased risk of 
all-cause mortality and other serious adverse events in people with type 2 diabetes 
receiving insulin with or without metformin, however, the use of metformin in 
combination with insulin was associated with a reduction in risk compared with insulin 
alone. 
 
10.1.2. Specific findings 
There has been a significant increase in the clinically diagnosed and recorded incidence 
of type 2 diabetes between 1991 and 2010 from 169 to 515 cases per 100,000 person-
years (Chapter 4). The percentage of patients with a recorded diagnosis for type 2 
diabetes before the age of 40 also increased with each increasing 5-year calendar 
period (5.9% in 1991–1995, 8.4% in 1996–2000, 8.5% in 2001–2005 and 12.4% in 
2006–2010, respectively). In addition, the estimated crude prevalence of type 2 
diabetes trebled between 1991 and 2012 (increasing from 1.32% to 4.54%, Chapter 5).  
The estimated number of people with type 2 diabetes treated with insulin increased 
seven-fold between 1991 and 2010 from 37.0 (95%CI 30.2–46.2) thousand to 277.4 
(262.8–293.3) thousand (Chapter 6). During the same period, the proportion of people 
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with type 2 diabetes treated with insulin was estimated to have increased from 5% to 
15%. In addition, over a 10-year period, the total annual cost of insulin increased from 
£156 million in 2000 to £359 million in 2009, an increase of 130% (Chapter 7). 
Although an increase in prescribing of the more expensive insulin analogues has 
contributed to this increase in spending on insulin, the volume of insulin prescribed 
also increased during the same period. The percentage of people with type 2 diabetes 
treated with insulin prescribed as monotherapy decreased from 97% to 37% between 
1991 and 2010, while the percentage of people prescribed insulin in combination with 
metformin increased to 43%. 
Improved glycaemic control and survival was observed in people with type 2 diabetes. 
Mean HbA1c for type 2 diabetes decreased from 8.4% in 1991 to 7.5% in 2003 but then 
plateaued. For type 2 diabetes HbA1c levels were highest in people receiving insulin 
therapy and remained relatively constant from 1992 onwards (HbA1c levels between 
8.4% and 8.7%). For type 2 diabetes, survival increased between 1991 and 2013 where 
the aHR for all-cause mortality was 1.75 (1.60–1.92) in 1991 and 0.58 (0.48–0.70) in 
2013 (where 2001 was taken as the reference year). The average life expectancy for 
incident treated type 2 diabetes increased by around eight years between 1991 and 
2009.  
Estimated insulin dose was associated with an increased risk of all-cause mortality in 
people with type 2 diabetes receiving insulin monotherapy (aHR 1.54, 95% CI 1.32–
1.78, for 1 unit/kg/day increase in insulin dose, Chapter 8) and in those treated with 
insulin with or without metformin (1.48, 1.31–1.70, Chapter 9). However, the use of 
metformin in combination with insulin was associated with a reduction in risk of all-
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cause mortality when compared with insulin alone (0.60, 0.52–0.68). This reduction in 
risk was also observed following propensity score matching (0.62, 0.52–0.75). 
 
10.2. Study strengths and limitations 
The advantages and disadvantages of retrospective observational studies have been 
described in Chapter 3. In addition, the strengths and limitations of the studies 
conducted have been described in detail at the end of each chapter. This series of 
retrospective, observational studies have several advantages. Despite the cost of data 
acquisition, retrospective observational studies are considerably cheaper to carry out 
when compared with RCTs. Due to the size of CPRD GOLD (approximately 12 million 
patients), the sample size for each study was relatively large and the follow-up time 
was moderate. The data in CPRD have already been collected and collated, therefore, 
these retrospective observational studies could be completed more quickly than an 
RCT. CPRD GOLD is thought to be representative of the general population in the UK in 
terms of age and gender structure and crude mortality.364,365 In a systematic review, 
Khan and colleagues reported that the positive predictive value for most conditions 
investigated was more than 50% and 14 of the conditions investigating had a positive 
predictive value of more than 90%.367 In a more recently conducted systematic review, 
Herrett and colleagues reported that the median proportion of cases with a diagnosis 
confirmed by data within CPRD or from an external resource was 89% (range 24–
100%).368  Similar results have been reported when a study originally carried out using 
data from CPRD was replicated using data from QResearch.533 A cohort study with 
nested case-control analysis investigating the association between statin use and the 
risk of mortality in patients with ischaemic heart disease carried out using data from 
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CPRD reported that patients taking statins had a 55% decreased risk of death in the 
cohort analysis and a 31% lower odds of death in the case-control analysis.533 The 
corresponding results using data from QResearch were 53% and 39%, respectively.533 
Statistical methods were used to adjust for potential confounding factors. In 
retrospective observational studies, only those people who have actually been 
prescribed the therapy or therapies of interest in the real world are included in the 
study and are therefore more likely to reflect clinical practice when compared with 
RCTs which can apply strict inclusion and exclusion criteria. In addition, RCTs are 
subject to selection bias as they include only those people who have consented to be 
part of the study. In addition, observational studies can be used to answer questions 
that would be difficult to answer using any other study design. 
This series of retrospective observational studies also have some limitations. The data 
recorded in CPRD GOLD has been recorded by the primary care physician as part of the 
routine care of the patients and not for the purposes of research. Primary care 
physicians are therefore likely to record only the information that they consider to be 
important in terms of the ongoing care of the patient. Missing values were unlikely to 
be missing completely at random. For example, patients with poor glycaemic control 
may have more frequent HbA1c tests and GPs may be more likely to record a BMI if 
the patient is obese. In a validation study exploring the effect of antihypertensive 
therapy on blood pressure in GPRD, Delaney and colleagues found that missing blood 
pressure data was not missing completely at random.534 Multiple imputation was used 
to impute missing values for the studies described in Chapters 8 and 9. 
Changes in coding during the study period including overall improvements in recording 
and changes in terminology from IDDM and NIDDM to type 1 and type 2 diabetes may 
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have impacted on case selection. Misclassification of patients with a diagnosis of IDDM 
as type 1 instead of type 2 would have led to an underestimation in the incidence and 
prevalence of diagnosed type 2 diabetes and is more likely to have affected years prior 
to 1997, when this terminology was used more often.367 Consequently, the increase in 
the estimated incidence and prevalence of diagnosed and recorded type 2 diabetes 
may be exaggerated. The distinction between type 1 and type 2 diabetes is 
problematic due to the presence of conflicting diagnoses and prescriptions in some 
patient histories. However, robust selection criteria were used throughout. Increased 
prescribing of insulin in type 2 diabetes (Chapter 6) may have led to greater 
misclassification of type 2 diabetes as type 1 diabetes over time, which could have 
impacted on prevalence and survival estimates. Information recorded as free text in 
CPRD was not accessed, as data stored as free text are not routinely provided as part 
of CPRD, incur a financial cost and are challenging to analyse. Therefore, patients with 
diagnoses recorded as free text as opposed to Read code were not identifiable. The 
use of free text fields is likely to depend on the user and the GP system used. Free text 
recorded within the Vision system is always linked to specific coded data.359  
Validation of type 2 diabetes recording in CPRD was not carried out. However, De 
Lusignan and colleagues investigated miscoding, misclassification and misdiagnosis of 
diabetes in primary care and found that 5.8% of patients with diabetes had potential 
classification errors. However, of the 5.8% of people identified with potential 
classification errors, only 40% were confirmed to have had errors in their diabetes 
coding.535 Patient consultation rates for diabetes have been reported to be lower in 
GPRD when compared with those obtained from the MSGP4 in a study conducted 
between September 1991 and August 1992.464 However, data recording requirements 
differed between sources.464 A chronic condition need only be recorded at the time of 
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diagnosis in GPRD whereas every consultation was recorded in the MSGP4.464 For the 
prevalence study described in Chapter 5, patients remained a prevalent case from the 
date of presentation until the end of their recorded data. A systematic review of 
measures of data quality in primary care electronic patients records found that a 
consistently high positive predictive value was reported by included studies but 
prescribing data were found to be more sensitive when compared to diagnostic and 
lifestyle data.536 This suggests that the use of both diagnoses for diabetes and 
prescriptions for glucose-lowering therapies in the selection of patients will have led to 
improved case selection. When identifying incident cases of type 2 diabetes, a wash-in 
was applied in order to exclude patients with prevalent disease. However, the 
incidence of newly diagnosed type 2 diabetes may be higher in the first few months 
following registration at a GP practice as routine health checks associated with the 
registration process537 may include a test for diabetes. Therefore, excluding patients 
without the specified wash-in period may have led us to underestimate the incidence 
of type 2 diabetes. 
Several of the studies conducted utilised CPRD-linked HES data in order to improve the 
capture of health events occurring in secondary care. The use of other linked datasets 
including ONS mortality data and MINAP (at an additional cost) could have been 
considered. Linked datasets are only available for a proportion of the CPRD population 
registered at English practices. ONS mortality data provides the date of death and the 
cause of death (post 1st January 2001) for English practices consenting to participate in 
the linkage scheme. However, it has been reported by GPRD that 99.2% of acceptable 
patients registered at linked practices who die on or after 1st January 2001 and have a 
recorded cause of death were also identified as dead in GPRD, where the mean and 
median death date differences were 3.65 and 0 days, respectively (unpublished data). 
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In a study conducted by Herrett and colleagues, the crude incidence of myocardial 
infarction was reported to be 25% lower when only CPRD was used when compared to 
the use of CPRD, HES and ONS mortality data combined.538 However, when compared 
with MINAP, the positive predictive value of acute myocardial infarction recorded in 
CPRD and HES was 92.2% (95% CI 9.16%–92.8%) and 91.5% (90.8%–92.1%), 
respectively.538 
There were limitations associated with using diagnosed and recorded incidence and 
prevalence of type 2 diabetes in order to understand the true incidence and 
prevalence of the condition. The incidence and prevalence of type 2 diabetes has been 
estimated from 1991–2010 and 1991–2013, respectively. The recording of diabetes 
may have improved during this time. The introduction of QOF in 2004 incentivised GPs 
to keep adequate records of patients with diabetes.404 In 1993, 90% of practices were 
computerised, however, only 8% were paperless.539 In a review published by 
employees of GPRD, it was suggested that post-2000, the dataset was more clinically 
rich due to the use of the more complex but easier to use Vision system.359 However, 
in a study of people using non-steroidal anti-inflammatory drugs conducted between 
November 1989 and February 1991 by Jick and colleagues, it was found that 87% of 
diagnoses recorded in consultation letters were also present in the computer 
record.369 Only acceptable patients registered at up-to-standard practices were used 
for this series of studies.  
A prescription recorded in the therapy table in CPRD indicates an intention to treat on 
the part of the primary care physician. The proportion of prescribed medications 
actually dispensed to and taken by the patient is unknown. Insulin dose was not 
routinely recorded in CPRD and was therefore estimated from the quantity of insulin 
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prescribed. Limitations associated with the estimation of insulin dose have been 
discussed in detail in Chapter 8. The distribution of insulin dose was heavily skewed 
with a long right hand tail. Patients who switch between insulin types are likely to 
waste more insulin leading to an overestimate in daily dose. These patients may have 
worse glycaemic control and outcomes when compared with those patients who 
remain stable on the same insulin product.  
Epidemiological studies are often criticized because of the risk of a form of analytical 
bias that is termed confounding by indication. That is, those treated with insulin are at 
a more advanced stage in the natural history of the disease or they have phenotypic 
characteristics that require a switch to insulin. The risk of this bias was minimised as 
only those patients prescribed insulin were selected. However, increasing insulin dose 
is likely to be a measure of diabetes deterioration. This confounding bias is likely to 
favour the lower doses of insulin. In order to minimise this bias, statistical methods 
that adjusted for various confounders, including duration of diagnosed diabetes, age, 
comorbidities and baseline HbA1c, were used. In addition, several sensitivity analyses 
were conducted in order to explore the effect of different estimations of insulin dose 
on the study endpoints. These different estimations in order to overcome possible 
limitations including change in insulin dose prior to endpoint and fluctuations in insulin 
dose due to intermittent collection of prescriptions. 
Unlike an RCT, patients were not randomised to receive insulin monotherapy or insulin 
plus metformin. The reason why patients prescribed insulin monotherapy did not 
receive concomitant therapy with metformin was not clear. Current guidelines 
recommend that metformin should be continued when insulin is initiated.7,55 However, 
in 2010, 43% of people with insulin treated type 2 diabetes did not appear to be 
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receiving metformin concomitantly. Some of these people could have had other 
concomitant conditions that lead to an increased risk of lactic acidosis, for example 
renal impairment, dehydration, severe infection, shock, sepsis, acute heart failure, 
respiratory failure or hepatic impairment, or recent myocardial infarction.47 Metformin 
is also associated with a greater than 1 in 10 risk of gastrointestinal side effects on 
initiation.540 Gastrointestinal side effects can resolve spontaneously following 
initiation, but may persist in some people, particularly when high doses are 
prescribed.47 A trial of a modified release formulation is recommended by NICE in 
people with gastrointestinal side effects that could lead to discontinuation of 
metformin.54 However, it is possible that gastrointestinal side effects could lead to 
poor compliance or discontinuation in some patients. Median serum creatinine levels 
were higher in the insulin monotherapy group when compared with those treated with 
insulin plus metformin (Table 9.1). If patients with contraindications to metformin are 
more likely to receive insulin as monotherapy, this is likely to have resulted in a bias 
that favoured insulin plus metformin. In order to minimise the risk of this bias, 
statistical methods were used that adjusted for known confounders including serum 
creatinine. In addition, propensity score matching was carried out. 
The endpoints used for the studies in Chapters 8 and 9 are also potential complications 
of diabetes as discussed in Chapter 2. Statistical methods were adopted that adjusted 
for many baseline covariates, however, there exists the possibility that outcome 
depended on factors that were either known or unknown that could not be fully 
adjusted for in the Cox proportional hazards model. Retrospective observational 
studies can only demonstrate possible associations with events; prospective 
randomised controlled trials are required to establish causality. Comparison between 
results obtained from RCTs and observational studies vary with some reporting 
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comparable results349,350 and others reporting differences in the estimated magnitude 
of treatment effects but good correlation between the different study types.240 
Registration of the study protocol prior to carrying out the study would increase 
transparency and reduce the risk of publication and reporting bias. 
 
10.3. Study implications and future research 
The estimated prevalence and incidence of diagnosed and recorded type 2 diabetes 
has increased. The proportion of earlier onset type 2 diabetes continued to increase as 
a proportion of those diagnosed and these people have a greater opportunity to 
develop long-term complications. The study results could be explained, at least in part, 
by a true increase in type 2 diabetes in the UK population due to changes in diet and 
lifestyle leading to a rise in obesity.63 In addition, an increase in life expectancy in the 
UK population541 and survival in type 2 diabetes (Chapter 5) has also contributed to an 
increase in prevalence of the condition. However, other explanations for this trend 
also exist. Due to the limitations in the recording of type 2 diabetes in CPRD, our 
estimates of the prevalence and incidence of type 2 diabetes are likely to be 
conservative. However, during the study period, improved recording of diagnoses may 
have played a part in the trends observed. Furthermore, only the incidence and 
prevalence of diagnosed type 2 diabetes could be estimated. The corresponding rates 
of undiagnosed type 2 diabetes remain unknown. Changes in diagnostic thresholds 
increased the number of people who were labelled as having type 2 diabetes. 
Enhanced detection of diabetes may have reduced the time between the true onset of 
type 2 diabetes and its diagnosis, which will reduce the population of undiagnosed 
cases. The introduction of QOF incentivised both the identification, recording and 
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monitoring of people with type 2 diabetes. This could be viewed positively as patients 
will receive appropriate diabetes care at an earlier stage of their disease. The relative 
contributions that each component has made to the increase in incidence and 
prevalence observed remains unknown. However, measures to reduce obesity through 
healthy eating and increased exercise need to remain top of the agenda with respect 
to health policy in the UK in order to have an impact on diabetes prevalence in the 
future. 
In Chapter 4, a decrease in the estimated incidence of diagnosed and recorded type 2 
diabetes in the UK between 2009 and 2010 from 533 to 515 newly diagnosed people 
per 100,000 person-years was reported.421 Furthermore, several studies have reported 
that the incidence and prevalence of diabetes in the US has remained relatively stable 
in recent years.423,542,543 The increase in the estimated prevalence of diagnosed and 
recorded type 2 diabetes between 2012 and 2013 was less than expected based on the 
rate of increase observed prior to 2012. However, further research is required to 
determine whether the incidence and prevalence of diagnosed type 2 diabetes in the 
UK is starting to plateau. 
Survival in people with type 2 diabetes increased between 1991 and 2013, suggesting 
that the overall management of this condition has improved. Although glycaemic 
control improved initially, HbA1c levels remained relatively constant between 2003 and 
2013. Therefore, improvements in survival may not be fully explained by improved 
glycaemic control. In several meta-analyses, intensive glucose control has not been 
associated with a significantly different risk in all-cause mortality when compared with 
conventional control of blood glucose.111,202,219 Improvements in blood pressure and 
total cholesterol were observed during the study period and more patients were 
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prescribed antiplatelet, antihypertensive and lipid-lowering therapy. Tighter control of 
blood pressure has been shown to be associated with a reduction in the risk of deaths 
and complications related to diabetes.46 The results from ADVANCE demonstrated that 
people assigned to indapamide and perindopril had improved reduction in blood 
pressure versus placebo and lower risk of major vascular events and deaths (RR 0·82, 
95%CI 0·68–0·98 cardiovascular death and 0·86, 0·75–0·98 for all-cause mortality).544 
However, for ACCORD, intensive control of systolic blood pressure statistically, 
significantly reduced the risk of stroke (aHR .59, 95% CI 0.39–0.89 for any stroke and 
0.63, 0.41–0.96 for non-fatal stroke) but not the rate of a composite outcome of fatal 
and non-fatal major cardiovascular events. The use of statins has been shown to 
reduce the risk of coronary and vascular events.545 Aspirin has been shown to have a 
protective effect in people with established cardiovascular disease.546 In a study 
conducted by Vamos and colleagues using GPRD, the introduction of QOF was 
associated with improvements in blood pressure and total cholesterol, which were 
greater than could be predicted from trends prior to the introduction of QOF.547 
However, no significant additional improvement was observed for glycaemic 
control.547 Improvements in survival could also be related to the early detection of 
type 2 diabetes. A retrospective study using data from GPRD carried out a longitudinal 
analysis of achievement rates for 42 QOF indicators including four diabetes quality 
indicators to identify patients with a recorded HbA1c , blood pressure, total cholesterol 
and serum creatinine measurement.548 Achievement rates improved in the years prior 
to the introduction of QOF (2001-2002 and 2002-2003) before reaching a plateau after 
2004–2005.548 A small detrimental effect was observed for non-incentivised aspects of 
patient care.548 However, the impact of changes in data recording procedures on these 
results was not investigated.548 
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The number of people with type 2 diabetes treated with insulin increased considerably 
between 1991 and 2010. Findings from UKPDS in 1998, recommendations from NICE in 
2002 and the introduction of QOF in 2004 could have advocated and incentivised 
tighter glucose control.67,404,549 In a recent retrospective study carried out using data 
from GPRD, it was reported that a greater proportion of people with diabetes were 
iniated on glucose-lowering therapy within one or two years of diagnosis following the 
introduction of QOF.550 Marketing of the new insulin analogues, which are thought to 
be associated with a lower risk of hypoglycaemia and have a longer duration of action, 
may have also reduced the barriers to insulin initiation. However, the baseline 
characteristics of patients starting insulin did not support the theory of earlier insulin 
initiation. Therefore, the increase in insulin use in type 2 diabetes may reflect a true 
change in the population of people with type 2 diabetes with an increase in the 
proportion of people with more advanced disease due to improved survival. The 
increasing prevalence of insulin also partly reflects an increase in the overall 
prevalence of type 2 diabetes. The use of insulin in type 2 diabetes is common. 
Therefore, it is vital to understand the risks and benefits of insulin use in type 2 
diabetes, determine when it should be prescribed and characterise the patients who 
will benefit most from this type of glucose-lowering therapy. 
Increasing insulin exposure has been shown to be associated with an increased risk of 
all-cause mortality, MACE and cancer in Chapters 8 and 9 and elsewhere.255 Chapter 6 
has shown that any risks associated with insulin could affect an estimated 277,000 
people in the UK with type 2 diabetes and currently using insulin (2010 figures). As 
discussed in Chapter 3, epidemiological studies can only show associations between 
insulin use and risks and it is possible that residual bias or confounding could account 
for the results.  The results of ORIGIN indicated that insulin use had no statistically 
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significant effect on cardiovascular or cancer risk.80 While this provides some 
reassurance, the people selected did not reflect those patients who receive insulin in 
the real world.80 Although, insulin use was not associated with a significant increase in 
the risk of cardiovascular events, no statistically significant decrease in the risk of these 
events was observed either. Insulin is costly and needs to be injected. In addition, the 
risk of weight gain and hypoglycaemia is higher with insulin compared with other 
glucose-lowering therapies.80,171,191,209,210 Further research is therefore required in 
order to investigate these results. 
Not starting insulin and leaving patients in a state of hyperglycaemia is also not an 
attractive option for clinicians and is associated with increased risk of developing 
diabetic complications.67 Despite this, a recent retrospective cohort study has reported 
that treatment intensification with oral glucose-lowering therapies or insulin is delayed 
despite poor glucose control.461 It is likely that insulin will become necessary for a 
proportion of people with type 2 diabetes due to the progressive loss of beta-cell 
function over time. Further research could be conducted to determine the potential 
predictors of a good response to insulin, taking into account both the change in HbA1c 
and weight and the risk of hypoglycaemia, all-cause mortality, cardiovascular events 
and cancer. Unlike some other medical conditions, diabetes outcomes depend not only 
on pharmacological interventions but also, importantly, on the willingness of the 
patient to make necessary adjustments to their lifestyle.  
The results of Chapter 9 suggest that insulin can be prescribed in a way that reduces 
the possible risk associated with this therapy. When metformin was prescribed in 
combination with insulin, there was a substantial decrease in the risk of all-cause 
mortality by approximately half. Compared with insulin monotherapy, insulin in 
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combination with metformin has been found to be associated with less weight gain, 
reduced insulin requirements, and a reduced risk of macrovascular disease, MACE, 
cancer and all-cause mortality.61,83,345,529 Conversely, a systematic review of RCTs 
conducted by Hemmingsen and colleagues did not find that insulin plus concomitant 
metformin was associated with a reduced risk of all-cause or cardiovascular mortality 
compared with insulin alone in people with type 2 diabetes but the number of events 
reported was small.528 However, a recently published retrospective study found that 
the addition of insulin to metformin was associated with an increased risk of a 
composite of nonfatal cardiovascular outcomes and all-cause mortality when 
compared with the addition of a sulfonylurea (aHR 1.30, 95% CI 1.07–1.58).346  
Several RCTs have compared the effect of glucose-lowering therapies on glycaemic 
control but there is a lack of RCT data using hard outcomes such as cardiovascular 
events, cancer and death. As tight glycaemic control was only shown to significantly 
reduce the risk of macrovascular complications in the follow-up study to the UKPDS, 
and not in the original UKPDS, ACCORD, VADT or ADVANCE studies,67,79,217,218 
interventional studies using hard endpoints may be preferred in order to further 
investigate the risks and benefits of exogenous insulin in type 2 diabetes. 
Both NICE and ADA/EASD guidelines recommend that when insulin is initiated, it is 
added to existing metformin therapy in patients with type 2 diabetes.7,55 The findings 
from Chapter 9 are in agreement with this recommendation and therefore help to 
reinforce existing clinical guidelines. This study occupies level 2 on Oxford Centre for 
Evidence-based Medicine’s Levels of Evidence.225 However, epidemiological studies are 
often criticized because of the risk of a form of analytical bias that is termed 
confounding by indication. The endpoint and the therapy of interest may be associated 
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with a confounding factor or the increased risk of the endpoint of interest may 
predispose that patient to receiving a particular therapy. Therefore, interventional trial 
designs could be used to further investigate the results produced in Chapters 8 and 9. 
However, consideration would need to be given to the principle of clinical equipoise. In 
an RCT, clinical equipoise describes a state of genuine uncertainty in the medical 
community as to whether one treatment arm will be superior to the other. The 
evidence base for metformin may be such that the state of clinical equipoise does not 
exist rendering the commencement of a clinical trial unethical. Even in situations 
where metformin is usually contraindicated and there is more uncertainty as to 
whether metformin therapy is beneficial, the state of clinical equipoise may still be 
difficult to achieve. Eurich and colleagues attempted to conduct a pilot study to 
investigate the effect of metformin on functionality, morbidity, and mortality 
outcomes in patients with type 2 diabetes and heart failure using a double blinded 
randomised placebo controlled design.551 However, the uncertainty that appeared to 
exist in the scientific community as to the beneficial impact of metformin in a situation 
where it is normally contraindicated did not apply in clinical practice where more than 
50% of patients were already receiving metformin at baseline.551  
However, contrary to this, in real-world clinical practice, insulin is still prescribed as 
monotherapy for a large proportion of insulin treated patients (43% in 2010). Although 
the proportion of people in which metformin could not be prescribed due to 
contraindications or side effects was not identified, this could illustrate that insulin 
monotherapy is seen as an alternative to insulin plus metformin. In terms of RCTs using 
hard clinical endpoints, guidelines supporting the use of metformin in type 2 diabetes 
are largely based on results from UKPDS which reported that patients randomised to 
metformin therapy had a reduced risk of all-cause mortality (36%, 95% CI 9%–55%) 
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and any diabetes related endpoint (32%, 13%–47%) when compared with conventional 
therapy.82 The Michael Berger debate at the 2014 EASD annual meeting illustrates that 
some of the scientific community believe the evidence base for metformin is not 
strong enough.552 The Glucose Lowering In Non-diabetic hyperglycaemia Trial (GLINT) 
is currently being conducted.553 This illustrates that, dependingon the study design, 
RCTs investigating the risks and benefits of metformin on hard clinical endpoints 
remain feasible. The results from this study will provide important evidence on the use 
of metformin in the prevention of cardiovascular outcomes.553  
Metformin plus a sulfonylurea are recommended as a second-line glucose lowering 
regimen for type 2 diabetes by NICE.55 When insulin is initiated, NICE recommends that 
it should be added to the metformin plus sulfonylurea combination.55 However, the 
number of people identified who were prescribed insulin in combination with 
metformin plus sulfonylurea and met the selection criteria outlined in Chapter 9 was 
small. In addition, the benefits of combining insulin with newer agents could be further 
investigated. A recent review by Frandsen and Madsbad has shown that the addition 
of a DPP4-inhibitor to insulin therapy is associated a moderate effect on HbA1c, no 
effect on weight and no increased risk of hypoglycaemia.554 The risk of all-cause 
mortality, MACE and cancer associated with insulin in combination with other glucose-
lowering therapies is an important area for future research. 
New glucose-lowering medications such as GLP-1 agonists, DPP-4 inhibitors and SGLT-2 
inhibitors have been approved for the control of blood glucose in type 2 diabetes in 
the last decade.69 In fact, NICE guidelines suggest that a DPP-4 inhibitor, GLP-1 agonist 
or a thiazolidinedione could be used as an alternative to insulin as third-line therapy in 
type 2 diabetes.55 A potential area for future research could be to investigate whether 
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any of these new therapies (alone or in combination with other types of glucose-
lowering medications) provide better or worse outcomes in comparison with insulin at 
the same stage of the treatment pathway.  
Due to its theoretically unlimited potential to lower blood glucose, it is likely that 
insulin will remain the mainstay for people with hyperglycaemia that cannot be 
controlled using non-insulin glucose-lowering medicines.  
 
10.4. Conclusion 
The estimated prevalence of diagnosed and recorded type 2 diabetes is increasing. 
Furthermore, the proportion of people diagnosed at a relatively early age (<40) is also 
increasing. Measures to tackle obesity in the UK (e.g. the UK government Change for 
Life scheme555) are important in order to curb this trend. 
Insulin has become a commonly prescribed therapy for the control of blood glucose in 
type 2 diabetes and at a large financial cost to the NHS. Therefore, it is important to 
understand the full risks and benefits associated with insulin for the management of 
hyperglycaemia in type 2 diabetes. Current NICE, ADA and EASD guidelines 
recommend that metformin therapy should be continued when insulin is initiated. 7,55 
The results of this thesis are in support of this recommendation.  
An association between estimated insulin dose and an increased risk of MACE, cancer 
and all-cause mortality has been demonstrated. The risk of all-cause mortality and 
other serious adverse events was reduced markedly in insulin- treated people 
receiving concomitant metformin. However, retrospective observational studies do 
have limitations. Despite statistical adjustment for many known confounders, these 
  
 294 
studies can still be criticised due to the potential for the results to be attributed to 
factors that are either unknown or cannot be fully adjusted for. Therefore, changes in 
clinical practice cannot be recommended based on this study alone.  
The results presented in this thesis and the results of previously published 
observational studies60–62,223,224,251,253,255,259,260,270–272,279,346 are discordant with the 
findings from the most relevant RCT conducted, ORIGIN. However, study subjects were 
treated with insulin earlier in their treatment pathway compared with those who 
receive insulin in normal clinical practice. The results of this thesis suggest that further 
research is required in order to improve our understanding of the risks and benefits of 
exogenous insulin in type 2 diabetes.  
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13.2. Appendix 2 Rules for attributing the total international units 
represented by insulin prescriptions in CPRD 
 If insulin presentation is a vial and quantity field = 10, then volume prescribed is 
assumed to be 100ml UNLESS ml or millilitres appears in text or pack type field 
where volume prescribed then = 10ml 
 If insulin presentation is a vial and the quantity is a multiple of 10 and ≥20, the 
volume prescribed = quantity 
 If the insulin presentation is cartridges, quantity is a multiple of 5, and the text 
or pack type is original pack (OP), then 1 OP = 1 cartridge or pen UNLESS text or 
pack type description indicates the number of boxes supplied. For example, if 
quantity = 5 and pack type description or text field indicates 5 boxes have been 
supplied then volume prescribed = 75ml or 37.5ml depending on cartridge size. 
 If text or pack type field = millilitres or ml AND quantity = a multiple of the 
volume per unit for the insulin presentation in question, then the volume 
prescribed = quantity 
 If the volume prescribed > 200ml, then volume prescribed is coded as missing 
 Apply a default volume and year if only one insulin presentation was available 
after a specific date. For example: 
 All Novo Nordisk penfills were assumed to be 3ml after 2003 
 All Novo Nordisk pens were assumed to be 3ml after 1997 
 All Humulin cartridges were assumed to be 3ml after 2000 
 Where there was conflicting information in two or more of product name, pack 
type, text, and quantity fields, the volume prescribed was coded as missing 
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 If the origin of the insulin was not specified (as animal or human), the insulin 
was assumed to be of human origin. 
                                                     
 
